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A B S T R A C T
Background
Omega-6 fats are polyunsaturated fats vital for many physiological functions, but their effect on cardiovascular disease (CVD) risk is
debated.
Objectives
To assess effects of increasing omega-6 fats (linoleic acid (LA), gamma-linolenic acid (GLA), dihomo-gamma-linolenic acid (DGLA)
and arachidonic acid (AA)) on CVD and all-cause mortality.
Search methods
We searchedCENTRAL,MEDLINE and Embase toMay 2017 and clinicaltrials.gov and theWorldHealthOrganization International
Clinical Trials Registry Platform to September 2016, without language restrictions. We checked trials included in relevant systematic
reviews.
Selection criteria
We included randomised controlled trials (RCTs) comparing higher versus lower omega-6 fat intake in adults with or without CVD,
assessing effects over at least 12 months. We included full texts, abstracts, trials registry entries and unpublished studies. Outcomes were
all-cause mortality, CVDmortality, CVD events, risk factors (blood lipids, adiposity, blood pressure), and potential adverse events. We
excluded trials where we could not separate omega-6 fat effects from those of other dietary, lifestyle or medication interventions.
Data collection and analysis
Two authors independently screened titles/abstracts, assessed trials for inclusion, extracted data, and assessed risk of bias of included
trials. We wrote to authors of included studies. Meta-analyses used random-effects analysis, while sensitivity analyses used fixed-effects
and limited analyses to trials at low summary risk of bias. We assessed GRADE quality of evidence for ’Summary of findings’ tables.
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Main results
We included 19 RCTs in 6461 participants who were followed for one to eight years. Seven trials assessed the effects of supplemental
GLA and 12 of LA, none DGLA or AA; the omega-6 fats usually displaced dietary saturated or monounsaturated fats. We assessed
three RCTs as being at low summary risk of bias.
Primary outcomes: we found low-quality evidence that increased intake of omega-6 fats may make little or no difference to all-
cause mortality (risk ratio (RR) 1.00, 95% confidence interval (CI) 0.88 to 1.12, 740 deaths, 4506 randomised, 10 trials) or CVD
events (RR 0.97, 95% CI 0.81 to 1.15, 1404 people experienced events of 4962 randomised, 7 trials). We are uncertain whether
increasing omega-6 fats affects CVD mortality (RR 1.09, 95% CI 0.76 to 1.55, 472 deaths, 4019 randomised, 7 trials), coronary
heart disease events (RR 0.88, 95% CI 0.66 to 1.17, 1059 people with events of 3997 randomised, 7 trials), major adverse cardiac
and cerebrovascular events (RR 0.84, 95% CI 0.59 to 1.20, 817 events, 2879 participants, 2 trials) or stroke (RR 1.36, 95% CI
0.45 to 4.11, 54 events, 3730 participants, 4 trials), as we assessed the evidence as being of very low quality. We found no evidence
of dose-response or duration effects for any primary outcome, but there was a suggestion of greater protection in participants with
lower baseline omega-6 intake across outcomes.
Additional key outcomes: we found increased intake of omega-6 fats may reduce myocardial infarction (MI) risk (RR 0.88, 95%
CI 0.76 to 1.02, 609 events, 4606 participants, 7 trials, low-quality evidence). High-quality evidence suggests increasing omega-6 fats
reduces total serum cholesterol a little in the long term (mean difference (MD)−0.33 mmol/L, 95% CI −0.50 to−0.16, I2 = 81%;
heterogeneity partially explained by dose, 4280 participants, 10 trials). Increasing omega-6 fats probably has little or no effect on
adiposity (body mass index (BMI) MD −0.20 kg/m2, 95% CI −0.56 to 0.16, 371 participants, 1 trial, moderate-quality evidence).
It may make little or no difference to serum triglycerides (MD −0.01 mmol/L, 95% CI −0.23 to 0.21, 834 participants, 5 trials),
HDL (MD −0.01 mmol/L, 95% CI −0.03 to 0.02, 1995 participants, 4 trials) or low-density lipoprotein (MD −0.04 mmol/L,
95% CI −0.21 to 0.14, 244 participants, 2 trials, low-quality evidence).
Authors’ conclusions
This is the most extensive systematic assessment of effects of omega-6 fats on cardiovascular health, mortality, lipids and adiposity to
date, using previously unpublished data. We found no evidence that increasing omega-6 fats reduces cardiovascular outcomes other
than MI, where 53 people may need to increase omega-6 fat intake to prevent 1 person from experiencing MI. Although benefits of
omega-6 fats remain to be proven, increasing omega-6 fats may be of benefit in people at high risk of MI. Increased omega-6 fats reduce
serum total cholesterol but not other blood fat fractions or adiposity.
P L A I N L A N G U A G E S U M M A R Y
Omega-6 fats to prevent and treat heart and circulatory diseases
Review question
We reviewed randomised trials (participants had an equal chance to be assigned to either treatment) examining effects of higher omega-
6 fats compared to lower omega-6 fats on deaths and heart and circulatory diseases (cardiovascular diseases (CVD), which include heart
attacks and strokes).
Background
Omega-6 fats are essential, we must obtain some from food. They are important for regulating energy production (part of metabolism),
bone, skin and hair health. Many foods contain omega-6 fats, particularly vegetable oils and nuts. Omega-6 fats include linoleic acid
(LA), gamma-linolenic acid (GLA), dihomo-gamma-linolenic acid (DGLA) and arachidonic acid (AA).
Some evidence suggests that a higher intake of omega-6 fats, along with a lower intake of saturated fat (from animal sources such as meat
and cheese) can reduce coronary heart disease. In contrast, there is concern that high levels of omega-6 fats may worsen cardiovascular
risk by increasing inflammation. Overall, there is no conclusive evidence on the benefits or harms of omega-6 fat intake on heart and
circulatory diseases or on other health outcomes.
Study characteristics
Evidence in this review is current to May 2017. We found 19 studies recruiting 6461 adults. These studies assessed the effects of
higher compared to lower omega-6 fat intake on heart and circulatory diseases as well as deaths. We found that three trials were highly
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trustworthy (with good designs that produce reliable evidence). Studies took place in North America, Asia, Europe and Australia, and
eight were funded only by national or charitable agencies. Participants increased their omega-6 fats or maintained their usual fats for
at least one year and up to eight years.
Key results
We found that increasing omega-6 fats may make little or no difference to deaths or cardiovascular events but may reduce risk of heart
attacks (low-quality evidence). Evidence was weakened by study design problems, small numbers of events, low numbers of participants
from developing countries, and few women.
Evidence suggests that increasing omega-6 fats reduces blood cholesterol (high-quality evidence), probably has little or no effect on
body weight adjusted for height (all moderate-quality evidence), and may make little or no difference to triglycerides, high-density
lipoprotein (HDL, the ’good’ cholesterol) or low-density lipoprotein (LDL, the ’bad’ cholesterol, low-quality evidence).
3Omega-6 fats for the primary and secondary prevention of cardiovascular disease (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Higher versus lower omega-6 for adults with or without CVD
Patient or population: adults with or without exist ing CVD
Setting: includes f ree-living part icipants and those living in inst itut ions. Includes part icipants f rom North America, Australia, Asia and Europe but most events occurred in
studies carried out in Europe or North America
Intervention: higher omega-6
Comparison: lower omega-6
Eligible trials compared higher with lower omega-6 fat (including LA, GLA, DGLA, AA, or any combinat ion) intakes. The intervent ion had to be dietary supplementat ion, or a
provided diet, or advice on diet
Outcomes Anticipated absolute effects* (95% CI) Relative effect
(95% CI)
of participants
(studies)
Certainty of the evi-
dence
(GRADE)
Comments
Risk with lower omega-
6
Risk with higher
omega-6
All-cause mortality
Study durat ion range
12-96 months
Omega-6 dose range 1.
5%-24.5%E
Study populat ion RR 1.00
(0.88 to 1.12)
4506
(10 RCTs)
⊕⊕©©
Lowa
Increasing omega-
6 fats may make lit t le
or no dif ference to risk
of all-cause mortality.
Downgraded once each
for risk of bias and im-
precision. As there was
no suggest ion of bene-
f it or harm the number
needed to treat (NNTB)
was inf inite (NNTB ,
95% CI NNTH 50 to
NNTB 50)
167 per 1000 167 per 1000
(147 to 187)
Cardiovascular mortal-
ity
Study durat ion range
24-96 months
Omega-6 dose range 2.
8%-24.5%E
Study populat ion RR 1.09
(0.76 to 1.55)
4019
(7 RCTs)
⊕©©©
Very lowb
We are
uncertain whether in-
creasing omega-6 fats
af fects CVD mortality
risk. Downgraded for
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risk of bias, imprecision
and inconsistency
114 per 1000 125 per 1000
(87 to 177)
Cardiovascular events:
any
Study durat ion range
12-96 months
Omega-6 dose range 2.
8%-24.5%E
Study populat ion RR 0.97
(0.81 to 1.15)
4962
(7 RCTs)
⊕⊕©©
Lowc
Increasing omega-6
fats may make lit t le or
no dif ference to risk of
cardiovascular events.
Downgraded once each
for risk of bias and im-
precision. 100 people
would need to increase
the amount of omega-6
fat in their diet to pre-
vent 1 person having a
CVD event (NNTB 100,
95% CI −21 to 17)
311 per 1000 301 per 1000
(252 to 357)
CHD events: myocar-
dial infarct ion (fatal or
non-fatal) or angina
Study durat ion range
12-96 months
Omega-6 dose range 2.
8%-24.5%E
Study populat ion RR 0.88
(0.66 to 1.17)
3997
(7 RCTs)
⊕©©©
Very lowd
We are
uncertain whether in-
creasing omega-6 fats
af fects CHD risk. Down-
graded for risk of bias,
imprecision and incon-
sistency
277 per 1,000 244 per 1000
(183 to 324)
MACCEs
Study durat ion range
24-96 months
Omega-6 dose range 2.
8%-12.0%E
Study populat ion RR 0.84
(0.59 to 1.20)
2879
(2 RCTs)
⊕©©©
Very lowe
We are uncer-
tain whether increas-
ing omega-6 af fects
MACCE risk. Down-
graded for risk of bias,
inconsistency and im-
precision
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295 per 1000 248 per 1000
(174 to 354)
Stroke: fatal or non-fa-
tal
Study durat ion range
24-96 months
Omega-6 dose range 2.
8%-21.9%E
Study populat ion RR 1.36
(0.45 to 4.11)
3730
(4 RCTs)
⊕©©©
Very lowf
We are uncer-
tain whether increas-
ing omega-6 fats af -
fects stroke risk. Down-
graded once for risk of
bias, twice for impreci-
sion
14 per 1000 20 per 1000
(7 to 59)
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
AA: arachidonic acid; CI: conf idence interval; CHD: coronary heart disease; CVD: cardiovascular disease; DGLA: dihomo-gamma-linolenic acid; GLA: gamma-linolenic acid; LA:
linoleic acid; MACCE: major adverse cardiovascular or cerebrovascular event; NNTB: number needed to treat for an addit ional benef icial outcome; NNTH: number needed to
treat for an addit ional harmful outcome; RCT : randomised controlled trial; RR: risk rat io; %E: percentage of energy intake f rom this nutrient.
GRADE Working Group grades of evidence
High certainty: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate certainty: we are moderately conf ident in the ef fect est imate: the true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low certainty: our conf idence in the ef fect est imate is lim ited: the true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low certainty: we have very lit t le conf idence in the ef fect est imate: the true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
aAll- cause mortality
• Risk of bias: two included trials were at low summary risk of bias, including 682 part icipants report ing 69 deaths.
Lim it ing analyses to these trials suggested that increasing omega-6 fats may increase mortality risk, as did lim it ing to
studies with no commercial funding. Other sensit ivity analyses suggested lit t le or no ef fect. It was further noted by the WHO
NUGAG Subgroup on Diet and Health that most studies did not report on allocat ion concealment or otherwise had unclear
risk of bias for allocat ion concealment. Although low risk of bias in other elements of bias assessment (e.g. randomisat ion,
blinding of outcome assessment) m ight suggest that the trials were well-conducted and thus allocat ion concealment may
have been maintained, many of the trials are older and detailed information on the conduct of the trials can be scarce.
Therefore, a conservat ive approach was taken. Downgraded once.
• Inconsistency: there was lit t le or no indicat ion of heterogeneity between trials (I2 < 30%). Not downgraded.
• Indirectness: Most data related to high-income countries, and trials of men, but included people with and without CVD at
baseline. Not downgraded.
• Imprecision: the 95%CI crossed the null and did not exclude important benef its or harms. Downgraded once.
• Publication bias: no suggest ion of publicat ion or small study bias in the funnel plot. Not downgraded.6
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bCardiovascular mortality
• Risk of bias: one included study with 458 part icipants, 62 of whom died of CVD, was at low summary risk of bias.
Lim it ing analyses to this trial suggested that increasing omega-6 fats may increase risk of CVD death, as did lim it ing to
studies without commercial funding, while trials at low risk of attent ion bias suggested benef it f rom increasing omega-6
fats. WHO NUGAG Subgroup on Diet and Health notes: ‘‘Most studies did not report on allocat ion concealment or otherwise
had unclear risk of bias for allocat ion concealment. Although low risk of bias in other elements of bias assessment (e.g.
randomisat ion, blinding of outcome assessment) m ight suggest that the trials were well-conducted and thus allocat ion
concealment may have been maintained, many of the trials are older, and detailed information on the conduct of the trials
can be scarce. Therefore, a conservat ive approach was taken. Downgraded once.
• Inconsistency: I2 > 60%. Downgraded for inconsistency.
• Indirectness: Most data related to high-income countries, and trials of men, but included people with and without CVD at
baseline. Not downgraded.
• Imprecision: the 95%CI crossed the null and did not exclude important benef its or harms. Downgraded once.
• Publication bias: f ewer than 10 included studies so no funnel plot run. Not downgraded.
cCardiovascular events
• Risk of bias: two included trials in 1525 part icipants, 68 of whom experienced at least 1 CVD event, were at low
summary risk of bias. This sensit ivity analysis, lim it ing to trials of low summary risk of bias, suggested that increasing
omega-6 fats increased risk of experiencing CVD events, as did lim it ing to studies with no commercial funding, while lim it ing
to studies at low risk of bias f rom attent ion dif ferences suggested benef it f rom increasing omega-6 fats. It was further noted
by the WHO NUGAG Subgroup on Diet and Health that most studies did not report on allocat ion concealment or otherwise
had unclear risk of bias for allocat ion concealment. Although low risk of bias in other elements of bias assessment (e.g.
randomisat ion, blinding of outcome assessment) m ight suggest that the trials were well-conducted and thus allocat ion
concealment may have been maintained, many of the trials are older and detailed information on the conduct of the trials can
be scarce. Therefore, a conservat ive approach was taken. Downgraded once.
• Inconsistency: I2 was between 30 and 60%. Not downgraded.
• Indirectness: Most data related to high-income countries, and trials of men, but included people with and without CVD at
baseline. Not downgraded.
• Imprecision: the 95%CI crossed the null and did not exclude important benef its or harms.Downgraded once.
• Publication bias: f ewer than 10 included studies so no funnel plot run. Not downgraded.
dCoronary heart disease events
• Risk of bias: one included study in 458 part icipants, 58 of whom experienced at least 1 CHD event, was at low summary
risk of bias. This study suggested an increased risk with higher omega-6 intake (RR 1.63, 95% CI 1.00 to 2.67), though this
was not mirrored in any other sensit ivity analysis. Lim it ing to pre-2010 or trials registry registered trials, those with no
commercial funding, those at low risk of attent ion bias and those that randomised at least 100 part icipants all suggested
some benef it of increasing omega-6 fats. It was further noted by the WHO NUGAG Subgroup on Diet and Health that most
studies did not report on allocat ion concealment or otherwise had unclear risk of bias for allocat ion concealment. Although
low risk of bias in other elements of bias assessment (e.g. randomisat ion, blinding of outcome assessment) m ight suggest
that the trials were well-conducted and thus allocat ion concealment may have been maintained, many of the trials are older
and detailed information on the conduct of the trials can be scarce. Therefore, a conservat ive approach was taken.
Downgraded once.7
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• Inconsistency: I2 > 60%. Downgraded once.
• Indirectness: Most data related to high-income countries, and trials of men, but included people with and without CVD at
baseline. Not downgraded.
• Imprecision: the 95%CI crossed the null and did not exclude important benef its or harms. Downgraded once.
• Publication bias: f ewer than 10 included studies so no funnel plot run. Not downgraded.
e Major adverse cardiac and cerebrovascular events
• Risk of bias: no included studies were at low summary risk of bias or were without commercial funding. All other
sensit ivity analyses suggested benef its f rom increasing omega-6 fats. Downgraded once.
• Inconsistency: I2 > 60%. Downgraded once.
• Indirectness: Most data related to high-income countries, and trials of men, but included people with and without CVD at
baseline. Not downgraded.
• Imprecision: the 95%CI crossed the null and did not exclude important benef its or harms. Downgraded once.
• Publication bias: f ewer than 10 included studies so no funnel plot run. Not downgraded.
f Stroke
• Risk of bias: one included study with 458 part icipants, 4 of whom experienced a stroke, was at low summary risk of
bias. Sensit ivity analyses including pre-2010 or trials registry registered trials, only trials without commercial funding and
larger trials all suggested that increasing omega-6 fats increased stroke risk, while the single study at low risk of attent ion
bias suggested reduced stroke risk, and f ixed-ef fect analysis suggested lit t le or no ef fect of increasing omega-6 fats. It was
further noted by the WHO NUGAG Subgroup on Diet and Health that most studies did not report on allocat ion concealment or
otherwise had unclear risk of bias for allocat ion concealment. Although low risk of bias in other elements of bias
assessment (e.g. randomisat ion, blinding of outcome assessment) m ight suggest that the trials were well-conducted and
thus allocat ion concealment may have been maintained, many of the trials are older and detailed information on the conduct
of the trials can be scarce. Therefore, a conservat ive approach was taken. Downgraded once.
• Inconsistency: I2 was between 30 and 60%. Not downgraded.
• Indirectness: Most data related to high-income countries, and trials of men, but included people with and without CVD at
baseline. Not downgraded.
• Imprecision: the 95%CI crossed the null and included large benef its (RR < 0.5) and large harms (RR > 2.0) f rom omega-6
fats. Downgraded twice.
• Publication bias: f ewer than 10 included studies so no funnel plot run. Not downgraded.
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B A C K G R O U N D
Description of the condition
Cardiovascular diseases (CVDs) are a group of conditions that af-
fect the heart and blood vessels (WHO 2017), and they include
cerebrovascular disease, coronary heart disease (CHD), and pe-
ripheral arterial disease (PAD). One mechanism thought to cause
CVD is atherosclerosis, which is when a person’s arteries become
narrowed by plaques or atheroma (NHS 2016). This narrowing
can lead to angina. Atherosclerosis can cause myocardial infarction
(MI) or stroke when part of the plaque breaks off and blocks a
smaller vessel, or when a blood clot is formed on the rough plaque
surface, blocking the vessel. A narrowed or blocked artery restricts
blood flow limiting the amount of blood and oxygen reaching or-
gans or tissue (BHF 2017). Arteries may narrow and become less
elastic with age, and the atherosclerotic process may accelerate un-
der conditions including smoking, high cholesterol, hypertension,
obesity, sedentary lifestyle, and specific ethnicity (NHS 2016).
Rupture of unstable plaques may also cause CVD by activating
an inflammatory response. This causes the atherosclerotic plaque
structure to weaken and rupture further, leading to superimposed
thrombosis (blood clots, Spagnoli 2007).
CVDs are the leading causes of death worldwide (WHO 2017).
In 2015 an estimated 31% of all global deaths were due to
CVD (WHO 2017). The burden of CVD also varies substantially
between regions (Müller-Nordhorn 2008), with low- and mid-
dle-income countries (LMICs) disproportionally affected (WHO
2017). In 2001, three-quarters of global deaths from CHD took
place in LMICs (Gaziano 2010), and in 2015 37% of premature
deaths (deaths before 70 years of age) in LMICs were from CVD
(WHO 2017). Gaziano 2010 suggested that this rapid increase in
CHD burden is attributable to increased lifespan, socioeconomic
changes and acquisition of behavioural risk factors.
Targeting modifiable risk factors, including dietary factors, for
CVDprevention is a key public health priority. Studies have found
a number of diet and dietary factors to be associated with CVD
risk, including low consumption of potassium, fruit and vegetables
(Aburto 2013b; AIHW 2016), as well as high intake of salt and
saturated fat (Aburto 2013a; Hooper 2015). Such risk factors are
extremely important since their modification has the potential to
lower CVD risk, making them a main target for CVD primary
prevention.
Description of the intervention
Polyunsaturated fatty acids (PUFAs) are characterised by the pres-
ence of at least two carbon-carbon double bonds. Omega-6 (n-6)
and omega-3 (n-3) fats are both PUFAs. The distinction between
omega-6 and omega-3 fats is based on the position and distance
of this double bond from the methyl group end of the fatty acid
molecule (Calder 2013; Hall 2009). For omega-6 fats, the double
bond pair is sixth from the methyl terminus while for omega-3
fats, it is third (Calder 2013; Harris 2009). Linoleic acid (LA) (18:
2n6), one of the omega-6 fats, is an essential fatty acid because
the human body is unable to synthesise it, so people must obtain
it through diet (Groff 1995). Gamma-linolenic acid (GLA, 18:
3n6), another omega-6 fat, may become conditionally essential
in the event of reduced activity of delta-6-desaturase (the enzyme
that converts LA into GLA, Rincón-Cervera 2009).
Other members of the omega-6 fats group include dihomo-
gamma-linolenic acid (DGLA) (20:3n6) and arachidonic acid
(AA) (20:4n6), which can be derived from LA and synthesised in
the healthy human body (though synthesis is minimal, Hussein
2005). LA is widely available in the diet from a variety of sources,
such as vegetable oils, nut oils, nuts, poultry, meat, egg, milk, mar-
garines and spreads (Russo 2009), while DGLA is not found in
the diet.
Omega-6 fats play a vital role in many physiological functions,
stimulating skin and hair growth, regulating metabolism and
maintaining bone health (Baylink 1993). However, evidence on
the effect of omega-6 fats on CVD risk remains controversial.
How the intervention might work
Dietary fat modification may improve CVD risk and risk factors.
Mensink 2003 searched for trials between1979 to1999 examining
effects of individual fatty acids on blood lipids.They included 60
trials randomising 1672 participants and suggested a beneficial
effect of PUFAs (including omega-6 fats) on blood lipids (Mensink
2003). Other studies suggest that a proportionally higher intake of
omega-6 fats along with a low intake of saturated fat is associated
with significant reductions in CHD (Katan 2009).
A meta-analysis of observational studies aimed to evaluate studies
assessing the relationship between blood/tissue omega-6 fat con-
tent and CHD events and was based on 25 case-control studies
with 1998 cases and 6913 controls. Harris 2007 found that LA
content of blood and tissues was inversely associated with CHD
risk, while AA was not related to CHD risk. A more recent meta-
analysis included only prospective cohort studies that provided
multivariate-adjusted risk estimates for dietary LA consumption
on CHD endpoints (Farvid 2014). The search identified 13 co-
hort studies that included 310,602 individuals and 12,479 CHD
events, including 5882 CHD deaths. Farvid 2014 reported an in-
verse relationship between LA intake and CHD events and deaths.
They estimated that replacing 5% of energy (5% E) from satu-
rated fat intake with LA would be associated with 9% lower risk of
CHD events and a 13% lower risk of CHD deaths (Farvid 2014).
These observational data are supported by a meta-analysis of eight
RCTs including 13,614 participants, which found that replacing
saturated fatty acids by increasing PUFA consumption, including
omega-6 fats, reduced the occurrence of CHDevents (Mozaffarian
2010). A Cochrane Review of RCTs investigated the effect of re-
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ducing or modifying dietary fats on total CVDmortality andmor-
bidity over at least sixmonths. The findings suggest thatmodifying
dietary fat by replacing saturated fats with monounsaturated fatty
acids or PUFAs reduces CVD risk (Hooper 2011). The American
Heart Association recommends replacing saturated and trans fats
with monounsaturated or polyunsaturated fats, stating that ”con-
sumption of at least 5% to 10% of energy from omega-6 PUFAs
reduces the risk of CHD relative to lower intakes“ (Eckel 2014;
Harris 2009).
However, there is concern that consuming a relatively high
proportion of dietary omega-6 fats compared with omega-3
fats increases production of 2-series prostaglandins and 4-series
leukotrienes to the detriment of 3-series prostaglandins and 5-
series leukotrienes. As the 2-series prostaglandins and 4-series
leukotrienes exert a more potent pro-inflammatory effect, and in-
flammation leads to increased blood clotting, omega-6 fats may
theoreticallyworsen cardiovascular risk (Russo 2009; Siriwardhana
2012; Tortosa-Caparós 2017). This relationship is disputed, but it
has led to the concept that the ratio between omega-6 and omega-
3 fats, rather than absolute intakes, may be crucial (Bibus 2015).
Increasing omega-3 fat intake may have different effects than re-
ducing omega-6 fat intakes, even though their effect on the ratio
may be identical (Bibus 2015). There is also concern that highly
unsaturated fatty acids such as AA may increase the susceptibility
of lipoproteins such as low- and very low-density lipoproteins to
oxidation, making them more atherogenic (Russo 2009).
Some studies have found no association between omega-6 fat in-
take and risk of CVD. Earlier prospective cohort studies found no
association between dietary intakes of omega-6 fats and stroke (He
2003), CHD (McGee 1984; Pietinen 1997), and CHDmortality
(Esrey 1996). Chowdhury 2014 conducted a systematic review of
prospective, observational studies and RCTs, reporting non-sig-
nificant associations between omega-6 fat supplementation and
coronary disease or outcomes.
Why it is important to do this review
Omega-6 fats are essential fatty acids that play a vital role in many
physiological functions, and everyone consumes some. There is
controversy concerning the effect of increasing the amount people
eat on cardiovascular risk. Although data tend to support a protec-
tive role for omega-6 fats in CVD, results from clinical trials and
observational studies are inconsistent. There is a need to review
the current evidence from randomised controlled trials (RCTs).
An up-to-date systematic review is required to clarify the associa-
tion between CVD risk and omega-6 fat intake. This can under-
pin guidance for national and international agencies, practition-
ers, and members of the public.
The World Health Organization (WHO) is currently updating
its guidance on polyunsaturated fatty acid intake in adults and
children. The update and extension of scope of this review was
commissioned by WHO in order to inform and contribute to
the development of updated WHO recommendations. The re-
sults of this review including GRADE assessments were discussed
and reviewed by the WHO Nutrition Guidance Expert Advisory
Group (NUGAG)SubgrouponDiet andHealth as part ofWHO’s
guideline development process. This review updates Al-Khudairy
2015 and forms a set with Abdelhamid 2018a (assessing effects
of omega-3 fats), Abdelhamid 2018b (which overviews health ef-
fects of increasing polyunsaturated fats generally), reviews of di-
abetes and glucose tolerance (Brown 2017), inflammatory bowel
disease (IBD) (Thorpe 2017), cognition (Jimoh 2017), depression
(Hanson 2017a), bone andmuscle health (Abdelhamid 2017), and
cancers (Hanson 2017b). This review systematically assessed ef-
fects of omega-6 fats on cardiovascular outcomes, mortality, lipids
and body fatness.
Weundertook thisCochraneReview to assess the current evidence.
The review extends Al-Khudairy 2015 in that it includes stud-
ies on participants with or without CVD at baseline and slightly
extends the outcomes of interest. We included RCTs that stated
an intention to increase omega-6 fats by following dietary advice,
omega-6 fat supplementation, or a provided diet, compared to
usual diets or diets providing fewer omega-6 fats. We examined
effects over longer time periods (at least 12 months) as these are
most relevant for public health interventions and assessing effects
on CVD events, deaths and adiposity.
O B J E C T I V E S
To assess the effects of increasing omega-6 fats (linoleic acid
(LA), gamma-linolenic acid (GLA), dihomo-gamma-linolenic
acid (DGLA) and arachidonic acid (AA)) for CVD and all-cause
mortality.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included randomised controlled trials (RCTs) that compared
higher versus lower omega-6 fat intake and assessed effects over at
least 12 months of continuous involvement. We included stud-
ies reported as full texts, those published as abstracts only, as tri-
als registry entries and/or unpublished data. We did not include
cross-over studies (unless we could use data from the first part of
the cross-over only), as this design is inappropriate for outcomes
such as CVD events or mortality, but we did include cluster-ran-
domised studies, as long as there were at least six clusters (to facil-
itate appropriate statistical testing, MRC 2002).
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Types of participants
We included studies in adults (18 years of age and above) regardless
of whether they were healthy, at increased risk of cancer, undergo-
ing - or had undergone - coronary artery bypass grafting or angio-
plasty, or if they had current or previous CVD, diabetes mellitus,
rheumatoid arthritis, depression, cognitive impairment or multi-
ple sclerosis. We were interested in both primary and secondary
prevention, so we included people with or without a history of
CVD.
We excluded participants who were pregnant or acutely ill, defin-
ing acute illness as having a current diagnosis of cancer, HIV or
AIDS; undergoing heart or renal transplantation; on haemodialy-
sis; with immunoglobulin A (IgA) glomerulonephritis; or having
any other renal problem except diabetic nephropathy. Our rea-
soning was to exclude people with conditions that may affect the
relationship between polyunsaturated fats and CVD events.
Where trials included some adults and some people under 18 years
of age, we included the study if at least 90% of the participants
were aged 18 years or over at baseline, or where outcomes for adults
could be separated from those for younger people.
Types of interventions
Eligible trials compared higher versus lower omega-6 fat (includ-
ing LA, GLA, DGLA, AA, or any combination) intakes. The in-
tervention had to be dietary supplementation, a provided diet, or
advice on diet. The advice, foodstuffs or supplements had to aim
to increase or decrease intake of omega-6 fats, or a dietary compo-
nent high in omega-6 fats such as sunflower oil, or, if no clear aim
was stated (but implied, such as aiming to provide a ’heart health’
or ’Mediterranean’ diet) then the intervention had to achieve an
increase or decrease of at least 10% of the baseline omega-6 fat
level. Energy replacement for changes in omega-6 fat intake could
be by carbohydrates, saturated fats, protein, alcohol, or monoun-
saturated fats.
Supplementation had to be in oil or capsule form, or as foodstuffs
provided to be consumed by mouth (we excluded enteral and
parenteral feeds and enemas).
We excluded studies that includedmultiple risk factor intervention
on lifestyle factors such as weight reduction, smoking or physical
activity, or differential dietary interventions not involving dietary
fats (except where that other intervention was a direct replacement
for polyunsaturated fats, or the effect of diet or supplementation
could be separated out from the other interventions).
Studieswere eligible if they compared the effect of this intervention
versus usual diet, no advice, no supplementation or placebo (as
appropriate) with a lower omega-6 fat intake. We excluded studies
that aimed to increase both omega-6 and omega-3 fats (these were
included in Abdelhamid 2018a).
Types of outcome measures
We included studies where data on any primary or secondary out-
come had been collected by the investigators.
Where it was clear that no participants experienced a particular
primary or secondary outcome (and data were not available on
other primary or secondary outcomes), we included the trial or
study arm in the review for comprehensiveness, but these did not
contribute data.
Primary outcomes
1. All-cause mortality
2. CVD mortality
3. CVD events (all available data on fatal and non-fatal
myocardial infarction, angina and/or stroke)
4. Coronary heart disease events: myocardial infarction (fatal
or non-fatal) or angina
5. Major adverse cardiac and cerebrovascular events
(MACCEs), used where we could assess the numbers of
participants experiencing fatal and non-fatal myocardial
infarction, unstable angina and stroke
6. Stroke (total, fatal and non-fatal, ischaemic and
haemorrhagic)
We assessed dichotomous outcomes at the latest point of available
follow-up within the RCT and continuous outcomes at the latest
point available in the trial (and after at least 12 months).
Secondary outcomes
1. Myocardial infarction (MI, total, fatal and non-fatal)
2. Angina
3. Sudden cardiac death
4. Atrial fibrillation (AF) (new or recurrent, ventricular
tachycardia and/or ventricular fibrillation)
5. Heart failure
6. Revascularisation (angioplasty or coronary artery bypass
grafting)
7. Peripheral arterial disease (PAD)
8. Serum lipids (including total cholesterol, fasting
triglycerides, high- (HDL) and low-density lipoprotein (LDL)
cholesterol)
9. Body mass index (BMI), body weight and other measures
of adiposity
Tertiary outcomes
1. Blood pressure (systolic and diastolic)
2. Quality of life measures (such as self-reported health and
time off work)
3. Economic costs
4. Serious adverse events (including breast cancer, all cancers,
inflammatory bowel disease, diabetes, depression, and
neurocognitive outcomes such as dementia)
We collated data on tertiary outcomes where they were present
in included trials (so we did not truly systematically review them
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in this paper). Data on cancers (Hanson 2017b), inflammatory
bowel disease (Thorpe 2017), neurocognitive outcomes includ-
ing dementia (Jimoh 2017), diabetes (Brown 2017), bone and
functional outcomes (Abdelhamid 2017), anddepression (Hanson
2017a) are reported fully and systematically in associated reviews
within this series.
Key outcomes
When the World Health Organization (WHO) Nutrition Guid-
ance Expert Advisory Group (NUGAG) requested this review up-
date they named the following as key outcomes to inform their
planned dietary guidance:
1. All-cause mortality
2. CVD mortality
3. CVD events
4. CHD events
5. Stroke
6. Myocardial infarction
7. Serum lipids including total cholesterol, fasting
triglycerides, HDL and LDL
8. Measures of adiposity (body weight and BMI)
We were not able make all of these key outcomes into primary
outcomes. However, because WHO NUGAG Subgroup on Diet
and Health will use these outcomes to underpin guidance, we
carried out sensitivity analyses, subgroup analyses and GRADE
assessment of quality of evidence for them, even when they were
not primary outcomes. We explained this change to our methods
in Differences between protocol and review.
Search methods for identification of studies
Electronic searches
We searched the following electronic databases on 2 May 2017 to
identify reports of relevant randomised clinical trials.
1. Cochrane Central Register of Controlled Trials
(CENTRAL; 2017 Issue 4) in the Cochrane Library.
2. Epub Ahead of Print, In-Process & Other Non-Indexed
Citations, MEDLINE Daily and MEDLINE Ovid (1946 to 2
May 2017).
3. Embase Classic and Embase Ovid (1947 to 1 May 2017).
We adapted the search strategy for MEDLINE (Ovid) from the
search strategy in Al-Khudairy 2015 (Appendix 1), and we used
the single search strategy to locate trials for this review and for
Abdelhamid 2018b. We adapted this complex strategy for use
in the other databases (Appendix 2). We applied the Cochrane
sensitivity and precision-maximising RCT filter to MEDLINE
(Ovid) andEmbase, applying terms recommended in theCochrane
Handbook for Systematic Reviews of Interventions (Lefebvre 2011).
As we were also running searches in April 2017 for a concurrent
Cochrane Review of the effects of omega-3 fats on health outcomes
(Abdelhamid 2018a), and there was a great deal of overlap between
the searches, the results of these searches were de-duplicated with
the results from the searches for this review and all the titles and
abstracts assessed as a single set. We created a dataset of RCTs that
compared higher versus lower omega-6 fats, omega-3 fats or total
PUFA in adults with a duration of at least six months. We used
this dataset as the wider study pool fromwhich to select studies for
all reviews (Abdelhamid 2018a; Abdelhamid 2018b; Abdelhamid
2017; Al-Khudairy 2015; Brown 2017; Hanson 2017a; Hanson
2017b; Jimoh 2017; Thorpe 2017).
We searched two clinical trials registers, ClinicalTrials.gov (
www.ClinicalTrials.gov) and theWHO International Clinical Tri-
als Registry Platform (ICTRP, www.who.int/ictrp/en), in Septem-
ber 2016 for registry entries of relevant completed and ongoing
studies.
Searching other resources
We checked included trials of relevant systematic reviews and
wrote to authors of included studies for additional studies and trial
data (including unpublished outcome data).
We attempted to obtain full-text translations and/or evaluations
of all relevant non-English articles. Where these were not available
we translated papers ourselves using our existing language skills
and language translation software.
Data collection and analysis
Selection of studies
All authors carried out screening, with each record being indepen-
dently screened by two review authors. We initially screened titles
and abstracts of all the potential studies identified as a result of
the searches and coded them as ’retrieve’ (eligible or potentially
eligible/unclear) or ’do not retrieve’. We retrieved the full text of
all records that either reviewer had coded for retrieval. Two re-
view authors (LH and one other reviewer) independently screened
the full texts, assessed studies for inclusion, and identified and
recorded reasons for exclusion of ineligible studies. We resolved
any disagreement through discussion or consulted a third reviewer
(AA). Where a study fit all our inclusion criteria except the re-
porting of any relevant outcomes, we wrote to the study author
to ask whether they had measured but not reported any outcomes
relevant to our review. Where we learnt that no primary or sec-
ondary outcome events had occurred (for example no deaths or
CVD events occurred and no continuous outcomes measured),
we included the study, but it did not contribute data to the meta-
analyses.
We identified and excluded duplicates and collated multiple re-
ports of the same study (as each study - rather than each report -
was the unit of interest in the review). We recorded the selection
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process in sufficient detail to complete a PRISMA flow diagram
and Characteristics of excluded studies table.
Data extraction and management
We developed a draft data collection form for collating study char-
acteristics and outcome data, then all reviewers piloted the formon
a single included study to standardise data extraction and improve
the data extraction form. All authors took part in data extraction.
Two review authors each extracted the following study character-
istics from included studies, independently and in duplicate.
1. Bibliographic details.
2. Trial registration database and number.
3. Methods: study design, total duration of study, details of
any ’run-in’ period, number of study centres and location, study
setting, withdrawals and date of study.
4. Participants: number randomised in each arm, number
analysed in each arm, mean age, age range, sex, health status,
baseline CVD risk and a brief description of participants. We
categorised baseline CVD risk as low (no specific CVD risk
factors in the inclusion criteria), moderate (people recruited on
the basis of hyperlipidaemia, diabetes, metabolic syndrome,
familial risk, high blood pressure, obesity or a high CVD risk
score) or high (those with existing CVD such as angina or a
previous stroke or myocardial infarction).
5. Interventions: intervention (including composition and
dose of omega-6 intake advised or supplement used),
comparison, concomitant medications and excluded
medications.
6. Outcomes: primary and secondary outcomes specified in
trial registry, data on outcomes reported in publications and by
contact with authors, time points reported.
7. Process data: mean and standard deviation (SD) of total
PUFA, omega-3 fat, omega-6 fat, total fat, saturated fat (SFA),
monounsaturated fat (MUFA) and trans fat intake plus
erythrocyte, serum or adipose tissue fatty acid status data in
intervention and control groups at latest point available during
RCT.
8. Trial funding and notable conflicts of interest of trial
authors.
We resolved disagreements between data extractions by consensus
and/or by involving a third reviewer (LH or AA). One review
author (AA or LH) transferred data into the Review Manager 5
file (RevMan 2014). We double-checked that data were entered
correctly from the agreed data extraction by comparing the data
presented in the systematic review with data extraction (AA, JB,
TB or LH).
Assessment of risk of bias in included studies
Two review authors independently assessed risk of bias for each
study, alongside data extraction, using the criteria outlined in the
Cochrane Handbook for Systematic Reviews of Interventions (Higgins
2011, all review authors carried out data extraction and assessment
of risk of bias). We resolved disagreements by discussion or by
involving another author (LH or AA). We assessed the risk of bias
according to the following domains.
1. Random sequence generation (selection bias).
2. Allocation concealment (selection bias).
3. Blinding of participants and personnel (performance bias).
4. Blinding of outcome assessment (detection bias).
5. Incomplete outcome data (attrition bias).
6. Selective outcome reporting (reporting bias).
7. Attention bias (another aspect of performance bias, where
the intervention or control groups receive more time and/or
attention from study or health personnel during the trial).
8. Compliance bias (we considered studies to be at low risk of
compliance bias when they assessed and clearly reported
compliance for both intervention and control arms, and where
most participants appeared to have taken at least 64% of the
intended PUFA dose).
9. Other risk of bias.
These are the domains of the Cochrane Risk of Bias tool, with the
exceptions of attention and compliance bias, which were specific
to our review. We followed recommendations in Higgins 2011,
recording funding data in the Characteristics of included studies
but not using them as a separate issue for assessing risk of bias.
We graded each potential source of bias as conferring high, low or
unclear risk of bias and provided details from the study and/or a
quotation from the study report together with a justification for
our judgment in the ’Risk of bias’ tables. We summarised the risk
of bias judgements across different studies for each of the domains
listed. Where information on risk of bias related to unpublished
data or correspondence with a trialist, we noted this in the ’Risk of
bias’ tables. Table 1 presents further details of how we interpreted
the risk of bias elements across studies.
Summary risk of bias
Schultz 1995 found that poorly concealed allocation was associ-
ated with a 40% greater effect size, so randomisation and allo-
cation concealment are core issues for all trials. Lack of blinding
is associated with bias, though smaller levels of bias than lack of
allocation concealment (Savovic 2012), especially in studies with
objectively measured outcomes (Wood 2008). Most of our out-
comes were objectively measured. Although we originally planned
to assess summary risk of bias for all included trials in the same
way across this review (Al-Khudairy 2015), the omega-3 review
(Abdelhamid 2018a), and the total PUFA review (Abdelhamid
2018b), we adopted a different approach after discussing the dif-
ferent nature of supplement trials compared to dietary advice or
food provision trials with the NUGAG Subgroup on Diet and
Health. Discussion centred on blinding for supplement-type trials
and on compliance for dietary advice type trials.
We considered supplement or capsule type trials to be at low sum-
mary risk of bias where we judged randomisation, allocation con-
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cealment, blinding of participants and personnel and blinding of
outcome assessors (selection, performance and detection bias) to
be adequate. All other trials were considered at moderate or high
risk of bias (a single category).
We considered dietary advice or all-food-provided type trials to be
at low summary risk of bias where we judged randomisation, allo-
cation concealment, and blinding of outcome assessors (selection
and detection bias) to be adequate. We considered all other trials
to be at moderate or high risk of bias (a single category).
Assessment of bias in conducting the systematic
review
We conducted this Cochrane Review according to the methods
used in Al-Khudairy 2015 and reported deviations from it in the
Differences between protocol and review section.
Measures of treatment effect
We analysed dichotomous data as risk ratios (RRs) with 95% con-
fidence intervals (CIs) and continuous data as mean difference
(MD) with 95% CIs. We presented continuous data with a con-
sistent direction of effect (as a smaller reading is generally bene-
ficial), with the exception of HDL cholesterol, where an increase
was beneficial.
We used change data (change from baseline to latest point in study
in each arm) for continuous data where available with appropriate
variance data. When change data were not available and baseline
data were comparable between arms, we used absolute data from
the latest point in each study arm.We considered absolute data too
different to use when the change in both arms (from baseline to
end data) was smaller than the baseline difference between arms.
Where continuous data were too different to use, we noted this in
the ’Outcomes’ section of Characteristics of included studies but
did not add data to meta-analyses.
We intended a narrative description of skewed data reported as
medians and interquartile ranges or as medians without variance
data. We added these data to forest plots to enable visual compari-
son of findings (thoughwe did not include these data inmeta-anal-
ysis). We intended to use standardised mean differences (SMD)
to combine data where trials used different scales to measure the
same variable (such as quality of life). We found no such data so
did not use SMDs.
Unit of analysis issues
Studies with multiple intervention groups
Within this review, most included studies with more than two
intervention arms also had separate control arms relevant to each
of the intervention arms, so we used the relevant control arm
for each of the intervention arms. We never had to use the same
control group twice. For the exceptions (NDHS Faribault 1968;
NDHS Open 1st 1968), we combined the intervention arms and
compared themwith the single control arm. Thismeant there were
no problems with study participants appearing more than once in
any forest plot.
Cluster-RCTs
For cluster-randomised trials, we planned to account for unit of
analysis issues by extracting a direct estimate of the required effect
measure (for example, a risk ratiowith its confidence interval) from
an analysis that accounted for the cluster design properly (for ex-
ample, an analysis based on a ’multilevel model’, a ’variance com-
ponents analysis’ or that used ’generalised estimating equations
(GEEs)’). Where these data were available, we would have used
them in meta-analysis using the generic inverse-variance method
(Higgins 2011). Where no such correct analysis of the cluster-
randomised data were available, we planned to use approximate
analyses using intracluster correlation coefficient (ICC) analysis as
outlined in the Cochrane Handbook for Systematic Reviews of In-
terventions (Higgins 2011, section 16.3.4). We identified no such
cluster randomised trials, so did not need this methodology.
Dealing with missing data
We contacted (or attempted to contact) the authors of all poten-
tially included, included and ongoing RCTs to request available
data on all of the study outcomes relevant to our set of reviews and
key information on risk of bias. We sent an email and a posted
letter to the corresponding author at the latest address we were
able to obtain (tracking latest publications inMEDLINE). Where
data on at least one review outcome were available, we included
the RCT and asked the authors to provide any additional data
about study methodology or risk of bias.
Where papers reported continuous results as change frombaseline,
we used these data, otherwise we used data at the latest point
available. We did not impute change data.
Assessment of heterogeneity
We used the I2 statistic to measure heterogeneity among the tri-
als in each analysis. Where we identified substantial heterogeneity
(assumed when I2 was greater than 60%, as 30% to 60% repre-
sents moderate heterogeneity and we were allowing for the varied
dietary interventions included as well as potential dose-response
effects) we reported it and explored possible causes by prespecified
subgroup analysis.
Assessment of reporting biases
We assessed reporting biases using a funnel plot where wewere able
to pool at least 10 trials.We ran a funnel plot for all-causemortality
and serum total cholesterol because these analyses included 10
trials. We did not create funnel plots for other outcomes, as fewer
than 10 trials were available for meta-analyses. We noted where
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we were aware of missing data. This occurred where trialists noted
measuring but not reporting an outcome (or not reporting it by
study arm), where continuous data were unbalanced at baseline, or
where trialists presented data as medians or as means but without
variance information.
Data synthesis
Weundertook meta-analyses only where we considered this mean-
ingful, i.e. where the treatments, participants and the underlying
clinical question were similar enough for pooling to make sense.
We carried out statistical analysis using RevMan 2014. We used
a random-effects model, as dietary interventions are complex and
somewhat heterogeneous by nature (more so than most medical
treatments), but we compared the results of random-effects and
fixed-effect meta-analyses in sensitivity analyses. As the random-
effects model assigns more weight to smaller studies, it is more
conservative and may lead to imprecise estimates of effect.We also
carried out sensitivity analyses to assess the effects of methodolog-
ical rigour, removing studies at moderate to high summary risk of
bias (for other sensitivity analyses see below).
When we judged evidence from dichotomous outcomes to be
low, moderate or high GRADE quality, we calculated the number
needed to treat for an additional beneficial outcome (NNTB) and
its 95% confidence interval using standard equations (Evidence
Based Medicine Toolkit 2008).
Subgroup analysis and investigation of heterogeneity
We explored the effects of omega-6 fat intake on all primary re-
view outcomes and also key review outcomes where these were
secondary outcomes in our review and included at least six studies
by subgroup. The planned subgroup analyses were by:
1. omega-6 fat type (primarily LA vs GLA);
2. intervention type (dietary advice, supplements (capsules),
supplemental foods or all foods provided);
3. replacement of SFA, MUFA, carbohydrate, protein or
alcohol with omega-6 fat;
4. baseline risk of CVD (low or moderate risk, equivalent to
primary prevention, or secondary prevention);
5. omega-6 fat dose (and dose-response, < 4% E from omega-
6 fats, 4% to 12% E from omega-6 fats and > 12% E from
omega-6 fats in the intervention compared with control). We
added the > 12% E subgroup post hoc to provide some
separation between studies with a wide range of higher doses.
The original 4% E cut-off was suggested when the PICO
question for the review was set out as part of a 2016 WHO
NUGAG Subgroup on Diet and Health meeting;
6. trial duration: studies with medium follow-up (12 to 23
months), medium to long follow-up (24 to 47 months), and
long follow-up (48 months or more). There was some discussion
within WHO NUGAG Subgroup on Diet and Health about
whether to limit trials to those of at least two years’ duration, but
as some proposed omega-6 fat mechanisms may affect
cardiovascular health more quickly (anti-thrombotic and anti-
inflammatory mechanisms for example), we agreed to include
trials of at least 12 months, subgrouping to assess for duration
effects;
7. statin use (at least 50% of control group on statins versus
fewer than 50% on statins);
8. baseline omega-6 fat intake (we used omega-6 fat intake
where available, but otherwise used baseline PUFA intake,
usually mostly LA, where this was available): < 5% E from
omega-6 fats, 5% to < 8% E from omega-6 fats, ≥ 8% E from
omega-6 fats, with cut-offs based on recommendations that
populations should consume 5% to 8% of dietary energy from
omega-6 fats (WHO 2003); and
9. participants’ sex.
We also planned to subgroup by change in the omega-3/omega-
6 fat ratio (assessing whether the intervention primarily increased
omega-3 fats (putting up the ratio) or omega-6 fats (lowering the
ratio)). However, we rarely had enough information to calculate
this ratio so did not carry out the subgroup analysis.
WHO NUGAG Subgroup on Diet and Health requested these
analyses to better help them understand the data. The danger of
having so many subgroup analyses is over-interpretation, increas-
ing the risk of a type 1 error.We used the formal test for subgroup
interactions in RevMan 2014 to minimise this risk.
Meta-regression
We used meta-regression to further explore effects of omega-6 fat
dose (looking for evidence of dose response), baseline omega-6 fat
dose and duration on primary outcomes. We used the dataset of
all included trials (of at least 12 months’ duration) that reported
each outcome from this review and its sister reviews (omega-6 fat
trials from this review, omega-3 fat trials from Abdelhamid 2018a,
and total PUFA trials from Abdelhamid 2018b) to assess effects of
omega-6 fat dose. We also used the set of trials within this review
alone to assess relationships between omega-6 fat dose, baseline
omega-6 dose and duration with each of the dichotomous primary
outcomes with at least seven included trials.
We carried out random-effects meta-regression, as described in
Berkley 1995, using the STATA command metareg (Sharp 1998):
log(e) relative risk vs (dose or primary/secondary prevention or
type of intervention or risk of bias or duration), weighted by the
standard error of the log(e) relative risk. Where there were no
events in one armwe added 0.1 to the numbers for both groups (so
we would have entered a trial with 10 people experiencing stroke
in one arm but none in the other arm as 10.1 and 0.1).
Sensitivity analysis
We carried out the following sensitivity analyses on all primary
outcomes (regardless of the number of included trials) as well as
15Omega-6 fats for the primary and secondary prevention of cardiovascular disease (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
on secondary outcomes that were key outcomes and where at least
six trials provided data. These were our main sensitivity analyses.
1. Using fixed-effect meta-analysis.
2. Limiting analyses to studies at low summary risk of bias.
These were additional sensitivity analyses.
1. Only including all studies up to 2010, plus studies post-
2010 that were registered on a trials register (Roberts 2015).
2. Only including studies with no industry funding (where
funding was stated, but did not include any commercial funds or
gifts).
3. Only including studies with less than 10% difference in
intake of trans fats between study arms during the intervention
(trans fats are formed when solidifying polyunsaturated oils so
may have been given at increased doses in early diets high in
omega-6 fats where those fats were solidified to use in margarines
and baking - however, we now know that they are likely to
increase our risk of CVD so may confound any beneficial effects
of increasing omega-6 fats).
4. Only including studies with a low risk of attention bias.
5. Only including studies that randomised at least 250
participants, or at least 100 participants.
Unfortunately almost no data on trans fats were available, so we
did not perform sensitivity analyses around this variable.
’Summary of findings’ tables
Outcome data were interpreted as follows:
1. Is there an effect? (options were ‘increased risk’, ‘decreased
risk’, or ‘little or no effect’). Our main outcome measure was RR
so we decided on existence of an effect using RR. RR <8% (RR
<0.92 or >1.08) for the highest quality evidence suggested
increased or decreased risk (otherwise little or no effect). The
presence or not of an effect was decided on the RR for the main
analysis and sensitivity analyses.
2. Quality of evidence was assessed using GRADE assessment
for key outcomes. We used the five GRADE considerations
(study limitations, consistency of effect, imprecision, indirectness
and publication bias) to assess the quality of the body of evidence
as it related to the studies that contributed data to the meta-
analyses for the prespecified outcomes. We used methods and
recommendations described in Section 8.5 and Chapter 12 of
the Cochrane Handbook for Systematic Reviews of Interventions
(Higgins 2011), plus GRADEpro GDT software (GRADEpro
GDT 2015). We justified all decisions to downgrade the quality
of studies using footnotes and made comments to aid reader’s
understanding of the review.
3. Where there was a suggested effect the size of effect was
assessed using the NNT or ARR.
We created a ’Summary of findings’ table for the primary out-
comes.
1. All-cause mortality
2. CVD mortality
3. CVD events
4. Coronary heart disease events
5. Major adverse cardiac and cerebrovascular events
6. Stroke
To enable readers to easily access data on the key outcomes that
were secondary outcomes in this review, and which were also for-
mally systematically reviewed, we created a second ’Summary of
findings’ table for key secondary outcomes.
1. Myocardial infarction
2. Total serum cholesterol
3. Serum triglycerides
4. Low-density lipoprotein
5. High-density lipoprotein
6. Body weight
7. Body mass index
R E S U L T S
Description of studies
Results of the search
The electronic searches for the full set of reviews (populating the
dataset of all trials that assessed effects of higher versus lower
omega-6 fats, omega-3 fats or PUFA over at least six months) gen-
erated 37,810 titles and abstracts, or 19,772 unique records af-
ter de-duplication. We assessed these along with 53 previously in-
cluded studies (from Al-Khudairy 2015 and Abdelhamid 2018a,
to reassess for inclusion), 986 potentially relevant trials registry
entries and 35 new references gained from other systematic review
reference lists, so that we assessed a total of 20,846 titles and ab-
stracts in duplicate to decide on potential inclusion. We retrieved
2155 full texts, including 226 systematic reviews and 1929 papers
whose full text we assessed in duplicate for inclusion and to group
into studies. Of these, we included 208 RCTs of omega-3 fats,
omega-6 fats or total PUFA interventions with a duration of at
least 24 weeks, regardless of what outcomes were reported in our
wider study pool. This was the pool of trials we used for the full set
of reviews. Of this pool, 28 studies assessed the effects of omega-
6 fats, and of these, 19 were of at least 12 months’ duration and
are included in this review.
We identified a single ongoing trial, which we describe in
Characteristics of ongoing studies. Figure 1 presents details of the
flow of studies.
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Figure 1. Study flow diagram.
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Included studies
Details of methods, participants, intervention, comparison,
and outcome measures for each included trial are shown in
Characteristics of included studies. We found that 19 trials in-
cluding 6461 randomised participants met the inclusion criteria.
Trial duration varied from one year (our minimum for inclusion)
up to eight years (Veterans Admin 1969), with a median of 24
months and mean duration of over 31 months (for the 17 trials
that provided data for the review). However, the mean duration
of participants experiencing the intervention was slightly shorter
(as participants dropped out over time).
Participants in 17 of the 19 included trials had experienced at
least one outcome event or had a relevant continuous outcome
measured.We included twoother trials in the review aswe are fairly
certain that no deaths or CVD events occurred in participants,
and none of our continuous outcomes were assessed (Belch 1988;
Mansel 1990).One trial provideddata on twouseful comparisons (
Bates 1977); however, althoughmortality appears to have occurred
in several arms, the numbers of deaths are no longer available to the
authors (for this reason we included both arms but they constitute
missing data that could not be used in the all-causemortalitymeta-
analysis). Another trial ran two comparisons (Bates 1978), but no
deaths or other events occurred in one comparison (so the relevant
intervention and control arms are included but not represented
in the analyses); only the other comparison is included in meta-
analyses. The 2 × 2 × 2 factorial trial only provided one comparison
relevant to this review (DART 1989), and we combined several
smaller arms into a single comparison for NDHS Faribault 1968
and NDHS Open 1st 1968. All in all, we included 19 trials, 17 of
which contributed data to 18 comparisons. No cluster-RCTs met
the inclusion criteria.
Ten trials recruited bothmen and women, butDART 1989,MRC
1968, NDHS Faribault 1968, NDHS Open 1st 1968, Sydney
Diet-Heart 1978 and Veterans Admin 1969 recruited only men,
one trial recruited 94% women (Belch 1988), and one trial only
women (Mansel 1990). One trial did not specify the sex of its
participants (Rose 1965). Participants were generally of early to
late middle age, but some studies included a few older adults (aged
65 years or more). Mean age of study participants ranged from 33
years in Bates 1978 to 65 years in Veterans Admin 1969, with a
median mean age of 50 years in the 13 trials that reported mean
age (estimated as 50 years in NDHS Faribault 1968 and NDHS
Open 1st 1968, which included participants aged 45 to 54 years).
Bates 1977 andHoutsmuller 1979 did not report age details, while
Mendis 2001 recruited participants aged 22 to 55 years; Mansel
1990, women aged 36 to 60 years; and MRC 1968, participants
aged less than 60 years.
The trials varied in the types of participants recruited and their
level of CVD risk. Participants in 10 trials were at low risk of
CVD. Bates 1977 and Bates 1978 recruited people with multi-
ple sclerosis; NDHS Faribault 1968, men living in mental hospi-
tals; Veterans Admin 1969, men living in a Veterans Administra-
tion Centre; Schirmer 2007, healthy adults following weight loss;
Mendis 2001, healthy adults; McIllmurray 1987, people follow-
ing treatment for colorectal cancer; Black 1994, people with non-
melanoma skin cancer; Mansel 1990, women with breast cysts;
Belch 1988, people with rheumatoid arthritis; and NDHS Open
1st 1968, free-livingmenwithout particularCVDrisk or other dis-
ease. Three trials included people atmoderate CVDrisk (GLAMT
1993 recruited people with mild diabetic neuropathy; Dullart
1992, people with diabetes; and Houtsmuller 1979, people with
newly diagnosed diabetes), while five trials included those with
existing CVD (DART 1989, MRC 1968 and Sydney Diet-Heart
1978 recruitedmen followingmyocardial infarction; Vijayakumar
2014, people with stable coronary artery disease; and Rose 1965,
people with ischaemic heart disease).
Five trials took place in North America (Black 1994; NDHS
Faribault 1968; NDHS Open 1st 1968; Schirmer 2007; Veterans
Admin 1969), 1 in Australia (Sydney Diet-Heart 1978), 2 in Asia
(Mendis 2001; Vijayakumar 2014), and 11 inEurope (Bates 1977;
Bates 1978; Belch 1988, DART 1989; Dullart 1992; GLAMT
1993;Houtsmuller 1979;Mansel 1990;McIllmurray 1987;MRC
1968; Rose 1965).
The interventions and controls varied. Seven trials assessed effects
of GLA: providing supplementary capsules, of GLA plus LA vs
oleic acid (both comparisons of Bates 1977 and the single in-
cluded comparison of Bates 1978), GLA versus monounsaturated
fats (Schirmer 2007), GLA capsules versus paraffin (Belch 1988;
GLAMT 1993; Mansel 1990), or GLA versus an ’inert placebo’
that was not described further (McIllmurray 1987). Twelve trials
altered LA intake, most increasing LA in the intervention arm,
but Black 1994 aimed to reduce total fat intake in the interven-
tion arm, reducing LA intake in the process (this trial was en-
tered in meta-analysis with the control arm as the higher omega-
6 fat arm). In some trials the LA mainly replaced a single dietary
component, but in others LA replaced several components (the
description below is not additive). No studies assessed effects of
DGLA or AA. The omega-6 fat dose delivered was the difference
between omega-6 fats in the intervention and the control. Doses
ranged from 0.8% of energy intake (% E) from omega-6 fats in
Schirmer 2007 to 20.6% E in Rose 1965. Eight trials provided
a dose of less than 4% E from omega-6 fats (Bates 1977; Bates
1978; Belch 1988; Black 1994; DART 1989; McIllmurray 1987;
Mendis 2001; Schirmer 2007); six trials, 4% to 12% E (Dullart
1992;GLAMT1993;Houtsmuller 1979; NDHSOpen 1st 1968;
Sydney Diet-Heart 1978; Veterans Admin 1969); and four trials,
a dose of over 12% E omega-6 fats (MRC 1968; NDHS Faribault
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1968; Rose 1965; Vijayakumar 2014). Baseline omega-6 fat intake
was less than 5% E in three trials (NDHS Faribault 1968; NDHS
Open 1st 1968; Veterans Admin 1969), 5% to < 8% E in three
trials (DART 1989; Dullart 1992; Sydney Diet-Heart 1978), and
at least 8% E in one trial (Black 1994). The remaining 12 trials
did not report baseline intake.
As the omega-6 fat LA rose, saturated fat intake fell in nine
trials (DART 1989; Dullart 1992; Houtsmuller 1979; MRC
1968; NDHS Faribault 1968; NDHS Open 1st 1968; Sydney
Diet-Heart 1978; Veterans Admin 1969; Vijayakumar 2014),
MUFA fell in five (NDHSFaribault 1968;NDHSOpen1st 1968;
Rose 1965; SydneyDiet-Heart 1978; Veterans Admin 1969), both
carbohydrates and protein intake fell in one (Black 1994), and
carbohydrates fell in one other (Houtsmuller 1979). For Mansel
1990, Mendis 2001 and Belch 1988 the replacement for omega-
6 LA was unclear, and in MRC 1968, while LA partially replaced
SFA the remainder of the replacement was unclear. Readers should
keep in mind that we have assessed these effects from either the
trial’s intentions or reported intakes in both arms, but papers fre-
quently omit the mention of important dietary components; re-
placement can be considered our best understanding, but it is not
definitive.
Included trials were published over 50 years between 1965 and
2014, with five published during the 1960s, four during the 1970s,
three during the 1980s, four during the 1990s, two during the
2000s and one in 2014.
Mansel 1990 andRose 1965 didnot report funding sources. Fund-
ing appeared to be purely from national or charitable agencies in
eight trials (Black 1994;Dullart 1992;Houtsmuller 1979;Mendis
2001; MRC 1968; NDHS Faribault 1968; NDHS Open 1st
1968; Sydney Diet-Heart 1978). A further six trials had funding
from mixed national or charitable sources, with some products or
funding appearing to come from commercial sources (Bates 1977;
Bates 1978; Belch 1988; DART 1989; Veterans Admin 1969;
Vijayakumar 2014). Three trials acknowledged only commercial
funding sources or sources of intervention products (GLAMT
1993; McIllmurray 1987; Schirmer 2007).
The single ongoing trial we identified was in people with pre-dia-
betes, comparing a low fat diet with raised PUFA to SFA ratio ver-
sus a control diet over three years (Chandrakala 2010). The authors
have presented this study in several conference abstracts, without
usable outcome data. They confirmed that it is not yet fully pub-
lished anddeclined toprovide further information (Characteristics
of ongoing studies).
Excluded studies
We have presented details and reasons for exclusion of the studies
thatmost closelymissed the inclusion criteria in theCharacteristics
of excluded studies table. Appendix 3 lists studies of less than
12 months’ duration (as there were so many). Other than short
duration, themost common reasons for exclusion of studies were a
non-RCT design or an inappropriate intervention or comparison.
Risk of bias in included studies
We have provided details regarding the risk of bias judgements for
the included trials in the ’Risk of bias’ tables in Characteristics of
included studies, with details of how wemade specific judgements
in Table 1. We have presented a ’Risk of bias’ summary in Figure
2.
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Figure 2. ’Risk of bias’ summary: review authors’ judgements about each ’Risk of bias’ item for each
included study.
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We judged three studies to be at low summary risk of bias (NDHS
Faribault 1968;NDHSOpen1st 1968; SydneyDiet-Heart 1978).
All three were dietary advice trials, so they were at low risk of bias
from random sequence generation, allocation concealment and
blinding of outcome assessors. We considered the remaining 16
trials to be at moderate to high risk of bias.
Allocation
We judged 10 of the 19 studies to be at low risk of bias for ran-
dom sequence generation, while the remainder were at unclear
risk (often simply described as ”randomised“ in the Methodology
sections). We considered only four trials to be at low risk of bias
for allocation concealment (Dullart 1992; NDHS Faribault 1968;
NDHS Open 1st 1968; Sydney Diet-Heart 1978), with the rest
providing too few details of the randomisation process to make a
judgement. This was despite trying to elicit information on the
process of randomisation from authors. When asking open ques-
tions about the randomisation process, many authors quoted or
referred to their published papers or stated that they did not re-
member. We did not push further with these questions, as asking
closed questions was likely to elicit inappropriate answers.
Blinding
Blinding of participants and personnel is often very difficult in di-
etary trials, but we considered 9 of the 19 studies to be at low risk of
performance bias. This included five capsule-supplemented trials
(Bates 1977; Bates 1978; Belch 1988; GLAMT 1993; Schirmer
2007), three institutional or shop-based studies where participants
received all or most food (NDHS Faribault 1968; NDHS Open
1st 1968; Veterans Admin 1969), and one study providing oils
to both intervention and control groups (Rose 1965). Lack of
blinding of participants and/or personnel put six trials at high risk
of bias (Black 1994; DART 1989; Dullart 1992; Mendis 2001;
MRC 1968; Sydney Diet-Heart 1978), while the remaining stud-
ies were at unclear risk.We considered nine studies to be at low risk
of detection bias for blinding of outcome assessors (Black 1994;
DART 1989; MRC 1968; NDHS Faribault 1968; NDHS Open
1st 1968; Rose 1965; Schirmer 2007; Sydney Diet-Heart 1978;
Veterans Admin 1969), while this domain was unclear in the re-
mainder.
Incomplete outcome data
We judged 11 trials to be at low risk of attrition bias (Bates 1978;
Black 1994; Belch 1988; DART 1989; Mansel 1990; NDHS
Faribault 1968; NDHS Open 1st 1968; Rose 1965; Sydney Diet-
Heart 1978; Veterans Admin 1969; Vijayakumar 2014), 4 at high
risk (GLAMT 1993; Mendis 2001; MRC 1968; Schirmer 2007),
and the remainder at unclear risk.
Selective reporting
We did not find a pre-published trials registry entry or protocol
for any of the included studies (most were published many years
before trials registries became available), so we found all to be at
unclear risk of reporting bias.
Other potential sources of bias
We assessed risk of bias from differences in trialists’ attention or
time between arms (attention bias) and compliance problems, as
well as noting any other sources of bias.
We noted high risk of attention bias for five dietary advice trials
where the control participants were told to consume their normal
diets (Black 1994;DART1989;Dullart 1992;MRC1968; Sydney
Diet-Heart 1978). The remaining 14 trials were judged at low risk
of attention bias.
We judged compliance adequate (at low risk of causing bias) for
seven trials (Black 1994; DART 1989;Houtsmuller 1979; NDHS
Faribault 1968; NDHS Open 1st 1968; Schirmer 2007; Sydney
Diet-Heart 1978), poor in six where biomarkers suggested that
dietary goals had not altered omega-6 fats appreciably (Bates 1978;
Dullart 1992; Mendis 2001; Rose 1965; Veterans Admin 1969;
Vijayakumar 2014), and unclear in the remaining six.
We did not note sources of other bias in 16 trials (resulting in
low risk of other bias), but McIllmurray 1987 did not specify the
composition of their placebo capsules, and Mendis 2001 did not
state the form or composition of the intervention or control fats,
resulting in unclear risk of other bias.We foundHoutsmuller 1979
to be at high risk of other bias as concerns about fraud of the first
author were raised around his later research (on cancer diets), and
numbers of events were unclear by arm and had to be assessed
across several unclear publications. Additionally, this study was
extremely vague across all publications about its methods.
Effects of interventions
See: Summary of findings for the main comparison Higher
versus lower omega-6: primary outcomes; Summary of findings
2 Higher versus lower omega-6: additional key outcomes
Primary outcomes
See Summary of findings for the main comparison.
All-cause mortality
Increasing omega-6 fats may make little or no difference to the
risk of all-cause mortality (low-quality evidence, downgraded for
risk of bias and imprecision, Summary of findings for the main
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comparison). This section reports the data and gives the reasoning
for this assessment.
Ten trials contributed data to assess effects of increasing omega-6
fats on all-cause mortality, with 740 deaths in 4506 participants
(Figure 3; Analysis 1.1). We found little or no effect of increasing
omega-6 fats on mortality (RR 1.00, 95% CI 0.88 to 1.12) and
this lack of effect was consistent across trials (I2 = 0%). The funnel
plot for all-cause mortality did not suggest serious small study bias
(not shown), but we are aware of some missing data on all-cause
mortality. Some deaths occurred in Bates 1977, but the trialists no
longer have access to this information (7 of 76 randomised partic-
ipants died or withdrew in the two intervention arms and 11 of 76
in the two control arms). There were also deaths in Houtsmuller
1979, but we knowonly numbers of CHDdeaths.Wewere unable
to establish contact with authors of two trials (that randomised
111 participants between them), which appeared eligible for in-
clusion but where no deaths or other relevant outcomes were re-
ported, so these may include some further missing data (Harbige
2007; Millar 1973).
Figure 3. Forest plot of comparison: 1 Primary outcomes - higher omega-6 vs lower omega-6, outcome: 1.1
All-cause mortality (overall).
Sensitivity analyses limited to studies at low risk of summary bias
(RR 1.54, 95% CI 0.98 to 2.41, 69 deaths in two trials; Analysis
1.3) or using fixed-effect meta-analysis did not alter this lack of
effect (RR 1.00, 95% CI 0.89 to 1.13; Analysis 1.2). Other sen-
sitivity analyses, limited to studies: up to 2010, plus studies post-
2010 that were registered on a trials register (Roberts 2015); with
no industry funding; with a low risk of attention bias; randomising
at least 250 participants, or at least 100 participants; all concurred
in suggesting little or no effect of omega-6 fats on all-cause mor-
tality (Analysis 1.3). We intended another sensitivity analysis with
studies reporting less than 10% difference in intake of trans fats
between study arms during the intervention, but as information
on trans fats was almost completely lacking we did not attempt it.
None of the subgroup analyses, by omega-6 fat type (Analysis 1.4),
intervention type (Analysis 1.5), energy replacement (Analysis
1.6), primary or secondary prevention of CVD (Analysis 1.7),
omega-6 fat dose (Analysis 1.8), trial duration (Analysis 1.9), statin
use (Analysis 1.10), baseline omega-6 fat intake (Analysis 1.11)
or participant sex (Analysis 1.12) suggested important differences
between subgroups or any effect of omega-6 fats on all-cause mor-
tality. Trials often failed to report baseline omega-6 fat intake, and
where feasible we estimated this from omega-6 fat or PUFA goals
or dietary intake data. Replacement data were also unclear, but
we considered dietary factors that reduced as omega-6 fat intake
went up (or vice versa) to be replacements, and we assessed them
separately from other dietary changes aimed at or assessed. The
extent in the change in omega-3/omega-6 fat ratio was generally
unclear, so we did not use this subgrouping.
There was no suggestion of any effect of omega-6 fats on all-cause
mortality or heterogeneity among studies (RR 1.0 and I2 = 0%),
andmeta-regression did not suggest any relationships between risk
of all-cause mortality and omega-6 fat dose in trials across the
omega-6, omega-3 and total PUFA reviews, or from this review
alone (P = 0.82); baseline omega-6 intake (P = 0.68); or trial
duration (P = 0.87).
More than half of the weight of the meta-analysis came from one
study, Veterans Admin 1969, with a further 24% from DART
1989.VeteransAdmin 1969 andDART1989 both included a sub-
stantial number of person-years (Veterans Admin 1969 included
846 men for an average of 4 years, or 3384 person-years, while
DART 1989 included 2033 men for an average of 1.79 years, or
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3639 person-years). Veterans Admin 1969 had longer follow-up,
allowing more time for effects of the intervention to be expressed.
The death rate in Veterans Admin 1969 was 10% per year while in
DART 1989 it was 6% per year, perhaps reflecting socioeconomic
and age differences. Veterans Admin 1969 participants were older,
so more likely to die, with a mean age of 65 (up to 88 years) com-
pared to DART 1989 with a mean age of 56 (all aged < 70 years).
In GRADE assessment, we downgraded the data for risk of bias
(there was a suggestion that increasing omega-6 fats increased risk
of death in the two trials at low summary risk of bias) and im-
precision (the 95% CI crossed the null). Increasing omega-6 fats
may make little or no difference to risk of all-cause mortality (low-
quality evidence, Summary of findings for the main comparison).
As there is no suggestion of protection or harm the number needed
to treat for an additional beneficial outcome (NNTB) is infinitely
large - an infinite number of people would need to increase the
amount of omega-6 fat in their diet to prevent one person dying
of any cause (NNTB , 95% CI NNTH (number needed to treat
for an additional harmful outcome) 50 to NNTB 50).
Cardiovascular mortality (CVD mortality)
We are uncertain whether increasing omega-6 fats alters risk of
CVD mortality, as the quality of evidence was very low (down-
graded for risk of bias, imprecision and inconsistency, Summary
of findings for the main comparison).
There was important heterogeneity between trials increasing
omega-6 fats when assessing effects on CVD mortality (RR 1.09,
95% CI 0.76 to 1.55, I2 = 61%, 472 CVD deaths in 4019 partici-
pants randomised into 7 trials, Analysis 1.13). Effects in included
trials varied from statistically significantly protective (Veterans
Admin 1969, 138 CVD deaths, taking 26% of the weight of the
meta-analysis) to almost statistically significantly harmful (Sydney
Diet-Heart 1978, 62 CVD deaths and DART 1989 with 205
CVD deaths, taking 20% and 28% of the weight in the meta-
analysis, respectively). This variation in effects in different trials
results in a high level of heterogeneity (I2 = 61%). Effects in sensi-
tivity (Analysis 1.14; Analysis 1.15) and subgroup analyses appear
to depend on which of these trials we included in each analysis
or subgroup. This heterogeneity led to downgrading for inconsis-
tency in GRADE assessment. As there were only seven trials we
did not create a funnel plot.
One included trial was at low summary risk of bias (RR 1.59,
95% CI 0.99 to 2.55, 62 people died of CVD). Because this
trial suggested that increasing omega-6 intake may increase risk of
CVD deaths, we downgraded for risk of bias in GRADE, Analysis
1.15). No included trials had published protocols or trials register
entries, but all were published before 2010. Almost all CVDdeaths
occurred in men and in high-income countries.
All included trials increased LA, and all were in low statin use tri-
als. Subgrouping by baseline omega-6 fat intake reduced hetero-
geneity and suggested significant differences between subgroups
(Analysis 1.21), though there were few trials in each subgroup. The
data suggested that in populations with low omega-6 fat intake
(< 5% E) additional omega-6 fats may be beneficial, but as base-
line omega-6 fat intake increases there is suggestion that adding
more leads to harm. Subgroup analysis by intervention type sug-
gested a significant difference between subgroups, with harmful
effects of omega-6 fat suggested in four dietary advice trials (RR
1.33, 95% CI 0.86 to 2.05, I2 = 38%), and beneficial effects in
the single trial where all foods were provided (RR 0.70, 95% CI
0.51 to 0.96), with a statistically significant difference between
subgroups (P = 0.04, Analysis 1.16). Subgrouping by primary or
secondary prevention of CVD did not suggest important differ-
ences between subgroups but did reduce heterogeneity and sug-
gested harmful effects of omega-6 fat in secondary prevention tri-
als (Analysis 1.18). None of the other subgroup analyses, by en-
ergy replacement (Analysis 1.17) or participant sex (Analysis 1.22)
suggested significant differences between subgroups.
We did not note dose-response or duration effects; higher omega-
6 fat dose and longer duration appeared to cause smaller effects
of omega-6 fats on CVDmortality (Analysis 1.19; Analysis 1.20),
which is counterintuitive. Meta-regression did not suggest any
relationships between risk of CVD mortality and: omega-6 fat
dose in the wider set of trials (P = 0.81), omega-6 fat dose in
trials of this review alone (P = 0.64), baseline omega-6 intake (P
= 0.29) or trial duration (P = 0.13). However, as there were only
seven included trials in this review we had very little power to see
any potential relationships, and this lack of power was exacerbated
with regard to omega-6 baseline intake, as several studies did not
report this measure.
We found that effects of omega-6 fats onCVDdeathswere unclear,
as results were imprecise, inconsistent and at risk of bias, so we
assessed evidence as being of very lowquality (Summary of findings
for the main comparison).
Cardiovascular events (CVD events)
Increasing omega-6 fats may make little or no difference to risk
of CVD events (low-quality evidence, downgraded for risk of bias
and imprecision, Summary of findings for the main comparison).
There was little or no effect of increasing omega-6 fats on CVD
events in seven trials including 4962 participants, 1404 of whom
experienced a CVD event (RR 0.97, 95% CI 0.81 to 1.15, I2
= 45%, Figure 4; Analysis 1.23). This lack of effect was not al-
tered in any sensitivity analyses apart from the one for risk of bias
(Analysis 1.24; Analysis 1.25). Meta-analysis of the two studies at
low summary risk of bias suggested harm from increased omega-
6 (RR 1.62, 95% CI 1.02 to 2.57, 68 people experienced at least
one CVD event). As this effect was distinct from the lack of ef-
fect seen overall we downgraded for risk of bias in GRADE as-
sessment. Almost all CVD events occurred in men and in high-
income countries.
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Figure 4. Forest plot of comparison: 1 Primary outcomes - higher omega-6 vs lower omega-6, outcome:
1.23 Any cardiovascular event (overall).
There were no statistically significant differences for any sub-
group (Analysis 1.26; Analysis 1.27; Analysis 1.28; Analysis 1.29;
Analysis 1.30; Analysis 1.31; Analysis 1.32; Analysis 1.33; Analysis
1.34). All trials used low levels only of statins. There was no sug-
gestion of greater effect with higher omega-6 fat dose or longer
study duration. Meta-regression within the wider set of trials did
not suggest any effect of omega-6 fat dose on CVD events (P =
0.34), or omega-6 fat dose in trials of this review alone (P = 0.55),
baseline omega-6 intake (P = 0.63) or trial duration (P = 0.37).
As there were only seven included trials in this review, we had
very little power to see any potential relationships, and this lack
of power was exacerbated with regard to omega-6 baseline intake,
as several studies did not report this measure.
We found that increasing omega-6 fats may make little or no dif-
ference to risk of CVD events (low-quality evidence, downgraded
due to risk of bias and imprecision, Summary of findings for the
main comparison). One hundred people would need to increase
the amount of omega-6 fat in their diet to prevent one person hav-
ing a CVD event (the NNTB is 100, 95% CI−21 to 17, or from
treating 21 people to cause one additional person to experience a
cardiovascular event to treating 17 people to prevent one person
having a CVD event).
Coronary heart disease events (CHD events, including MI or
angina)
We are uncertain whether increasing omega-6 fats alters the risk
of CHD events, as the quality of evidence was very low (down-
graded for risk of bias, imprecision and inconsistency, Summary
of findings for the main comparison).
Seven trials in 3997 participants, 1059 of whom experienced coro-
nary heart disease events, assessed whether increasing omega-6 fats
alters the risk ofCHDevents. Themeta-analysiswas highly hetero-
geneous (RR 0.88, 95% CI 0.66 to 1.17, I2 = 71%, Analysis 1.35,
GRADE downgraded for inconsistency). Heterogeneity only fell
below I2 = 50% in one sensitivity analysis, limited to studies at
low risk of attention bias (RR 0.83, 95% CI 0.62 to 1.09, I2 =
0%, 160 of 1011 participants experienced a CHD event in 3 trials,
Analysis 1.37). One study was at low summary risk of bias (RR
1.63, 95% CI 1.00 to 2.67, 58 people experienced CHD events,
P = 0.05), and the suggested increase in CHD event risk with in-
creased omega-6 fats led to us downgrade the quality of evidence
for risk of bias in GRADE assessment. CHD events almost all oc-
curred in men and in high-income countries. Fixed-effect analysis
suggested similar effect size to random-effects analysis (Analysis
1.36).
Subgrouping did not explain the high levels of heterogene-
ity (Analysis 1.38; Analysis 1.39; Analysis 1.41; Analysis 1.42;
Analysis 1.43; Analysis 1.44; Analysis 1.45), but there were sig-
nificant differences in subgroup analyses by CVD risk at baseline,
sex and replacement. Where omega-6 fat replaced MUFA, there
was an increased risk of CHD events, while omega-6 fat replacing
carbohydrates appeared to reduce CHD event risk (Analysis 1.40).
Illogically there were effects in subgroups of men and women, but
not of men or women alone (Analysis 1.45), and effects in people
with moderate CVD risk but not high or low baseline CVD risk
(Analysis 1.41). All trials used low levels only of statins. However
there were only one to three trials in each relevant subgroup, so
caution is warranted when drawing conclusions.
There were no statistically significant differences between sub-
groups for dose (Analysis 1.42) or duration (Analysis 1.43). As
meta-regression did not suggest any effect of omega-6 fat dose on
coronary heart disease events in the wider set of trials (P = 0.76)
or only in trials in this review (P = 0.79), we assumed these effects
were likely to be spurious. Meta-regression did not suggest any
relationships between baseline omega-6 intake (P = 0.66) or trial
duration (P = 0.39) and risk of CHD events, but as there were
only seven included trials in this review we had little power to see
potential relationships.
We found that effects of omega-6 fats on coronary heart dis-
ease events were unclear, as evidence was very low quality (down-
graded for risk of bias, imprecision and inconsistency, Summary
of findings for the main comparison).
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Major adverse cardiac and cerebrovascular events
(MACCEs)
We are uncertain whether increasing omega-6 fats alters risk of
MACCEs, as the quality of evidence was very low (downgraded for
risk of bias, imprecision and inconsistency, Summary of findings
for the main comparison).
Only two trials in 2879 participants, 817 of whom experienced a
MACCE, provided data on this outcome (RR 0.84, 95% CI 0.59
to 1.20, I2 = 79%, Analysis 1.46; wide confidence intervals did
not exclude important benefits or harms, so we downgraded for
imprecision). The two trials provided highly heterogeneous results
(so were downgraded for inconsistency). There was a suggestion of
reduced risk of MACCEs in the single trial at low risk of attention
bias, but no trialswere at low summary risk of bias (downgraded for
risk of bias) and no other sensitivity analyses suggested important
effects of omega-6 fats onMACCEs (Analysis 1.48; Analysis 1.47).
Both included studies were inmen only, studied increased LA, and
had low levels of statin use. Therewere only two included trials, but
these were very different, so that there were significant differences
in subgroup analyses withmore than one subgroup (Analysis 1.49;
Analysis 1.50; Analysis 1.51; Analysis 1.52; Analysis 1.53; Analysis
1.54), and therewere insufficient data to carry outmeta-regression.
Both included trials were in men living in developed countries.
We are uncertain whether increasing omega-6 fats affects risk of
MACCEs, as the quality of evidence has been assessed as very
low (downgraded for risk of bias, imprecision and inconsistency,
Summary of findings for the main comparison).
Stroke (fatal or non-fatal)
We are uncertain whether increasing omega-6 fats alters risk of
stroke, as the quality of evidence was very low (downgraded for
once for risk of bias, twice for imprecision, Summary of findings
for the main comparison).
Only four trials provided stroke data, and only 54of 3730 included
participants experienced a stroke (Analysis 1.55). These studies
suggested that omega-6 fats increase stroke risk (RR 1.36, 95%
CI 0.45 to 4.11, I2 = 56%), but studies were heterogeneous and
confidence intervals very wide (as important benefits and harms
were not excluded, we downgraded for imprecision). One study
with only four people experiencing a stroke was at low summary
risk of bias (RR 1.07, 95% CI 0.15 to 7.55; we downgraded
for risk of bias as there were almost no data from studies at low
summary risk of bias). The single study at low risk of attention
bias suggested a reduction in stroke risk with increased omega-
6 fats (Analysis 1.57). Fixed-effect analysis suggested little or no
effect of omega-6 fats (RR 1.0, 95% CI 0.59 to 1.68, Analysis
1.56), while other sensitivity analyses suggested increased risk of
stroke with increased omega-6 fat (Analysis 1.57).
All included studies were of LA rather than GLA, in men only,
and none were in populations using statins. None were from low-
and middle-income countries. Subgrouping by intervention type
(Analysis 1.58: dietary advice was harmful, and providing all foods
had a protective effect), baseline CVD risk (Analysis 1.60: increas-
ing omega-6 fat was protective in primary prevention and harmful
in people with existing CVD), omega-6 fat dose (Analysis 1.61: a
low omega-6 fat dose was harmful and a higher dose protective),
duration (Analysis 1.62: in trials under four years duration omega-
6 fats were harmful and in longer trials protective) and baseline
omega-6 dose ( Analysis 1.63: omega-6 fat supplementation is
useful when baseline dose is low) appeared to reduce heterogene-
ity, but with only four trials contributing, this appeared to relate
to whether DART 1989 and Veterans Admin 1969 were in the
same or different subgroups. Other analyses were not informative
(Analysis 1.60; Analysis 1.63; Analysis 1.64; Analysis 1.65).
Effects of dose and duration were counter-intuitive (as above) and
meta-regression did not suggest any effect of omega-6 fat dose on
stroke (P = 0.19) in the wider set of trials. There were insufficient
trials to carry out meta-regression on data from trials within this
review only.
We are uncertain whether increasing omega-6 fats affects stroke
risk, as the quality of evidence was very low (GRADE assessment
was downgraded once for risk of bias and twice for imprecision,
Summary of findings for the main comparison).
Secondary outcomes
We formally systematically reviewed secondary outcomes, includ-
ing all relevant studies that assessed any of these outcomes in the
review, so results below are systematic review results for effects of
omega-6 fats on these outcomes over at least one year duration.
Summary of findings 2 presents results for key outcomes.
We carried out sensitivity and subgroup analyses for key outcomes
that were secondary outcomes in this review when the main forest
plot included at least six trials contributing data to the analysis.
These outcomes were myocardial infarction, lipids and adipos-
ity, but only myocardial infarction and total cholesterol included
enough studies for us to run sensitivity analyses and subgroups.
Other CVD events
Myocardial infarction (MI)
Increasing omega-6 fats may reduce risk of myocardial infarction.
Seven included studies reported on risk of a new or recurrent MI,
and meta-analysis suggested a 12% reduction in risk of MI with
increased omega-6 fat from 15.4% to 13.5% (RR 0.88, 95% CI
0.76 to 1.02, 609 events, I2 = 0%, Figure 5; Analysis 2.1). Few
reported MIs (only 49) were fatal, and the effect on non-fatal
MIs appeared protective (RR 0.76, 95% CI 0.58 to 1.01, 189
people experiencing non-fatal MI, data not shown). Sensitivity
analyses included one trial (with 5 participants having an MI) at
low summary risk of bias (downgraded for risk of bias as most
event data were from trials at moderate to high summary risk of
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bias). All the other sensitivity analyses suggested reduction in MI
risk with increasing omega-6 fats (Analysis 2.3; Analysis 2.2).
Figure 5. Forest plot of comparison: 2 Secondary outcomes - higher omega-6 vs lower omega-6, outcome:
2.1 Myocardial infarction (MI), overall.
There were no statistically significant differences between sub-
groups for intervention type (Analysis 2.4), replacement (Analysis
2.5), CVD risk (Analysis 2.6), omega-6 dose (Analysis 2.7), du-
ration (Analysis 2.8), statin use (Analysis 2.9), baseline omega-6
intake (Analysis 2.10) or sex (Analysis 2.11). Almost all MIs in
included trials occurred in men living in high-income countries.
We found that increasing omega-6 fats may reduce risk of my-
ocardial infarction (low-quality evidence, GRADE downgraded
for risk of bias and imprecision, Summary of findings 2). Fifty-
three people would need to increase the amount of omega-6 fat
in their diet to prevent one person having a myocardial infarction
(the NNTB is 53, 95% CI −334 to 28, or from 334 people in-
creasing their omega-6 fats to cause one additional person to have
an MI to 28 people increasing their omega-6 fats to prevent one
person experiencing an MI).
Angina
Trials reported few cases of new or worsening angina, but there
was a suggestion of protection against angina with omega-6 fats
(RR 0.61, 95% CI 0.27 to 1.40, 63 events in 4 trials, I2 = 51%,
Analysis 2.12). We are uncertain whether increasing omega-6 fats
affects risk of angina as the quality of evidence was very low.
Sudden cardiac death
Three trials reported sudden cardiac death, including 65 sudden
cardiac deaths. Meta-analysis suggested reduced risk of sudden
cardiac death with omega-6 fats (RR 0.79, 95% CI 0.49 to 1.29,
I2 = 0%, Analysis 2.13). We are uncertain whether omega-6 fats
alter the risk of sudden cardiac death as the evidence is of very low
quality.
New or recurrent arrhythmia, including atrial fibrillation
(AF), ventricular tachycardia (VT) and ventricular
fibrillation (VF)
No included trials reported any of these events.
Heart failure
With only 10 heart failure diagnoses (in two trials) the effect of
omega-6 fats on heart failure was unclear (RR 0.66, 95% CI 0.19
to 2.35, I2 = 0%, Analysis 2.14).We are uncertain whether omega-
6 fats alter the risk of heart failure, as the evidence is of very low
quality.
Revascularisation
Only four participants in a single trial reported on revascularisa-
tion (RR 1.00, 95% CI 0.14 to 6.96, Analysis 2.15). We are un-
certain whether omega-6 fats alter the risk of revascularisation as
the evidence is of very low quality.
Peripheral arterial disease (PAD) events
Three studies reported 53 PAD events, with no suggestion of any
effect of omega-6 fats (RR 1.01, 95% CI 0.60 to 1.70, I2 = 0%,
Analysis 2.16) .We are uncertain whether omega-6 fats alter the
risk of PAD, as the evidence is of very low quality.
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Risk factors
Serum lipids
Increasing omega-6 fats reduces serum total cholesterol (high-
quality evidence, not downgraded), and may make little or no
difference to serum triglycerides (TG), LDL or HDL (low-qual-
ity evidence, TG downgraded once for imprecision and once for
inconsistency and risk of bias (combined), LDL and HDL both
downgraded for risk of bias and imprecision, Summary of findings
2).
Therewas a 6%reduction in total serumcholesterol in participants
who increased omega-6 fats compared to control (MD −0.33
mmol/L, 95% CI −0.50 to −0.16, I2 = 81%, including data
from 4280 participants in 10 trials, Figure 6; Analysis 2.17). As
serum total cholesterol was a key outcome, we ran sensitivity and
subgroup analyses. All sensitivity analyses showed reduced total
serum cholesterol with increased omega-6 fats, including the trials
at low summary risk of bias (MD−0.53 mmol/L, 95% CI−0.82
to −0.26, 1179 participants, Analysis 2.19; Analysis 2.18).
Figure 6. Forest plot of comparison: 2 Secondary outcomes - higher omega-6 vs lower omega-6, outcome:
2.17 Serum total cholesterol (TC), mmol/L.
All included studies increased LA, rather than GLA. There were
statistically significant differences between subgroups by interven-
tion type, replacement and statin use. Subgroup analyses by in-
tervention type suggested reduced serum total cholesterol with di-
etary advice and interventions providing all food, but not with
supplementary foods or advice plus supplementary foods (Analysis
2.20). There was reduced total cholesterol when omega-6 fat re-
placed saturated fat, monounsaturated fat and carbohydrate, but
not in the subgroup analysis where the replacement was unclear
(Analysis 2.21). Subgroup analyses by statin use suggested greater
reductions in TC in people not taking statins (only one trial in-
cluded most people on statins, Analysis 2.25). There were no
statistically significant differences between subgroups by baseline
omega-6 fat intake (Analysis 2.26), sex (Analysis 2.27), baseline
CVD risk (Analysis 2.22), duration (Analysis 2.24) or omega-6
fat dose (Analysis 2.23).
The funnel plot did not suggest any publication or small study
bias (not shown).We are aware of missing data on total cholesterol
in MRC 1968, as the provided data lacked any information on
variance, but data clearly corroborated the greater reductions in
total cholesterol in the higher omega-6 fat arm in meta-analysis
(data shown in Analysis 2.17). Total cholesterol data in Dullart
1992 were too different between study arms at baseline to include
in analysis.
We found that increasing omega-6 fats reduces serum total choles-
terol over at least one year (high-quality evidence, inconsistency
partially explained by dose effects, Summary of findings 2).
Data on serum triglycerides (MD−0.01 mmol/L, 95%CI−0.23
to 0.21, I2 = 72%, 834 participants in 5 trials, Analysis 2.28),
HDL (MD−0.01mmol/L, 95%CI−0.03 to 0.02, I2 =0%, 1995
participants in 4 trials, Analysis 2.30), and LDL cholesterol (MD
−0.04 mmol/L, 95%CI−0.21 to 0.14, I2 = 0%, 244 participants
in 2 trials, Analysis 2.29) were much more limited, without any
clear suggestion of alteration with increased omega-6 fats. Due to
the limited numbers of trials for these outcomes, we did not run
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sensitivity or subgroup analyses. We are aware of missing data on
TGs from NDHS Faribault 1968 and NDHS Open 1st 1968,
and missing data on LDL in Dullart 1992. In NDHS Faribault
1968 the percentage change for TG from baseline to 44 week was
−6.4% in the control group and −12.7% in intervention group
B,−7.1% in C,−16.9% in E, but data were less clear for NDHS
Open 1st 1968. LDL data in Dullart 1992 were too different
between study arms at baseline to include in analysis.
We found that increasing omega-6 fat may have little or no effect
on serum HDL or LDL (both low-quality evidence, downgraded
for risk of bias and imprecision), or triglycerides (low-quality ev-
idence, downgraded once for imprecision and once for inconsis-
tency and risk of bias combined, Summary of findings 2).
Adiposity
Only two small trials in 66 participants fully reported on body
weight (MD−3.12 kg, 95%CI−12.6 to 6.36, I2 = 58%, Analysis
2.31), and one trial in 371 participants on body mass index (MD
−0.20 kg/m2, 95% CI −0.56 to 0.16, Analysis 2.32; this study
was at low summary risk of bias). Both outcomes suggested slightly
lower adiposity associated with higher omega-6 fat intake (though
body weight was higher in the omega-6 fat arms of the two tri-
als that could not be included in body weight assessment due to
lack of variance information, suggesting possible publication bias,
Analysis 2.31). One small trial (30 participants) suggested that
omega-6 fats resulted in lower fat weight (MD −7.7 kg, 95%
CI −14.6 to −0.8, Analysis 2.33) - a surprisingly large suggested
effect. Weight data were measured but not included in analyses
for Black 1994 and MRC 1968 (shown in Analysis 2.31 but not
included in meta-analysis because variance data were missing), as
well as NDHS Faribault 1968 and NDHS Open 1st 1968, so
publication bias may be an issue for this outcome.
Overall, we found that increasing omega-6 fats probably has little
or no effect on adiposity, measured using body mass index, over
at least one year (moderate-quality evidence, downgraded for im-
precision, evidence for body weight and fat weight were of very
low quality, Summary of findings 2).
Tertiary outcomes
We did not formally systematically review these outcomes, but
where included studies reported them, we collated and analysed
them.
Blood pressure
We found limited information on blood pressure, and there were
no important effects of omega-6 fats on either systolic or diastolic
blood pressure. One trial fully reported systolic and diastolic blood
pressure (sBP MD −1.10 mmHg, 95% CI −4.05 to 1.85, 458
participants, dBP MD −0.30 mmHg, 95% CI −2.04 to 1.44,
458 participants), and another partially reported it (Analysis 3.1).
Lack of data on this commonly collected outcome may suggest
publication bias.
Quality of life, economic costs, dropouts
No included trials assessed effects of increased omega-6 fats on
quality of life or economic costs. The effect of the intervention on
dropouts was heterogeneous, suggesting that increasing omega-6
fats was fairly acceptable in some trials, but not in others. The
pooled risk ratio suggested greater risk of dropping out in the
higher omega-6 fat arms (RR 1.49, 95% CI 1.18 to 1.89, 242
events in 8 trials, I2 = 61%, Analysis 3.2, with almost 60% of the
weight from one trial that had many more dropouts in the higher
omega-6 arm (Veterans Admin 1969)).
Adverse and other potential health effects
Effects of omega-6 fats on dementia and neurocognitive outcomes
(Jimoh 2017), type 2 diabetes andmeasures of glucose metabolism
(Brown 2017), inflammatory bowel disease and inflammatory
markers (Thorpe 2017), cancers (Hanson 2017b), depression and
anxiety (Hanson 2017a), and functional outcomes (Abdelhamid
2017) are systematically reviewed elsewhere, so we do not report
the results of effects seen in studies included in this review (as they
are potentially misleading). The systematic reviews on these health
outcomes are not yet published, so references are provided to the
protocols so the systematic reviews can be located.
We found limited data on multiple sclerosis progress and pul-
monary embolism. Two trials reported only seven cases of pul-
monary embolism, so that effects of omega-6 fats were unclear
(RR 2.15, 95% CI 0.48 to 9.57, I2 = 0%, Analysis 3.3). Two trials
reported risk of worsening multiple sclerosis or an acute attack,
with a suggestion of increased risk of worsening MS with GLA
supplementation (RR 1.11, 95% CI 0.95 to 1.30, 142 events in
2 trials, I2 = 0%, Analysis 3.3), although the confidence intervals
were very wide.
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Higher versus lower omega-6 for adults with or without CVD
Patient or population: adults with or without exist ing CVD
Setting: includes f ree-living part icipants and those living in inst itut ions. Includes part icipants f rom North America, Australia, Asia and Europe, but most events occurred in
studies carried out in Europe or North America
Intervention: higher omega-6
Comparison: lower omega-6
Eligible trials compared higher with lower omega-6 fat (including LA, GLA, DGLA, AA, or any combinat ion) intakes. The intervent ion had to be dietary supplementat ion, or a
provided diet, or advice on diet
Outcomes Anticipated absolute effects* (95% CI) Relative effect
(95% CI)
of participants
(studies)
Certainty of the evi-
dence
(GRADE)
Comments
Risk with lower omega-
6
Risk with higher
omega-6
MI
Study durat ion range
12-96 months
Omega-6 dose range 2.
8%-24.5%E
Study populat ion RR 0.88
(0.76 to 1.02)
4606
(7 RCTs)
⊕⊕©©
Lowa
Increasing
omega-6 fats may re-
duce risk of myocardial
infarct ion. Downgraded
once each for risk of
bias and imprecision.
53 people would need
to increase the amount
of omega-6 fat in their
diet to prevent one per-
son having a myocar-
dial infarct ion (NNTB
53, 95%CI −334 to 28)
154 per 1000 135 per 1000
(117 to 157)
Serum TC
Study durat ion range
12-96 months
Omega-6 dose range 2.
0%-24.5%E
The mean serum to-
tal cholesterol was 5.88
mmol/ L
MD 0.33 mmol/ L lower
(0.5 lower to 0.16
lower)
- 4280
(10 RCTs)
⊕⊕⊕⊕
Highb
Increasing omega-6
fats reduces serum to-
tal cholesterol over at
least 1 year; not down-
graded
2
9
O
m
e
g
a
-6
fa
ts
fo
r
th
e
p
rim
a
ry
a
n
d
se
c
o
n
d
a
r
y
p
re
v
e
n
tio
n
o
f
c
a
rd
io
v
a
sc
u
la
r
d
ise
a
se
(R
e
v
ie
w
)
C
o
p
y
rig
h
t
©
2
0
1
8
T
h
e
C
o
c
h
ra
n
e
C
o
lla
b
o
ra
tio
n
.
P
u
b
lish
e
d
b
y
Jo
h
n
W
ile
y
&
S
o
n
s,
L
td
.
Serum TG
Study durat ion range
12-72 months
Omega-6 dose range 2.
0%-15.0%E
The mean serum
triglycerides was 1.45
mmol/ L
MD 0.01 mmol/ L lower
(0.23 lower to 0.21
higher)
- 834
(5 RCTs)
⊕⊕©©
Lowc
Increasing
omega-6 fats maymake
lit t le or no dif ference
to serum triglycerides
over at least one year.
Downgraded once for
imprecision, and once
for inconsistency and
risk of bias combined
LDL
Study durat ion range
12-24 months
Omega-6 dose range 2.
0%-15.0%E
The mean low density
lipoprotein was 2.35
mmol/ L
MD 0.04 mmol/ L lower
(0.21 lower to 0.14
higher)
- 244
(2 RCTs)
⊕⊕©©
Lowd
Increasing omega-
6 fats may make lit t le
or no dif ference to LDL
over at least one year.
Downgraded for risk of
bias and imprecision
HDL
Study durat ion range
12-24 months
Omega-6 dose range 2.
0%-15.0%E
The mean high den-
sity lipoprotein was 1.
15 mmol/ L
MD 0.01 mmol/ L lower
(0.03 lower to 0.02
higher)
- 1995
(4 RCTs)
⊕⊕©©
Lowe
Increasing
omega-6 fats may have
lit t le or no ef fect on HDL
over at least one year.
Downgraded once each
for risk of bias and im-
precision
Body weight (kg)
Study durat ion range
12-48 months
Omega-6 dose range 0.
8%-2.8%E
The mean body weight
was 77.9 kg
MD 3.12 kg lower
(12.6 lower to 6.36
higher)
- 358
(4 RCTs)
⊕©©©
Very lowf
We are
uncertain whether in-
creasing omega-6 fats
alters body weight as
the evidence is of
very low quality. Down-
graded for risk of bias,
imprecision and publi-
cat ion bias
3
0
O
m
e
g
a
-6
fa
ts
fo
r
th
e
p
rim
a
ry
a
n
d
se
c
o
n
d
a
r
y
p
re
v
e
n
tio
n
o
f
c
a
rd
io
v
a
sc
u
la
r
d
ise
a
se
(R
e
v
ie
w
)
C
o
p
y
rig
h
t
©
2
0
1
8
T
h
e
C
o
c
h
ra
n
e
C
o
lla
b
o
ra
tio
n
.
P
u
b
lish
e
d
b
y
Jo
h
n
W
ile
y
&
S
o
n
s,
L
td
.
BMI
Study durat ion 51
months
Omega-6 dose 6.6%E
The mean body mass
index was 24.5 kg/ m2
MD 0.2 kg/ m2 lower
(0.56 lower to 0.16
higher)
- 371
(1 RCT)
⊕⊕⊕©
Moderateg
Increasing
omega-6 fats probably
has lit t le or no ef fect on
body mass index over
at least one year. Down-
graded for imprecision
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
AA: arachidonic acid;BMI: body mass index; CI: conf idence interval;DGLA: dihomo-gamma-linolenic acid;GLA: gamma-linolenic acid; HDL: high-density lipoprotein; LA: linoleic
acid; LDL: low-density lipoprotein; MD: mean dif ference; MI: myocardial infarct ion; NNTB: number needed to treat for an addit ional benef icial outcome; RCT : randomised
controlled trial; RR: risk rat io; TC: total cholesterol; TG: t riglycerides; %E: percentage of energy intake f rom this nutrient.
GRADE Working Group grades of evidence
High certainty: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
Moderate certainty: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low certainty: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low certainty: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
aMyocardial infarction
• Risk of bias: only one trial with fewer than 10 part icipants experiencing events was at low summary risk of bias. All
other sensit ivity analyses suggested that increasing omega-6 fats reduced risk of MI. It was further noted by the WHO
NUGAG Subgroup on Diet and Health that most studies did not report on allocat ion concealment or otherwise had unclear
risk of bias for allocat ion concealment. Although low risk of bias in other elements of bias assessment (e.g. randomisat ion,
blinding of outcome assessment) m ight suggest that the trials were well-conducted and thus allocat ion concealment may
have been maintained, many of the trials are older and detailed information on the conduct of the trials can be scarce.
Therefore, a conservat ive approach was taken. Downgraded once.
• Inconsisency: I2 = 0%, not downgraded.
• Indirectness: Most events occurred in men living in high-income countries, but included people with and without CVD at
baseline. Not downgraded.
• Imprecision: the 95%CI crossed the null. Downgraded once.
• Publication bias: f ewer than 10 trials were included so funnel plot not useful. Not downgraded.
bSerum total cholesterol
• Risk of bias: reduct ions in total serum cholesterol were greater in studies with low summary risk of bias, and all
sensit ivity analyses suggested that increasing omega-6 fats reduced serum total cholesterol. Not downgraded.
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• Inconsistency: I2 > 60% but part ly explained by dose ef fects in subgrouping. There was a suggest ion of greater
reduct ions in TC with greater increases in omega-6 fats in subgrouping. Not downgraded.
• Indirectness: data came f rom men and women with and without baseline CVD, and f rom low- to middle income and high-
income countries. Not downgraded.
• Imprecision: 95%CI did not cross the null and included only benef its (reduct ions in total serum cholesterol with
increased omega-6 fats). Not downgraded.
• Publication bias: the funnel plot did not suggest small study bias. Not downgraded.
c Serum triglycerides
• Risk of bias: the one study at low summary risk of bias included 458 part icipants and found that omega-6 fats caused a
small reduct ion in TG (MD −0.10mmol/ L, 95%CI −0.26 to 0.06), but single study. Sensit ivity analyses not conducted.
Downgraded once (in combinat ion with inconsistency).
• Inconsistency: I2 > 60%. Downgraded once (in combinat ion with risk of bias).
• Indirectness: data came f rom men and women with and without baseline CVD, and f rom low- to middle income and high-
income countries. Not downgraded.
• Imprecision: the 95%CI included small benef its and harms of omega-6. Downgraded once.
• Publication bias: f ewer than 10 trials were included so funnel plot not useful. Not downgraded.
d Low-density lipoprotein
• Risk of bias: no included studies were at low summary risk of bias. Sensit ivity analyses not conducted. Downgraded
once.
• Inconsistency: I2 = 0%, not downgraded.
• Indirectness: only trials of men and women living in developing countries were included. Not downgraded.
• Imprecision: the 95%CI crossed the null and included small benef its and harms of omega-6. Downgraded once.
• Publication bias: f ewer than 10 trials were included so funnel plot not useful. Not downgraded.
e High-density lipoprotein
• Risk of bias: No included studies were at low summary risk of bias. Sensit ivity analyses not conducted. Downgraded
once.
• Inconsistency: I2 = 0%, not downgraded.
• Indirectness: data came f rom men and women with and without baseline CVD, and f rom low- to middle income and high-
income countries. Not downgraded.
• Imprecision: the 95%CI crossed the null and included small benef its and harms of omega-6. Downgraded once.
• Publication bias: f ewer than 10 trials were included so funnel plot not useful. Not downgraded.
f Body weight
• Risk of bias: no included studies were at low summary risk of bias. Sensit ivity analyses not conducted. It was further
noted by the WHO NUGAG Subgroup on Diet and Health that most studies did not report on allocat ion concealment or
otherwise had unclear risk of bias for allocat ion concealment. Although low risk of bias in other elements of bias
assessment (e.g. randomisat ion, blinding of outcome assessment) m ight suggest that the trials were well-conducted and
thus allocat ion concealment may have been maintained, many of the trials are older and detailed information on the conduct
of the trials can be scarce. Therefore, a conservat ive approach was taken. Downgraded once.
• Inconsistency: I2 = 30 to 60%. Not downgraded.
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• Indirectness: Most data related to men and women without exist ing CVD living in high-income countries. Not
downgraded.
• Imprecision: 95%CI crossed the null and included important harms and benef its of omega-6. Downgraded once.
• Publication bias: f ewer than 10 trials so funnel plot not attempted. However we are aware of at least 2 studies with data
that could not be added to the meta-analysis. Downgraded once.
g Body mass index
• Risk of bias: the single included trial was at low summary risk of bias. Sensit ivity analyses not conducted. Not
downgraded.
• Inconsistency: only one trial included. Not downgraded.
• Indirectness: only one trial included, of men with previous MI and in a developed country. Not downgraded.
• Imprecision: the 95%CI crossed the null and included small benef its and harms of omega-6. Downgraded once.
• Publication bias: f ewer than 10 trials were included so funnel plot not useful. Not downgraded.
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D I S C U S S I O N
Summary of main results
We included 19 RCTs in 6461 randomised participants followed
up for one to eight years in this Cochrane Review. We identified
one ongoing trial. Seven trials assessed effects of small quantities
of GLA as supplements, while 12 assessed effects of larger versus
smaller quantities of dietary LA, usually displacing SFA or MUFA
in the diet. We judged three studies to be at low summary risk of
bias. We found that increasing omega-6 fats may make little or no
difference to all-cause mortality or CVD events, but evidence for
both outcomes was of low quality. We are uncertain whether in-
creasing omega-6 fats affects risk of CVDmortality, CHD events,
MACCEs or stroke, as evidence for all of these outcomes was of
very low quality.
For secondary outcomes we found that increasing omega-6 fats
may reduce risk of myocardial infarction, but we are uncertain
whether increasing omega-6 fat affects risk of angina, sudden car-
diac death, heart failure, revascularisation or PAD (all very low-
quality evidence). We found no data on arrhythmia.
High-quality evidence suggests that increasing omega-6 fats re-
duces total serum cholesterol by 6% over at least one year, and this
effect was consistent in sensitivity analysis including only trials at
low summary risk of bias. Increasing omega-6 fats probably has
little or no effect on body mass index (moderate-quality evidence),
andmaymake little or no difference to triglycerides, HDL or LDL
cholesterol (low-quality evidence).
We found limited information on blood pressure, quality of life,
economic outcomes and adverse health effects. Effects of omega-
6 fats on serious adverse health effects (cancers, inflammatory
bowel disease, depression or anxiety, neurocognitive outcomes,
functional outcomes and diabetes) are reported elsewhere.
Overall completeness and applicability of
evidence
Included trials randomised 6461 participants for at least a year.
Participants were men and women aged from their 20s into their
80s, but themedianmean age was 50 years old.While we included
6 trials in men, 10 in both men and women, and 2 in mostly
women (1 trial did not report participant gender), most deaths
(703/740) and CVD events (1377/1404) occurred in the trials of
men, so it is not clear whether any effects also apply to women.
Similarly, while younger adults are included, most events occurred
in older adults, which partly explains the lack of appearance of
some studies of younger adults in many of the analyses on health
events. We included these trials because they reported data on
lipids and/or adiposity and sometimes one or two health events.
Two included trials were from lower middle-income countries (
Mendis 2001 from Sri Lanka and Vijayakumar 2014 from India),
but while both provided data on lipids, the only events were two
deaths in Vijayakumar 2014. This means that the bulk of the
information in this review is from high-income countries, and
much of it from trials carried out 30 to 50 years ago.
Participants were at low CVD risk in 11 trials (they were recruited
for living in mental hospital or veterans accomodation, having
multiple sclerosis, rheumatoid arthritis or breast cysts, having had
cancer or lostweight or simply beinghealthy), haddiabetes in three
trials (moderate CVD risk) or had existing CVD in five trials, so
results relate to both primary and secondary prevention of CVD.
However, most events occurred in those with existing CVD.
We are aware of a missing study - we were unable to access data
for Chandrakala 2010, which is completed but unpublished (see
Characteristics of ongoing studies). We are also aware of some
missing data within included studies - for example there were
deaths in Bates 1977, but theywere reported combined with drop-
outs, and the author no longer has the data. Houtsmuller 1979
reported CHD events and mortality, but not all-cause deaths or
CVD events. Black 1994, MRC 1968, NDHS Faribault 1968,
NDHS Open 1st 1968 and Schirmer 2007 each reported at least
one continuous outcome without variance data (so we missed at
least one set of data on total cholesterol, two sets on blood pressure
and triglycerides, four sets on weight), and Dullart 1992 provided
total cholesterol and LDL data that were too different between
study arms at baseline to use (with no change data). On the other
hand, we were provided the full dataset on events for DART 1989,
so we were able to include data for almost all of our outcomes.
Data for Sydney Diet-Heart 1978 were also well reported in re-
cent re-analyses, and the authors kindly augmented these data, and
outcome data in Veterans Admin 1969 were very well reported,
so data are probably almost complete for these trials.
We have included trials of LA and GLA, but other omega-6 fats
such as DGLA or AA do not appear to have been tested in RCTs
lasting at least one year.We have gathered some information on ef-
fects of LA on mortality, CVD events, lipids and adiposity, but we
have limited data on both LA andGLA for dichotomous outcomes
such as all-cause mortality. Data on effects of GLA on CVDmor-
tality, CVD events, and CHD events are almost entirely absent.
DGLA and AA can be synthesised from LA, although conversion
may be minimal. DGLA is not part of the diet (it is present only
following metabolism), but AA is a dietary component. Trials of
increasing LA will presumably also increase availability of DGLA
and AA, even if only a small amount, so trials of DGLA and AA
may be unnecessary.
In this review, we aimed to assess effects of omega-6 fats on CVD
outcomes. Because omega-6 fats are an essential nutrient for hu-
mans (we all eat it already), it would be useful to understand
whether increasing omega-6 fats in people who eat very little has
the same effect as increasing omega-6 fats in people already con-
suming large amounts. Unfortunately, only 7 of the 17 included
trials reported baseline omega-6 or PUFA intake, so our under-
standing of this aspect is limited. That said, across outcomes there
is a suggestion of benefit from increasing omega-6 fats where base-
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line omega-6 fat intake is below 5% E, and this effect is lost where
omega-6 fat intake is at least 5% E (seen in subgroup analyses for
baseline omega-6 fat intake for all primary outcomes, including
all-cause mortality, CVD mortality , CVD events, CHD events,
MACCEs and stroke). We also subgrouped by baseline omega-6
intake for serum total cholesterol, finding greater cholesterol re-
ductions where baseline omega-6 fats were below 5% E but also
seeing reductions, though smaller ones, in populations with higher
omega-6 fats at baseline. We carried out meta-regression to assess
effects of omega-6 fat intake at baseline on primary outcomes with
at least seven included trials. We did not see any suggested ef-
fects for all-cause mortality, CVDmortality, CVD events or CHD
events (other outcomes included too few trials), but as there were
only seven trials in most of these data sets, and some included
trials didn’t provide omega-6 fat intake at baseline, our power to
see any effects was extremely low. Future trials should evaluate this
relationship.
Another key question relates to trans fat intake. It is possible that
in trying to increase omega-6 fat intake, some trials may have
increased intake of hydrogenated vegetable oils high in trans fats.
Trans fats are associated with increased risk of CVD (De Souza
2015), so that we may see increases in CVD due to increased trans
fat intake, balanced against any underlying benefits of omega-
6 fats. Unfortunately, none of the included trials provided data
on trans fats. Some trials clearly did not increase trans fats in
the higher omega-6 fat arms, as they specifically provided liquid
oils (e.g. MRC 1968; Rose 1965), but these were unpalatable to
participants, and later trials altered their interventions to provide
other products or advice to increase omega-6 fat intake. These
studies provide little detail on types of fats taken by participants
advised to increase their omega-6 fat intake - in at least some of
these, trans fats may have been substantially increased in higher
omega-6 fat arms, which may confound our understanding of the
effects of increasing omega-6 fats.
Overall, included data are highly applicable but not entirely com-
plete. At present the dataset of RCTs appears to be underpow-
ered for truly understanding the health effects of omega-6 fats. We
suggest that further large, long duration, high-quality trials of LA
are needed, particularly in women and in countries across income
brackets to help clarify the health effects of omega-6 fats. These
trials should include participants with low omega-6 intake at base-
line, as well as those with higher intake. Dietary advice needs to
ensure that trans fat intake is kept low as omega-6 fats increase,
and omega-6 fat adherence and trans fat intakes should be checked
using biomarkers.
Quality of the evidence
GRADE assessment includes consideration of risk of bias, incon-
sistency, indirectness, publication bias and imprecision (Summary
of findings for the main comparison; Summary of findings 2).
We assessed risk of bias by assessing whether effect sizes altered in
sensitivity analyses when limited to studies at low summary risk
of bias, those with trials registry entries, those without commer-
cial funding, with low risk from attention bias and larger trials.
We defined supplement studies as being at low summary risk of
bias where we considered randomisation, allocation concealment,
blinding of participants and personnel, and blinding of outcome
assessors to be adequate. We defined dietary advice and diet provi-
sion trials as being at low summary risk of bias where we considered
randomisation, allocation concealment and blinding of outcome
assessors to be adequate.
We assessed only 3 of 19 included trials as being at low sum-
mary risk of bias (NDHS Faribault 1968; NDHS Open 1st 1968;
Sydney Diet-Heart 1978). These were all dietary advice trials, and
we judged randomisation, allocation concealment and compliance
to be adequate. As poorly concealed allocation has been associated
with a 40% greater effect size (Schultz 1995), this is particularly
important for assessing risk of bias. Four included trials were at low
risk of bias from allocation concealment (Dullart 1992; NDHS
Faribault 1968;NDHSOpen1st 1968; SydneyDiet-Heart 1978),
but most were at unclear risk despite our enquiring about the
method of randomisation in some detail of all authors we were
able to contact. We downgraded all dichotomous primary and sec-
ondary outcomes for risk of bias, as sensitivity analyses limited to
these trials tended to suggest that increasing omega-6 fats increased
the risk of mortality and CVD events, unlike the main analyses,
or there were very few if any events in trials at low summary risk
of bias.
We judged imprecision by whether the 95% CI in the main anal-
ysis crossed the null, randomised at least 4000 participants (as
suggested by Schünemann 2013), and whether the 95% CI in-
cluded important benefits and harms. Where the 95% CI crossed
the null we downgraded. Despite there being large numbers of
participants randomised in primary outcomes, confidence inter-
vals were often wide, suggesting that included studies may still
be underpowered to determine effectiveness on these outcomes.
Further studies of effects of omega-6 fats on mortality and CVD
outcomes are needed.
We assessed inconsistency using I2 for each primary and secondary
outcome. We considered I2 values of more than 60% to be a prob-
lem and downgraded for inconsistency unless we found an element
that explained that inconsistency (through subgroup analysis or
meta-regression). We downgraded the primary outcomes of CVD
mortality, CHD events and MACCEs, along with the secondary
outcomes of angina and serum triglycerides, for this reason.
We assessed indirectness according to whether data on an out-
come related to women and men, those with and without CVD
at baseline, and whether low-, middle- and high-income coun-
tries were represented.While indirectness is important, we suspect
that the mechanisms of action of omega-6 fats are similar in men
and women, and those with and without CVD at baseline, and in
different countries Information on indirectness is reported in the
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summary of findings tables, but we did not downgrade for this
factor.
We judged publication bias according to whether there was any
suggestion of publication or small study bias in the funnel plot,
or where we knew that data were missing that differed from the
summary assessment (where we included fewer than 10 trials). We
downgraded evidence for body weight alone for publication bias.
Study funding can be an important indicator of study bias, but
we did not include it in the ’Risk of bias’ assessment. Funding
appeared to be from only national or charitable agencies in eight
trials, and from mixed charitable or national sources with some
commercial products or funds provided in a further five trials.
Three trials reported only commercial sources: GLAMT 1993,
which reported only oneMI, oneCHDevent and oneCVDevent;
McIllmurray 1987, with 22 deaths and with no data on CVD
events; and Schirmer 2007, which provided data on adiposity only.
As data from these studies were very limited, they were unlikely
to have biased results greatly, though omission of data from other
outcomes could have. Rose 1965 did not mention funding.
Trial pre-registration or early publication of a study protocol is
helpful in understanding potential biases in data presentation (in-
cluding outcome selection bias). We ran sensitivity analyses as-
sessing whether trials that were pre-registered or had a published
protocol suggested different effects than trials without such docu-
mentation. Unfortunately, we did not find a trials registry entry or
pre-published protocol for any of our included trials (most were
published before the availability of trials registers). Pre-registration
would be helpful for future trials, helping ensure that important
outcomes are published regardless of direction of effect or statis-
tical significance. Making datasets of all outcomes available via
trials registers would also help systematic reviewers to gather all
appropriate data, minimising publication bias.
A particular issue for dietary trials (the LA trials in this review) is
adherence. Where we see little effect on key outcomes, all-cause
mortality and CVD events, we need to consider whether this is
due to omega-6 fats not having any effect on these outcomes, or
to participants not actually increasing their omega-6 fat intake
substantially following dietary advice. Dietary trials often assess
adherence by asking participants what they are eating, but this may
be subject to participant exaggeration or wanting to believe that
they are indeed following advice provided. Objective biomarkers
such as serum total cholesterol or fatty acid tissuemarkers are more
conclusive (Sacks 2017). We assessed adherence in included trials
and found that five trials showed statistically significant reductions
in serum total cholesterol in the higher omega-6 fat arm compared
to the lower omega-6 fat arm (DART 1989; Houtsmuller 1979;
NDHS Faribault 1968; NDHS Open 1st 1968; Sydney Diet-
Heart 1978). Four studies did not show a statistically significant
effect on total cholesterol (Mendis 2001; Rose 1965; Veterans
Admin 1969; Vijayakumar 2014) and one did not provide any
variance data (so statistical significance was not clear; MRC 1968,
Analysis 2.17). Other trials assessed change in tissue fatty acids,
finding significant changes in higher omega-6 arms compared to
the lower omega-6 fat arms (Black 1994; Schirmer 2007), or lack
of any statistically significant difference in these markers (Bates
1978; Dullart 1992), while others provided no biomarker data
for compliance (Bates 1977; GLAMT 1993; McIllmurray 1987).
Although biomarkers are not perfect markers of compliance (the
degree of total cholesterol change will depend on whether omega-
6 fats are replacing saturated or monounsaturated fats, or other
dietary components, for example) the lack of change in biomarkers
in some studies highlights the difficulty of interpreting this limited
dataset and the possibility that we are not seeing health effects
because omega-6 fats did not alter much in some studies.
Applying the GRADE criteria suggests that we have high-qual-
ity evidence on effects of omega-6 fats on serum total cholesterol
(not downgraded), moderate-quality evidence on BMI (down-
graded once), and low-quality evidence for all-cause mortality and
CVDevents,myocardial infarction, TG,HDLand andLDL (each
downgraded for risk of bias and imprecision). All other evidence
was of very low quality. We present justifications for grading and
statements of findings based on these levels in Summary of findings
for the main comparison and Summary of findings 2.
Potential biases in the review process
We performed a comprehensive search across major databases for
interventions involving increased omega-6 fat intake for this re-
view update. In addition, we checked reference lists of all primary
studies and relevant systematic and non-systematic reviews for ad-
ditional references. While we may have missed trials, we believe
thatwe have includedmost of the larger studies, including somewe
missed in the original version of this review (Al-Khudairy 2015).
Two review authors independently performed all screening, inclu-
sion and exclusion determination, data extraction and assessment
of risk of bias. We contacted authors of all included studies to ask
for information on all relevant outcomes and methodology related
to risk of bias. We conducted sensitivity analyses to check whether
the outcomes were stable to a range of quality assessments.
We conducted a large number of sensitivity and subgroup analyses
for each primary outcome, as well as some secondary outcomes.
The danger in these is that statistical significance may be spurious
in subgroups, but rather than be informed by effects in small
subgroups we assessed whether there were statistically significant
differences between subgroups. We also looked for dose-response
and duration effects using meta-regression. We have tried not to
over-interpret these analyses.
We only considered trials with interventions or follow-up periods
of 12 months or more, which makes the studies relevant for public
health interventions. We considered including shorter studies, but
we were concerned that if we found little or no effect then this
might be due to including studies too short to reflect any effects of
the omega-6 fat intervention. The decision on duration depends
on the assumedmechanism of action of omega-6 fats. If we assume
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a cholesterol-led atherosclerotic mechanism, then we could justify
deciding to include only studies of at least two years (as in Hooper
2015; Sacks 2017). However, another mechanism discussed for
omega-3 and omega-6 fats is inflammation - likely to work more
quickly than atherosclerosis, so allowing six months for equilibra-
tion of body tissues with the new dietary intake, and a further six
months to allow for reflection of this new status in health out-
comes, appears appropriate to us. We hope this compromise is a
reasonable balance between excluding useful studies and including
unhelpful ones. We ran subgroup analyses to assess whether study
duration made an important difference to our primary outcomes.
We did not find any suggestion of greater effects in longer trials
(those of at least 4 years) compared to shorter trials (1 to < 2 years,
or 2 to < 4 years) for all-cause mortality or CVD mortality. There
may arguably be slightly greater protective effects in longer trials
for CVD events, CHD events, MACCEs and stroke, but meta-
regression did not confirm this. Trials of 1 to < 2 years contributed
few or no data to primary outcomes so would be unlikely to dilute
any effects in longer trials. There were only important differences
between duration subgroups for MACCEs and stroke. This sug-
gests we need more longer trials and that carrying out more short
trials, or adding trials of less than one year duration to this review,
would be unhelpful.
Within the review we have combined data on GLA and LA (apart
from in subgroup analyses), which may be inappropriate. LA is an
essential fat available from a variety of dietary fats and oils (Sacks
2017), while GLA has to be provided by supplemental capsules
in trials, so their effects could be distinct. However, data on GLA
are very limited, so they probably neither substantially add to nor
detract from the LA data.
Agreements and disagreements with other
studies or reviews
This update has built on the findings of the previous version of
this review (Al-Khudairy 2015), which included five comparisons
randomising 660 participants each for 24 weeks. This version in-
cluded no studies reporting CVD outcomes, and effects of omega-
6 fats on lipids, blood pressure, diabetes or adverse events were
unclear. This update excluded all of these trials (as they were all
of less than one year duration) and included 17 more, many of
which did assess mortality and/or CVD events. This updated re-
view includes a much greater volume of data (more studies, more
participants, longer term and larger studies), though there are still
limited numbers of studies and of our primary outcome events.
A review of highly controlled (metabolic-type) trials found that
replacement of saturated fats with cis-PUFAs (which the authors
considered equivalent to omega-6 fats) significantly reduced to-
tal cholesterol levels (estimated regression coefficient for mean
change, −0.066 mmol/L per 1% E replaced, 95% CI −0.073 to
−0.060, Mensink 2016). Replacing carbohydrates and monoun-
saturated fats also resulted in reductions in total cholesterol, but
smaller reductions (−0.019mmol/L per 1%E from carbohydrates
replaced, 95% CI −0.025 to −0.013, and −0.016 mmol/L per
1% EMUFA replaced, 95% CI−0.022 to−0.011). This careful
analysis confirmed earlier findings using the same methodology
(Mensink 2003). This analysis of highly controlled trials also found
that replacing SFA, MUFA and carbohydrates with cis-omega-6
fats reduced LDL cholesterol (−0.058 mmol/L per 1% E from
SFA replaced, 95% CI −0.064 to −0.052 with smaller effects
when MUFA and carbohydrates are replaced), HDL cholesterol
(−0.005 mmol/L per 1% E from SFA replaced, 95% CI −0.007
to−0.004 with smaller effects whenMUFA are replaced, and op-
posite effects when carbohydrates are replaced) and triglycerides
(−0.010mmol/Lper 1%E fromSFA replaced, 95%CI−0.014 to
−0.006 with smaller effects when MUFA are replaced, and larger
effects when carbohydrates are replaced). This confirms our find-
ings of reduced serum total cholesterol with increased omega-6
fats and suggests that we were underpowered to see effects on other
lipids (in our less highly controlled trial environments over much
longer durations we didn’t see changes in TG, LDL or HDL). Ef-
fects clearly depend on which dietary elements omega-6 fats are
replacing in the diet, and this is probably responsible for some of
the heterogeneity between studies assessing effects on triglycerides
and lack of effect on LDL.
A meta-analysis of cohort studies that examined associations be-
tween LA intake and CHD outcomes (myocardial infarction, is-
chaemic heart disease, coronary artery bypass graft, sudden car-
diac arrest, acute coronary syndrome, and CHD deaths) found an
inverse dose-response association between dietary LA intake and
CHD risk (Farvid 2014). Observational studies are at greater risk
of confounding from a variety of lifestyle factors, though they are
often larger and of longer duration than trials. The Farvid 2014
analysis agreed with this reviews’ suggested reduction in risk of
myocardial infarction with increased omega-6 fats, but we did not
see any effect of omega-6 fat intake on CHD or CVD events. A
recent meta-analysis of 20 cohort studies has suggested that higher
LA in body tissues was associated with reduced diabetes risk (Wu
2017), but we did not assess diabetes risk in this review (as Brown
2017 assesses it in part of this review series).
A systematic review of RCTs increasing omega-6 fats, Ramsden
2010, found no significant effects on all-cause mortality (RR 1.16,
95%CI 0.95 to 1.42), non-fatal MI (RR 1.03, 95% CI 0.62 to
1.73),CHDdeath (RR1.17, 95%CI0.82 to 1.68) orCVDevents
RR 1.13, 95% CI 0.84 to 1.53), and these results have not altered
substantially in their most recent update of the review (Ramsden
2016). A recent review of systematic reviews and presidential ad-
visory from the American Heart Association found that increasing
LA to replace saturated fats in the diet significantly reduced CVD
outcomes (Sacks 2017). Sacks 2017 combined data from four key
trials (MRC 1968; Veterans Admin 1969; Finnish Mental Hosp
1972; Oslo Diet Heart 1966) comparing high PUFA diets with
high saturated fat diets, controlled diets over at least two years,
proved adherence using biomarkers such as tissue lipids or serum
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cholesterol, collected and validated CVD outcomes of some type,
and limited trans fat differences between arms. We included only
two of their four key trials (MRC 1968; Veterans Admin 1969),
excluding Oslo Diet Heart 1966 as it increased both omega-3
and omega-6 fats and included a multivitamin in the intervention
group (so was multifactorial), and Finnish Mental Hosp 1972 as it
was a cluster-randomised trial, with only two clusters (and used a
cross-over approach inappropriate for outcomes that develop over
time such as CVD). Both trials we excluded reported statistically
significant reductions in their primary outcomes. Sacks 2017 took
the unusual step of meta-analysing only the primary outcome of
each trial (using a different outcome for each trial). They state
that this reduces outcome selection bias as they used pre-speci-
fied primary outcomes, but as none of these trials pre-published
protocols, their published composite primary outcomes may have
already experienced outcome selection bias (Chan 2004a; Chan
2004b). Our review avoided selection bias by assessing effects over
a wide selection of prespecified outcomes. Combining these di-
verse outcomes for these four trials, Sacks 2017 found that CVD
events were reduced by 29% (RR 0.71, 95% CI 0.62 to 0.81, I2 =
20%, with 60% of the weight of the analysis coming from the two
studies we excluded). This Cochrane Review concurs with Sacks
2017 in seeing reductions in serum total cholesterol where omega-
6 fats replace saturated fats. We did not subgroup by replacement
for secondary outcomes likemyocardial infarction.We found little
or no effect of increasing omega-6 fats at the expense of saturated
fats (when subgrouping for replacement) for all-cause mortality or
CVD mortality. We did see the suggestion of protection against
CVD events, CHD events and MACCEs when assessing effects of
omega-6 fats replacing saturated fats. However, all of these anal-
yses would be downgraded for risk of bias and imprecision (as a
minimum), so evidence would be of low quality at best.
We recently published a Cochrane Review of long-term RCTs that
assessed effects of reducing saturated fats, replacing them with a
variety of other energy sources (Hooper 2015). This review found
little or no effect of reducing saturated fats on all-cause mortal-
ity or CVD mortality, but the evidence suggested that reducing
saturated fats reduced the risk of CVD events (RR 0.83, 95% CI
0.72 to 0.96, I2 = 65%, including 4377 events in over 53,000 ran-
domised participants). Subgroup analyses assessing whether the
saturated fats were being replaced by PUFA, MUFA, carbohy-
drates and/or protein found that only where PUFA was replacing
SFA did this protection occur (RR 0.73, 95% CI 0.58 to 0.92, I2
= 69%, 884 events in over 3000 participants). The trials included
in the saturated fat review and this one are distinct due to rather
different inclusion criteria (for example, the saturated fat review
only included trials of at least two years’ duration and included tri-
als with dietary interventions of increased saturated fat plus other
dietary variables). The implications of the reviews are different,
but related: Hooper 2015 and Sacks 2017 suggest that reducing
saturated fat and replacement by polyunsaturated fats reduces the
risk of CVD events, while the present review suggests that increas-
ing omega-6 fats may reduce the risk of myocardial infarction, but
we did not find evidence of an effect on CVD events.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
We found that increasing omega-6 fats may reduce risk of my-
ocardial infarction (low-quality evidence), but 53 people would
need to increase the amount of omega-6 fat in their diet to prevent
one person having a myocardial infarction (NNTB 53, 95% CI
−334 to 28). Increasing omega-6 fats may make little or no differ-
ence to all-cause mortality or CVD events (low-quality evidence),
and we are uncertain of effects on CVDmortality, coronary heart
disease, MACCEs and stroke (very low-quality evidence). Overall
the evidence is limited by low numbers of events (data are impre-
cise), and risk of bias of included studies. Increasing omega-6 fats
does reduce serum total cholesterol in the long term, so increasing
omega-6 fats at the expense of saturated or monounsaturated fats
will support lower serum cholesterol (high-quality evidence).
In spite of its limitations, the weak evidence we collected in this
review appears to suggest that omega-6 fats are not harmful. There
is no evidence for increasing omega-6 fats to reduce cardiovascu-
lar outcomes other than myocardial infarction. Although the po-
tential benefit of omega-6 fats in reducing myocardial infarction
remains to be proven, increasing omega-6 fats may be of benefit
in patients with high risk of MI.
Implications for research
While we have included 19 trials in 6461 participants, there is a
need for further large trials of LA of at least five years’ duration
that are well randomised, with good allocation concealment, well
masked with pre-published trials registry entries. These large trials
should assess baseline omega-6 fat intake and include participants
with low omega-6 intakes at baseline, as well as those with higher
intakes. Trials are needed particularly in women and in low- and
middle-income countries as well as in high-income countries. Di-
etary advice needs to ensure that trans fat intake is kept low as
omega-6 fats increase, and omega-6 fat compliance and trans fat
status should be checked using biomarkers. These trials need to as-
sess effects of increasing dietary omega-6 fats (not supplements) in
place of saturated or monounsaturated fats and report important
adverse outcomes such as mortality and CVD events (including
coronary heart disease and stroke), plus potential harms such as
cancers, inflammatory bowel disease (IBD), diabetes, functional
outcomes, depression and dementia.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Bates 1977
Methods RCT, parallel, 4 arms (n-6 GLA + LA vsMUFA using either margarines or supplements)
, 2 years
Summary risk of bias: moderate to high
Participants People with chronic progressive multiple sclerosis
CVD risk: low
Intervention A, C: 38 per arm
Control B, D: 38 per arm
Mean years in trial: 2
% male: unclear (quote: ”no statistically significant difference between groups“)
Age: unclear (quote: ”no statistically significant difference between groups“)
Age range: unclear
Smokers: unclear
Hypertension: unclear
Medications taken by at least 50% of those in the control group: not reported
Medications taken by 20%-49% of those in the control group: not reported
Medications taken by some, but less than 20% of the control group: not reported
Location: UK
Ethnicity: not reported
Interventions Type: supplement
Comparison: GLA + linoleic (n-6) vs oleic (MUFA)
Intervention aims A: increase polyunsaturated fats with addition of 8 × 0.6 mL/d of
evening primrose oil (Naudicelle) in capsules (360 mg/d GLA plus 3.42 g/d linoleic acid
plus < 1% ALA)
Control aims B: increase monounsaturated fats with addition of 8 × 0.6mL/d of oleic
acid in capsules (4.8 g oleic acid/d)
A vs B dose aim: increase 0.34 g/d GLA, 3.78 g/d or 34 kcal or 1.7% E n-6
Intervention aims C: increase linoleic acid with addition of 11.5 g/d in a spread
Control aims D: increase oleic acid with addition of 4 g/d in a spread
C vs D dose aim: increase 11.5 g/d or 104 kcal or 5% E n-6
Baseline n-6: unclear
Compliance by biomarkers: unclear, no serum total cholesterol reported, no tissue fatty
acids reported
Compliance by dietary intake assessment: unclear, not reported
• Energy intake: not reported
• Total fat intake: not reported
• Saturated fat intake: not reported
• PUFA intake: not reported
• PUFA n-3 intake: not reported
• PUFA n-6 intake: not reported
• Trans fat intake: not reported
• MUFA intake: not reported
• CHO intake: not reported
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Bates 1977 (Continued)
• Sugars intake: not reported
• Protein intake: not reported
• Alcohol intake: not reported
Duration of intervention: 2 years
Outcomes Main study outcome: progression or regression of multiple sclerosis (MS)
Dropouts: A, 4; B, 7; C, 3; D, 4. (reported as died/withdrawn and not separated)
Available outcomes:MS progression (deaths clearly occurred, but reportedwith dropouts
(not separated) and the author did not have access to the data any longer)
Notes Study funding: Multiple Sclerosis Society, Van den Berghs provided intervention and
control spreads free
Response to contact: yes, Prof Bates states that data on mortality are no longer available.
Similar reply from Prof Robert Dworkin (who used Professor Bates’ data later for a joint
publication)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: ”randomly allocated“
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Paper states ”double blind“, capsules of
”identical appearance“ and ”similar spread“
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Paper states ”double blind“ with no further
details
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Deaths and dropouts combined; no reasons
for dropping out provided
Selective reporting (reporting bias) Unclear risk No protocol or trials registry entry located
Attention Bias Low risk Capsules and spreads provided to all par-
ticipants; no suggestion of attention bias
Compliance Unclear risk Not reported
Other bias Low risk None found
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Bates 1978
Methods RCT, parallel, 4 arms (n-6 GLA + LA vs MUFA and n-6 LA vs MUFA), 2 years
Summary risk of bias: moderate to high
Participants People with acute remitting multiple sclerosis
CVD risk: low
Intervention A, C: 29 per arm
Control B, D: 29 per arm
Mean years in trial: 2
% male: intervention A 34.48%; intervention C 17.24%; control B 34.48%; control D
37.93%
Mean age (SD) in years: intervention A 35 (9); intervention C 34 (8); control B 32 (7);
control D 33 (5)
Age range: unclear
Smokers: unclear
Hypertension: unclear
Medications taken by at least 50% of those in the control group: not reported
Medications taken by 20%-49% of those in the control group: not reported
Medications taken by some, but less than 20% of the control group: not reported
Location: UK
Ethnicity: not reported
Interventions Type: Supplement
Comparison: GLA and linoleic (n-6) vs oleic (MUFA)
Intervention aims A: 8 × evening primrose oil capsules (Naudicelle)/d, 2.92 g/d LA plus
0.34 g/d GLA
Control aims B: 8 × capsules/d (4 g/d oleic acid), 4 g/d MUFA
A vs B dose aim: increase 0.34 g/d GLA, 3.26 g/d or 29 kcal or 1.5% E n-6
Intervention aims C: linoleic acid spread (23 g/d linoleic acid)
Control aims D: oleic acid spread (16 g/d oleic acid)
C vs D dose aim: increase 23 g/d LA or 207 kcal or 10.4% E n-6
Baseline n-6: unclear
Compliance by biomarkers: good for C vs D, poor for A vs B, no serum total choles-
terol reported, ”estimations of total fatty acids in patients before and after 12-24 months’
treatment showed that the percentage of linoleic and arachidonic acids increased signif-
icantly only in those patients taking the linoleic acid spread (group C)“
Compliance by dietary intake: unclear, not reported
• Energy intake: not reported
• Total fat intake: not reported
• Saturated fat intake: not reported
• PUFA intake: not reported
• PUFA n-3 intake: not reported
• PUFA n-6 intake: not reported
• Trans fat intake: not reported
• MUFA intake: not reported
• CHO intake: not reported
• Sugars intake: not reported
• Protein intake: not reported
• Alcohol intake: not reported
Duration of intervention: 2 years
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Bates 1978 (Continued)
Outcomes Main study outcome: progression or regression of multiple sclerosis
Dropouts: A 0, B 1, C 3, D 6
Available outcomes: MS progression, deaths (no deaths in arms A, C and D, so only A
vs B has usable outcome data)
Notes Study funding: Multiple Sclerosis Society, Van den Berghs provided intervention and
control spreads free
Response to contact: yes, Prof Bates stated that the data are no longer available. Similar
reply from Prof Robert Dworkin (who used Professor Bates’ data later for a joint publi-
cation)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: ”randomly allocated“
Allocation concealment (selection bias) Unclear risk Quote: ”randomly allocated“
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Paper states ”double blind“, capsules of
”identical appearance“ and ”similar spread“
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Paper states ”double blind“ with no further
details
Incomplete outcome data (attrition bias)
All outcomes
Low risk Fairly well described, from 0 to 6 dropouts
per arm over 2 years (each 29 randomised)
Selective reporting (reporting bias) Unclear risk No protocol or trials registry entry located
Attention Bias Low risk Capsules and spreads provided to all par-
ticipants, no suggestion of attention bias
Compliance High risk A vs B compliance poor by biomarkers
Other bias Low risk None found
Belch 1988
Methods RCT, parallel, 2 arms (n-6 evening primrose oil vs non-fat paraffin), 12 months
Summary risk of bias: moderate to high
Participants People with rheumatoid arthritis (RA)
CVD risk: low
Intervention 16 randomised, 16 analysed
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Belch 1988 (Continued)
Control 18 randomised, 18 analysed
Mean years in trial: 1
% male: intervention 6%; control 6%
Age, years: intervention median 46 years, control 48 years
Age range: intervention 35-68 years, control 30-74 years
Smokers: unclear
Hypertension: unclear
Medications taken by at least 50% of those in the control group: NSAIDs
Medications taken by 20%-49% of those in the control group: not reported
Medications taken by some, but less than 20% of the control group: not reported
Location: UK
Ethnicity: not reported
Interventions Type: supplement
Comparison: GLA (n-6) vs non-fat
Intervention aims: 12 capsules of evening primrose oil (Efamol), including 540 mg of
gamma linolenic acid (GLA) per day
Control aims B: 12 capsules of liquid paraffin per day
Dose aim: increase 0.54 g/d GLA, 5 kcal or 0.25% E GLA, assume 70% LA*, 4.2 g/d
or 37.8 kcal/d or 1.9% E LA, 2.2% E n-6
Baseline n-6: unclear
Compliance by biomarkers: no serum total cholesterol or blood markers reported
Compliance by dietary intake: unclear, not reported
• Energy intake: not reported
• Total fat intake: not reported
• Saturated fat intake: not reported
• PUFA intake: not reported
• PUFA n-3 intake: not reported
• PUFA n-6 intake: not reported
• Trans fat intake: not reported
• MUFA intake: not reported
• CHO intake: not reported
• Sugars intake: not reported
• Protein intake: not reported
• Alcohol intake: not reported
Duration of intervention: 1 year
Outcomes Main study outcome: RA activity and NSAID dose
Dropouts: intervention 0, control 0
Available outcomes: ESR, CRP, functional status, RA status, NSAID use (authors stated
that no deaths or CVD events occurred during the trial)
Notes Study funding: Action Research for the Crippled Child, and Efamol Ltd provided the
supplements
Response to contact: Dr Belch contacted and provided some additional information,
stating that no deaths or CVD events occurred
Risk of bias
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Belch 1988 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: ”randomized double blind fash-
ion“, no detail provided
Allocation concealment (selection bias) Unclear risk As above, randomisation method not de-
scribed.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: ”All three types of capsules were
supplied by Efamol Ltd and were visually
identical. The capsules were issued to the
patients in a randomized double blind fash-
ion“. Participants andpersonnel were prob-
ably blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: ”Table 2 shows the number of pa-
tients withdrawn from the study by 12
months. One patient in the EPO group
and two in the EPO/fish oil group were
withdrawn owing to increasing symptoms
of RA, compared with 10/18 of the placebo
patients (both P < 0.001, Mann-Whitney)
. The results from all patients who were
withdrawn were analyzed throughout the
study on an intention to treat basis“
Selective reporting (reporting bias) Unclear risk No trial protocol or trials registry entry lo-
cated
Attention Bias Low risk Appeared appropriate. Quote: ”All partic-
ipants in all groups needed to attend the
clinic at monthly intervals for the first six
months and thereafter at 3 monthly inter-
vals.“
Compliance Unclear risk No serum lipid, serum fatty acid or dietary
intake data provided
Other bias Low risk None noted
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Black 1994
Methods RCT, parallel, (low fat diet vs usual diet), 24 months
Summary risk of bias: moderate or high
Participants People with non-melanoma skin cancer
N: 66 intervention, 67 control (analysed, 57 intervention, 58 control)
Level of risk for CVD: low
Male: 54% intervention, 67% control
Mean age in years (SD): 50.6 (9.7) intervention, 52.3 (13.2) control
Age range: not reported
Smokers: not reported
Hypertension: not reported
Medications taken by at least 50% of those in the control group: not reported
Medications taken by 20%-49% of those in the control group: not reported
Medications taken by some, but less than 20% of the control group: not reported
Location: USA
Ethenicity: white 100% (excluded from study if of Asian, Black, Hispanic or American
Indian ancestry)
Interventions Type: dietary advice
Comparison: reduced fat (lower omega-6 + total PUFA) vs usual diet (CHO + protein)
Intervention: aims total fat 20% E, protein 15% E, CHO 65% E; methods 8 × weekly
classes plus monthly follow up sessions, with behavioural techniques being taught fol-
lowing individual approach (not clear if in a group or individual). At 4-month intervals,
clinic examination by dermatologist. Intervention delivered face-to-face by a dietitian
Control: aims usual diet;methods nodietary change, clinic examinationby dermatologist
at 4-month intervals
Dose aim: reduce total fat to 20% E, including omega-6 and total PUFA (no aim
provided)
Baseline n-6: unclear, but baseline PUFA 8% E
Compliance by biomarkers: unclear, no serum total cholesterol reported, no tissue fatty
acids
Compliance by dietary intake: all assessed ”during study“, months 4-24, using 7-day
food records verified by a dietitian
• Energy intake: control 2196 kcal/d (SD 615), intervention 1995 kcal/d (SD 564)
• Total fat intake: control 37.8% E (SD 4.1), intervention 20.7% E (SD 5.5) (MD
−17.10%, 95% CI −18.88 to −15.32) significant reduction
• Saturated fat intake: control 12.8% E (SD 2.0), intervention 6.6% E (SD 1.8),
(MD −6.20%, 95% CI −6.90 to −5.50) significant reduction
• PUFA intake: control 7.8% E (SD 1.4), intervention 4.5% E (SD 1.3), (MD −3.
30%, 95% CI −3.79 to −2.81) significant reduction
• PUFA n-3 intake: not reported
• PUFA n-6 intake: LA, control 16.9 g (SD 5.6), intervention 8.5 (SD 3.3)
• Trans fat intake: not reported
• MUFA intake: control 14.4% E (SD 1.7), intervention 7.6% E (SD 2.2), (MD
−6.80%, 95% CI −7.52 to −6.08) significant reduction
• CHO intake: control 44.6% E (SD 6.9), intervention 60.3% E (SD 6.3), (MD
15.70%, 95% CI 13.29 to 18.11) significant increase
• Sugars intake: not reported
• Protein intake: control 15.7% E (SD 2.4), intervention 17.7% E (SD 2.2), (MD
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Black 1994 (Continued)
2.00%, 95% CI 1.16 to 2.84) significant increase
• Alcohol intake: control 3.2% E (SD 3.9), intervention 3.2% E (SD 3.4)
Duration of intervention: 24 months (mean 1.9 years in trial)
Outcomes Main study outcome: incidence of actinic keratosis and non-melanoma skin cancer
Dropouts: unclear intervention, unclear control
Available outcomes: deaths, CVD deaths, cancer deaths (none), (weight data provided
but without variance)
Notes Study funding: National Cancer Institute
Response to contact: Prof Black provided data on mortality
NOTE: for this trial the higher PUFA arm is the control, and lower PUFA arm is the
intervention
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: ”list of randomly generated num-
bers“
Allocation concealment (selection bias) Unclear risk Randomisation method not clearly de-
scribed
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Dietary advice provided, so participants
not blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: ”examined .... by dermatologists
unaware of their treatment assignments“.
Deaths (all-cause and CVD) not consid-
ered relevant to the intervention
Incomplete outcome data (attrition bias)
All outcomes
Low risk For mortality. Unclear for other outcomes
Selective reporting (reporting bias) Unclear risk No protocol or trials registry entry found
Attention Bias High risk Weekly classes and monthly follow-up in
intervention group, 4-monthly check-ups
only in control
Compliance Low risk Dietary intake data suggest omega-6 and
total PUFA were significantly reduced in
the intervention arm
Other bias Low risk None noted
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DART 1989
Methods Diet And Reinfarction Trial (DART)
RCT, 2 × 2 × 2 factorial (n-6 LA vs SFA), also increased fish and increased fibre arms, 2
years
Summary risk of bias: moderate to high
Participants Men recovering from an MI
CVD risk: high
Control: randomised 1015, analysed unclear
Intervention: randomised 1018, analysed unclear
Mean years in trial: control 1.9, intervention 1.9
% male: 100%
Mean age in years: control 56.8, intervention 56.4
Age range: all < 70 years
Smokers: control 62.7%, intervention 61.2%
Hypertension: control 23.3%, intervention 24%
Medications taken by at least 50% of those in the control group: not reported
Medications taken by 20%-49% of those in the control group: beta-blockers, other anti-
hypertensive drugs, anti-anginals
Medications taken by some, but less than 20% of the control group: anti-coagulant,
aspirin, other anti-platelets, digoxin, other cardiac drugs
Location: UK
Ethnicity: not reported
Interventions Type: dietary advice
Comparison: increased polyunsaturated oil and margarines (n-6) vs usual dietary fats
(SFA)
Intervention aims: reduce fat intake to 30% E, increase polyunsaturated: saturated fatty
acid ratio to 1.0 (using polyunsaturated oils and margarines), weight reducing advice
if BMI > 30 kg/m2 (dietitians provided the participants and their wives with initial
individual advice and a diet information sheet; participants were revisited for further
advice, recipes, encouragement at 1, 3, 6, 9, 12, 15, 18 and 21 months)
Control aims: no dietary advice on fat, weight reducing advice if BMI > 30 kg/m2
(dietitians provided ’sensible eating’ advice without specific information on fats)
Dose aim: unclear
Baseline n-6: unclear, but control PUFA intake 6.6% E
Compliance by biomarkers: good, serum total cholesterol significantly reduced in in-
tervention compared to control (−0.26 mmol/L, 95% CI −0.37 to −0.15)
Compliance by dietary intake: assessed using a 7 day weighted food diary, of a 25%
random sub-sample
• Energy intake: intervention 7.3 MJ/d (SD 1.8), control 7.7 MJ/d(SD 1.9)
• Total fat intake: intervention 31% E (SD 7), control 35% E (SD 6)
• Saturated fat intake: intervention 11% E (SD 3), control 15% E (SD 3), dose
−4% E
• PUFA intake: intervention 9.4% E, control 6.6% E, dose +2.8% E (most of
which omega-6)
• PUFA n-3 intake: not reported
• PUFA n-6 intake: not reported
• Trans fat intake: not reported
• MUFA intake: not reported
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DART 1989 (Continued)
• CHO intake: intervention 46% E (SD 7), control 44% E (SD 6)
• Sugars intake: not reported
• Protein intake: intervention 18 % E (SD 4), control 17 % E (SD 4)
• Alcohol intake: intervention 5% E (SD 6), control 4% E (SD 6)
Duration of intervention: 2 years
Outcomes Main study outcomes: mortality, reinfarction
Dropouts: all followed for events regardless of compliance (ITT)
Available outcomes: CVD events (CVD deaths plus non-fatal MI), cancer deaths, total
MI, non-fatal MI, total and HDL cholesterol. Data set used to examine causes of death
during trial, these data added
Notes Note: this was a 2 × 2 × 2 factorial trial, and so some in each group were randomised to
increased fatty fish and/or increased cereal fibre
Study funding: Welsh Scheme for Development of Health and Social Research, Welsh
Heart Research Foundation, Flora Project (commercial), Health Promotion Research
Trust
Response to contact: yes, ProfBurr provided extensive additional data and information
on methodology
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomised using sealed envelopes. The
random sequence was generated by the tri-
als unit and sequentially numbered (per-
sonal communication with Prof Burr)
Allocation concealment (selection bias) Unclear risk Unclear if envelopes were opaque (Profes-
sor Burr, personal communication, stated
that he did not know)
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Very difficult to blind trials where par-
ticipants need to make their own dietary
changes
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: ”outcome assessors were not aware
of study allocation“ (Prof Burr, personal
communication). Method of blinding not
stated
Incomplete outcome data (attrition bias)
All outcomes
Low risk GPs contacted for information on mortal-
ity and morbidity when patients did not
attend
Selective reporting (reporting bias) Unclear risk No protocol or trials registry entry located
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DART 1989 (Continued)
Attention Bias High risk Almost all participants received dietary ad-
vice - some on 3 diets, some 2, some 1
and some none. All those receiving dietary
fat advice will have received dietary advice,
while 25% of those in the control received
no dietary advice, dietetic time or attention
Compliance Low risk Compliance good as assessed by biomarkers
Other bias Low risk None found
Dullart 1992
Methods RCT, parallel, 2 arms (n-6 LA vs SFA), 2 years
Summary risk of bias: moderate to high
Participants Type I diabetics with elevated urinary albumin
CVD risk: moderate
Control: randomised 20, analysed 20
Intervention: randomised 18, analysed 16
% male: 81% intervention, 75% control
Mean (SD) age in years: control 41 (14), intervention 44 (12)
Age range: unclear (21-65 inclusion)
Smokers: control 55%, intervention 50%
Hypertension: control 10%, intervention 6%
Medications taken by at least 50% of those in the control group: insulin
Medications taken by 20%-49% of those in the control group: not reported
Medications taken by some, but less than 20% of the control group: anti-hypertensive
drugs
Location: Netherlands
Ethnicty: not reported
Interventions Type: dietary advice
Comparison: LA (n-6) vs usual diet
Intervention: diet advice given at every visit throughout the 2-year period to increase
linoleic acid achieving a polyunsaturated: saturated fatty acid ratio close to 1.0. Advice
to replace butter or saturated margarines by polyunsaturated margarines and to restrict
the intake of saturated fat from meat and milk products
Control: to continue their usual diet. All participants were urged not to alter total fat
and protein content
Dose: (intake data) intervention group 13% E SFA, P/S 0.985, PUFA 9.4% E. Control
group 15% E SFA, P/S 0.45, PUFA 6.6% E (CHO and protein were consistent between
groups across the trial). Increase 2.8% E PUFA, most of which n-6
Baseline n-6: unclear, 6.6% E PUFA, most of which was n-6
Compliance: poor, no significant difference between plasma cholesteryl ester LA in
intervention and control at 2 years
Plasma cholesteryl esters at 2 years
• LA mol %: intervention 62.2% (SD 4.2), control 57.4% (SD 4.9)
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Dullart 1992 (Continued)
• Oleic acid mol %: intervention 13.7% (SD 1.8), control 16.5% (SD 1.4)
Dietary assessment using 1 week dietary recall, reported at 2 years
• Energy intake: intervention 7.42 MJ/d (SD 2.02), control 8.48 MJ/d (SD 2.48)
• Total fat intake: intervention 37% E (SD 4), control 40% E (SD 7)
• Saturated fat intake: intervention 13% E (SD 2), control 16% E (SD 3)
• PUFA intake: not reported
• PUFA n-3 intake: not reported
• PUFA n-6 intake: not reported
• n-6 LA: intervention 11% E (SD 2), control 7% E (SD 3)
• PUFA/SFA ratio: intervention 0.96% E (SD 0.16), control 0.56% E (SD 0.25)
• MUFA intake: not reported
• CHO intake: intervention 43% E (SD 4), control 41% E (SD 7)
• Protein intake: intervention 18% E (SD 4), control 17% E (SD 3)
• Trans fat intake: not reported
• Cholesterol intake, mg/d: intervention 174 (SD 49), control 245 (SD 120)
Duration of intervention: 2 years
Outcomes Main study outcomes: albuminurea and lipids
Dropouts: intervention 2 of 20, control 4 of 20
Available outcomes: weight, HDL cholesterol, TGs, HbA1c (total cholesterol, LDL,
glucose, insulin reported but too different at baseline to use, renal outcomes such as
GFR, albuminurea, mean arterial pressure not used)
Notes Most outcomes are estimated from figures
Study funding: Dutch Diabetes Research Fund
Response to contact: yes, Prof Dullart confirmed that no CVD events or deaths occurred
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: ”patients were stratified according
to sex and randomised in blocks of tenmen
and six women“
Allocation concealment (selection bias) Low risk Assigned using opaque sealed envelopes by
independent statistical investigator with no
contact with participants
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No information on blinding. Participants
could not be blinded as they received di-
etary advice
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No details
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Dullart 1992 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No details on dropouts apart from the ex-
clusion of 2 intervention participants from
the trial due to pregnancy and decision not
to participate
Selective reporting (reporting bias) Unclear risk No protocol or trial registration located
Attention Bias High risk Intervention groups received diet advice at
every visit. As the control group were ad-
vised to stick to their usual diet it is likely
that they received less attention and time
Compliance High risk Compliance poor assessed by biomarkers
Other bias Low risk None noted
GLAMT 1993
Methods Gamma linolenic acid multicentre trial (GLAMT)
RCT, 2-arm, parallel (n-6 GLA vs non-fat), 1 year
Summary risk of bias: moderate to high
Participants People with mild diabetic neuropathy
CVD risk: moderate
Control: randomised 57, analysed 48 (with at least one evaluation)
Intervention: randomised 54, analysed 52
Mean years in trial: control 1.0, randomised 1.0
% male: control 79%, intervention 67%
Mean age (SD) in years: control 52.9 (11.4), intervention 53.3 (11.1)
Age range: unclear
Smokers: unclear
Hypertension: unclear
Medications taken by at least 50% of those in the control group: insulin
Medications taken by 20%-49% of those in the control group: not reported
Medications taken by some, but less than 20% of the control group: not reported
Location: UK and Finland
Ethnicity: not reported
Interventions Type: supplement
Comparison: GLA (n-6) vs placebo (paraffin)
Control aims: 12 capsules/d paraffin
Intervention aims: 12 capsules/d evening primrose oil (EP4, equivalent to Epogam): 0.
48 g/d GLA plus LA (stated as the major constituent, dose not given, if assume 0.7 g/
capsule then 8.4 g/d*)
Dose aim: increase 0.48 g/d GLA or 4 kcal or 0.2% E GLA, increase ~8.4 g/d LA or
76 kcal or 3.8% E LA, total 4% E n-6
Baseline n-6: unclear
Compliance by biomarkers: unclear, no serum total cholesterol or tissue fatty acid levels
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GLAMT 1993 (Continued)
reported
Compliance by dietary intake: unclear
• Energy intake: not reported
• Total fat intake: not reported
• Saturated fat intake: not reported
• PUFA intake: not reported
• PUFA n-3 intake: not reported
• PUFA n-6 intake: not reported
• Trans fat intake: not reported
• MUFA intake: not reported
• CHO intake: not reported
• Sugars intake: not reported
• Protein intake: not reported
• Alcohol intake: not reported
Duration of intervention: 1 year
Outcomes Main study outcome: measures of diabetic neuropathy
Dropouts: control 17, intervention 10
Available outcomes: MI, cancer (no deaths)
Notes Study funding: Scotia Pharmaceuticals
*EPO described as being ~70% LA in some publications, this and a 1-g capsule size have
been assumed where no other details are provided
Response to contact: no response to our attempted contact
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Described as double-blind, and ”[a]ctive
and placebo capsules were indistinguish-
able in taste or appearance“
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Unclear, though study described as double-
blind no methods or statement of blinding
of outcome assessors was mentioned
Incomplete outcome data (attrition bias)
All outcomes
High risk Reasons for withdrawal usually given, but
high and dissimilar
Selective reporting (reporting bias) Unclear risk No clear protocol or trials registry entry
found
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GLAMT 1993 (Continued)
Attention Bias Low risk Capsule only intervention and provided to
all, other followups appeared consistent for
all
Compliance Unclear risk Not reported
Other bias Low risk None identified
Houtsmuller 1979
Methods RCT, parallel, (increase LA vs usual diet), 72 months maximum
Summary risk of bias: moderate or high
Participants Adults with newly diagnosed diabetes
N: 51 intervention, 51 control (analysed unclear intervention, unclear control)
Level of risk for CVD: moderate
Male: 56% overall (not stated by intervention arm)
Mean age (SD): not reported
Age range: not reported
Smokers: not reported
Hypertension: not reported
Medications taken by at least 50% of those in the control group: not reported
Medications taken by 20%-49% of those in the control group: not reported
Medications taken by some, but less than 20% of the control group: statins (probably)
Location: Netherlands
Ethenicity: not reported
Interventions Type: dietary advice
Comparison: omega-6 vs SFA and CHO
Intervention: aims total fat 40% E, 1/3 linoleic acid, CHO 45% E, protein 15% E;
methods unclear, surveyed by dietitian. Intervention appears to be delivered by dietitian
but no clear details on format or frequency
Control: aims SFA 35% E, CHO 50% E, protein 15% E; methods unclear, surveyed by
dietitian
Dose aims: increase ~9% E LA (aims imply no LA in control, but paper states LA was 4
× higher in intervention than control, est 3% E control, 12% E intervention, so increase
of ~9% E)
Baseline n-6: unclear
Compliance by biomarkers: good, serum total cholesterol significantly reduced in in-
tervention compared to control (−0.47mmol/L, 95% CI −0.76 to −0.18), no signifi-
cant differences in men, but significant improvements in women from 3 years
Compliance by dietary intake: unclear (not reported)
• Energy intake: not reported
• Total fat intake: not reported
• Saturated fat intake: not reported
• PUFA intake: not reported
• PUFA n-3 intake: not reported
• PUFA n-6 intake: not reported
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Houtsmuller 1979 (Continued)
• Trans fat intake: not reported
• MUFA intake: not reported
• CHO intake: not reported
• Sugars intake: not reported
• Protein intake: not reported
• Alcohol intake: not reported
Duration of intervention: 72 months
Outcomes Main study outcome: progression of diabetic retinopathy
Dropouts: unclear
Available outcomes: CHD events (total MI and angina), total cholesterol, TGs (data
read off graph), CHDmortality (fatal MI), progression of retinopathy, GTT and insulin
(measured but results are reported in figures for a subgroup)
Notes Study funding: Dutch Heart Foundation
Response to contact: attempted but no contact established
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Participants matched in pairs then ran-
domised
Allocation concealment (selection bias) Unclear risk Randomisation method not clearly de-
scribed
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Unclear, though unlikely as dietary advice
provided
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Blinding of outcome assessors not men-
tioned
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Unclear, deaths, cancer and CV events are
drop-outs, trialists asked for data - unclear
if any data missing
Selective reporting (reporting bias) Unclear risk No protocol or trials registry entry found
Attention Bias Unclear risk Unclear as methods unclear
Compliance Low risk Compliance good assessed by biomarkers
Other bias High risk Some concerns around fraud in the first au-
thors later research on diet in cancer. No al-
legations found regardinghis research in di-
abetes (but much information is in Dutch).
65Omega-6 fats for the primary and secondary prevention of cardiovascular disease (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Houtsmuller 1979 (Continued)
Numbers of events are not clear by arm and
assumed from adding across various publi-
cations
Mansel 1990
Methods RCT, 2 arm, parallel (n-6 GLA vs non-fat), 1 year
Summary risk of bias: moderate to high
Participants Women with macroscopic breast cysts
CVD risk: low
Intervention: 100
Control: 100
Mean years in trial: 1
% male: 0
Age: unclear (no statistically significant difference between groups)
Age range: 35 to 60 years
Smokers: unclear
Hypertension: unclear
Medications taken by at least 50% of those in the control group: not reported
Medications taken by 20%-49% of those in the control group: not reported
Medications taken by some, but less than 20% of the control group: not reported
Location: UK
Ethnicity: not reported
Interventions Type: supplement
Comparison: GLA (n-6) vs placebo (paraffin)
Intervention aims: 6 capsules/d EPO (Efamol) containing ≥ 9% GLA (total volume
unclear)
Control aims: 6 capsules/d paraffin (total volume unclear)
Dose: (assuming each capsule is 1 g) increase 0.54 g/d GLA, increase 6 g/d or 54 kcal
or 2.7% E n-6
Baseline n-6: unclear
Compliance: unclear
Duration of intervention: 1 year
Outcomes Main study outcome: unclear, recurrent cysts?
Dropouts: intervention 7, control 8
Available outcomes: breast cancer (no deaths or CVD events appear to have occurred)
Response to contact: no response to attempted contact
Notes Study funding: not stated
Risk of bias
Bias Authors’ judgement Support for judgement
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Mansel 1990 (Continued)
Random sequence generation (selection
bias)
Unclear risk Quote: ”randomised“
Allocation concealment (selection bias) Unclear risk Randomisation process not discussed
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Placebo controlled but similarity of placebo
unclear; paper suggests that participants
and physicians were blinded to allocation
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Quote: ”examined by a clinician who
was blind to the treatment allocated“ but
method of this blinding unclear
Incomplete outcome data (attrition bias)
All outcomes
Low risk Attrition below 20% and well documented
Selective reporting (reporting bias) Unclear risk No protocol or trials registry entry found
Attention Bias Low risk All seen 2-monthly, all took capsules, clin-
icians blind to treatment allocation
Compliance Unclear risk Not reported
Other bias Low risk None noted
McIllmurray 1987
Methods RCT, parallel, 2 arms (GLA vs ”inert placebo“), 40 months
Summary risk of bias: moderate to high
Participants People within one month following operation to remove Dukes’s C colorectal cancer
N: intervention 25 (plus some dropouts), control: 24 (plus some dropouts (analysed
intervention 25, control 24). 5 dropped out, but arms unclear
Level of risk for CVD: low
Male: not reported
Mean age (SD) in years: intervention 62.1 (not reported), control 64.8 (not reported)
Age range: intervention 48-81, control 45-77
Smokers: not reported
Hypertension: not reported
Medications taken by at least 50% of those in the control group: not reported
Medications taken by 20%-49% of those in the control group: not reported
Medications taken by some, but less than 20% of the control group: not reported
Location: UK
Ethnicity: not reported
Interventions Type: supplement (EPO)
Comparison: GLA vs ”inert placebo“ (unclear what)
Intervention: 6 capsules/d containing 500 mg GLA plus 10 mg natural vitamin E
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McIllmurray 1987 (Continued)
(Efamol). GLA 0.5 g/d, 60 mg/d vitamin E plus vitamin supplements including vitamin
C, zinc sulphate and pyridoxine
Control: 6 capsules/d containing an inert placebo, identical in appearance (not specified
what). Plus vitamin supplements including vitamin C, zinc sulphate and pyridoxine
Dose aim: (assuming placebo contains no PUFA) increase 0.5 g/d GLA, 5 kcal or 0.
2% E GLA, assume 70% LA*, 4.2 g/d or 37.8 kcal/d or 1.9% E LA, 2.1% E n-6
Baseline n-6: unclear
Compliance by biomarkers: unclear, no serum total cholesterol or tissue fatty acid levels
reported
Compliance by dietary intake: unclear, states that one participant stopped taking the
supplements at 12 months
• Energy intake: not reported
• Total fat intake: not reported
• Saturated fat intake: not reported
• PUFA intake: not reported
• PUFA n-3 intake: not reported
• PUFA n-6 intake: not reported
• Trans fat intake: not reported
• MUFA intake: not reported
• CHO intake: not reported
• Sugars intake: not reported
• Protein intake: not reported
• Alcohol intake: not reported
Duration of intervention: 40 months
Outcomes Main study outcome: unclear, ”survival“, probably mortality
Dropouts: 5 (unclear from which groups)
Available outcomes: mortality, cancer mortality (face flushing reported as a side effect,
but no numbers provided and assumed due to concomitant pyridoxine)
Notes Study funding: not stated, Efamol Ltd provided the EPO capsules and inert capsules
*EPO described as being ~70% LA in some publications, this and a 1 g capsule size have
been assumed where no other details are provided
Response to contact: Prof McIllmurray replied ”I don’t have the records ... so I have
nothing more than what appears in the publication. I do not recall there being any
cardiovascular events.“
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: ”assigned at random“
Allocation concealment (selection bias) Unclear risk No details
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk No details apart from the placebowas iden-
tical in appearance to the EPO capsules
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McIllmurray 1987 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 5 dropouts, unclear from which arms
Selective reporting (reporting bias) Unclear risk No protocol or trials register entry found
Attention Bias Low risk Probably as intervention was capsules in
both groups
Compliance Unclear risk Not stated
Other bias Unclear risk None noted, but contents of placebo cap-
sules unclear
Mendis 2001
Methods RCT, 2 arm, parallel (n-6 LA vs non-fat), 1 year
Summary risk of bias: moderate to high
Participants Healthy volunteers responding to survey. Some had hyperlipidaemia
CVD risk: low
N: 30 intervention, 30 control (analysed 26 intervention, 28 control)
% male: 78% (total)
Mean age: not reported
Age range: 20-65 years
Smokers: not reported
Hypertension: not reported
Medications taken by at least 50% of those in the control group: not reported
Medications taken by 20%-49% of those in the control group: not reported
Medications taken by some, but less than 20% of the control group: not reported
*Lipid lowering medications as well as many others were not allowed
Location: Sri Lanka
Ethnicity: 100% Sri Lanakan
Interventions Type: diet advice plus test fat supplement
Comparison: n-6 vs non-fat (unclear if CHO, protein or both)
Intervention: group B received a diet containing 20% E as fat (4.7% coconut fat) plus
7.5 g/day test fat containing soybean fat-sesame fat (3:1, v/v containing PUFA:MUFA
ratio 2). Fat intake in group B was, therefore, 24% E (test fat provided additional 5 g/d
PUFA mainly LA)
Control: group A received a diet containing 20% E as fat (4.7% E coconut fat)
Dose aim: increase 5 g/d PUFA or 45 kcal or 2.2% E PUFA, assume~2% E LA
Baseline n-6: unclear
Compliance by biomarkers: poor, serum total cholesterol was not significantly reduced
in intervention compared to control (0.16 mmol/L, 95% CI−0.18 to 0.50). The inter-
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Mendis 2001 (Continued)
vention group were stated as having higher dietary PUFA:SFA ratio than controls, but
no blood levels of FAs were reported
Compliance by dietary intake: unclear, measured by field workers’ visits and using food
diaries
• Energy intake: intervention 7962 kJ/d (SD 1568), control 8030 kJ/d (SD 1465)
• Total fat intake: intervention 24% E (SD not reported), control 20% E (SD not
reported)
• Saturated fat intake: intervention 11.4% E (SD not reported), control 11.8% E
(SD not reported)
• PUFA intake: not reported (unsaturated fat intake intervention 12.6% E, control
8.2% E, test fat reported as mainly LA)
• PUFA n-3 intake: not reported
• PUFA n-6 intake: (unsaturated fat intake intervention 12.6% E, control 8.2% E,
test fat reported as mainly LA)
• Trans fat intake: not reported
• MUFA intake: not reported
• CHO intake, % E: intervention 64 (SD not reported), control 67 (SD not
reported)
• Sugars intake: not reported
• Protein intake: intervention 12.2% E (SD not reported), control 12.1% E (SD
not reported)
• Alcohol intake: not reported
Duration of intervention: 1 year
Outcomes Main study outcome: serum lipids
Dropouts: intervention 4, control 2
Available outcomes: lipids
Notes Study funding: National Science Foundation of Sri Lanka
Response to contact: no response to attempted contact
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Participants were randomised to 2 groups
(groups A and B). This was done in such
a way that the 38 hyperlipidaemic subjects
were equally divided between the 2 groups
Allocation concealment (selection bias) Unclear risk No details
Blinding of participants and personnel
(performance bias)
All outcomes
High risk The groups had different diets with test fat
added to intervention group
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No details
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Incomplete outcome data (attrition bias)
All outcomes
High risk 6 participants dropped out at 6months but
their data is not included in the analysis at
all
Selective reporting (reporting bias) Unclear risk No protocol or trial register entry found
Attention Bias Low risk Both groups had twice weekly visits by field
workers
Compliance High risk Compliance poor when assessed by
biomarkers
Other bias Unclear risk No details provided on the form or method
of supply of diet or test fat
MRC 1968
Methods Medical Research Council (MRC)
RCT, 2 arm, parallel (n-6 LA vs mixed fats), 4 years
Summary risk of bias: moderate to high
Participants Free-living men who have survived a first MI (UK)
CVD risk: high
Control: randomised 194, analysed 181 at 2 years
Intervention: randomised 199, analysed 172 at 2 years
Mean years in trial: control 3.7, intervention 3.8
% male: 100
Age: unclear
Age range: all < 60 years
Smokers: control 84%, intervention 81%
Hypertension: control 12%, intervention 8%
Medications taken by at least 50% of those in the control group: not reported
Medications taken by 20%-49% of those in the control group: not reported
Medications taken by some, but less than 20% of the control group: not reported
Location: UK
Ethnicty: not reported
Interventions Type: diet advice plus supplement
Comparison: increased soya oil (n-6) vs usual diet (some SFA replacement, otherwise
unclear)
Control aims: usual diet
Intervention aims: reduce dietary fat to 35 g/d fat, add 84 g/d soya oil
Dose aim: increase 84 g/d soya oil or 756 kcal or 37.8% E soya (assume 50% LA, so
18.9% E LA, assume 58% PUFA so21.9% E PUFA)
Baseline n-6: unclear
Compliance by biomarkers: unclear, serum total cholesterol reported but without any
variance info. Report stated that ”tissue fat of the men on the soya-bean oil diet was less
saturated than that of the controls“ and that further information would be published
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elsewhere. No statistical significance or variance data mentioned
Compliance by dietary intake: unclear
• Energy intake: intervention 2380 kcal/d (SD not reported), control 2274 kcal/d
(SD not reported)
• Total fat intake: not reported
• Saturated fat intake: not reported
• PUFA intake: not reported
• PUFA n-3 intake: not reported
• PUFA n-6 intake: not reported
• Trans fat intake: not reported
• MUFA intake: not reported
• CHO intake: intervention 243 g/d (SD not reported), control 228 g/d (SD not
reported)
• Sugars intake: intervention 66 g/d (SD not reported), control 60 g/d (SD not
reported)
• Protein intake: intervention 80 g/d (SD not reported), control 88 g/d (SD not
reported)
• Alcohol intake: not reported
Duration of intervention: 4 years
Outcomes Main study outcomes: MI or sudden death
Dropouts: intervention 199 randomised, 181 at 2 years, 91 at 4 years. Control: 194
randomised, 172 at 2 years, 85 at 4 years
Available outcomes: mortality, CVD mortality (CVD deaths plus non-fatal MI), total
MI, non-fatal MI (data for weight, total cholesterol and BP, but no variance info)
Notes Study funding: Medical Research Council
Response to contact: reply from retired trial statistician, JA Heady, in 1999
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: ”using random numbers, by blocks
within hospitals“
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Big changes to fat intake in intervention
group while control group ate their usual
diet
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: ”[s]uspected relapses were assessed
at regular intervals by a review committee
unaware of the patients diet group“
Incomplete outcome data (attrition bias)
All outcomes
High risk Data collection was thorough, but some
participants dropped out and contact was
lost
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Selective reporting (reporting bias) Unclear risk No protocol or trials registry entry located
Attention Bias High risk Likely that intervention group received
more time, training and encouragement (as
dietary intervention, and control ate usual
diet)
Compliance Unclear risk Not reported
Other bias Low risk None noted
NDHS Faribault 1968
Methods National Diet-Heart Study (NDHS) - Faribault site
RCT, several arms, parallel (n-6 LA vs SFA + MUFA), 1 year
Summary risk of bias: low
Participants Men living in a mental health institute
CVD risk: low
Control: randomised 57, analysed 52
Interventions B, C, E combined: randomised 167, analysed 143
Mean years in trial: control 1.0, Interventions 0.9
% male: 100
Age: unclear
Age range: all 45-54 years
Smokers: 55% to 59% current smokers in each arm
Hypertension: unclear
Medications taken by at least 50% of those in the control group: not reported
Medications taken by 20%-49% of those in the control group: not reported
Medications taken by some, but less than 20% of the control group: not reported
Location: USA
Ethnicty: not reported
Interventions Type: diet provided (residential institution)
Comparison: increased PUFA (n-6) vs usual institutional diet (SFA + MUFA)
Control aims: total fat 40% E, SFA 16-18% E, dietary cholesterol 650-750 mg/d, P/S
0.4 (so PUFA 6.8% E) (whole diet provided)
Intervention aims: B (C, E) total fat 30% E (40% E, 40% E), SFA < 9% E (< 9% E,
not stated), dietary cholesterol 350-450 mg/d (350-450 mg/d, not stated), PUFA 15%
E (18-20% E, not stated), P/S 1.5 (2.0, 4.4) (equivalent to Minnesota Coronary Study
diet) (whole diet provided)
Dose aim: increase B 8.2% E, C 12.2% E, E unclear n-6
Baseline n-6 (table IX2): 4.4% E LA, 4.8% E PUFA
Compliance by biomarkers: good, serum total cholesterol significantly reduced in in-
tervention compared to control (−0.91 mmol/L, 95% CI −1.17 to −0.65). Data on
fatty acid composition of red blood cells provided in chapter 10 (table X6: LA rose by 4
in control, by 5 to 7 in other arms, at the expense of MUFA which rose by 1 in control,
fell by 4 or 5 in other arms. Palmitic acid fell by 5 in control, and fell by 4 in intervention
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arms, stearic did not alter in control, rose by 1 or 2 in intervention arms - no statistical
significance or variance info provided, units unclear, probably % of LA + oleic + palmitic
+ stearic)
Compliance by dietary intake: good. Assessed from 7-day food records after 28 and
44 weeks combined (tables IX8 and 9)
• Energy intake: intervention B 2549 kcal/d, intervention C 2599 kcal/d,
intervention E 2560 kcal/d, control D 2593 kcal/d
• Total fat intake: intervention B 29.0% E, intervention C 38.5% E, intervention E
37.1% E, control 39.5% E (decrease B 10.5% E, C 1.0% E, E 2.4 total fat)
• Saturated fat intake: intervention B 6.1% E, intervention C 7.0% E, intervention
E 4.6% E, control D 15.6% E (decrease B 9.5% E, C 8.6% E, E 11.0% E SFA)
• PUFA intake: intervention B 12.1% E, intervention C 17.8% E, intervention E
22.3% E, control D 4.6% E (increase B 7.5% E, C 13.2% E, E 17.7% E PUFA)
• PUFA n-3 intake: not reported
• PUFA n-6 intake, % E LA: intervention B 11.6% E, intervention C 16.9% E,
intervention E 21.9% E, control D 4.3% E (increase B 7.3% E, C 12.6% E, E 17.6%
E LA)
• Trans fat intake: not reported
• MUFA intake: intervention B 10.8% E, intervention C 13.7% E, intervention E
10.2% E, control D 19.3% E (decrease B 8.5% E, C 5.6% E, E 9.1% E MUFA)
• CHO intake: intervention B 55.3% E, intervention C 45.8% E, intervention E
48.6% E, control D 45.1% E (increase B 10.1% E, C 0.7% E, E 3.5% E CHO)
• Sugars intake: not reported
• Protein intake: intervention B 17.0% E, intervention C 16.7% E, intervention E
15.7% E, control D 16.4% E (increase B 0.6% E, C 0.3% E, E −0.7% E protein)
• Alcohol intake: not reported
Duration of intervention: 1 year
Outcomes Main study outcomes: lipid levels and dietary assessment
Dropouts: B 7, C 10, E 7, D (control) 5
Available outcomes: mortality, total cholesterol (weight and TG data available but with-
out SDs)
Notes Data entered as all interventions combined (B + C + E) vs control (D)
Study funding: National Heart Institute
Response to contact: not attempted as study completed in 1967
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Stratified randomisation by the statistical
centre
Allocation concealment (selection bias) Low risk As above
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Institution so all participants and study
staff blinded to allocation
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Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcome assessors were reported as
blinded to treatment allocation
Incomplete outcome data (attrition bias)
All outcomes
Low risk Institution so able to follow up all partici-
pants through study
Selective reporting (reporting bias) Unclear risk No protocol or trials registry entry found
Attention Bias Low risk Interventions and follow ups delivered in
an equivalent way across arms
Compliance Low risk Good compliance by biomarkers
Other bias Low risk None found
NDHS Open 1st 1968
Methods National Diet-Heart Study (NDHS) - Open First phase
RCT, several arms, parallel (n-6 LA vs SFA + MUFA), 1 year
Summary risk of bias: low
Participants Free-living men aged 45-54 years
CVD risk: low
Control: randomised 382, analysed 341
Interventions B, C, X combined: randomised 829, analysed 726
Mean years in trial: control 0.95, intervention 0.93
% male: 100
Age: unclear
Age range: all 45-54 years
Smokers: 39% to 40% current smokers in each arm
Hypertension: unclear
Medications taken by at least 50% of those in the control group: not reported
Medications taken by 20%-49% of those in the control group: not reported
Medications taken by some, but less than 20% of the control group: not reported
Location: USA
Ethnicty: white 98.2%, non-white 1.8% (not reported by intervention arm)
Interventions Type: diet provided (bought from a trial shop)
Comparison: increased PUFA (n-6) vs usual diet (replacement of SFA + MUFA)
Control aims: total fat 40% E, dietary cholesterol 650-750 mg/d, P/S 0.4 (assume PUFA
6.8% E as at Faribault) (foods bought from a trial shop - normal foods)
Intervention aims: B (C, X) total fat 30% E (40% E, 30% E), SFA < 9% E (< 9% E, <
9% E), dietary cholesterol 350-450 mg/d (350-450 mg/d, 350-450 mg/d), PUFA 15%
E (18-20% E, 15% E), P/S 1.5 (2.0, 1.5) (foods bought from a trial shop - saturated fats
removed and replaced by polyunsaturated oils and fats)
Dose aim:increase B 8.2% E, C 12.2% E, X 8.2% E n-6
Baseline n-6 (tables IX 1 and 3): 3.7% LA, 3.9% PUFA
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NDHS Open 1st 1968 (Continued)
Compliance by biomarkers: good, serum total cholesterol significantly reduced in in-
tervention compared to control (−0.45 mmol/L, 95% CI −0.55 to −0.35). Data on
fatty acid composition of red blood cells provided in chapter 10 (table X6: LA rose by 1 in
control, by 2 to 3 in other arms, at the expense of MUFA which did not alter in control,
fell by 2 or 3 in other arms. Palmitic acid remained constant in control and remained
constant or fell by 1 in intervention arms, stearic did not alter in control and remained
constant or rose by 1 in intervention arms - no statistical significance or variance info
provided, units unclear, probably % of LA + oleic + palmitic+stearic)
Compliance by dietary intake: good. Nutritionists subjective adherence ratings of ex-
cellent or good (as compared to fair or poor) intervention B 58%, intervention C 60%,
control D 55%. Dietary intake computed from 7-day food records at 28 weeks (table
IX3, no later data found):
• Energy intake: intervention B 2154 kcal/d (SD 432), intervention C 2262 kcal/d
(SD 435), intervention X 2117 kcal/d (SD 447), control D 2228 kcal/d (SD 456)
• Total fat intake: intervention B 29.7% E, intervention C 34.4% E, intervention X
31.7% E, control D 34.9% E (decrease B 5.2% E, C 0.5% E, X 3.2 total fat)
• Saturated fat intake: intervention B 7.1% E, intervention C 7.4% E, intervention
X 8.9% E, control D 11.6% E (decrease B 4.5% E, C 4.2% E, X 2.7% E SFA)
• PUFA intake: intervention B 9.9% E, intervention C 13.2% E, intervention X 6.
5% E, control D 4.9% E (increase B 5.0% E, C 8.3% E, X 1.6 PUFA)
• PUFA n-3 intake: not reported
• PUFA n-6 intake: not reported, probably similar to PUFA
• Trans fat intake: not reported
• MUFA intake (by subtraction of SFA and PUFA from total fat): intervention B
12.7% E, intervention C 13.8% E, intervention X 16.3% E, control D 18.4% E
(decrease B 5.7% E, C 4.6% E, X 2.1% E MUFA)
• CHO intake: intervention B 48.7% E, intervention C 45.3% E, intervention X
49.5% E, control D 44.7% E (increase B 4.0% E, C 0.6% E, X 4.8% E CHO)
• Sugars intake: not reported
• Protein intake: intervention B 18.6% E, intervention C 17.6% E, intervention X
17.1% E, control D 17.4% E (increase B 1.2% E, C 0.2% E, X −0.3% E protein,
little change)
• Alcohol intake: intervention B 2.1% E, intervention C 2.1% E, intervention X 1.
7% E, control D 2.2% E (minimal change)
Duration of intervention: 1 year
Outcomes Main study outcomes: lipid levels and dietary assessment
Dropouts: intervention B 42, C 34, X 5, control D 36
Available outcomes: CVD events (MI and PAD events), cancer diagnoses, total choles-
terol (weight, diastolic BP and TG data available but without SDs)
Notes Study funding: National Heart Institute
Response to contact: not attempted as study completed in 1967
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Low risk Stratified randomisation by the statistical
centre
Allocation concealment (selection bias) Low risk Stratified randomisation by the statistical
centre
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Participants and study personnel (aside
from the store manager) were blinded to
allocation. Blinding of participants was
checked using a questionnaire which found
no difference between intervention and
control participants in guesses at dietary
composition
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcome assessors were reported as
blinded to treatment allocation
Incomplete outcome data (attrition bias)
All outcomes
Low risk 12% dropouts, well described
Selective reporting (reporting bias) Unclear risk No protocol or trial registry entry found
Attention Bias Low risk Interventions and follow-ups delivered in
an equivalent way across arms
Compliance Low risk Good compliance by biomarkers
Other bias Low risk None noted
Rose 1965
Methods RCT, 2-arm, parallel (n-6 LA vs MUFA), 24 months
Summary risk of bias: moderate to high
Participants Patients with ischaemic heart disease (IHD)
CVD risk: high
N: 28 intervention, 26 control (analysed 15 intervention, 12 control)
% male: not reported
Mean age in years: 52.6 intervention, 55 control (no SDs)
Age range: not reported
Smokers: not reported
Hypertension: not reported
Medications taken by at least 50% of those in the control group: not reported
Medications taken by 20%-49% of those in the control group: not reported
Medications taken by some, but less than 20% of the control group: not reported
Location: UK
Ethnicty: not reported
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Interventions Type: dietary advice + test oil provided
Comparison: n-6 vs MUFA
Intervention: 80 g/d corn oil to be taken in 3 equal doses at meal-times plus patients
were instructed to avoid fried foods, fatty meat, sausages, pastry, ice-cream, cheese, cakes,
milk, eggs, butter were restricted: assuming 80% LA in corn oil, 64 g/d LA or 576 kcal/
d or 28.8% E from LA
Control: 80 g/day olive oil plus patients were instructed to avoid fried foods, fatty meat,
sausages, pastry, ice-cream, cheese, cakes, milk, eggs, butter were restricted. assuming
12% LA and 69% MUFA in olive oil, 9.6 g/d LA or 4.3% E LA and 55.2 g/d MUFA
or 24.8% E
Dose aim: +24.5% E from LA, −24.8% E MUFA
Baseline n-6: unclear
Compliance using biomarkers: poor, serum total cholesterol not significantly reduced
in intervention compared to control (−0.49 mmol/L, 95% CI −1.34 to 0.36)
Compliance using dietary assessment: poor. Measured using questionnaire
Mean intake of oil in intervention was 595 kcal/d or 476 kcal/d LA or 23.8% E, in
control 540 kcal/d or 3.2% E LA and 18.6% E MUFA
Dose achieved: +20.6% E from LA, −18.6% E MUFA within the oils, unclear how
diet altered
• Energy intake: intervention 2070 kcal/d control 2045 kcal/d
• Total fat intake: intervention 50 g/d + 595 kcal from oil or 1045 kcal/d or 52% E,
control 45 g/d + 540 kcal from oil or 945 kcal/d or 47.3% E
• Saturated fat intake: not reported
• PUFA intake: not reported
• PUFA n-3 intake: not reported
• PUFA n-6 intake: +20.6% E (higher in intervention than control)
• Trans fat intake: not reported (oils provided so not likely to be a problem)
• MUFA intake: −18.6% E (lower in intervention than control)
• CHO intake: intervention 189 g/d or 756 kcal/d or 37.8% E, control 216 g/d or
864 kcal/d or 43.2% E
• Sugars intake: not reported
• Protein intake: intervention 57 g/d or 228 kcal/d or 11.4% E, control 49 g/d or
196 kcal/d or 9.8% E
• Alcohol intake: not reported
Duration of intervention: 2 years
Outcomes Main study outcome: occurrence of infarction
Dropouts: 6 intervention, 11? control, details provided in table but unclear how many
dropped out
Available outcomes: major CVD events, MI (fatal and non-fatal), sudden death, serum
cholesterol
Notes Study funding: no details
The study had a third control arm (no intervention) which has not been used here
Response to contact: contact attempted but not achieved
Risk of bias
Bias Authors’ judgement Support for judgement
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Rose 1965 (Continued)
Random sequence generation (selection
bias)
Low risk When a new patient was accepted for the
trial a sealed envelope was opened contain-
ing the allocation instructions. In the case
of patients allocated to an oil group the in-
structions referred only to a code number
Allocation concealment (selection bias) Unclear risk As above, opacity of envelope unclear
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Physicians in charge knew which patients
were receiving oil, but they did not know
until the end of the trial the kind of oil that
they were receiving
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk The electrocardiograms were assessed with-
out the knowledge of the patients treatment
group
Incomplete outcome data (attrition bias)
All outcomes
Low risk 52% intervention, and 57% control re-
mained in the trial after 24 months. How-
ever, the list of reasons and complications
is provided
Selective reporting (reporting bias) Unclear risk No trial registry record or protocol found
Attention Bias Low risk Both groups appear to have the same treat-
ment
Compliance High risk Compliance poor; assessed by biomarkers
Other bias Low risk None noted
Schirmer 2007
Methods RCT, 2 arm, parallel (n-6 GLA vs MUFA), 1 year
Summary risk of bias: moderate to high
Participants Formerly obese adults with a recent minimum weight loss of 12 kg, a current BMI of <
34 kg/m2, otherwise healthy
CVD risk: low
N: 23 intervention, 22 control (analysed only completers 13 intervention, 17 control)
% male: 8% intervention, 6% control
Mean age (SD) in years: 44.2 (10.1) intervention, 52.6 (8.1) control
Age range: not reported
Smokers: not reported
Hypertension: 0%
Medications taken by at least 50% of those in the control group: anorexigenic agent
Medications taken by 20%-49% of those in the control group: not reported
Medications taken by some, but less than 20% of the control group: not reported
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Location: USA
Ethnicty: not reported
Interventions Type: supplement (capsule)
Comparison: n-6 (GLA) vs MUFA
Intervention: 5 g/d of 500 mg borage oil capsules providing 0.89 g/d GLA
Control: 5 g/d of identical 500 mg olive oil capsules
Subjects in both groups were required to take a balanced multivitamin-mineral supple-
ment daily, which included 80 mg of d-alpha-tocopherol
Dose aim: increase 0.89 g/d GLA or 8 kcal or 0.4% E GLA, plus approx 0.9 g/d LA or
0.4% E LA, 0.8% E n-6
Baseline n-6: unclear
Compliance by biomarkers: good. Measurement of adipose GLA showed increased
GLA in intervention (2.16 µmol/g of adipose TG at baseline to 5.39 µmol/g at 1 year)
but not in control (2.51 µmol/g of adipose TG at baseline to 2.87 µmol/g at 1 year,
statistically significant difference suggested). DGLA increased in intervention group, but
fell in control
Compliance by dietary intake: unclear, participants maintained daily food intake and
exercise records
• Energy intake: not reported
• Total fat intake: not reported
• Saturated fat intake: not reported
• PUFA intake: not reported
• PUFA n-3 intake: not reported
• PUFA n-6 intake: not reported
• Trans fat intake: not reported
• MUFA intake: not reported
• CHO intake: not reported
• Sugars intake: not reported
• Protein intake: not reported
• Alcohol intake: not reported
Duration of intervention: 1 year (results reported only for participants completing a
minimum of 50 weeks)
Outcomes Main study outcome: measures of adiposity
Dropouts: unclear, only one withdrew after randomisation but trial was terminated and
only reported on 30/45 completers
Available outcomes: weight, fat weight (fasting blood glucose and blood pressure mea-
sured but not reported)
Notes Study funding: supported in part by a gift from Shaklee Technica
Response to contact: Prof Phinney replied ”I am sorry to inform you that I cannot
provide meaningful feedback within the parameters of your survey“
Risk of bias
Bias Authors’ judgement Support for judgement
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Schirmer 2007 (Continued)
Random sequence generation (selection
bias)
Unclear risk Quote: ”randomly assigned“
Allocation concealment (selection bias) Unclear risk No details
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: ”Both oil supplements were admin-
istered in a double-blind protocol as iden-
tical 500 mg capsules“
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: ”The initial study was terminated,
and all remaining subjects were assessed
over a 6-wk period. Unblinding revealed“
…”the monitoring of their weights (sim-
ple ANOVA of group means while inves-
tigators and subjects remained unaware of
treatment)“
Incomplete outcome data (attrition bias)
All outcomes
High risk Quote: ”At the termination of the ran-
domized placebo-controlled trial, 45 sub-
jects remained in the study“. Mentions one
dropped out between randomisation and
treatment commencement but no details/
explanation of remaining dropouts/non-
completers
Selective reporting (reporting bias) Unclear risk No protocol or trial register entry
Attention Bias Low risk Both groups appear to have the same care
Compliance Low risk Adipose GLA was significantly higher in
intervention group compared to control (P
< 0.0001)
Other bias Low risk None noted
Sydney Diet-Heart 1978
Methods Sydney Diet-Heart Study
RCT, 2 arm, parallel (n-6 LA vs SFA + MUFA), 4.3 years
Summary risk of bias: low
Participants Men with previous MI
CVD risk: high
Control: randomised 237, analysed 221 at 2 years
Intervention: randomised 221, analysed 205 at 2 years
Mean years in trial: control 4.3, intervention 4.3
% male: 100
Mean age (SD) in years: control 49.1 (6.5), intervention 48.7 (6.8)
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Sydney Diet-Heart 1978 (Continued)
Age range: 30-59 years
Smokers: control 68.8%, intervention 71.5%
Hypertension: unclear
Medications taken by at least 50% of those in the control group: not reported
Medications taken by 20%-49% of those in the control group: not reported
Medications taken by some, but less than 20% of the control group: not reported
Location: Australia
Ethnicity: not reported
Interventions Type: diet advice
Comparison: increased safflower oil and safflower oil based margarine (n-6) vs usual diet
(reduced SFA and MUFA)
Control aims: reduction in energy if overweight, no other specific dietary advice, allowed
touse PUFAmargarine instead of butter (no specific dietary instruction, except reweight)
Intervention aims: SFA 10% E, PUFA 15% E, reduction in energy if overweight, dietary
cholesterol < 300 mg/d through provision of safflower oil and safflower margarine (ad-
vised and tutored individually, diet assessed 3 times in first year,twice annually thereafter)
Dose aim: increase 6.6% E PUFA, most of which n-6
Baseline n-6: unclear, 6.1% E PUFA, mostly n-6
Compliance by biomarkers: good, serum total cholesterol significantly reduced in in-
tervention compared to control (−0.30 mmol/L, 95% CI −0.51 to −0.09)
Compliance by dietary intake: good. From diet records, medians provided.
• Energy intake: intervention 2256 kcal/d, control 2194 kcal/d
• Total fat intake: intervention −1.9% E, control −1.1% E (reduction of 0.8% E
total fat)
• Saturated fat intake: intervention −6.9% E, control −2.1% E (reduction of 4.8%
E SFA)
• PUFA intake: intervention +9.3% E, control +2.2% E (increase of 7.1% E PUFA)
• PUFA n-3 intake: not reported
• PUFA n-6 intake: not reported
• Trans fat intake: not reported
• MUFA intake: intervention −3.4% E, control −0.7% E (reduction of 2.7% E
MUFA)
• CHO intake: intervention +1.4% E, control +0.1% E (increase of 1.3% E CHO)
• Sugars intake: not reported
• Protein intake: intervention +0.4% E, control +1.2% E (decrease of 0.8% E
protein)
• Alcohol intake: intervention +0.7% E, control +1.7% E (decrease of 1.0% E
alcohol)
Duration of intervention: 2-7 years
Outcomes Main study outcomes: CVD mortality and morbidity
Dropouts: unclear, probably 16 dropouts in each arm, but participants were included
from 2 to 7 years
Available outcomes:mortality, total cholesterol, TG.Additional data provided or checked
on all-cause mortality, CHD events, stroke and CVD mortality
Notes Study funding: Life Insurance Medical Research Fund of Australia and New Zealand
Response to contact: Dr Leelarthepin and Dr Zamora both provided additional data
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Sydney Diet-Heart 1978 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: ”table of random numbers ... gen-
erated by a research assistant and was con-
cealed until after medical evaluations and
testing at baseline were completed“
Allocation concealment (selection bias) Low risk As above
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Very difficult to blind trials where par-
ticipants need to make their own dietary
changes
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Initially masked to group assignment
(though success of blinding not checked)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Survival analysis used
Selective reporting (reporting bias) Unclear risk No protocol or trials registry entry located
Attention Bias High risk Different levels of dietary support (non-di-
etary aspects were equivalent)
Compliance Low risk Compliance good assessed by biomarkers
Other bias Low risk None noted
Veterans Admin 1969
Methods Veterans Administration Study
RCT, 2 arms, parallel (n-6 LA vs SFA + MUFA), up to 8 years
Summary risk of bias: moderate to high
Participants Men living at the Veterans Administration Centre
CVD risk: low
Control: randomised 422, analysed 422
Intervention: randomised 424, analysed 424
Mean years in trial: control 3.7, intervention 3.7
% male: 100
Mean age in years: control 65.6, intervention 65.4
Age range: all 54 to 88 years
Smokers: intervention 283, control 279 (unknown intervention 41, control 58)
Hypertension: unclear
Medications taken by at least 50% of those in the control group: not reported
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Medications taken by 20%-49% of those in the control group: not reported
Medications taken by some, but less than 20% of the control group: digitalis, diuretics,
estrogens, corticoids, androgens, coumarins, nicotinic acid
Location: USA
Ethnicity: white 90%, black 7%, Asian 1%, Mexican 1%, other 1%
Interventions Type: diet provided (residential institution)
Comparison: increased corn, soybean, safflower and cottonseed oils (n-6) vs usual insti-
tutional diet
Control aims: provided, total fat 40% E (whole diet provided)
Intervention aims: total fat 40% E, 2/3 of SFA replaced by unsaturated fats (from corn,
soybean, safflower and cottonseed oils), dietary cholesterol reduced (whole diet provided)
Dose aim: 2/3 of baseline SFA is increase of ~12% E PUFA
Baseline n-6: 4% E LA
Compliance by biomarkers: poor, serum total cholesterol not significantly reduced in
intervention compared to control (−0.37 mmol/L, 95% CI −0.77 to 0.03)
Compliance by dietary intake: unclear, checked using coloured tickets to assess dining
room attendance - described as 49% in intervention and 56% in controls. Laboratory
analysis of the mean of over 400 weekly collections of diet provided:
• Energy intake: intervention 2496 kcal/d, control 2496 kcal/d
• Total fat intake: intervention 38.9% E (SD 1.9), control 40.1% E (SD 2.2)
• Saturated fat intake: intervention 8.3% E, control 18.5% E (decrease 10.2% E
SFA)
• PUFA intake: not reported but shown in graph as stearate being almost half in
intervention compared to control, and palmate similar
• PUFA n-3 intake: intervention 16.1% E (SD not reported), control 4.4% E (SD
not reported) (increase of 11.8% E PUFA)
• PUFA n-6 intake: intervention 16.1% E, control 4.4% E (increase 11.7% E LA)
• Trans fat intake: not reported
• MUFA intake: intervention 14.6% E, control 17.1% E (decrease 2.5% E
MUFAs)
• CHO intake: not reported
• Sugars intake: not reported
• Protein intake: intervention 15.6% E (SD not reported), control 15.4% E (SD
not reported)
• Alcohol intake: not reported
Duration of intervention: up to 8-9 years
Outcomes Main study outcomes: mortality, heart disease
Dropouts: intervention 117, control 58 withdrawals over whole study, a few participants
were involved for up to 8-9 years
Available outcomes: mortality, CVD mortality (sudden death, definite MI, definite
stroke, angina, peripheral vascular events), cancer deaths, cancer diagnoses, stroke, non-
fatal MI, total MI, CHD deaths (fatal MI and sudden death due to CHD), CHD events
(any MI or sudden death due to CHD), total cholesterol
Notes Trial dates: recruitment 1959 to 1967
Study funding: mainly US Public Health Service, Los Angeles County Heart Assoc,
Arthur Dodd Fuller Assoc, but Corn Products Co (provided Corn oil and margarine),
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Veterans Admin 1969 (Continued)
National Soybean Processors Assoc (provided soybean oil), Pitman-Moore Co (provided
margarine), Frozen Desserts Co (imitation ice cream). All authors worked for academic
or health institutions
Response to contact: not contacted as the study started in 1959
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: ”table of random numbers used“
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Institution provided diet in a masked fash-
ion
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Physician knowledge of allocation was as-
sessed and found not much better than ran-
dom
Incomplete outcome data (attrition bias)
All outcomes
Low risk All followed up via Veterans Admin system
Selective reporting (reporting bias) Unclear risk No protocol or trials registry entry located
Attention Bias Low risk Both groups appear to have been treated
very similarly
Compliance High risk Compliance poor assessed by biomarkers
Other bias Low risk None found
Vijayakumar 2014
Methods RCT, 2 arms, parallel (n-6 LA vs SFA), 2 years
Summary risk of bias: moderate to high
Participants People with stable coronary artery disease
CVD risk: high
Intervention (sunflower oil): 100 randomised, analysed at 2 years 94
Control (coconut oil): 100 randomised, analysed at 2 years 96
Mean years in trial: 2
% male: intervention 92.9%, control 93.9%
Mean age (SD) in years: intervention 59.0 (8.9), control 59.0 (8.4)
Age range: unclear
Smokers, ex: intervention 57.1%, control 54.1%
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Vijayakumar 2014 (Continued)
Hypertension: intervention 55.1%, 58.2%
Medications taken by at least 50% of those in the control group: statins
Medications taken by 20%-49% of those in the control group: not reported
Medications taken by some, but less than 20% of the control group: fibrates, nicotinic
acid
Location: India
Ethnicity: not reported
Interventions Type: food (cooking oil) provided
Comparison: sunflower oil (n-6) vs coconut oil (SFA)
Intervention aims: whole family to use branded sunflower oil for cooking (15% E pro-
vided in form of sunflower oil)
Control aims: whole family to use branded coconut oil for cooking (15% E provided in
form of coconut oil)
Dose aim: increase 15% E n-6
Baseline n-6: unclear
Compliance by biomarkers:poor, serum total cholesterol not significantly reduced in
intervention compared to control (0.06 mmol/L, 95% CI −0.22 to 0.34)
Compliance by dietary intake:unclear. Reports that 7-day recall and diet diaries were
used to monitor intake, but results not provided
• Energy intake: not reported
• Total fat intake: not reported
• Saturated fat intake: not reported
• PUFA intake: not reported
• PUFA n-3 intake: not reported
• PUFA n-6 intake: not reported
• Trans fat intake: not reported
• MUFA intake: not reported
• CHO intake: not reported
• Sugars intake: not reported
• Protein intake: not reported
• Alcohol intake: not reported
Duration of intervention: 2 years
Outcomes Main study outcome: CVD risk factors
Dropouts: intervention 6 lost, control 4 lost
Available outcomes: lipids, death, re-vascularisation (glycaemic control, weight, BMI
available but unbalanced at baseline). Author confirmed no CVD events or deaths, no
atrial fibrillation. Provided data on HbA1c and CRP
Notes Study funding: Coconut development board, Amrita Institute of Medical Science and
Research. Sponsors had no role in study design or analysis
Response to contact: Dr Vijayakumar replied with information on outcomes and
methodology
Risk of bias
Bias Authors’ judgement Support for judgement
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Vijayakumar 2014 (Continued)
Random sequence generation (selection
bias)
Low risk Block randomisation with 5 blocks of 40
Allocation concealment (selection bias) Unclear risk Unclear
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Open label. Participants and their families
used branded oils, which were not identical
in taste and other properties. Author states
that only the dietitian was aware of the oil
allocation
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Unclear, as above. Author suggests that out-
comes assessors were blinded but does not
provide a method for this
Incomplete outcome data (attrition bias)
All outcomes
Low risk 5% withdrawals. Clear, with reasons
Selective reporting (reporting bias) Unclear risk Unclear, no protocol or trials register entry
found
Attention Bias Low risk Unlikely as cooking oil was the interven-
tion, and assessments appeared similarly
timed
Compliance High risk Compliance poor assessed by biomarkers
Other bias Low risk None noted
ALA: alpha linolenic acid (n-3 18:3); BP: blood pressure; CHD: coronary heart disease; CHO: carbohydrate;CRP: C-reactive protein;
CVD: cardiovascular disease;DHA: docosahexaenoic acid (n-3 22:6);DPA: docosapentaenoic acid (n-3 22:5);EPA: eicosapentaenoic
acid (n-3 20:5); EPO: evening primrose oil; ESR: erythrocyte sedimentation rate; GFR: glomerular filtration rate; GLA: gamma
linolenic acid (n-6 18:3); GP: general practitioner; GTT: glucose tolerance test; HbA1c: glycated haemoglobin (a measure of
glucose metabolism); HDL: high-density lipoprotein, a lipid (fat) fraction measured in human blood. HDL is thought to be
protective; IHD: ischaemic heart disease; intervention: intervention arm; ITT: intention-to-treat; LA: linoleic acid (n-6 18:2);
LDL: low-density lipoprotein, a lipid (fat) fraction measured in human blood. LDL is thought to contribute to atherosclerosis;
MI: myocardial infarction; MS: multiple sclerosis; MUFA: monounsaturated fatty acid; NSAID: non-steroidal anti-inflammatory
drug; PAD: peripheral arterial disease; P/S: polyunsaturated: saturated fatty acid ratio; PUFA: polyunsaturated fatty acid; RA:
rheumatoid arthritis; RCT: randomised controlled trial; SD: standard deviation; SE: standard error; SFA: saturated fatty acid; TC:
total cholesterol (combined lipid or fat, measured in human blood, includes TG, HDL and LDL); TG: triglyceride (a type of lipid
or fat, measured in human blood); % E: percentage of energy intake from this nutrient.
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Bierenbaum 1963 Duration only 50 weeks
Bramkamp 1974 Not an RCT
Dembinska-Kiec 2010 Not an RCT
Dembinska-Kiec 2011 Not an RCT
Elisha 2011 Not an RCT
Finnegan 2003a Irrelevant outcomes and control not minimal
Finnegan 2003b Irrelevant intervention
Finnish Mental Hosp 1972 Not randomised (cluster-randomised, but < 6 clusters)
Gaullier 2004 Irrelevant intervention
Gaullier 2005 Not an RCT and control irrelevant
Gaullier 2007 Irrelevant intervention
Ghafoorunissa 1995 Control not minimal and short term trial (8 weeks)
Ghafoorunissa 2002 Not an RCT
Harbige 2007 No relevant outcomes reported and no author contact established
Harris 2009 Not an RCT
Heine 1989 Irrelevant participants
Hui 1989 Intervention in rats
Jamal 1990 First author of this publication Goran Jamal, was reprimanded by the GeneralMedical Council in 2003
after being found guilty of research fraud in a drug trial involving EPO, the topic of this paper. The
professional conduct committee of the GMC found Dr Jamal guilty of serious professional misconduct
for falsifying his results in a multicentre trial of the drug Tarabetic, also known as Efamol, a constituent
of evening primrose oil, intended for the treatment of diabetic peripheral neuropathy. We believe that
this throws doubt on Dr Jamal’s work on Efamol, including this trial
Khan 2003 Duration was 8 months only
Kruger 1998 GLA + EPA vs olive oil
Lands 1992 Not an RCT
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Larsen 2006 Irrelevant intervention (CLA)
Leng 1998 GLA + EPA vs sunflower oil (so n-6 + n-3 vs n-6), no assessment of n-6
Ley 2004 No aim to increase omega-6 or PUFA, PUFA increased by over 10% but no information provided on
omega-6 fats
MARGARIN 2002 Irrelevant intervention, ALA vs LA
Michalsen 2006 Multifactorial (assessment of stress reduction and activity as well as diet)
Middleton 2002 EPA + DHA + GLA vs LA, unclear which arm was higher in PUFA
Millar 1973 No relevant outcomes reported and no reply from trialists
Minnesota Coronary 1989 While participants were involved in this study for over 1 year on average they could move in and out of
the institution in which the study took place, and therefore in and out of the study over the duration
of the trial. Most participants were not involved in the study continuously for at least one year
Moy 2001 Aim was to reduce dietary fat (total and saturated fat reductions appear to have been achieved) but
effects on PUFAs unclear (total, omega-6 and omega-3 intakes not reported)
Oslo Diet Heart 1966 Intervention group received dietary advice for a diet rich in vegetable oils and low in animal fats, and
also received a multivitamin. Multifactorial. Recommended that whale meat be substituted for land
animal meats
Oxford Retinopathy 1978 Advice in intervention was to alter fats and also to raise carbohydrates while limiting simple sugars,
multifactorial
Reed 2014 GLA plus omega-3 vs sunflower oil plus omega-3 - both arms high in n-6
Roche 2009 Intervention and control irrelevant
Simon 1997 No intention stated to alter omega-6 or PUFA fats, and omega-6 intake not reported
Sluijs 2010 Trial of CLA, not relevant
STARS 1992 Intervention encouraged to increase plant-derived soluble fibre as well as alter dietary fats, multifactorial
Van der Merwe 1990 Intervention <1 year
Vergroesen 1980 Not an RCT
WHI 2006 Dietary intervention was of dietary fat and also fruit and vegetables, multifactorial
WINS 2006 Aim was to reduce total fat, no aim for omega-6 fats and omega-6 intakes not reported
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(Continued)
Ziboh 2004 GLA vs LA, not relevant intervention and control
ALA: alpha linolenic acid (n-3 18:3); CLA: conjugated linoleic acid (a family of isomers of linoleic acid, some of which are trans fats);
DHA: docosahexaenoic acid (n-3 22:6); EPA: eicosapentaenoic acid (n-3 20:5); EPO: evening primrose oil; GLA: gamma linolenic
acid (n-6 18:3); LA: linoleic acid (n-6 18:2); PUFA: polyunsaturated fatty acid; RCT: randomised controlled trial.
Characteristics of ongoing studies [ordered by study ID]
Chandrakala 2010
Trial name or title Long-term effects of a reduced fat diet intervention in pre-diabetes
Methods RCT
Participants Participants with pre-diabetes (IFG/IGT), 201 participants discussed in one abstract, 134 in a later abstract
Interventions Each for 3 years:
Arm 1: reduced fat diet (fat content at or below 20% total energy, ratio of PUFA/SFA 0.8 to 1.0)
Arm 2: normal/control diet
Outcomes Incidence of diabetes, BMI, lipids, insulin, plasma glucose, HbA1c, blood pressure, nutritional intake
Starting date Registered on trials registry: no registration found
Study start date: not reported
Estimated study completion date: not reported
Contact information Chandrakala Galla, chandrakala.galla@gmail.com; Arpana Gaddam, dr.arpanag@gmail.com
Notes Authors written to in 2016: Dr Gaddam confirmed work submitted as a PhD but not published in full
Requested copy of PhD thesis, but no reply to date
Funding: DiabetOmics India
BMI: body mass index;HbA1c: glycated haemoglobin (a measure of glucose metabolism); IFG: impaired fasting glucose, another name
for IGT; IGT: impaired glucose tolerance (a pre-diabetic state); PUFA: polyunsaturated fatty acid; RCT: randomised controlled
trial; SFA: saturated fatty acid
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D A T A A N D A N A L Y S E S
Comparison 1. Primary outcomes - higher omega-6 vs lower omega-6
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 All-cause mortality (overall) 10 4506 Risk Ratio (M-H, Random, 95% CI) 1.00 [0.88, 1.12]
2 All-cause mortality - sensitivity
analysis by fixed-effect analysis
10 4506 Risk Ratio (M-H, Fixed, 95% CI) 1.00 [0.89, 1.13]
3 All-cause mortality - sensitivity
analyses
10 Risk Ratio (M-H, Random, 95% CI) Subtotals only
3.1 Studies at low risk of bias 2 682 Risk Ratio (M-H, Random, 95% CI) 1.54 [0.98, 2.41]
3.2 Pre-2010 or prospective
trials registry entry
9 4306 Risk Ratio (M-H, Random, 95% CI) 1.00 [0.89, 1.13]
3.3 No commercial funding 4 1208 Risk Ratio (M-H, Random, 95% CI) 1.19 [0.84, 1.69]
3.4 Low risk of attention bias 6 1489 Risk Ratio (M-H, Random, 95% CI) 0.97 [0.83, 1.13]
3.5 Randomised 250+
participants
4 3730 Risk Ratio (M-H, Random, 95% CI) 1.01 [0.87, 1.17]
3.6 Randomised 100+
participants
8 4403 Risk Ratio (M-H, Random, 95% CI) 1.00 [0.88, 1.13]
4 All-cause mortality - subgroup
by LA or GLA
10 4506 Risk Ratio (M-H, Random, 95% CI) 1.00 [0.88, 1.12]
4.1 Mainly LA 8 4341 Risk Ratio (M-H, Random, 95% CI) 1.01 [0.89, 1.14]
4.2 GLA supplements 2 165 Risk Ratio (M-H, Random, 95% CI) 0.76 [0.41, 1.39]
5 All-cause mortality - subgroup
by intervention type
10 4506 Risk Ratio (M-H, Random, 95% CI) 1.00 [0.88, 1.12]
5.1 Dietary advice 3 2624 Risk Ratio (M-H, Random, 95% CI) 1.15 [0.82, 1.61]
5.2 Supplements (capsules) 2 165 Risk Ratio (M-H, Random, 95% CI) 0.76 [0.41, 1.39]
5.3 Supplemental foods 1 200 Risk Ratio (M-H, Random, 95% CI) 0.20 [0.01, 4.11]
5.4 Dietary advice plus
supplement
2 447 Risk Ratio (M-H, Random, 95% CI) 0.94 [0.60, 1.46]
5.5 Diet (all foods) provided 2 1070 Risk Ratio (M-H, Random, 95% CI) 0.98 [0.84, 1.15]
6 All-cause mortality - subgroup
by replacement
10 Risk Ratio (M-H, Random, 95% CI) Subtotals only
6.1 N-6 replacing SFA 6 4154 Risk Ratio (M-H, Random, 95% CI) 1.00 [0.88, 1.15]
6.2 N-6 replacing MUFA 5 1698 Risk Ratio (M-H, Random, 95% CI) 1.13 [0.83, 1.53]
6.3 N-6 replacing nil, low n-6 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
6.4 N-6 replacement unclear 2 442 Risk Ratio (M-H, Random, 95% CI) 0.85 [0.58, 1.24]
6.5 N-6 replacing CHO 1 133 Risk Ratio (M-H, Random, 95% CI) 1.97 [0.18, 21.21]
6.6 N-6 replacing protein 1 133 Risk Ratio (M-H, Random, 95% CI) 1.97 [0.18, 21.21]
7 All-cause mortality - subgroup
by baseline CVD risk
10 4506 Risk Ratio (M-H, Random, 95% CI) 1.00 [0.88, 1.12]
7.1 Primary prevention - low
CVD risk
5 1368 Risk Ratio (M-H, Random, 95% CI) 0.97 [0.83, 1.13]
7.2 Primary prevention -
moderate CVD risk
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
7.3 Secondary prevention -
existing CVD
5 3138 Risk Ratio (M-H, Random, 95% CI) 1.06 [0.83, 1.35]
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8 All-cause mortality - subgroup
by omega-6 dose
10 4506 Risk Ratio (M-H, Random, 95% CI) 1.00 [0.88, 1.12]
8.1 N-6 < 4% E 4 2331 Risk Ratio (M-H, Random, 95% CI) 0.95 [0.76, 1.19]
8.2 N-6 4% to 12% E 2 1304 Risk Ratio (M-H, Random, 95% CI) 1.15 [0.76, 1.74]
8.3 N-6 > 12% E 4 871 Risk Ratio (M-H, Random, 95% CI) 0.93 [0.60, 1.44]
9 All-cause mortality - subgroup
by duration
10 4506 Risk Ratio (M-H, Random, 95% CI) 1.00 [0.88, 1.12]
9.1 Medium duration 1 to < 2
years in study
1 224 Risk Ratio (M-H, Random, 95% CI) 3.11 [0.17, 56.84]
9.2 Medium-long duration 2
to < 4 years
6 2585 Risk Ratio (M-H, Random, 95% CI) 0.96 [0.76, 1.20]
9.3 Long duration 4+ years in
study
3 1697 Risk Ratio (M-H, Random, 95% CI) 1.05 [0.81, 1.36]
10 All-cause mortality - subgroup
by statin use
10 4506 Risk Ratio (M-H, Random, 95% CI) 1.00 [0.88, 1.12]
10.1 ≥ 50% of control group
on statins
1 200 Risk Ratio (M-H, Random, 95% CI) 0.20 [0.01, 4.11]
10.2 < 50% of control group
on statins
9 4306 Risk Ratio (M-H, Random, 95% CI) 1.00 [0.89, 1.13]
10.3 Statin use unclear 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
11 All-cause mortality - subgroup
by baseline omega-6
10 4506 Risk Ratio (M-H, Random, 95% CI) 1.00 [0.88, 1.12]
11.1 ≥ 8% E from n-6 1 133 Risk Ratio (M-H, Random, 95% CI) 1.97 [0.18, 21.21]
11.2 5% to < 8% E from n-6 2 2491 Risk Ratio (M-H, Random, 95% CI) 1.16 [0.77, 1.76]
11.3 < 5% E from n-6 2 1070 Risk Ratio (M-H, Random, 95% CI) 0.98 [0.84, 1.15]
11.4 baseline n-6 not reported 5 812 Risk Ratio (M-H, Random, 95% CI) 0.85 [0.60, 1.22]
12 All-cause mortality - subgroup
by sex
10 4506 Risk Ratio (M-H, Random, 95% CI) 1.00 [0.88, 1.12]
12.1 Men only 5 3954 Risk Ratio (M-H, Random, 95% CI) 1.01 [0.89, 1.14]
12.2 Women only 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
12.3 Men and women 4 498 Risk Ratio (M-H, Random, 95% CI) 0.76 [0.43, 1.36]
12.4 Sex not reported 1 54 Risk Ratio (M-H, Random, 95% CI) 1.55 [0.41, 5.84]
13 Cardiovascular mortality
(overall)
7 4019 Risk Ratio (M-H, Random, 95% CI) 1.09 [0.76, 1.55]
14 CVD mortality - sensitivity
analysis by fixed-effect analysis
7 4019 Risk Ratio (M-H, Fixed, 95% CI) 1.05 [0.89, 1.25]
15 CVD mortality - sensitivity
analyses
7 Risk Ratio (M-H, Random, 95% CI) Subtotals only
15.1 Studies at low risk of bias 1 458 Risk Ratio (M-H, Random, 95% CI) 1.59 [0.99, 2.55]
15.2 Pre-2010 or prospective
trials registry entry
7 4019 Risk Ratio (M-H, Random, 95% CI) 1.09 [0.76, 1.55]
15.3 No commercial funding 4 1086 Risk Ratio (M-H, Random, 95% CI) 1.22 [0.67, 2.23]
15.4 Low risk of attention bias 2 900 Risk Ratio (M-H, Random, 95% CI) 0.79 [0.45, 1.39]
15.5 Randomised 250+
participants
4 3730 Risk Ratio (M-H, Random, 95% CI) 1.08 [0.76, 1.54]
15.6 Randomised 100+
participants
6 3965 Risk Ratio (M-H, Random, 95% CI) 1.06 [0.73, 1.55]
16 CVD mortality - subgroup by
intervention type
7 Risk Ratio (M-H, Random, 95% CI) Subtotals only
16.1 Dietary advice 4 2726 Risk Ratio (M-H, Random, 95% CI) 1.33 [0.86, 2.05]
16.2 Supplements (capsules) 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
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16.3 Supplemental foods 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
16.4 Dietary advice plus
supplement
2 447 Risk Ratio (M-H, Random, 95% CI) 1.11 [0.69, 1.78]
16.5 Diet (all foods) provided 1 846 Risk Ratio (M-H, Random, 95% CI) 0.70 [0.51, 0.96]
17 CVD mortality - subgroup by
replacement
7 Risk Ratio (M-H, Random, 95% CI) Subtotals only
17.1 N-6 replacing SFA 5 3832 Risk Ratio (M-H, Random, 95% CI) 1.04 [0.71, 1.52]
17.2 N-6 replacing MUFA 3 1358 Risk Ratio (M-H, Random, 95% CI) 1.10 [0.56, 2.16]
17.3 N-6 replacing nil, low n-
6
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
17.4 N-6 replacement unclear 1 393 Risk Ratio (M-H, Random, 95% CI) 1.05 [0.63, 1.75]
17.5 N-6 replacing CHO 2 235 Risk Ratio (M-H, Random, 95% CI) 0.65 [0.01, 33.17]
17.6 N-6 replacing protein 1 133 Risk Ratio (M-H, Random, 95% CI) 4.93 [0.24, 100.70]
18 CVD mortality - subgroup by
baseline CVD risk
7 Risk Ratio (M-H, Random, 95% CI) Subtotals only
18.1 Primary prevention - low
CVD risk
2 979 Risk Ratio (M-H, Random, 95% CI) 1.02 [0.22, 4.66]
18.2 Primary prevention -
moderate CVD risk
1 102 Risk Ratio (M-H, Random, 95% CI) 0.09 [0.01, 1.60]
18.3 Secondary prevention -
existing CVD
4 2938 Risk Ratio (M-H, Random, 95% CI) 1.28 [1.04, 1.57]
19 CVD mortality - subgroup by
omega-6 dose
7 Risk Ratio (M-H, Random, 95% CI) Subtotals only
19.1 N-6 < 4% E 2 2166 Risk Ratio (M-H, Random, 95% CI) 1.26 [0.97, 1.64]
19.2 N-6 4% to 12% E 3 1406 Risk Ratio (M-H, Random, 95% CI) 0.87 [0.38, 1.99]
19.3 N-6 > 12% E 2 447 Risk Ratio (M-H, Random, 95% CI) 1.11 [0.69, 1.78]
20 CVD mortality - subgroup by
duration
7 Risk Ratio (M-H, Random, 95% CI) Subtotals only
20.1 Medium duration 1 to <
2 years in study
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
20.2 Medium-long duration 2
to < 4 years
3 2220 Risk Ratio (M-H, Random, 95% CI) 1.27 [0.98, 1.64]
20.3 Long duration 4+ years
in study
4 1799 Risk Ratio (M-H, Random, 95% CI) 0.96 [0.56, 1.63]
21 CVD mortality - subgroup by
baseline omega-6
7 Risk Ratio (M-H, Random, 95% CI) Subtotals only
21.1 ≥ 8% E from n-6 1 133 Risk Ratio (M-H, Random, 95% CI) 4.93 [0.24, 100.70]
21.2 5% to < 8% E from n-6 2 2491 Risk Ratio (M-H, Random, 95% CI) 1.32 [1.05, 1.66]
21.3 < 5% E from n-6 1 846 Risk Ratio (M-H, Random, 95% CI) 0.70 [0.51, 0.96]
21.4 Baseline n-6 not reported 3 549 Risk Ratio (M-H, Random, 95% CI) 0.95 [0.38, 2.34]
22 CVD mortality - subgroup by
sex
7 Risk Ratio (M-H, Random, 95% CI) Subtotals only
22.1 Men only 4 3730 Risk Ratio (M-H, Random, 95% CI) 1.08 [0.76, 1.54]
22.2 Women only 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
22.3 Men and women 2 235 Risk Ratio (M-H, Random, 95% CI) 0.65 [0.01, 33.17]
22.4 Sex not reported 1 54 Risk Ratio (M-H, Random, 95% CI) 1.55 [0.41, 5.84]
23 Any cardiovascular event
(overall)
7 4962 Risk Ratio (M-H, Random, 95% CI) 0.97 [0.81, 1.15]
24 CVD events - sensitivity
analysis by fixed-effect analysis
7 4962 Risk Ratio (M-H, Fixed, 95% CI) 0.97 [0.89, 1.05]
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25 CVD events - sensitivity
analyses
7 Risk Ratio (M-H, Random, 95% CI) Subtotals only
25.1 Studies at low risk of bias 2 1525 Risk Ratio (M-H, Random, 95% CI) 1.62 [1.02, 2.57]
25.2 Pre-2010 or prospective
trials registry entry
7 4962 Risk Ratio (M-H, Random, 95% CI) 0.97 [0.81, 1.15]
25.3 No commercial funding 3 1918 Risk Ratio (M-H, Random, 95% CI) 1.16 [0.64, 2.12]
25.4 Low risk of attention bias 4 2078 Risk Ratio (M-H, Random, 95% CI) 0.90 [0.66, 1.22]
25.5 Randomised 250+
participants
5 4797 Risk Ratio (M-H, Random, 95% CI) 0.95 [0.78, 1.16]
25.6 Randomised 100+
participants
6 4908 Risk Ratio (M-H, Random, 95% CI) 0.95 [0.79, 1.14]
26 CVD events - subgroup by LA
or GLA
7 4962 Risk Ratio (M-H, Random, 95% CI) 0.97 [0.81, 1.15]
26.1 Mainly LA 6 4851 Risk Ratio (M-H, Random, 95% CI) 0.97 [0.81, 1.17]
26.2 GLA supplements 1 111 Risk Ratio (M-H, Random, 95% CI) 0.35 [0.01, 8.45]
27 CVD events - subgroup by
intervention type
7 4962 Risk Ratio (M-H, Random, 95% CI) 0.97 [0.81, 1.15]
27.1 Dietary advice 2 2491 Risk Ratio (M-H, Random, 95% CI) 1.18 [0.76, 1.85]
27.2 Supplements (capsules) 1 111 Risk Ratio (M-H, Random, 95% CI) 0.35 [0.01, 8.45]
27.3 Supplemental foods 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
27.4 Dietary advice plus
supplement
2 447 Risk Ratio (M-H, Random, 95% CI) 0.95 [0.63, 1.42]
27.5 Diet (all foods) provided 2 1913 Risk Ratio (M-H, Random, 95% CI) 0.80 [0.64, 1.01]
28 CVD events - subgroup by
replacement
7 Risk Ratio (M-H, Random, 95% CI) Subtotals only
28.1 N-6 replacing SFA 5 4797 Risk Ratio (M-H, Random, 95% CI) 0.95 [0.78, 1.16]
28.2 N-6 replacing MUFA 4 2425 Risk Ratio (M-H, Random, 95% CI) 1.15 [0.73, 1.81]
28.3 N-6 replacing nil, low n-
6
1 111 Risk Ratio (M-H, Random, 95% CI) 0.35 [0.01, 8.45]
28.4 N-6 replacement unclear 1 393 Risk Ratio (M-H, Random, 95% CI) 0.82 [0.62, 1.07]
28.5 N-6 replacing CHO 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
28.6 N-6 replacing protein 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
29 CVD events - subgroup by
baseline CVD risk
7 4962 Risk Ratio (M-H, Random, 95% CI) 0.97 [0.81, 1.15]
29.1 Primary prevention - low
CVD risk
2 1913 Risk Ratio (M-H, Random, 95% CI) 0.80 [0.64, 1.01]
29.2 Primary prevention -
moderate CVD risk
1 111 Risk Ratio (M-H, Random, 95% CI) 0.35 [0.01, 8.45]
29.3 Secondary prevention -
existing CVD
4 2938 Risk Ratio (M-H, Random, 95% CI) 1.04 [0.83, 1.29]
30 CVD events - subgroup
by primary vs secondary
prevention
7 4962 Risk Ratio (M-H, Random, 95% CI) 0.97 [0.81, 1.15]
30.1 Primary prevention - low
or mod CVD risk
3 2024 Risk Ratio (M-H, Random, 95% CI) 0.80 [0.64, 1.00]
30.2 Secondary prevention -
existing CVD
4 2938 Risk Ratio (M-H, Random, 95% CI) 1.04 [0.83, 1.29]
31 CVD events - subgroup by
omega-6 dose
7 4962 Risk Ratio (M-H, Random, 95% CI) 0.97 [0.81, 1.15]
31.1 N-6 < 4% E 2 2144 Risk Ratio (M-H, Random, 95% CI) 0.99 [0.90, 1.09]
31.2 N-6 4% to 12% E 3 2371 Risk Ratio (M-H, Random, 95% CI) 1.15 [0.61, 2.16]
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31.3 N-6 > 12% E 2 447 Risk Ratio (M-H, Random, 95% CI) 0.95 [0.63, 1.42]
32 CVD events - subgroup by
duration
7 4962 Risk Ratio (M-H, Random, 95% CI) 0.97 [0.81, 1.15]
32.1 Medium duration 1 to <
2 years in study
2 1178 Risk Ratio (M-H, Random, 95% CI) 1.30 [0.22, 7.67]
32.2 Medium-long duration 2
to < 4 years
2 2087 Risk Ratio (M-H, Random, 95% CI) 1.00 [0.91, 1.09]
32.3 Long duration 4+ years
in study
3 1697 Risk Ratio (M-H, Random, 95% CI) 0.95 [0.68, 1.33]
33 CVD events - subgroup by
baseline omega-6
7 4962 Risk Ratio (M-H, Random, 95% CI) 0.97 [0.81, 1.15]
33.1 ≥ 8% E from n-6 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
33.2 5% to < 8% E from n-6 2 2491 Risk Ratio (M-H, Random, 95% CI) 1.18 [0.76, 1.85]
33.3 < 5% E from n-6 2 1913 Risk Ratio (M-H, Random, 95% CI) 0.80 [0.64, 1.01]
33.4 baseline n-6 not reported 3 558 Risk Ratio (M-H, Random, 95% CI) 0.90 [0.67, 1.21]
34 CVD events - subgroup by sex 7 4962 Risk Ratio (M-H, Random, 95% CI) 0.97 [0.81, 1.15]
34.1 Men only 5 4797 Risk Ratio (M-H, Random, 95% CI) 0.95 [0.78, 1.16]
34.2 Men and women 1 111 Risk Ratio (M-H, Random, 95% CI) 0.35 [0.01, 8.45]
34.3 Sex not reported 1 54 Risk Ratio (M-H, Random, 95% CI) 1.27 [0.72, 2.23]
35 Coronary heart disease events
(overall): myocardial infarction
(fatal or non-fatal) or angina
7 3997 Risk Ratio (M-H, Random, 95% CI) 0.88 [0.66, 1.17]
36 CHD events - sensitivity
analysis by fixed-effect analysis
7 3997 Risk Ratio (M-H, Fixed, 95% CI) 0.91 [0.82, 1.00]
37 CHD events - sensitivity
analyses
7 Risk Ratio (M-H, Random, 95% CI) Subtotals only
37.1 Studies at low risk of bias 1 458 Risk Ratio (M-H, Random, 95% CI) 1.63 [1.00, 2.67]
37.2 Pre-2010 or prospective
trials registry entry
7 3997 Risk Ratio (M-H, Random, 95% CI) 0.88 [0.66, 1.17]
37.3 No commercial funding 3 953 Risk Ratio (M-H, Random, 95% CI) 0.78 [0.33, 1.82]
37.4 Low risk of attention bias 3 1011 Risk Ratio (M-H, Random, 95% CI) 0.83 [0.62, 1.09]
37.5 Randomised 250+
participants
4 3730 Risk Ratio (M-H, Random, 95% CI) 0.97 [0.78, 1.19]
37.6 Randomised 100+
participants
6 3943 Risk Ratio (M-H, Random, 95% CI) 0.84 [0.61, 1.15]
38 CHD events - subgroup by LA
or GLA
7 3997 Risk Ratio (M-H, Random, 95% CI) 0.88 [0.66, 1.17]
38.1 Mainly LA 6 3886 Risk Ratio (M-H, Random, 95% CI) 0.88 [0.66, 1.19]
38.2 GLA supplements 1 111 Risk Ratio (M-H, Random, 95% CI) 0.35 [0.01, 8.45]
39 CHD events - subgroup by
intervention type
7 3997 Risk Ratio (M-H, Random, 95% CI) 0.88 [0.66, 1.17]
39.1 Dietary advice 3 2593 Risk Ratio (M-H, Random, 95% CI) 0.78 [0.38, 1.61]
39.2 Dietary advice plus
supplement
2 447 Risk Ratio (M-H, Random, 95% CI) 1.02 [0.76, 1.38]
39.3 Supplemental foods 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
39.4 Supplements (capsules) 1 111 Risk Ratio (M-H, Random, 95% CI) 0.35 [0.01, 8.45]
39.5 Diet (all foods) provided 1 846 Risk Ratio (M-H, Random, 95% CI) 0.77 [0.56, 1.04]
40 CHD events - subgroup by
replacement
7 Risk Ratio (M-H, Random, 95% CI) Subtotals only
40.1 N-6 replacing SFA 5 3832 Risk Ratio (M-H, Random, 95% CI) 0.85 [0.61, 1.17]
40.2 N-6 replacing MUFA 3 1358 Risk Ratio (M-H, Random, 95% CI) 1.38 [1.07, 1.77]
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40.3 N-6 replacing nil, low n-
6
1 111 Risk Ratio (M-H, Random, 95% CI) 0.35 [0.01, 8.45]
40.4 N-6 replacement unclear 1 393 Risk Ratio (M-H, Random, 95% CI) 0.97 [0.69, 1.37]
40.5 N-6 replacing CHO 1 102 Risk Ratio (M-H, Random, 95% CI) 0.27 [0.14, 0.52]
40.6 N-6 replacing protein 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
41 CHD events - subgroup by
baseline CVD risk
7 3997 Risk Ratio (M-H, Random, 95% CI) 0.88 [0.66, 1.17]
41.1 Primary prevention - low
CVD risk
1 846 Risk Ratio (M-H, Random, 95% CI) 0.77 [0.56, 1.04]
41.2 Primary prevention -
moderate CVD risk
2 213 Risk Ratio (M-H, Random, 95% CI) 0.27 [0.14, 0.52]
41.3 Secondary prevention -
existing CVD
4 2938 Risk Ratio (M-H, Random, 95% CI) 1.05 [0.84, 1.32]
42 CHD events - subgroup by
omega-6 dose
7 3997 Risk Ratio (M-H, Random, 95% CI) 0.88 [0.66, 1.17]
42.1 N-6 < 4% E 2 2144 Risk Ratio (M-H, Random, 95% CI) 0.93 [0.82, 1.05]
42.2 N-6 4% to 12% E 3 1406 Risk Ratio (M-H, Random, 95% CI) 0.72 [0.31, 1.64]
42.3 N-6 > 12% E 2 447 Risk Ratio (M-H, Random, 95% CI) 1.02 [0.76, 1.38]
43 CHD events - subgroup by
duration
7 3997 Risk Ratio (M-H, Random, 95% CI) 0.88 [0.66, 1.17]
43.1 Medium duration 1 to <
2 years in study
1 111 Risk Ratio (M-H, Random, 95% CI) 0.35 [0.01, 8.45]
43.2 Medium-long duration 2
to < 4 years
2 2087 Risk Ratio (M-H, Random, 95% CI) 0.94 [0.83, 1.05]
43.3 Long duration 4+ years
in study
4 1799 Risk Ratio (M-H, Random, 95% CI) 0.79 [0.46, 1.35]
44 CHD events - subgroup by
baseline omega-6
7 3997 Risk Ratio (M-H, Random, 95% CI) 0.88 [0.66, 1.17]
44.1 ≥ 8% E from n-6 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
44.2 5% to < 8% E from n-6 2 2491 Risk Ratio (M-H, Random, 95% CI) 1.17 [0.68, 2.01]
44.3 < 5% E from n-6 1 846 Risk Ratio (M-H, Random, 95% CI) 0.77 [0.56, 1.04]
44.4 Baseline omega 6 not
reported
4 660 Risk Ratio (M-H, Random, 95% CI) 0.68 [0.31, 1.47]
45 CHD events - subgroup by sex 7 3997 Risk Ratio (M-H, Random, 95% CI) 0.88 [0.66, 1.17]
45.1 Men only 4 3730 Risk Ratio (M-H, Random, 95% CI) 0.97 [0.78, 1.19]
45.2 Women only 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
45.3 Men and women 2 213 Risk Ratio (M-H, Random, 95% CI) 0.27 [0.14, 0.52]
45.4 Sex not reported 1 54 Risk Ratio (M-H, Random, 95% CI) 1.24 [0.63, 2.44]
46 Major adverse cardiac
and cerebrovascular events
(MACCEs), overall
2 2879 Risk Ratio (M-H, Random, 95% CI) 0.84 [0.59, 1.20]
47 MACCEs - sensitivity analysis
by fixed-effect analysis
2 2879 Risk Ratio (M-H, Fixed, 95% CI) 0.92 [0.82, 1.04]
48 MACCEs - sensitivity analyses 2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
48.1 Low risk of bias 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
48.2 Pre-2010 or prospective
trials registry entry
2 2879 Risk Ratio (M-H, Random, 95% CI) 0.84 [0.59, 1.20]
48.3 No commercial funding 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
48.4 Low risk of attention bias 1 846 Risk Ratio (M-H, Random, 95% CI) 0.69 [0.51, 0.93]
48.5 Randomised 250+
participants
2 2879 Risk Ratio (M-H, Random, 95% CI) 0.84 [0.59, 1.20]
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48.6 Randomised 100+
participants
2 2879 Risk Ratio (M-H, Random, 95% CI) 0.84 [0.59, 1.20]
49 MACCEs - subgroup by
intervention type
2 2879 Risk Ratio (M-H, Random, 95% CI) 0.84 [0.59, 1.20]
49.1 Dietary advice 1 2033 Risk Ratio (M-H, Random, 95% CI) 0.99 [0.87, 1.12]
49.2 Supplements (capsules) 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
49.3 Supplemental foods 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
49.4 Dietary advice plus
supplement
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
49.5 Diet (all foods) provided 1 846 Risk Ratio (M-H, Random, 95% CI) 0.69 [0.51, 0.93]
50 MACCEs - subgroup by
replacement
2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
50.1 N-6 replacing SFA 2 2879 Risk Ratio (M-H, Random, 95% CI) 0.84 [0.59, 1.20]
50.2 N-6 replacing MUFA 1 846 Risk Ratio (M-H, Random, 95% CI) 0.69 [0.51, 0.93]
50.3 N-6 replacing nil, low n-
6
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
50.4 N-6 replacement unclear 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
50.5 N-6 replacing CHO 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
50.6 N-6 replacing protein 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
51 MACCEs - subgroup by
baseline CVD risk
2 2879 Risk Ratio (M-H, Random, 95% CI) 0.84 [0.59, 1.20]
51.1 Primary prevention - low
CVD risk
1 846 Risk Ratio (M-H, Random, 95% CI) 0.69 [0.51, 0.93]
51.2 Primary prevention -
moderate CVD risk
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
51.3 Secondary prevention -
existing CVD
1 2033 Risk Ratio (M-H, Random, 95% CI) 0.99 [0.87, 1.12]
52 MACCEs - subgroup by
omega-6 dose
2 2879 Risk Ratio (M-H, Random, 95% CI) 0.84 [0.59, 1.20]
52.1 N-6 < 4% E 1 2033 Risk Ratio (M-H, Random, 95% CI) 0.99 [0.87, 1.12]
52.2 N-6 4% to 12% E 1 846 Risk Ratio (M-H, Random, 95% CI) 0.69 [0.51, 0.93]
52.3 N-6 > 12% E 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
53 MACCEs - subgroup by
duration
2 2879 Risk Ratio (M-H, Random, 95% CI) 0.84 [0.59, 1.20]
53.1 Medium duration 1 to <
2 years in study
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
53.2 Medium-long duration 2
to < 4 years
1 2033 Risk Ratio (M-H, Random, 95% CI) 0.99 [0.87, 1.12]
53.3 Long duration 4+ years
in study
1 846 Risk Ratio (M-H, Random, 95% CI) 0.69 [0.51, 0.93]
54 MACCEs - subgroup by
baseline omega-6
2 2879 Risk Ratio (M-H, Random, 95% CI) 0.84 [0.59, 1.20]
54.1 ≥ 8% E from n-6 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
54.2 5% to < 8% E from n-6 1 2033 Risk Ratio (M-H, Random, 95% CI) 0.99 [0.87, 1.12]
54.3 < 5% E from n-6 1 846 Risk Ratio (M-H, Random, 95% CI) 0.69 [0.51, 0.93]
54.4 Baseline n-6 not reported 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
55 Stroke: fatal or non-fatal
(overall)
4 3730 Risk Ratio (M-H, Random, 95% CI) 1.36 [0.45, 4.11]
56 Stroke - sensitivity analysis by
fixed-effect analysis
4 3730 Risk Ratio (M-H, Fixed, 95% CI) 1.00 [0.59, 1.68]
57 Stroke - sensitivity analyses 4 Risk Ratio (M-H, Random, 95% CI) Subtotals only
97Omega-6 fats for the primary and secondary prevention of cardiovascular disease (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
57.1 Low risk of bias 1 458 Risk Ratio (M-H, Random, 95% CI) 1.07 [0.15, 7.55]
57.2 Pre-2010 or prospective
trials registry entry
4 3730 Risk Ratio (M-H, Random, 95% CI) 1.36 [0.45, 4.11]
57.3 No commercial funding 2 851 Risk Ratio (M-H, Random, 95% CI) 1.67 [0.32, 8.62]
57.4 Low risk of attention bias 1 846 Risk Ratio (M-H, Random, 95% CI) 0.59 [0.30, 1.15]
57.5 Randomised 250+
participants
4 3730 Risk Ratio (M-H, Random, 95% CI) 1.36 [0.45, 4.11]
57.6 Randomised 100+
participants
4 3730 Risk Ratio (M-H, Random, 95% CI) 1.36 [0.45, 4.11]
58 Stroke - subgroup by
intervention type
4 3730 Risk Ratio (M-H, Random, 95% CI) 1.36 [0.45, 4.11]
58.1 Dietary advice 2 2491 Risk Ratio (M-H, Random, 95% CI) 2.36 [0.81, 6.91]
58.2 Supplements (capsules) 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
58.3 Supplemental foods 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
58.4 Dietary advice plus
supplement
1 393 Risk Ratio (M-H, Random, 95% CI) 4.88 [0.24, 100.89]
58.5 Diet (all foods) provided 1 846 Risk Ratio (M-H, Random, 95% CI) 0.59 [0.30, 1.15]
59 Stroke - subgroup by
replacement
4 Risk Ratio (M-H, Random, 95% CI) Subtotals only
59.1 N-6 replacing SFA 4 3730 Risk Ratio (M-H, Random, 95% CI) 1.36 [0.45, 4.11]
59.2 N-6 replacing MUFA 2 1304 Risk Ratio (M-H, Random, 95% CI) 0.63 [0.33, 1.18]
59.3 N-6 replacing nil, low n-
6
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
59.4 N-6 replacement unclear 1 393 Risk Ratio (M-H, Random, 95% CI) 4.88 [0.24, 100.89]
59.5 N-6 replacing CHO 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
59.6 N-6 replacing protein 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
60 Stroke - subgroup by baseline
CVD risk
4 3730 Risk Ratio (M-H, Random, 95% CI) 1.36 [0.45, 4.11]
60.1 Primary prevention - low
CVD risk
1 846 Risk Ratio (M-H, Random, 95% CI) 0.59 [0.30, 1.15]
60.2 Primary prevention -
moderate CVD risk
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
60.3 Secondary prevention -
existing CVD
3 2884 Risk Ratio (M-H, Random, 95% CI) 2.56 [0.93, 7.04]
61 Stroke - subgroup by omega-6
dose
4 3730 Risk Ratio (M-H, Random, 95% CI) 1.36 [0.45, 4.11]
61.1 N-6 < 4% E 1 2033 Risk Ratio (M-H, Random, 95% CI) 3.32 [0.92, 12.04]
61.2 N-6 ≥ 4% to < 12% E 2 1304 Risk Ratio (M-H, Random, 95% CI) 0.63 [0.33, 1.18]
61.3 N-6 ≥ 12% E 1 393 Risk Ratio (M-H, Random, 95% CI) 4.88 [0.24, 100.89]
62 Stroke - subgroup by duration 4 3730 Risk Ratio (M-H, Random, 95% CI) 1.36 [0.45, 4.11]
62.1 Medium duration 1 to <
2 years in study
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
62.2 Medium-long duration 2
to < 4 years
1 2033 Risk Ratio (M-H, Random, 95% CI) 3.32 [0.92, 12.04]
62.3 Long duration 4+ years
in study
3 1697 Risk Ratio (M-H, Random, 95% CI) 0.69 [0.36, 1.33]
63 Stroke - subgroup by baseline
omega-6
4 3730 Risk Ratio (M-H, Random, 95% CI) 1.36 [0.45, 4.11]
63.1 ≥ 8% E from n-6 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
63.2 5% to < 8% E from n-6 2 2491 Risk Ratio (M-H, Random, 95% CI) 2.36 [0.81, 6.91]
63.3 < 5% E from n-6 1 846 Risk Ratio (M-H, Random, 95% CI) 0.59 [0.30, 1.15]
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63.4 Baseline n-6 not reported 1 393 Risk Ratio (M-H, Random, 95% CI) 4.88 [0.24, 100.89]
64 Stroke - subgroup by stroke
type
1 4066 Risk Ratio (M-H, Random, 95% CI) 2.93 [0.64, 13.49]
64.1 Ischaemic stroke 1 2033 Risk Ratio (M-H, Random, 95% CI) 6.98 [0.86, 56.62]
64.2 Haemorrhagic stroke 1 2033 Risk Ratio (M-H, Random, 95% CI) 1.50 [0.25, 8.93]
65 Stroke - subgroup by fatality 2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
65.1 Fatal stroke 2 1304 Risk Ratio (M-H, Random, 95% CI) 0.48 [0.16, 1.40]
65.2 Non-fatal stroke 1 846 Risk Ratio (M-H, Random, 95% CI) 0.77 [0.34, 1.73]
Comparison 2. Secondary outcomes - higher omega-6 vs lower omega-6
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Myocardial infarction (MI),
overall
7 4606 Risk Ratio (M-H, Random, 95% CI) 0.88 [0.76, 1.02]
2 MI - sensitivity analysis by
fixed-effect analysis
7 4606 Risk Ratio (M-H, Fixed, 95% CI) 0.87 [0.75, 1.00]
3 MI - sensitivity analyses 7 Risk Ratio (M-H, Random, 95% CI) Subtotals only
3.1 Low summary risk of bias 1 1067 Risk Ratio (M-H, Random, 95% CI) 1.88 [0.21, 16.75]
3.2 Pre-2010 or prospective
trials registry entry
7 4606 Risk Ratio (M-H, Random, 95% CI) 0.88 [0.76, 1.02]
3.3 No commercial funding 3 1562 Risk Ratio (M-H, Random, 95% CI) 0.76 [0.22, 2.65]
3.4 Low risk of attention bias 4 2078 Risk Ratio (M-H, Random, 95% CI) 0.89 [0.62, 1.28]
3.5 Randomised 250+
participants
4 4339 Risk Ratio (M-H, Random, 95% CI) 0.88 [0.76, 1.02]
3.6 Randomised 100+
participants
6 4552 Risk Ratio (M-H, Random, 95% CI) 0.87 [0.75, 1.01]
4 MI - subgroup by intervention
type
7 4606 Risk Ratio (M-H, Random, 95% CI) 0.88 [0.76, 1.02]
4.1 Dietary advice 2 2135 Risk Ratio (M-H, Random, 95% CI) 0.40 [0.04, 3.75]
4.2 Supplements (capsules) 1 111 Risk Ratio (M-H, Random, 95% CI) 0.35 [0.01, 8.45]
4.3 Supplemental foods 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
4.4 Dietary advice plus
supplement
2 447 Risk Ratio (M-H, Random, 95% CI) 0.99 [0.69, 1.42]
4.5 Diet (all foods) provided 2 1913 Risk Ratio (M-H, Random, 95% CI) 0.84 [0.56, 1.27]
5 MI - subgroup by replacement 7 Risk Ratio (M-H, Random, 95% CI) Subtotals only
5.1 N-6 replacing SFA 5 4441 Risk Ratio (M-H, Random, 95% CI) 0.87 [0.75, 1.01]
5.2 N-6 replacing MUFA 3 1967 Risk Ratio (M-H, Random, 95% CI) 0.90 [0.62, 1.30]
5.3 N-6 replacing nil, low n-6 1 111 Risk Ratio (M-H, Random, 95% CI) 0.35 [0.01, 8.45]
5.4 N-6 replacement unclear 1 393 Risk Ratio (M-H, Random, 95% CI) 0.95 [0.64, 1.41]
5.5 N-6 replacing CHO 1 102 Risk Ratio (M-H, Random, 95% CI) 0.08 [0.00, 1.33]
5.6 N-6 replacing protein 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
6 MI - subgroup by baseline CVD
risk
7 4606 Risk Ratio (M-H, Random, 95% CI) 0.88 [0.76, 1.02]
6.1 Primary prevention - low
CVD risk
2 1913 Risk Ratio (M-H, Random, 95% CI) 0.84 [0.56, 1.27]
6.2 Primary prevention -
moderate CVD risk
2 213 Risk Ratio (M-H, Random, 95% CI) 0.15 [0.02, 1.26]
99Omega-6 fats for the primary and secondary prevention of cardiovascular disease (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
6.3 Secondary prevention -
existing CVD
3 2480 Risk Ratio (M-H, Random, 95% CI) 0.89 [0.77, 1.04]
7 MI - subgroup by omega-6 dose 7 4606 Risk Ratio (M-H, Random, 95% CI) 0.88 [0.76, 1.02]
7.1 N-6 < 4% E 2 2144 Risk Ratio (M-H, Random, 95% CI) 0.87 [0.73, 1.03]
7.2 N-6 4% to 12% E 3 2015 Risk Ratio (M-H, Random, 95% CI) 0.70 [0.21, 2.29]
7.3 N-6 > 12% E 2 447 Risk Ratio (M-H, Random, 95% CI) 0.99 [0.69, 1.42]
8 MI - subgroup by duration 7 4606 Risk Ratio (M-H, Random, 95% CI) 0.88 [0.76, 1.02]
8.1 Medium duration 1 to < 2
years in study
2 1178 Risk Ratio (M-H, Random, 95% CI) 1.10 [0.18, 6.65]
8.2 Medium-long duration 2
to < 4 years in study
2 2087 Risk Ratio (M-H, Random, 95% CI) 0.88 [0.75, 1.04]
8.3 Long duration 4+ years in
study
3 1341 Risk Ratio (M-H, Random, 95% CI) 0.84 [0.55, 1.27]
9 MI - subgroup by statin use 7 4606 Risk Ratio (M-H, Random, 95% CI) 0.88 [0.76, 1.02]
9.1 ≥ 50% of control group
on statins
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
9.2 < 50% of control group
on statins
6 4495 Risk Ratio (M-H, Random, 95% CI) 0.88 [0.76, 1.02]
9.3 Statin use unclear 1 111 Risk Ratio (M-H, Random, 95% CI) 0.35 [0.01, 8.45]
10 MI - subgroup by baseline
omega-6
7 4606 Risk Ratio (M-H, Random, 95% CI) 0.88 [0.76, 1.02]
10.1 ≥ 8% E from n-6 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
10.2 5% to < 8% E from n-6 1 2033 Risk Ratio (M-H, Random, 95% CI) 0.87 [0.74, 1.04]
10.3 < 5% E from omega 6 2 1913 Risk Ratio (M-H, Random, 95% CI) 0.84 [0.56, 1.27]
10.4 Baseline n-6 not reported 4 660 Risk Ratio (M-H, Random, 95% CI) 0.90 [0.52, 1.57]
11 MI - subgroup by sex 7 4606 Risk Ratio (M-H, Random, 95% CI) 0.88 [0.76, 1.02]
11.1 Men and women 2 213 Risk Ratio (M-H, Random, 95% CI) 0.15 [0.02, 1.26]
11.2 Sex not reported 1 54 Risk Ratio (M-H, Random, 95% CI) 1.19 [0.52, 2.74]
11.3 Men only 4 4339 Risk Ratio (M-H, Random, 95% CI) 0.88 [0.76, 1.02]
12 Angina 4 1395 Risk Ratio (M-H, Random, 95% CI) 0.61 [0.27, 1.40]
13 Sudden cardiac death 3 1293 Risk Ratio (M-H, Random, 95% CI) 0.79 [0.49, 1.29]
14 Heart failure 2 2426 Risk Ratio (M-H, Random, 95% CI) 0.66 [0.19, 2.35]
15 Revascularisation - angioplasty
or coronary artery bypass
grafting
1 200 Risk Ratio (M-H, Random, 95% CI) 1.0 [0.14, 6.96]
16 Peripheral arterial disease events 3 3946 Risk Ratio (M-H, Random, 95% CI) 1.01 [0.60, 1.70]
17 Serum total cholesterol (TC),
mmol/L
10 4280 Mean Difference (IV, Random, 95% CI) -0.33 [-0.50, -0.16]
18 TC, mmol/L - sensitivity
analysis by fixed-effect analysis
10 4280 Mean Difference (IV, Fixed, 95% CI) -0.35 [-0.41, -0.29]
19 TC, mmol/L - sensitivity
analyses
10 Mean Difference (IV, Random, 95% CI) Subtotals only
19.1 Studies at low risk of bias 3 1179 Mean Difference (IV, Random, 95% CI) -0.54 [-0.82, -0.26]
19.2 Pre-2010 or prospective
trials registry entry
9 4090 Mean Difference (IV, Random, 95% CI) -0.38 [-0.55, -0.22]
19.3 No commercial funding 6 1506 Mean Difference (IV, Random, 95% CI) -0.41 [-0.66, -0.16]
19.4 Low risk of attention bias 6 1834 Mean Difference (IV, Random, 95% CI) -0.33 [-0.64, -0.02]
19.5 Randomised 250+
participants
5 3813 Mean Difference (IV, Random, 95% CI) -0.35 [-0.47, -0.23]
19.6 Randomised 100+
participants
7 4104 Mean Difference (IV, Random, 95% CI) -0.37 [-0.56, -0.18]
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20 TC, mmol/L - subgroup by
intervention type
10 Mean Difference (IV, Random, 95% CI) Subtotals only
20.1 Dietary advice 3 2269 Mean Difference (IV, Random, 95% CI) -0.29 [-0.38, -0.20]
20.2 Supplements (capsules) 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
20.3 Supplemental foods 1 190 Mean Difference (IV, Random, 95% CI) 0.06 [-0.22, 0.34]
20.4 Dietary advice plus
supplement
3 257 Mean Difference (IV, Random, 95% CI) -0.04 [-0.63, 0.55]
20.5 Diet (all foods) provided 3 1564 Mean Difference (IV, Random, 95% CI) -0.58 [-0.91, -0.26]
21 TC, mmol/L - subgroup by
replacement
10 Mean Difference (IV, Random, 95% CI) Subtotals only
21.1 N-6 replacing SFA 8 4200 Mean Difference (IV, Random, 95% CI) -0.38 [-0.56, -0.21]
21.2 N-6 replacing MUFA 5 2048 Mean Difference (IV, Random, 95% CI) -0.51 [-0.72, -0.29]
21.3 N-6 replacing nil, low n-
6
0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
21.4 N-6 replacement unclear 2 231 Mean Difference (IV, Random, 95% CI) 0.16 [-0.18, 0.50]
21.5 N-6 replacing CHO 1 96 Mean Difference (IV, Random, 95% CI) -0.47 [-0.76, -0.18]
21.6 N-6 replacing protein 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
22 TC, mmol/L - subgroup by
baseline CVD risk
10 Mean Difference (IV, Random, 95% CI) Subtotals only
22.1 Primary prevention - low
CVD risk
4 1618 Mean Difference (IV, Random, 95% CI) -0.41 [-0.77, -0.05]
22.2 Primary prevention -
moderate CVD risk
1 96 Mean Difference (IV, Random, 95% CI) -0.47 [-0.76, -0.18]
22.3 Secondary prevention -
existing CVD
5 2566 Mean Difference (IV, Random, 95% CI) -0.21 [-0.37, -0.06]
23 TC, mmol/L - subgroup by
omega-6 dose
10 Mean Difference (IV, Random, 95% CI) Subtotals only
23.1 N-6 < 4% E 2 1769 Mean Difference (IV, Random, 95% CI) -0.08 [-0.49, 0.32]
23.2 N-6 4% to 12% E 4 2017 Mean Difference (IV, Random, 95% CI) -0.42 [-0.51, -0.34]
23.3 N-6 > 12% E 4 494 Mean Difference (IV, Random, 95% CI) -0.44 [-1.20, 0.31]
24 TC, mmol/L - subgroup by
duration
10 Mean Difference (IV, Random, 95% CI) Subtotals only
24.1 Medium duration 1 to <
2 years in study
3 775 Mean Difference (IV, Random, 95% CI) -0.41 [-0.87, 0.04]
24.2 Medium-long duration 2
to < 4 years
3 1931 Mean Difference (IV, Random, 95% CI) -0.16 [-0.43, 0.10]
24.3 Long duration 4+ years
in study
4 1574 Mean Difference (IV, Random, 95% CI) -0.36 [-0.52, -0.20]
25 TC, mmol/L - subgroup by
statin use
10 Mean Difference (IV, Random, 95% CI) Subtotals only
25.1 ≥ 50% of control group
on statins
1 190 Mean Difference (IV, Random, 95% CI) 0.06 [-0.22, 0.34]
25.2 < 50% of control group
on statins
9 4090 Mean Difference (IV, Random, 95% CI) -0.38 [-0.55, -0.22]
25.3 Statin use unclear 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
26 TC, mmol/L - subgroup by
baseline omega-6
10 Mean Difference (IV, Random, 95% CI) Subtotals only
26.1 ≥ 8% E from n-6 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
26.2 5% to < 8% E from n-6 2 2173 Mean Difference (IV, Random, 95% CI) -0.27 [-0.36, -0.17]
26.3 < 5% E from n-6 3 1564 Mean Difference (IV, Random, 95% CI) -0.58 [-0.91, -0.26]
26.4 Baseline n-6 not reported 5 543 Mean Difference (IV, Random, 95% CI) -0.13 [-0.48, 0.21]
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27 TC, mmol/L - subgroup by sex 10 Mean Difference (IV, Random, 95% CI) Subtotals only
27.1 Men and women 3 340 Mean Difference (IV, Random, 95% CI) -0.09 [-0.47, 0.30]
27.2 Sex not reported 1 26 Mean Difference (IV, Random, 95% CI) -0.49 [-1.34, 0.36]
27.3 Men only 6 3914 Mean Difference (IV, Random, 95% CI) -0.44 [-0.63, -0.26]
28 Serum triglycerides (TG),
mmol/L
5 834 Mean Difference (IV, Random, 95% CI) -0.01 [-0.23, 0.21]
29 Low-density lipoprotein
(LDL), mmol/L
2 244 Mean Difference (IV, Random, 95% CI) -0.04 [-0.21, 0.14]
30 High-density lipoprotein
(HDL), mmol/L
4 1995 Mean Difference (IV, Random, 95% CI) -0.01 [-0.03, 0.02]
31 Body weight, kg 4 358 Mean Difference (IV, Random, 95% CI) -3.12 [-12.60, 6.36]
32 Body mass index, kg/m2 1 371 Mean Difference (IV, Random, 95% CI) -0.20 [-0.56, 0.16]
33 Fat weight, kg 1 30 Mean Difference (IV, Random, 95% CI) -7.70 [-14.60, -0.80]
Comparison 3. Tertiary outcomes - higher omega-6 vs lower omega-6
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 BP - systolic and diastolic blood
pressure, mmHg
2 Mean Difference (IV, Random, 95% CI) Subtotals only
1.1 sBP - systolic blood
pressure, mmHg
2 635 Mean Difference (IV, Random, 95% CI) -1.10 [-4.05, 1.85]
1.2 dBP - diastolic blood
pressure
2 635 Mean Difference (IV, Random, 95% CI) -0.30 [-2.04, 1.44]
2 Dropouts 7 1425 Risk Ratio (M-H, Random, 95% CI) 0.94 [0.52, 1.72]
3 Other serious adverse events 4 Risk Ratio (M-H, Random, 95% CI) Subtotals only
3.1 Pulmonary embolism 2 2087 Risk Ratio (M-H, Random, 95% CI) 2.15 [0.48, 9.57]
3.2 Multiple Sclerosis
worsened or had acute attack -
GLA supplement
2 268 Risk Ratio (M-H, Random, 95% CI) 1.11 [0.95, 1.30]
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Analysis 1.1. Comparison 1 Primary outcomes - higher omega-6 vs lower omega-6, Outcome 1 All-cause
mortality (overall).
Review: Omega-6 fats for the primary and secondary prevention of cardiovascular disease
Comparison: 1 Primary outcomes - higher omega-6 vs lower omega-6
Outcome: 1 All-cause mortality (overall)
Study or subgroup Higher omega 6 Lower omega 6 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Bates 1978 0/58 2/58 0.2 % 0.20 [ 0.01, 4.08 ]
Black 1994 2/67 1/66 0.3 % 1.97 [ 0.18, 21.21 ]
DART 1989 111/1018 113/1015 24.0 % 0.98 [ 0.76, 1.25 ]
McIllmurray 1987 10/25 12/24 3.7 % 0.80 [ 0.43, 1.49 ]
MRC 1968 28/199 31/194 6.6 % 0.88 [ 0.55, 1.41 ]
NDHS Faribault 1968 4/167 0/57 0.2 % 3.11 [ 0.17, 56.84 ]
Rose 1965 5/28 3/26 0.8 % 1.55 [ 0.41, 5.84 ]
Sydney Diet-Heart 1978 38/221 27/237 7.0 % 1.51 [ 0.95, 2.39 ]
Veterans Admin 1969 174/424 177/422 57.1 % 0.98 [ 0.83, 1.15 ]
Vijayakumar 2014 0/100 2/100 0.2 % 0.20 [ 0.01, 4.11 ]
Total (95% CI) 2307 2199 100.0 % 1.00 [ 0.88, 1.12 ]
Total events: 372 (Higher omega 6), 368 (Lower omega 6)
Heterogeneity: Tau2 = 0.0; Chi2 = 7.48, df = 9 (P = 0.59); I2 =0.0%
Test for overall effect: Z = 0.05 (P = 0.96)
Test for subgroup differences: Not applicable
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Analysis 1.2. Comparison 1 Primary outcomes - higher omega-6 vs lower omega-6, Outcome 2 All-cause
mortality - sensitivity analysis by fixed-effect analysis.
Review: Omega-6 fats for the primary and secondary prevention of cardiovascular disease
Comparison: 1 Primary outcomes - higher omega-6 vs lower omega-6
Outcome: 2 All-cause mortality - sensitivity analysis by fixed-effect analysis
Study or subgroup Higher omega 6 Lower omega 6 Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Bates 1978 0/58 2/58 0.7 % 0.20 [ 0.01, 4.08 ]
Black 1994 2/67 1/66 0.3 % 1.97 [ 0.18, 21.21 ]
DART 1989 111/1018 113/1015 30.6 % 0.98 [ 0.76, 1.25 ]
McIllmurray 1987 10/25 12/24 3.3 % 0.80 [ 0.43, 1.49 ]
MRC 1968 28/199 31/194 8.5 % 0.88 [ 0.55, 1.41 ]
NDHS Faribault 1968 4/167 0/57 0.2 % 3.11 [ 0.17, 56.84 ]
Rose 1965 5/28 3/26 0.8 % 1.55 [ 0.41, 5.84 ]
Sydney Diet-Heart 1978 38/221 27/237 7.0 % 1.51 [ 0.95, 2.39 ]
Veterans Admin 1969 174/424 177/422 47.9 % 0.98 [ 0.83, 1.15 ]
Vijayakumar 2014 0/100 2/100 0.7 % 0.20 [ 0.01, 4.11 ]
Total (95% CI) 2307 2199 100.0 % 1.00 [ 0.89, 1.13 ]
Total events: 372 (Higher omega 6), 368 (Lower omega 6)
Heterogeneity: Chi2 = 7.48, df = 9 (P = 0.59); I2 =0.0%
Test for overall effect: Z = 0.05 (P = 0.96)
Test for subgroup differences: Not applicable
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Analysis 1.3. Comparison 1 Primary outcomes - higher omega-6 vs lower omega-6, Outcome 3 All-cause
mortality - sensitivity analyses.
Review: Omega-6 fats for the primary and secondary prevention of cardiovascular disease
Comparison: 1 Primary outcomes - higher omega-6 vs lower omega-6
Outcome: 3 All-cause mortality - sensitivity analyses
Study or subgroup Higher omega 6 Lower omega 6 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Studies at low risk of bias
NDHS Faribault 1968 4/167 0/57 2.4 % 3.11 [ 0.17, 56.84 ]
Sydney Diet-Heart 1978 38/221 27/237 97.6 % 1.51 [ 0.95, 2.39 ]
Subtotal (95% CI) 388 294 100.0 % 1.54 [ 0.98, 2.41 ]
Total events: 42 (Higher omega 6), 27 (Lower omega 6)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.23, df = 1 (P = 0.63); I2 =0.0%
Test for overall effect: Z = 1.86 (P = 0.063)
2 Pre-2010 or prospective trials registry entry
Bates 1978 0/58 2/58 0.2 % 0.20 [ 0.01, 4.08 ]
Black 1994 2/67 1/66 0.3 % 1.97 [ 0.18, 21.21 ]
DART 1989 111/1018 113/1015 24.0 % 0.98 [ 0.76, 1.25 ]
McIllmurray 1987 10/25 12/24 3.8 % 0.80 [ 0.43, 1.49 ]
MRC 1968 28/199 31/194 6.6 % 0.88 [ 0.55, 1.41 ]
NDHS Faribault 1968 4/167 0/57 0.2 % 3.11 [ 0.17, 56.84 ]
Rose 1965 5/28 3/26 0.8 % 1.55 [ 0.41, 5.84 ]
Sydney Diet-Heart 1978 38/221 27/237 7.0 % 1.51 [ 0.95, 2.39 ]
Veterans Admin 1969 174/424 177/422 57.2 % 0.98 [ 0.83, 1.15 ]
Subtotal (95% CI) 2207 2099 100.0 % 1.00 [ 0.89, 1.13 ]
Total events: 372 (Higher omega 6), 366 (Lower omega 6)
Heterogeneity: Tau2 = 0.0; Chi2 = 6.40, df = 8 (P = 0.60); I2 =0.0%
Test for overall effect: Z = 0.01 (P = 0.99)
3 No commercial funding
Black 1994 2/67 1/66 2.2 % 1.97 [ 0.18, 21.21 ]
MRC 1968 28/199 31/194 47.0 % 0.88 [ 0.55, 1.41 ]
NDHS Faribault 1968 4/167 0/57 1.5 % 3.11 [ 0.17, 56.84 ]
Sydney Diet-Heart 1978 38/221 27/237 49.3 % 1.51 [ 0.95, 2.39 ]
Subtotal (95% CI) 654 554 100.0 % 1.19 [ 0.84, 1.69 ]
Total events: 72 (Higher omega 6), 59 (Lower omega 6)
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(. . . Continued)
Study or subgroup Higher omega 6 Lower omega 6 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Heterogeneity: Tau2 = 0.01; Chi2 = 3.20, df = 3 (P = 0.36); I2 =6%
Test for overall effect: Z = 0.97 (P = 0.33)
4 Low risk of attention bias
Bates 1978 0/58 2/58 0.3 % 0.20 [ 0.01, 4.08 ]
McIllmurray 1987 10/25 12/24 6.0 % 0.80 [ 0.43, 1.49 ]
NDHS Faribault 1968 4/167 0/57 0.3 % 3.11 [ 0.17, 56.84 ]
Rose 1965 5/28 3/26 1.3 % 1.55 [ 0.41, 5.84 ]
Veterans Admin 1969 174/424 177/422 91.8 % 0.98 [ 0.83, 1.15 ]
Vijayakumar 2014 0/100 2/100 0.3 % 0.20 [ 0.01, 4.11 ]
Subtotal (95% CI) 802 687 100.0 % 0.97 [ 0.83, 1.13 ]
Total events: 193 (Higher omega 6), 196 (Lower omega 6)
Heterogeneity: Tau2 = 0.0; Chi2 = 3.57, df = 5 (P = 0.61); I2 =0.0%
Test for overall effect: Z = 0.42 (P = 0.68)
5 Randomised 250+ participants
DART 1989 111/1018 113/1015 28.1 % 0.98 [ 0.76, 1.25 ]
MRC 1968 28/199 31/194 8.9 % 0.88 [ 0.55, 1.41 ]
Sydney Diet-Heart 1978 38/221 27/237 9.4 % 1.51 [ 0.95, 2.39 ]
Veterans Admin 1969 174/424 177/422 53.6 % 0.98 [ 0.83, 1.15 ]
Subtotal (95% CI) 1862 1868 100.0 % 1.01 [ 0.87, 1.17 ]
Total events: 351 (Higher omega 6), 348 (Lower omega 6)
Heterogeneity: Tau2 = 0.00; Chi2 = 3.49, df = 3 (P = 0.32); I2 =14%
Test for overall effect: Z = 0.13 (P = 0.89)
6 Randomised 100+ participants
Bates 1978 0/58 2/58 0.2 % 0.20 [ 0.01, 4.08 ]
Black 1994 2/67 1/66 0.3 % 1.97 [ 0.18, 21.21 ]
DART 1989 111/1018 113/1015 25.1 % 0.98 [ 0.76, 1.25 ]
MRC 1968 28/199 31/194 6.9 % 0.88 [ 0.55, 1.41 ]
NDHS Faribault 1968 4/167 0/57 0.2 % 3.11 [ 0.17, 56.84 ]
Sydney Diet-Heart 1978 38/221 27/237 7.3 % 1.51 [ 0.95, 2.39 ]
Veterans Admin 1969 174/424 177/422 59.9 % 0.98 [ 0.83, 1.15 ]
Vijayakumar 2014 0/100 2/100 0.2 % 0.20 [ 0.01, 4.11 ]
Subtotal (95% CI) 2254 2149 100.0 % 1.00 [ 0.88, 1.13 ]
Total events: 357 (Higher omega 6), 353 (Lower omega 6)
Heterogeneity: Tau2 = 0.0; Chi2 = 6.57, df = 7 (P = 0.48); I2 =0.0%
Test for overall effect: Z = 0.02 (P = 0.98)
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Analysis 1.4. Comparison 1 Primary outcomes - higher omega-6 vs lower omega-6, Outcome 4 All-cause
mortality - subgroup by LA or GLA.
Review: Omega-6 fats for the primary and secondary prevention of cardiovascular disease
Comparison: 1 Primary outcomes - higher omega-6 vs lower omega-6
Outcome: 4 All-cause mortality - subgroup by LA or GLA
Study or subgroup Higher omega 6 Lower omega 6 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Mainly LA
Black 1994 2/67 1/66 0.3 % 1.97 [ 0.18, 21.21 ]
DART 1989 111/1018 113/1015 24.0 % 0.98 [ 0.76, 1.25 ]
MRC 1968 28/199 31/194 6.6 % 0.88 [ 0.55, 1.41 ]
NDHS Faribault 1968 4/167 0/57 0.2 % 3.11 [ 0.17, 56.84 ]
Rose 1965 5/28 3/26 0.8 % 1.55 [ 0.41, 5.84 ]
Sydney Diet-Heart 1978 38/221 27/237 7.0 % 1.51 [ 0.95, 2.39 ]
Veterans Admin 1969 174/424 177/422 57.1 % 0.98 [ 0.83, 1.15 ]
Vijayakumar 2014 0/100 2/100 0.2 % 0.20 [ 0.01, 4.11 ]
Subtotal (95% CI) 2224 2117 96.1 % 1.01 [ 0.89, 1.14 ]
Total events: 362 (Higher omega 6), 354 (Lower omega 6)
Heterogeneity: Tau2 = 0.0; Chi2 = 5.88, df = 7 (P = 0.55); I2 =0.0%
Test for overall effect: Z = 0.13 (P = 0.90)
2 GLA supplements
Bates 1978 0/58 2/58 0.2 % 0.20 [ 0.01, 4.08 ]
McIllmurray 1987 10/25 12/24 3.7 % 0.80 [ 0.43, 1.49 ]
Subtotal (95% CI) 83 82 3.9 % 0.76 [ 0.41, 1.39 ]
Total events: 10 (Higher omega 6), 14 (Lower omega 6)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.84, df = 1 (P = 0.36); I2 =0.0%
Test for overall effect: Z = 0.90 (P = 0.37)
Total (95% CI) 2307 2199 100.0 % 1.00 [ 0.88, 1.12 ]
Total events: 372 (Higher omega 6), 368 (Lower omega 6)
Heterogeneity: Tau2 = 0.0; Chi2 = 7.48, df = 9 (P = 0.59); I2 =0.0%
Test for overall effect: Z = 0.05 (P = 0.96)
Test for subgroup differences: Chi2 = 0.82, df = 1 (P = 0.37), I2 =0.0%
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Analysis 1.5. Comparison 1 Primary outcomes - higher omega-6 vs lower omega-6, Outcome 5 All-cause
mortality - subgroup by intervention type.
Review: Omega-6 fats for the primary and secondary prevention of cardiovascular disease
Comparison: 1 Primary outcomes - higher omega-6 vs lower omega-6
Outcome: 5 All-cause mortality - subgroup by intervention type
Study or subgroup Higher omega 6 Lower omega 6 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Dietary advice
Black 1994 2/67 1/66 0.3 % 1.97 [ 0.18, 21.21 ]
DART 1989 111/1018 113/1015 24.0 % 0.98 [ 0.76, 1.25 ]
Sydney Diet-Heart 1978 38/221 27/237 7.0 % 1.51 [ 0.95, 2.39 ]
Subtotal (95% CI) 1306 1318 31.2 % 1.15 [ 0.82, 1.61 ]
Total events: 151 (Higher omega 6), 141 (Lower omega 6)
Heterogeneity: Tau2 = 0.03; Chi2 = 2.90, df = 2 (P = 0.23); I2 =31%
Test for overall effect: Z = 0.83 (P = 0.41)
2 Supplements (capsules)
Bates 1978 0/58 2/58 0.2 % 0.20 [ 0.01, 4.08 ]
McIllmurray 1987 10/25 12/24 3.7 % 0.80 [ 0.43, 1.49 ]
Subtotal (95% CI) 83 82 3.9 % 0.76 [ 0.41, 1.39 ]
Total events: 10 (Higher omega 6), 14 (Lower omega 6)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.84, df = 1 (P = 0.36); I2 =0.0%
Test for overall effect: Z = 0.90 (P = 0.37)
3 Supplemental foods
Vijayakumar 2014 0/100 2/100 0.2 % 0.20 [ 0.01, 4.11 ]
Subtotal (95% CI) 100 100 0.2 % 0.20 [ 0.01, 4.11 ]
Total events: 0 (Higher omega 6), 2 (Lower omega 6)
Heterogeneity: not applicable
Test for overall effect: Z = 1.04 (P = 0.30)
4 Dietary advice plus supplement
MRC 1968 28/199 31/194 6.6 % 0.88 [ 0.55, 1.41 ]
Rose 1965 5/28 3/26 0.8 % 1.55 [ 0.41, 5.84 ]
Subtotal (95% CI) 227 220 7.4 % 0.94 [ 0.60, 1.46 ]
Total events: 33 (Higher omega 6), 34 (Lower omega 6)
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(. . . Continued)
Study or subgroup Higher omega 6 Lower omega 6 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Heterogeneity: Tau2 = 0.0; Chi2 = 0.62, df = 1 (P = 0.43); I2 =0.0%
Test for overall effect: Z = 0.28 (P = 0.78)
5 Diet (all foods) provided
NDHS Faribault 1968 4/167 0/57 0.2 % 3.11 [ 0.17, 56.84 ]
Veterans Admin 1969 174/424 177/422 57.1 % 0.98 [ 0.83, 1.15 ]
Subtotal (95% CI) 591 479 57.3 % 0.98 [ 0.84, 1.15 ]
Total events: 178 (Higher omega 6), 177 (Lower omega 6)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.61, df = 1 (P = 0.43); I2 =0.0%
Test for overall effect: Z = 0.22 (P = 0.82)
Total (95% CI) 2307 2199 100.0 % 1.00 [ 0.88, 1.12 ]
Total events: 372 (Higher omega 6), 368 (Lower omega 6)
Heterogeneity: Tau2 = 0.0; Chi2 = 7.48, df = 9 (P = 0.59); I2 =0.0%
Test for overall effect: Z = 0.05 (P = 0.96)
Test for subgroup differences: Chi2 = 2.68, df = 4 (P = 0.61), I2 =0.0%
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Analysis 1.6. Comparison 1 Primary outcomes - higher omega-6 vs lower omega-6, Outcome 6 All-cause
mortality - subgroup by replacement.
Review: Omega-6 fats for the primary and secondary prevention of cardiovascular disease
Comparison: 1 Primary outcomes - higher omega-6 vs lower omega-6
Outcome: 6 All-cause mortality - subgroup by replacement
Study or subgroup Higher omega 6 Lower omega 6 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 N-6 replacing SFA
DART 1989 111/1018 113/1015 26.4 % 0.98 [ 0.76, 1.25 ]
MRC 1968 28/199 31/194 7.6 % 0.88 [ 0.55, 1.41 ]
NDHS Faribault 1968 4/167 0/57 0.2 % 3.11 [ 0.17, 56.84 ]
Sydney Diet-Heart 1978 38/221 27/237 8.1 % 1.51 [ 0.95, 2.39 ]
Veterans Admin 1969 174/424 177/422 57.5 % 0.98 [ 0.83, 1.15 ]
Vijayakumar 2014 0/100 2/100 0.2 % 0.20 [ 0.01, 4.11 ]
Subtotal (95% CI) 2129 2025 100.0 % 1.00 [ 0.88, 1.15 ]
Total events: 355 (Higher omega 6), 350 (Lower omega 6)
Heterogeneity: Tau2 = 0.00; Chi2 = 5.16, df = 5 (P = 0.40); I2 =3%
Test for overall effect: Z = 0.07 (P = 0.94)
2 N-6 replacing MUFA
Bates 1978 0/58 2/58 1.0 % 0.20 [ 0.01, 4.08 ]
NDHS Faribault 1968 4/167 0/57 1.1 % 3.11 [ 0.17, 56.84 ]
Rose 1965 5/28 3/26 5.0 % 1.55 [ 0.41, 5.84 ]
Sydney Diet-Heart 1978 38/221 27/237 28.5 % 1.51 [ 0.95, 2.39 ]
Veterans Admin 1969 174/424 177/422 64.4 % 0.98 [ 0.83, 1.15 ]
Subtotal (95% CI) 898 800 100.0 % 1.13 [ 0.83, 1.53 ]
Total events: 221 (Higher omega 6), 209 (Lower omega 6)
Heterogeneity: Tau2 = 0.03; Chi2 = 5.19, df = 4 (P = 0.27); I2 =23%
Test for overall effect: Z = 0.77 (P = 0.44)
3 N-6 replacing nil, low n-6
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Higher omega 6), 0 (Lower omega 6)
Heterogeneity: not applicable
Test for overall effect: not applicable
4 N-6 replacement unclear
McIllmurray 1987 10/25 12/24 36.2 % 0.80 [ 0.43, 1.49 ]
MRC 1968 28/199 31/194 63.8 % 0.88 [ 0.55, 1.41 ]
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(. . . Continued)
Study or subgroup Higher omega 6 Lower omega 6 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Subtotal (95% CI) 224 218 100.0 % 0.85 [ 0.58, 1.24 ]
Total events: 38 (Higher omega 6), 43 (Lower omega 6)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.06, df = 1 (P = 0.81); I2 =0.0%
Test for overall effect: Z = 0.84 (P = 0.40)
5 N-6 replacing CHO
Black 1994 2/67 1/66 100.0 % 1.97 [ 0.18, 21.21 ]
Subtotal (95% CI) 67 66 100.0 % 1.97 [ 0.18, 21.21 ]
Total events: 2 (Higher omega 6), 1 (Lower omega 6)
Heterogeneity: not applicable
Test for overall effect: Z = 0.56 (P = 0.58)
6 N-6 replacing protein
Black 1994 2/67 1/66 100.0 % 1.97 [ 0.18, 21.21 ]
Subtotal (95% CI) 67 66 100.0 % 1.97 [ 0.18, 21.21 ]
Total events: 2 (Higher omega 6), 1 (Lower omega 6)
Heterogeneity: not applicable
Test for overall effect: Z = 0.56 (P = 0.58)
Test for subgroup differences: Chi2 = 1.92, df = 4 (P = 0.75), I2 =0.0%
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Analysis 1.7. Comparison 1 Primary outcomes - higher omega-6 vs lower omega-6, Outcome 7 All-cause
mortality - subgroup by baseline CVD risk.
Review: Omega-6 fats for the primary and secondary prevention of cardiovascular disease
Comparison: 1 Primary outcomes - higher omega-6 vs lower omega-6
Outcome: 7 All-cause mortality - subgroup by baseline CVD risk
Study or subgroup Higher omega 6 Lower omega 6 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Primary prevention - low CVD risk
Bates 1978 0/58 2/58 0.2 % 0.20 [ 0.01, 4.08 ]
Black 1994 2/67 1/66 0.3 % 1.97 [ 0.18, 21.21 ]
McIllmurray 1987 10/25 12/24 3.7 % 0.80 [ 0.43, 1.49 ]
NDHS Faribault 1968 4/167 0/57 0.2 % 3.11 [ 0.17, 56.84 ]
Veterans Admin 1969 174/424 177/422 57.1 % 0.98 [ 0.83, 1.15 ]
Subtotal (95% CI) 741 627 61.5 % 0.97 [ 0.83, 1.13 ]
Total events: 190 (Higher omega 6), 192 (Lower omega 6)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.39, df = 4 (P = 0.66); I2 =0.0%
Test for overall effect: Z = 0.41 (P = 0.68)
2 Primary prevention - moderate CVD risk
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Higher omega 6), 0 (Lower omega 6)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Secondary prevention - existing CVD
DART 1989 111/1018 113/1015 24.0 % 0.98 [ 0.76, 1.25 ]
MRC 1968 28/199 31/194 6.6 % 0.88 [ 0.55, 1.41 ]
Rose 1965 5/28 3/26 0.8 % 1.55 [ 0.41, 5.84 ]
Sydney Diet-Heart 1978 38/221 27/237 7.0 % 1.51 [ 0.95, 2.39 ]
Vijayakumar 2014 0/100 2/100 0.2 % 0.20 [ 0.01, 4.11 ]
Subtotal (95% CI) 1566 1572 38.5 % 1.06 [ 0.83, 1.35 ]
Total events: 182 (Higher omega 6), 176 (Lower omega 6)
Heterogeneity: Tau2 = 0.01; Chi2 = 4.73, df = 4 (P = 0.32); I2 =15%
Test for overall effect: Z = 0.47 (P = 0.64)
Total (95% CI) 2307 2199 100.0 % 1.00 [ 0.88, 1.12 ]
Total events: 372 (Higher omega 6), 368 (Lower omega 6)
Heterogeneity: Tau2 = 0.0; Chi2 = 7.48, df = 9 (P = 0.59); I2 =0.0%
Test for overall effect: Z = 0.05 (P = 0.96)
Test for subgroup differences: Chi2 = 0.38, df = 1 (P = 0.54), I2 =0.0%
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Analysis 1.8. Comparison 1 Primary outcomes - higher omega-6 vs lower omega-6, Outcome 8 All-cause
mortality - subgroup by omega-6 dose.
Review: Omega-6 fats for the primary and secondary prevention of cardiovascular disease
Comparison: 1 Primary outcomes - higher omega-6 vs lower omega-6
Outcome: 8 All-cause mortality - subgroup by omega-6 dose
Study or subgroup Higher omega 6 Lower omega 6 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 N-6 < 4% E
Bates 1978 0/58 2/58 0.2 % 0.20 [ 0.01, 4.08 ]
Black 1994 2/67 1/66 0.3 % 1.97 [ 0.18, 21.21 ]
DART 1989 111/1018 113/1015 24.0 % 0.98 [ 0.76, 1.25 ]
McIllmurray 1987 10/25 12/24 3.7 % 0.80 [ 0.43, 1.49 ]
Subtotal (95% CI) 1168 1163 28.1 % 0.95 [ 0.76, 1.19 ]
Total events: 123 (Higher omega 6), 128 (Lower omega 6)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.74, df = 3 (P = 0.63); I2 =0.0%
Test for overall effect: Z = 0.43 (P = 0.66)
2 N-6 4% to 12% E
Sydney Diet-Heart 1978 38/221 27/237 7.0 % 1.51 [ 0.95, 2.39 ]
Veterans Admin 1969 174/424 177/422 57.1 % 0.98 [ 0.83, 1.15 ]
Subtotal (95% CI) 645 659 64.1 % 1.15 [ 0.76, 1.74 ]
Total events: 212 (Higher omega 6), 204 (Lower omega 6)
Heterogeneity: Tau2 = 0.07; Chi2 = 3.13, df = 1 (P = 0.08); I2 =68%
Test for overall effect: Z = 0.66 (P = 0.51)
3 N-6 > 12% E
MRC 1968 28/199 31/194 6.6 % 0.88 [ 0.55, 1.41 ]
NDHS Faribault 1968 4/167 0/57 0.2 % 3.11 [ 0.17, 56.84 ]
Rose 1965 5/28 3/26 0.8 % 1.55 [ 0.41, 5.84 ]
Vijayakumar 2014 0/100 2/100 0.2 % 0.20 [ 0.01, 4.11 ]
Subtotal (95% CI) 494 377 7.8 % 0.93 [ 0.60, 1.44 ]
Total events: 37 (Higher omega 6), 36 (Lower omega 6)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.27, df = 3 (P = 0.52); I2 =0.0%
Test for overall effect: Z = 0.31 (P = 0.75)
Total (95% CI) 2307 2199 100.0 % 1.00 [ 0.88, 1.12 ]
Total events: 372 (Higher omega 6), 368 (Lower omega 6)
Heterogeneity: Tau2 = 0.0; Chi2 = 7.48, df = 9 (P = 0.59); I2 =0.0%
Test for overall effect: Z = 0.05 (P = 0.96)
Test for subgroup differences: Chi2 = 0.69, df = 2 (P = 0.71), I2 =0.0%
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Analysis 1.9. Comparison 1 Primary outcomes - higher omega-6 vs lower omega-6, Outcome 9 All-cause
mortality - subgroup by duration.
Review: Omega-6 fats for the primary and secondary prevention of cardiovascular disease
Comparison: 1 Primary outcomes - higher omega-6 vs lower omega-6
Outcome: 9 All-cause mortality - subgroup by duration
Study or subgroup Higher omega 6 Lower omega 6 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Medium duration 1 to < 2 years in study
NDHS Faribault 1968 4/167 0/57 0.2 % 3.11 [ 0.17, 56.84 ]
Subtotal (95% CI) 167 57 0.2 % 3.11 [ 0.17, 56.84 ]
Total events: 4 (Higher omega 6), 0 (Lower omega 6)
Heterogeneity: not applicable
Test for overall effect: Z = 0.76 (P = 0.44)
2 Medium-long duration 2 to < 4 years
Bates 1978 0/58 2/58 0.2 % 0.20 [ 0.01, 4.08 ]
Black 1994 2/67 1/66 0.3 % 1.97 [ 0.18, 21.21 ]
DART 1989 111/1018 113/1015 24.0 % 0.98 [ 0.76, 1.25 ]
McIllmurray 1987 10/25 12/24 3.7 % 0.80 [ 0.43, 1.49 ]
Rose 1965 5/28 3/26 0.8 % 1.55 [ 0.41, 5.84 ]
Vijayakumar 2014 0/100 2/100 0.2 % 0.20 [ 0.01, 4.11 ]
Subtotal (95% CI) 1296 1289 29.1 % 0.96 [ 0.76, 1.20 ]
Total events: 128 (Higher omega 6), 133 (Lower omega 6)
Heterogeneity: Tau2 = 0.0; Chi2 = 3.27, df = 5 (P = 0.66); I2 =0.0%
Test for overall effect: Z = 0.39 (P = 0.69)
3 Long duration 4+ years in study
MRC 1968 28/199 31/194 6.6 % 0.88 [ 0.55, 1.41 ]
Sydney Diet-Heart 1978 38/221 27/237 7.0 % 1.51 [ 0.95, 2.39 ]
Veterans Admin 1969 174/424 177/422 57.1 % 0.98 [ 0.83, 1.15 ]
Subtotal (95% CI) 844 853 70.7 % 1.05 [ 0.81, 1.36 ]
Total events: 240 (Higher omega 6), 235 (Lower omega 6)
Heterogeneity: Tau2 = 0.02; Chi2 = 3.46, df = 2 (P = 0.18); I2 =42%
Test for overall effect: Z = 0.39 (P = 0.70)
Total (95% CI) 2307 2199 100.0 % 1.00 [ 0.88, 1.12 ]
Total events: 372 (Higher omega 6), 368 (Lower omega 6)
Heterogeneity: Tau2 = 0.0; Chi2 = 7.48, df = 9 (P = 0.59); I2 =0.0%
Test for overall effect: Z = 0.05 (P = 0.96)
Test for subgroup differences: Chi2 = 0.89, df = 2 (P = 0.64), I2 =0.0%
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Analysis 1.10. Comparison 1 Primary outcomes - higher omega-6 vs lower omega-6, Outcome 10 All-cause
mortality - subgroup by statin use.
Review: Omega-6 fats for the primary and secondary prevention of cardiovascular disease
Comparison: 1 Primary outcomes - higher omega-6 vs lower omega-6
Outcome: 10 All-cause mortality - subgroup by statin use
Study or subgroup Higher omega 6 Lower omega 6 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1≥ 50% of control group on statins
Vijayakumar 2014 0/100 2/100 0.2 % 0.20 [ 0.01, 4.11 ]
Subtotal (95% CI) 100 100 0.2 % 0.20 [ 0.01, 4.11 ]
Total events: 0 (Higher omega 6), 2 (Lower omega 6)
Heterogeneity: not applicable
Test for overall effect: Z = 1.04 (P = 0.30)
2 < 50% of control group on statins
Bates 1978 0/58 2/58 0.2 % 0.20 [ 0.01, 4.08 ]
Black 1994 2/67 1/66 0.3 % 1.97 [ 0.18, 21.21 ]
DART 1989 111/1018 113/1015 24.0 % 0.98 [ 0.76, 1.25 ]
McIllmurray 1987 10/25 12/24 3.7 % 0.80 [ 0.43, 1.49 ]
MRC 1968 28/199 31/194 6.6 % 0.88 [ 0.55, 1.41 ]
NDHS Faribault 1968 4/167 0/57 0.2 % 3.11 [ 0.17, 56.84 ]
Rose 1965 5/28 3/26 0.8 % 1.55 [ 0.41, 5.84 ]
Sydney Diet-Heart 1978 38/221 27/237 7.0 % 1.51 [ 0.95, 2.39 ]
Veterans Admin 1969 174/424 177/422 57.1 % 0.98 [ 0.83, 1.15 ]
Subtotal (95% CI) 2207 2099 99.8 % 1.00 [ 0.89, 1.13 ]
Total events: 372 (Higher omega 6), 366 (Lower omega 6)
Heterogeneity: Tau2 = 0.0; Chi2 = 6.40, df = 8 (P = 0.60); I2 =0.0%
Test for overall effect: Z = 0.01 (P = 0.99)
3 Statin use unclear
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Higher omega 6), 0 (Lower omega 6)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 2307 2199 100.0 % 1.00 [ 0.88, 1.12 ]
Total events: 372 (Higher omega 6), 368 (Lower omega 6)
Heterogeneity: Tau2 = 0.0; Chi2 = 7.48, df = 9 (P = 0.59); I2 =0.0%
Test for overall effect: Z = 0.05 (P = 0.96)
Test for subgroup differences: Chi2 = 1.09, df = 1 (P = 0.30), I2 =8%
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Analysis 1.11. Comparison 1 Primary outcomes - higher omega-6 vs lower omega-6, Outcome 11 All-cause
mortality - subgroup by baseline omega-6.
Review: Omega-6 fats for the primary and secondary prevention of cardiovascular disease
Comparison: 1 Primary outcomes - higher omega-6 vs lower omega-6
Outcome: 11 All-cause mortality - subgroup by baseline omega-6
Study or subgroup Higher omega 6 Lower omega 6 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1≥ 8% E from n-6
Black 1994 2/67 1/66 0.3 % 1.97 [ 0.18, 21.21 ]
Subtotal (95% CI) 67 66 0.3 % 1.97 [ 0.18, 21.21 ]
Total events: 2 (Higher omega 6), 1 (Lower omega 6)
Heterogeneity: not applicable
Test for overall effect: Z = 0.56 (P = 0.58)
2 5% to < 8% E from n-6
DART 1989 111/1018 113/1015 24.0 % 0.98 [ 0.76, 1.25 ]
Sydney Diet-Heart 1978 38/221 27/237 7.0 % 1.51 [ 0.95, 2.39 ]
Subtotal (95% CI) 1239 1252 30.9 % 1.16 [ 0.77, 1.76 ]
Total events: 149 (Higher omega 6), 140 (Lower omega 6)
Heterogeneity: Tau2 = 0.06; Chi2 = 2.65, df = 1 (P = 0.10); I2 =62%
Test for overall effect: Z = 0.71 (P = 0.48)
3 < 5% E from n-6
NDHS Faribault 1968 4/167 0/57 0.2 % 3.11 [ 0.17, 56.84 ]
Veterans Admin 1969 174/424 177/422 57.1 % 0.98 [ 0.83, 1.15 ]
Subtotal (95% CI) 591 479 57.3 % 0.98 [ 0.84, 1.15 ]
Total events: 178 (Higher omega 6), 177 (Lower omega 6)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.61, df = 1 (P = 0.43); I2 =0.0%
Test for overall effect: Z = 0.22 (P = 0.82)
4 baseline n-6 not reported
Bates 1978 0/58 2/58 0.2 % 0.20 [ 0.01, 4.08 ]
McIllmurray 1987 10/25 12/24 3.7 % 0.80 [ 0.43, 1.49 ]
MRC 1968 28/199 31/194 6.6 % 0.88 [ 0.55, 1.41 ]
Rose 1965 5/28 3/26 0.8 % 1.55 [ 0.41, 5.84 ]
Vijayakumar 2014 0/100 2/100 0.2 % 0.20 [ 0.01, 4.11 ]
Subtotal (95% CI) 410 402 11.5 % 0.85 [ 0.60, 1.22 ]
Total events: 43 (Higher omega 6), 50 (Lower omega 6)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.62, df = 4 (P = 0.62); I2 =0.0%
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(. . . Continued)
Study or subgroup Higher omega 6 Lower omega 6 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Test for overall effect: Z = 0.87 (P = 0.38)
Total (95% CI) 2307 2199 100.0 % 1.00 [ 0.88, 1.12 ]
Total events: 372 (Higher omega 6), 368 (Lower omega 6)
Heterogeneity: Tau2 = 0.0; Chi2 = 7.48, df = 9 (P = 0.59); I2 =0.0%
Test for overall effect: Z = 0.05 (P = 0.96)
Test for subgroup differences: Chi2 = 1.57, df = 3 (P = 0.67), I2 =0.0%
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Analysis 1.12. Comparison 1 Primary outcomes - higher omega-6 vs lower omega-6, Outcome 12 All-cause
mortality - subgroup by sex.
Review: Omega-6 fats for the primary and secondary prevention of cardiovascular disease
Comparison: 1 Primary outcomes - higher omega-6 vs lower omega-6
Outcome: 12 All-cause mortality - subgroup by sex
Study or subgroup Higher omega 6 Lower omega 6 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Men only
DART 1989 111/1018 113/1015 24.0 % 0.98 [ 0.76, 1.25 ]
MRC 1968 28/199 31/194 6.6 % 0.88 [ 0.55, 1.41 ]
NDHS Faribault 1968 4/167 0/57 0.2 % 3.11 [ 0.17, 56.84 ]
Sydney Diet-Heart 1978 38/221 27/237 7.0 % 1.51 [ 0.95, 2.39 ]
Veterans Admin 1969 174/424 177/422 57.1 % 0.98 [ 0.83, 1.15 ]
Subtotal (95% CI) 2029 1925 94.8 % 1.01 [ 0.89, 1.14 ]
Total events: 355 (Higher omega 6), 348 (Lower omega 6)
Heterogeneity: Tau2 = 0.00; Chi2 = 4.08, df = 4 (P = 0.40); I2 =2%
Test for overall effect: Z = 0.10 (P = 0.92)
2 Women only
Subtotal (95% CI) 0 0 Not estimable
0.1 0.2 0.5 1 2 5 10
Favours higher omega 6 Favours lower omega 6
(Continued . . . )
117Omega-6 fats for the primary and secondary prevention of cardiovascular disease (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(. . . Continued)
Study or subgroup Higher omega 6 Lower omega 6 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Total events: 0 (Higher omega 6), 0 (Lower omega 6)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Men and women
Bates 1978 0/58 2/58 0.2 % 0.20 [ 0.01, 4.08 ]
Black 1994 2/67 1/66 0.3 % 1.97 [ 0.18, 21.21 ]
McIllmurray 1987 10/25 12/24 3.7 % 0.80 [ 0.43, 1.49 ]
Vijayakumar 2014 0/100 2/100 0.2 % 0.20 [ 0.01, 4.11 ]
Subtotal (95% CI) 250 248 4.3 % 0.76 [ 0.43, 1.36 ]
Total events: 12 (Higher omega 6), 17 (Lower omega 6)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.23, df = 3 (P = 0.53); I2 =0.0%
Test for overall effect: Z = 0.92 (P = 0.36)
4 Sex not reported
Rose 1965 5/28 3/26 0.8 % 1.55 [ 0.41, 5.84 ]
Subtotal (95% CI) 28 26 0.8 % 1.55 [ 0.41, 5.84 ]
Total events: 5 (Higher omega 6), 3 (Lower omega 6)
Heterogeneity: not applicable
Test for overall effect: Z = 0.64 (P = 0.52)
Total (95% CI) 2307 2199 100.0 % 1.00 [ 0.88, 1.12 ]
Total events: 372 (Higher omega 6), 368 (Lower omega 6)
Heterogeneity: Tau2 = 0.0; Chi2 = 7.48, df = 9 (P = 0.59); I2 =0.0%
Test for overall effect: Z = 0.05 (P = 0.96)
Test for subgroup differences: Chi2 = 1.26, df = 2 (P = 0.53), I2 =0.0%
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Analysis 1.13. Comparison 1 Primary outcomes - higher omega-6 vs lower omega-6, Outcome 13
Cardiovascular mortality (overall).
Review: Omega-6 fats for the primary and secondary prevention of cardiovascular disease
Comparison: 1 Primary outcomes - higher omega-6 vs lower omega-6
Outcome: 13 Cardiovascular mortality (overall)
Study or subgroup Higher omega 6 Lower omega 6 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Black 1994 2/67 0/66 1.3 % 4.93 [ 0.24, 100.70 ]
DART 1989 114/1018 91/1015 26.9 % 1.25 [ 0.96, 1.62 ]
Houtsmuller 1979 0/51 5/51 1.4 % 0.09 [ 0.01, 1.60 ]
MRC 1968 27/199 25/194 19.1 % 1.05 [ 0.63, 1.75 ]
Rose 1965 5/28 3/26 5.7 % 1.55 [ 0.41, 5.84 ]
Sydney Diet-Heart 1978 37/221 25/237 20.1 % 1.59 [ 0.99, 2.55 ]
Veterans Admin 1969 57/424 81/422 25.4 % 0.70 [ 0.51, 0.96 ]
Total (95% CI) 2008 2011 100.0 % 1.09 [ 0.76, 1.55 ]
Total events: 242 (Higher omega 6), 230 (Lower omega 6)
Heterogeneity: Tau2 = 0.10; Chi2 = 15.26, df = 6 (P = 0.02); I2 =61%
Test for overall effect: Z = 0.47 (P = 0.64)
Test for subgroup differences: Not applicable
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Analysis 1.14. Comparison 1 Primary outcomes - higher omega-6 vs lower omega-6, Outcome 14 CVD
mortality - sensitivity analysis by fixed-effect analysis.
Review: Omega-6 fats for the primary and secondary prevention of cardiovascular disease
Comparison: 1 Primary outcomes - higher omega-6 vs lower omega-6
Outcome: 14 CVD mortality - sensitivity analysis by fixed-effect analysis
Study or subgroup Higher omega 6 Lower omega 6 Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Black 1994 2/67 0/66 0.2 % 4.93 [ 0.24, 100.70 ]
DART 1989 114/1018 91/1015 39.5 % 1.25 [ 0.96, 1.62 ]
Houtsmuller 1979 0/51 5/51 2.4 % 0.09 [ 0.01, 1.60 ]
MRC 1968 27/199 25/194 11.0 % 1.05 [ 0.63, 1.75 ]
Rose 1965 5/28 3/26 1.3 % 1.55 [ 0.41, 5.84 ]
Sydney Diet-Heart 1978 37/221 25/237 10.4 % 1.59 [ 0.99, 2.55 ]
Veterans Admin 1969 57/424 81/422 35.2 % 0.70 [ 0.51, 0.96 ]
Total (95% CI) 2008 2011 100.0 % 1.05 [ 0.89, 1.25 ]
Total events: 242 (Higher omega 6), 230 (Lower omega 6)
Heterogeneity: Chi2 = 15.26, df = 6 (P = 0.02); I2 =61%
Test for overall effect: Z = 0.62 (P = 0.54)
Test for subgroup differences: Not applicable
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Analysis 1.15. Comparison 1 Primary outcomes - higher omega-6 vs lower omega-6, Outcome 15 CVD
mortality - sensitivity analyses.
Review: Omega-6 fats for the primary and secondary prevention of cardiovascular disease
Comparison: 1 Primary outcomes - higher omega-6 vs lower omega-6
Outcome: 15 CVD mortality - sensitivity analyses
Study or subgroup Higher omega 6 Lower omega 6 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Studies at low risk of bias
Sydney Diet-Heart 1978 37/221 25/237 100.0 % 1.59 [ 0.99, 2.55 ]
Subtotal (95% CI) 221 237 100.0 % 1.59 [ 0.99, 2.55 ]
Total events: 37 (Higher omega 6), 25 (Lower omega 6)
Heterogeneity: not applicable
Test for overall effect: Z = 1.91 (P = 0.056)
2 Pre-2010 or prospective trials registry entry
Black 1994 2/67 0/66 1.3 % 4.93 [ 0.24, 100.70 ]
DART 1989 114/1018 91/1015 26.9 % 1.25 [ 0.96, 1.62 ]
Houtsmuller 1979 0/51 5/51 1.4 % 0.09 [ 0.01, 1.60 ]
MRC 1968 27/199 25/194 19.1 % 1.05 [ 0.63, 1.75 ]
Rose 1965 5/28 3/26 5.7 % 1.55 [ 0.41, 5.84 ]
Sydney Diet-Heart 1978 37/221 25/237 20.1 % 1.59 [ 0.99, 2.55 ]
Veterans Admin 1969 57/424 81/422 25.4 % 0.70 [ 0.51, 0.96 ]
Subtotal (95% CI) 2008 2011 100.0 % 1.09 [ 0.76, 1.55 ]
Total events: 242 (Higher omega 6), 230 (Lower omega 6)
Heterogeneity: Tau2 = 0.10; Chi2 = 15.26, df = 6 (P = 0.02); I2 =61%
Test for overall effect: Z = 0.47 (P = 0.64)
3 No commercial funding
Black 1994 2/67 0/66 3.8 % 4.93 [ 0.24, 100.70 ]
Houtsmuller 1979 0/51 5/51 4.1 % 0.09 [ 0.01, 1.60 ]
MRC 1968 27/199 25/194 45.1 % 1.05 [ 0.63, 1.75 ]
Sydney Diet-Heart 1978 37/221 25/237 47.0 % 1.59 [ 0.99, 2.55 ]
Subtotal (95% CI) 538 548 100.0 % 1.22 [ 0.67, 2.23 ]
Total events: 66 (Higher omega 6), 55 (Lower omega 6)
Heterogeneity: Tau2 = 0.14; Chi2 = 5.47, df = 3 (P = 0.14); I2 =45%
Test for overall effect: Z = 0.65 (P = 0.51)
4 Low risk of attention bias
Rose 1965 5/28 3/26 15.5 % 1.55 [ 0.41, 5.84 ]
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(. . . Continued)
Study or subgroup Higher omega 6 Lower omega 6 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Veterans Admin 1969 57/424 81/422 84.5 % 0.70 [ 0.51, 0.96 ]
Subtotal (95% CI) 452 448 100.0 % 0.79 [ 0.45, 1.39 ]
Total events: 62 (Higher omega 6), 84 (Lower omega 6)
Heterogeneity: Tau2 = 0.07; Chi2 = 1.30, df = 1 (P = 0.25); I2 =23%
Test for overall effect: Z = 0.81 (P = 0.42)
5 Randomised 250+ participants
DART 1989 114/1018 91/1015 29.7 % 1.25 [ 0.96, 1.62 ]
MRC 1968 27/199 25/194 20.6 % 1.05 [ 0.63, 1.75 ]
Sydney Diet-Heart 1978 37/221 25/237 21.8 % 1.59 [ 0.99, 2.55 ]
Veterans Admin 1969 57/424 81/422 27.9 % 0.70 [ 0.51, 0.96 ]
Subtotal (95% CI) 1862 1868 100.0 % 1.08 [ 0.76, 1.54 ]
Total events: 235 (Higher omega 6), 222 (Lower omega 6)
Heterogeneity: Tau2 = 0.09; Chi2 = 11.14, df = 3 (P = 0.01); I2 =73%
Test for overall effect: Z = 0.43 (P = 0.67)
6 Randomised 100+ participants
Black 1994 2/67 0/66 1.5 % 4.93 [ 0.24, 100.70 ]
DART 1989 114/1018 91/1015 28.2 % 1.25 [ 0.96, 1.62 ]
Houtsmuller 1979 0/51 5/51 1.6 % 0.09 [ 0.01, 1.60 ]
MRC 1968 27/199 25/194 20.5 % 1.05 [ 0.63, 1.75 ]
Sydney Diet-Heart 1978 37/221 25/237 21.5 % 1.59 [ 0.99, 2.55 ]
Veterans Admin 1969 57/424 81/422 26.7 % 0.70 [ 0.51, 0.96 ]
Subtotal (95% CI) 1980 1985 100.0 % 1.06 [ 0.73, 1.55 ]
Total events: 237 (Higher omega 6), 227 (Lower omega 6)
Heterogeneity: Tau2 = 0.11; Chi2 = 14.94, df = 5 (P = 0.01); I2 =67%
Test for overall effect: Z = 0.32 (P = 0.75)
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Analysis 1.16. Comparison 1 Primary outcomes - higher omega-6 vs lower omega-6, Outcome 16 CVD
mortality - subgroup by intervention type.
Review: Omega-6 fats for the primary and secondary prevention of cardiovascular disease
Comparison: 1 Primary outcomes - higher omega-6 vs lower omega-6
Outcome: 16 CVD mortality - subgroup by intervention type
Study or subgroup Higher omega 6 Lower omega 6 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Dietary advice
Black 1994 2/67 0/66 2.0 % 4.93 [ 0.24, 100.70 ]
DART 1989 114/1018 91/1015 57.1 % 1.25 [ 0.96, 1.62 ]
Houtsmuller 1979 0/51 5/51 2.2 % 0.09 [ 0.01, 1.60 ]
Sydney Diet-Heart 1978 37/221 25/237 38.7 % 1.59 [ 0.99, 2.55 ]
Subtotal (95% CI) 1357 1369 100.0 % 1.33 [ 0.86, 2.05 ]
Total events: 153 (Higher omega 6), 121 (Lower omega 6)
Heterogeneity: Tau2 = 0.07; Chi2 = 4.86, df = 3 (P = 0.18); I2 =38%
Test for overall effect: Z = 1.29 (P = 0.20)
2 Supplements (capsules)
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Higher omega 6), 0 (Lower omega 6)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Supplemental foods
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Higher omega 6), 0 (Lower omega 6)
Heterogeneity: not applicable
Test for overall effect: not applicable
4 Dietary advice plus supplement
MRC 1968 27/199 25/194 87.3 % 1.05 [ 0.63, 1.75 ]
Rose 1965 5/28 3/26 12.7 % 1.55 [ 0.41, 5.84 ]
Subtotal (95% CI) 227 220 100.0 % 1.11 [ 0.69, 1.78 ]
Total events: 32 (Higher omega 6), 28 (Lower omega 6)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.28, df = 1 (P = 0.60); I2 =0.0%
Test for overall effect: Z = 0.42 (P = 0.68)
5 Diet (all foods) provided
Veterans Admin 1969 57/424 81/422 100.0 % 0.70 [ 0.51, 0.96 ]
Subtotal (95% CI) 424 422 100.0 % 0.70 [ 0.51, 0.96 ]
Total events: 57 (Higher omega 6), 81 (Lower omega 6)
Heterogeneity: not applicable
Test for overall effect: Z = 2.25 (P = 0.025)
Test for subgroup differences: Chi2 = 6.33, df = 2 (P = 0.04), I2 =68%
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Analysis 1.17. Comparison 1 Primary outcomes - higher omega-6 vs lower omega-6, Outcome 17 CVD
mortality - subgroup by replacement.
Review: Omega-6 fats for the primary and secondary prevention of cardiovascular disease
Comparison: 1 Primary outcomes - higher omega-6 vs lower omega-6
Outcome: 17 CVD mortality - subgroup by replacement
Study or subgroup Higher omega 6 Lower omega 6 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 N-6 replacing SFA
DART 1989 114/1018 91/1015 28.6 % 1.25 [ 0.96, 1.62 ]
Houtsmuller 1979 0/51 5/51 1.7 % 0.09 [ 0.01, 1.60 ]
MRC 1968 27/199 25/194 20.8 % 1.05 [ 0.63, 1.75 ]
Sydney Diet-Heart 1978 37/221 25/237 21.9 % 1.59 [ 0.99, 2.55 ]
Veterans Admin 1969 57/424 81/422 27.1 % 0.70 [ 0.51, 0.96 ]
Subtotal (95% CI) 1913 1919 100.0 % 1.04 [ 0.71, 1.52 ]
Total events: 235 (Higher omega 6), 227 (Lower omega 6)
Heterogeneity: Tau2 = 0.11; Chi2 = 13.94, df = 4 (P = 0.01); I2 =71%
Test for overall effect: Z = 0.20 (P = 0.84)
2 N-6 replacing MUFA
Rose 1965 5/28 3/26 16.8 % 1.55 [ 0.41, 5.84 ]
Sydney Diet-Heart 1978 37/221 25/237 39.2 % 1.59 [ 0.99, 2.55 ]
Veterans Admin 1969 57/424 81/422 44.0 % 0.70 [ 0.51, 0.96 ]
Subtotal (95% CI) 673 685 100.0 % 1.10 [ 0.56, 2.16 ]
Total events: 99 (Higher omega 6), 109 (Lower omega 6)
Heterogeneity: Tau2 = 0.24; Chi2 = 8.65, df = 2 (P = 0.01); I2 =77%
Test for overall effect: Z = 0.28 (P = 0.78)
3 N-6 replacing nil, low n-6
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Higher omega 6), 0 (Lower omega 6)
Heterogeneity: not applicable
Test for overall effect: not applicable
4 N-6 replacement unclear
MRC 1968 27/199 25/194 100.0 % 1.05 [ 0.63, 1.75 ]
Subtotal (95% CI) 199 194 100.0 % 1.05 [ 0.63, 1.75 ]
Total events: 27 (Higher omega 6), 25 (Lower omega 6)
Heterogeneity: not applicable
0.5 0.7 1 1.5 2
Favours higher omega 6 Favours lower omega 6
(Continued . . . )
124Omega-6 fats for the primary and secondary prevention of cardiovascular disease (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(. . . Continued)
Study or subgroup Higher omega 6 Lower omega 6 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Test for overall effect: Z = 0.20 (P = 0.84)
5 N-6 replacing CHO
Black 1994 2/67 0/66 49.3 % 4.93 [ 0.24, 100.70 ]
Houtsmuller 1979 0/51 5/51 50.7 % 0.09 [ 0.01, 1.60 ]
Subtotal (95% CI) 118 117 100.0 % 0.65 [ 0.01, 33.17 ]
Total events: 2 (Higher omega 6), 5 (Lower omega 6)
Heterogeneity: Tau2 = 5.79; Chi2 = 3.57, df = 1 (P = 0.06); I2 =72%
Test for overall effect: Z = 0.21 (P = 0.83)
6 N-6 replacing protein
Black 1994 2/67 0/66 100.0 % 4.93 [ 0.24, 100.70 ]
Subtotal (95% CI) 67 66 100.0 % 4.93 [ 0.24, 100.70 ]
Total events: 2 (Higher omega 6), 0 (Lower omega 6)
Heterogeneity: not applicable
Test for overall effect: Z = 1.04 (P = 0.30)
Test for subgroup differences: Chi2 = 1.08, df = 4 (P = 0.90), I2 =0.0%
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Analysis 1.18. Comparison 1 Primary outcomes - higher omega-6 vs lower omega-6, Outcome 18 CVD
mortality - subgroup by baseline CVD risk.
Review: Omega-6 fats for the primary and secondary prevention of cardiovascular disease
Comparison: 1 Primary outcomes - higher omega-6 vs lower omega-6
Outcome: 18 CVD mortality - subgroup by baseline CVD risk
Study or subgroup Higher omega 6 Lower omega 6 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Primary prevention - low CVD risk
Black 1994 2/67 0/66 19.4 % 4.93 [ 0.24, 100.70 ]
Veterans Admin 1969 57/424 81/422 80.6 % 0.70 [ 0.51, 0.96 ]
Subtotal (95% CI) 491 488 100.0 % 1.02 [ 0.22, 4.66 ]
Total events: 59 (Higher omega 6), 81 (Lower omega 6)
Heterogeneity: Tau2 = 0.72; Chi2 = 1.60, df = 1 (P = 0.21); I2 =37%
Test for overall effect: Z = 0.03 (P = 0.98)
2 Primary prevention - moderate CVD risk
Houtsmuller 1979 0/51 5/51 100.0 % 0.09 [ 0.01, 1.60 ]
Subtotal (95% CI) 51 51 100.0 % 0.09 [ 0.01, 1.60 ]
Total events: 0 (Higher omega 6), 5 (Lower omega 6)
Heterogeneity: not applicable
Test for overall effect: Z = 1.64 (P = 0.10)
3 Secondary prevention - existing CVD
DART 1989 114/1018 91/1015 62.1 % 1.25 [ 0.96, 1.62 ]
MRC 1968 27/199 25/194 16.5 % 1.05 [ 0.63, 1.75 ]
Rose 1965 5/28 3/26 2.4 % 1.55 [ 0.41, 5.84 ]
Sydney Diet-Heart 1978 37/221 25/237 19.0 % 1.59 [ 0.99, 2.55 ]
Subtotal (95% CI) 1466 1472 100.0 % 1.28 [ 1.04, 1.57 ]
Total events: 183 (Higher omega 6), 144 (Lower omega 6)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.48, df = 3 (P = 0.69); I2 =0.0%
Test for overall effect: Z = 2.33 (P = 0.020)
Test for subgroup differences: Chi2 = 3.31, df = 2 (P = 0.19), I2 =40%
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Analysis 1.19. Comparison 1 Primary outcomes - higher omega-6 vs lower omega-6, Outcome 19 CVD
mortality - subgroup by omega-6 dose.
Review: Omega-6 fats for the primary and secondary prevention of cardiovascular disease
Comparison: 1 Primary outcomes - higher omega-6 vs lower omega-6
Outcome: 19 CVD mortality - subgroup by omega-6 dose
Study or subgroup Higher omega 6 Lower omega 6 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 N-6 < 4% E
Black 1994 2/67 0/66 0.7 % 4.93 [ 0.24, 100.70 ]
DART 1989 114/1018 91/1015 99.3 % 1.25 [ 0.96, 1.62 ]
Subtotal (95% CI) 1085 1081 100.0 % 1.26 [ 0.97, 1.64 ]
Total events: 116 (Higher omega 6), 91 (Lower omega 6)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.79, df = 1 (P = 0.37); I2 =0.0%
Test for overall effect: Z = 1.75 (P = 0.080)
2 N-6 4% to 12% E
Houtsmuller 1979 0/51 5/51 7.2 % 0.09 [ 0.01, 1.60 ]
Sydney Diet-Heart 1978 37/221 25/237 44.4 % 1.59 [ 0.99, 2.55 ]
Veterans Admin 1969 57/424 81/422 48.4 % 0.70 [ 0.51, 0.96 ]
Subtotal (95% CI) 696 710 100.0 % 0.87 [ 0.38, 1.99 ]
Total events: 94 (Higher omega 6), 111 (Lower omega 6)
Heterogeneity: Tau2 = 0.34; Chi2 = 10.46, df = 2 (P = 0.01); I2 =81%
Test for overall effect: Z = 0.33 (P = 0.74)
3 N-6 > 12% E
MRC 1968 27/199 25/194 87.3 % 1.05 [ 0.63, 1.75 ]
Rose 1965 5/28 3/26 12.7 % 1.55 [ 0.41, 5.84 ]
Subtotal (95% CI) 227 220 100.0 % 1.11 [ 0.69, 1.78 ]
Total events: 32 (Higher omega 6), 28 (Lower omega 6)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.28, df = 1 (P = 0.60); I2 =0.0%
Test for overall effect: Z = 0.42 (P = 0.68)
Test for subgroup differences: Chi2 = 0.84, df = 2 (P = 0.66), I2 =0.0%
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Analysis 1.20. Comparison 1 Primary outcomes - higher omega-6 vs lower omega-6, Outcome 20 CVD
mortality - subgroup by duration.
Review: Omega-6 fats for the primary and secondary prevention of cardiovascular disease
Comparison: 1 Primary outcomes - higher omega-6 vs lower omega-6
Outcome: 20 CVD mortality - subgroup by duration
Study or subgroup Higher omega 6 Lower omega 6 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Medium duration 1 to < 2 years in study
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Higher omega 6), 0 (Lower omega 6)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Medium-long duration 2 to < 4 years
Black 1994 2/67 0/66 0.7 % 4.93 [ 0.24, 100.70 ]
DART 1989 114/1018 91/1015 95.6 % 1.25 [ 0.96, 1.62 ]
Rose 1965 5/28 3/26 3.7 % 1.55 [ 0.41, 5.84 ]
Subtotal (95% CI) 1113 1107 100.0 % 1.27 [ 0.98, 1.64 ]
Total events: 121 (Higher omega 6), 94 (Lower omega 6)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.88, df = 2 (P = 0.64); I2 =0.0%
Test for overall effect: Z = 1.84 (P = 0.066)
3 Long duration 4+ years in study
Houtsmuller 1979 0/51 5/51 3.2 % 0.09 [ 0.01, 1.60 ]
MRC 1968 27/199 25/194 29.9 % 1.05 [ 0.63, 1.75 ]
Sydney Diet-Heart 1978 37/221 25/237 31.0 % 1.59 [ 0.99, 2.55 ]
Veterans Admin 1969 57/424 81/422 35.9 % 0.70 [ 0.51, 0.96 ]
Subtotal (95% CI) 895 904 100.0 % 0.96 [ 0.56, 1.63 ]
Total events: 121 (Higher omega 6), 136 (Lower omega 6)
Heterogeneity: Tau2 = 0.18; Chi2 = 10.85, df = 3 (P = 0.01); I2 =72%
Test for overall effect: Z = 0.17 (P = 0.87)
Test for subgroup differences: Chi2 = 0.90, df = 1 (P = 0.34), I2 =0.0%
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Analysis 1.21. Comparison 1 Primary outcomes - higher omega-6 vs lower omega-6, Outcome 21 CVD
mortality - subgroup by baseline omega-6.
Review: Omega-6 fats for the primary and secondary prevention of cardiovascular disease
Comparison: 1 Primary outcomes - higher omega-6 vs lower omega-6
Outcome: 21 CVD mortality - subgroup by baseline omega-6
Study or subgroup Higher omega 6 Lower omega 6 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1≥ 8% E from n-6
Black 1994 2/67 0/66 100.0 % 4.93 [ 0.24, 100.70 ]
Subtotal (95% CI) 67 66 100.0 % 4.93 [ 0.24, 100.70 ]
Total events: 2 (Higher omega 6), 0 (Lower omega 6)
Heterogeneity: not applicable
Test for overall effect: Z = 1.04 (P = 0.30)
2 5% to < 8% E from n-6
DART 1989 114/1018 91/1015 76.6 % 1.25 [ 0.96, 1.62 ]
Sydney Diet-Heart 1978 37/221 25/237 23.4 % 1.59 [ 0.99, 2.55 ]
Subtotal (95% CI) 1239 1252 100.0 % 1.32 [ 1.05, 1.66 ]
Total events: 151 (Higher omega 6), 116 (Lower omega 6)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.75, df = 1 (P = 0.39); I2 =0.0%
Test for overall effect: Z = 2.38 (P = 0.017)
3 < 5% E from n-6
Veterans Admin 1969 57/424 81/422 100.0 % 0.70 [ 0.51, 0.96 ]
Subtotal (95% CI) 424 422 100.0 % 0.70 [ 0.51, 0.96 ]
Total events: 57 (Higher omega 6), 81 (Lower omega 6)
Heterogeneity: not applicable
Test for overall effect: Z = 2.25 (P = 0.025)
4 Baseline n-6 not reported
Houtsmuller 1979 0/51 5/51 8.8 % 0.09 [ 0.01, 1.60 ]
MRC 1968 27/199 25/194 62.2 % 1.05 [ 0.63, 1.75 ]
Rose 1965 5/28 3/26 29.0 % 1.55 [ 0.41, 5.84 ]
Subtotal (95% CI) 278 271 100.0 % 0.95 [ 0.38, 2.34 ]
Total events: 32 (Higher omega 6), 33 (Lower omega 6)
Heterogeneity: Tau2 = 0.28; Chi2 = 3.27, df = 2 (P = 0.19); I2 =39%
Test for overall effect: Z = 0.11 (P = 0.91)
Test for subgroup differences: Chi2 = 11.43, df = 3 (P = 0.01), I2 =74%
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Analysis 1.22. Comparison 1 Primary outcomes - higher omega-6 vs lower omega-6, Outcome 22 CVD
mortality - subgroup by sex.
Review: Omega-6 fats for the primary and secondary prevention of cardiovascular disease
Comparison: 1 Primary outcomes - higher omega-6 vs lower omega-6
Outcome: 22 CVD mortality - subgroup by sex
Study or subgroup Higher omega 6 Lower omega 6 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Men only
DART 1989 114/1018 91/1015 29.7 % 1.25 [ 0.96, 1.62 ]
MRC 1968 27/199 25/194 20.6 % 1.05 [ 0.63, 1.75 ]
Sydney Diet-Heart 1978 37/221 25/237 21.8 % 1.59 [ 0.99, 2.55 ]
Veterans Admin 1969 57/424 81/422 27.9 % 0.70 [ 0.51, 0.96 ]
Subtotal (95% CI) 1862 1868 100.0 % 1.08 [ 0.76, 1.54 ]
Total events: 235 (Higher omega 6), 222 (Lower omega 6)
Heterogeneity: Tau2 = 0.09; Chi2 = 11.14, df = 3 (P = 0.01); I2 =73%
Test for overall effect: Z = 0.43 (P = 0.67)
2 Women only
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Higher omega 6), 0 (Lower omega 6)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Men and women
Black 1994 2/67 0/66 49.3 % 4.93 [ 0.24, 100.70 ]
Houtsmuller 1979 0/51 5/51 50.7 % 0.09 [ 0.01, 1.60 ]
Subtotal (95% CI) 118 117 100.0 % 0.65 [ 0.01, 33.17 ]
Total events: 2 (Higher omega 6), 5 (Lower omega 6)
Heterogeneity: Tau2 = 5.79; Chi2 = 3.57, df = 1 (P = 0.06); I2 =72%
Test for overall effect: Z = 0.21 (P = 0.83)
4 Sex not reported
Rose 1965 5/28 3/26 100.0 % 1.55 [ 0.41, 5.84 ]
Subtotal (95% CI) 28 26 100.0 % 1.55 [ 0.41, 5.84 ]
Total events: 5 (Higher omega 6), 3 (Lower omega 6)
Heterogeneity: not applicable
Test for overall effect: Z = 0.64 (P = 0.52)
Test for subgroup differences: Chi2 = 0.33, df = 2 (P = 0.85), I2 =0.0%
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Analysis 1.23. Comparison 1 Primary outcomes - higher omega-6 vs lower omega-6, Outcome 23 Any
cardiovascular event (overall).
Review: Omega-6 fats for the primary and secondary prevention of cardiovascular disease
Comparison: 1 Primary outcomes - higher omega-6 vs lower omega-6
Outcome: 23 Any cardiovascular event (overall)
Study or subgroup Higher omega 6 Lower omega 6 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
DART 1989 476/1018 478/1015 37.0 % 0.99 [ 0.91, 1.09 ]
GLAMT 1993 0/54 1/57 0.3 % 0.35 [ 0.01, 8.45 ]
MRC 1968 62/199 74/194 20.4 % 0.82 [ 0.62, 1.07 ]
NDHS Open 1st 1968 5/726 1/341 0.6 % 2.35 [ 0.28, 20.02 ]
Rose 1965 15/28 11/26 7.6 % 1.27 [ 0.72, 2.23 ]
Sydney Diet-Heart 1978 37/221 25/237 10.1 % 1.59 [ 0.99, 2.55 ]
Veterans Admin 1969 97/424 122/422 23.9 % 0.79 [ 0.63, 1.00 ]
Total (95% CI) 2670 2292 100.0 % 0.97 [ 0.81, 1.15 ]
Total events: 692 (Higher omega 6), 712 (Lower omega 6)
Heterogeneity: Tau2 = 0.02; Chi2 = 10.83, df = 6 (P = 0.09); I2 =45%
Test for overall effect: Z = 0.37 (P = 0.71)
Test for subgroup differences: Not applicable
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Analysis 1.24. Comparison 1 Primary outcomes - higher omega-6 vs lower omega-6, Outcome 24 CVD
events - sensitivity analysis by fixed-effect analysis.
Review: Omega-6 fats for the primary and secondary prevention of cardiovascular disease
Comparison: 1 Primary outcomes - higher omega-6 vs lower omega-6
Outcome: 24 CVD events - sensitivity analysis by fixed-effect analysis
Study or subgroup Higher omega 6 Lower omega 6 Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
DART 1989 476/1018 478/1015 67.0 % 0.99 [ 0.91, 1.09 ]
GLAMT 1993 0/54 1/57 0.2 % 0.35 [ 0.01, 8.45 ]
MRC 1968 62/199 74/194 10.5 % 0.82 [ 0.62, 1.07 ]
NDHS Open 1st 1968 5/726 1/341 0.2 % 2.35 [ 0.28, 20.02 ]
Rose 1965 15/28 11/26 1.6 % 1.27 [ 0.72, 2.23 ]
Sydney Diet-Heart 1978 37/221 25/237 3.4 % 1.59 [ 0.99, 2.55 ]
Veterans Admin 1969 97/424 122/422 17.1 % 0.79 [ 0.63, 1.00 ]
Total (95% CI) 2670 2292 100.0 % 0.97 [ 0.89, 1.05 ]
Total events: 692 (Higher omega 6), 712 (Lower omega 6)
Heterogeneity: Chi2 = 10.83, df = 6 (P = 0.09); I2 =45%
Test for overall effect: Z = 0.85 (P = 0.39)
Test for subgroup differences: Not applicable
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Analysis 1.25. Comparison 1 Primary outcomes - higher omega-6 vs lower omega-6, Outcome 25 CVD
events - sensitivity analyses.
Review: Omega-6 fats for the primary and secondary prevention of cardiovascular disease
Comparison: 1 Primary outcomes - higher omega-6 vs lower omega-6
Outcome: 25 CVD events - sensitivity analyses
Study or subgroup Higher omega 6 Lower omega 6 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Studies at low risk of bias
NDHS Open 1st 1968 5/726 1/341 4.6 % 2.35 [ 0.28, 20.02 ]
Sydney Diet-Heart 1978 37/221 25/237 95.4 % 1.59 [ 0.99, 2.55 ]
Subtotal (95% CI) 947 578 100.0 % 1.62 [ 1.02, 2.57 ]
Total events: 42 (Higher omega 6), 26 (Lower omega 6)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.12, df = 1 (P = 0.73); I2 =0.0%
Test for overall effect: Z = 2.04 (P = 0.042)
2 Pre-2010 or prospective trials registry entry
DART 1989 476/1018 478/1015 37.0 % 0.99 [ 0.91, 1.09 ]
GLAMT 1993 0/54 1/57 0.3 % 0.35 [ 0.01, 8.45 ]
MRC 1968 62/199 74/194 20.4 % 0.82 [ 0.62, 1.07 ]
NDHS Open 1st 1968 5/726 1/341 0.6 % 2.35 [ 0.28, 20.02 ]
Rose 1965 15/28 11/26 7.6 % 1.27 [ 0.72, 2.23 ]
Sydney Diet-Heart 1978 37/221 25/237 10.1 % 1.59 [ 0.99, 2.55 ]
Veterans Admin 1969 97/424 122/422 23.9 % 0.79 [ 0.63, 1.00 ]
Subtotal (95% CI) 2670 2292 100.0 % 0.97 [ 0.81, 1.15 ]
Total events: 692 (Higher omega 6), 712 (Lower omega 6)
Heterogeneity: Tau2 = 0.02; Chi2 = 10.83, df = 6 (P = 0.09); I2 =45%
Test for overall effect: Z = 0.37 (P = 0.71)
3 No commercial funding
MRC 1968 62/199 74/194 50.9 % 0.82 [ 0.62, 1.07 ]
NDHS Open 1st 1968 5/726 1/341 6.9 % 2.35 [ 0.28, 20.02 ]
Sydney Diet-Heart 1978 37/221 25/237 42.1 % 1.59 [ 0.99, 2.55 ]
Subtotal (95% CI) 1146 772 100.0 % 1.16 [ 0.64, 2.12 ]
Total events: 104 (Higher omega 6), 100 (Lower omega 6)
Heterogeneity: Tau2 = 0.17; Chi2 = 6.49, df = 2 (P = 0.04); I2 =69%
Test for overall effect: Z = 0.49 (P = 0.62)
4 Low risk of attention bias
GLAMT 1993 0/54 1/57 0.9 % 0.35 [ 0.01, 8.45 ]
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(. . . Continued)
Study or subgroup Higher omega 6 Lower omega 6 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
NDHS Open 1st 1968 5/726 1/341 2.0 % 2.35 [ 0.28, 20.02 ]
Rose 1965 15/28 11/26 23.8 % 1.27 [ 0.72, 2.23 ]
Veterans Admin 1969 97/424 122/422 73.3 % 0.79 [ 0.63, 1.00 ]
Subtotal (95% CI) 1232 846 100.0 % 0.90 [ 0.66, 1.22 ]
Total events: 117 (Higher omega 6), 135 (Lower omega 6)
Heterogeneity: Tau2 = 0.02; Chi2 = 3.45, df = 3 (P = 0.33); I2 =13%
Test for overall effect: Z = 0.69 (P = 0.49)
5 Randomised 250+ participants
DART 1989 476/1018 478/1015 38.1 % 0.99 [ 0.91, 1.09 ]
MRC 1968 62/199 74/194 22.8 % 0.82 [ 0.62, 1.07 ]
NDHS Open 1st 1968 5/726 1/341 0.8 % 2.35 [ 0.28, 20.02 ]
Sydney Diet-Heart 1978 37/221 25/237 12.0 % 1.59 [ 0.99, 2.55 ]
Veterans Admin 1969 97/424 122/422 26.3 % 0.79 [ 0.63, 1.00 ]
Subtotal (95% CI) 2588 2209 100.0 % 0.95 [ 0.78, 1.16 ]
Total events: 677 (Higher omega 6), 700 (Lower omega 6)
Heterogeneity: Tau2 = 0.02; Chi2 = 9.56, df = 4 (P = 0.05); I2 =58%
Test for overall effect: Z = 0.49 (P = 0.63)
6 Randomised 100+ participants
DART 1989 476/1018 478/1015 39.1 % 0.99 [ 0.91, 1.09 ]
GLAMT 1993 0/54 1/57 0.3 % 0.35 [ 0.01, 8.45 ]
MRC 1968 62/199 74/194 22.4 % 0.82 [ 0.62, 1.07 ]
NDHS Open 1st 1968 5/726 1/341 0.7 % 2.35 [ 0.28, 20.02 ]
Sydney Diet-Heart 1978 37/221 25/237 11.4 % 1.59 [ 0.99, 2.55 ]
Veterans Admin 1969 97/424 122/422 26.1 % 0.79 [ 0.63, 1.00 ]
Subtotal (95% CI) 2642 2266 100.0 % 0.95 [ 0.79, 1.14 ]
Total events: 677 (Higher omega 6), 701 (Lower omega 6)
Heterogeneity: Tau2 = 0.02; Chi2 = 9.95, df = 5 (P = 0.08); I2 =50%
Test for overall effect: Z = 0.56 (P = 0.57)
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Analysis 1.26. Comparison 1 Primary outcomes - higher omega-6 vs lower omega-6, Outcome 26 CVD
events - subgroup by LA or GLA.
Review: Omega-6 fats for the primary and secondary prevention of cardiovascular disease
Comparison: 1 Primary outcomes - higher omega-6 vs lower omega-6
Outcome: 26 CVD events - subgroup by LA or GLA
Study or subgroup Higher omega 6 Lower omega 6 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Mainly LA
DART 1989 476/1018 478/1015 37.0 % 0.99 [ 0.91, 1.09 ]
MRC 1968 62/199 74/194 20.4 % 0.82 [ 0.62, 1.07 ]
NDHS Open 1st 1968 5/726 1/341 0.6 % 2.35 [ 0.28, 20.02 ]
Rose 1965 15/28 11/26 7.6 % 1.27 [ 0.72, 2.23 ]
Sydney Diet-Heart 1978 37/221 25/237 10.1 % 1.59 [ 0.99, 2.55 ]
Veterans Admin 1969 97/424 122/422 23.9 % 0.79 [ 0.63, 1.00 ]
Subtotal (95% CI) 2616 2235 99.7 % 0.97 [ 0.81, 1.17 ]
Total events: 692 (Higher omega 6), 711 (Lower omega 6)
Heterogeneity: Tau2 = 0.02; Chi2 = 10.44, df = 5 (P = 0.06); I2 =52%
Test for overall effect: Z = 0.29 (P = 0.77)
2 GLA supplements
GLAMT 1993 0/54 1/57 0.3 % 0.35 [ 0.01, 8.45 ]
Subtotal (95% CI) 54 57 0.3 % 0.35 [ 0.01, 8.45 ]
Total events: 0 (Higher omega 6), 1 (Lower omega 6)
Heterogeneity: not applicable
Test for overall effect: Z = 0.64 (P = 0.52)
Total (95% CI) 2670 2292 100.0 % 0.97 [ 0.81, 1.15 ]
Total events: 692 (Higher omega 6), 712 (Lower omega 6)
Heterogeneity: Tau2 = 0.02; Chi2 = 10.83, df = 6 (P = 0.09); I2 =45%
Test for overall effect: Z = 0.37 (P = 0.71)
Test for subgroup differences: Chi2 = 0.39, df = 1 (P = 0.53), I2 =0.0%
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Analysis 1.27. Comparison 1 Primary outcomes - higher omega-6 vs lower omega-6, Outcome 27 CVD
events - subgroup by intervention type.
Review: Omega-6 fats for the primary and secondary prevention of cardiovascular disease
Comparison: 1 Primary outcomes - higher omega-6 vs lower omega-6
Outcome: 27 CVD events - subgroup by intervention type
Study or subgroup Higher omega 6 Lower omega 6 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Dietary advice
DART 1989 476/1018 478/1015 37.0 % 0.99 [ 0.91, 1.09 ]
Sydney Diet-Heart 1978 37/221 25/237 10.1 % 1.59 [ 0.99, 2.55 ]
Subtotal (95% CI) 1239 1252 47.1 % 1.18 [ 0.76, 1.85 ]
Total events: 513 (Higher omega 6), 503 (Lower omega 6)
Heterogeneity: Tau2 = 0.08; Chi2 = 3.69, df = 1 (P = 0.05); I2 =73%
Test for overall effect: Z = 0.74 (P = 0.46)
2 Supplements (capsules)
GLAMT 1993 0/54 1/57 0.3 % 0.35 [ 0.01, 8.45 ]
Subtotal (95% CI) 54 57 0.3 % 0.35 [ 0.01, 8.45 ]
Total events: 0 (Higher omega 6), 1 (Lower omega 6)
Heterogeneity: not applicable
Test for overall effect: Z = 0.64 (P = 0.52)
3 Supplemental foods
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Higher omega 6), 0 (Lower omega 6)
Heterogeneity: not applicable
Test for overall effect: not applicable
4 Dietary advice plus supplement
MRC 1968 62/199 74/194 20.4 % 0.82 [ 0.62, 1.07 ]
Rose 1965 15/28 11/26 7.6 % 1.27 [ 0.72, 2.23 ]
Subtotal (95% CI) 227 220 28.0 % 0.95 [ 0.63, 1.42 ]
Total events: 77 (Higher omega 6), 85 (Lower omega 6)
Heterogeneity: Tau2 = 0.05; Chi2 = 1.88, df = 1 (P = 0.17); I2 =47%
Test for overall effect: Z = 0.27 (P = 0.79)
5 Diet (all foods) provided
NDHS Open 1st 1968 5/726 1/341 0.6 % 2.35 [ 0.28, 20.02 ]
Veterans Admin 1969 97/424 122/422 23.9 % 0.79 [ 0.63, 1.00 ]
Subtotal (95% CI) 1150 763 24.6 % 0.80 [ 0.64, 1.01 ]
Total events: 102 (Higher omega 6), 123 (Lower omega 6)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.98, df = 1 (P = 0.32); I2 =0.0%
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(. . . Continued)
Study or subgroup Higher omega 6 Lower omega 6 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Test for overall effect: Z = 1.90 (P = 0.058)
Total (95% CI) 2670 2292 100.0 % 0.97 [ 0.81, 1.15 ]
Total events: 692 (Higher omega 6), 712 (Lower omega 6)
Heterogeneity: Tau2 = 0.02; Chi2 = 10.83, df = 6 (P = 0.09); I2 =45%
Test for overall effect: Z = 0.37 (P = 0.71)
Test for subgroup differences: Chi2 = 2.77, df = 3 (P = 0.43), I2 =0.0%
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Analysis 1.28. Comparison 1 Primary outcomes - higher omega-6 vs lower omega-6, Outcome 28 CVD
events - subgroup by replacement.
Review: Omega-6 fats for the primary and secondary prevention of cardiovascular disease
Comparison: 1 Primary outcomes - higher omega-6 vs lower omega-6
Outcome: 28 CVD events - subgroup by replacement
Study or subgroup Higher omega 6 Lower omega 6 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 N-6 replacing SFA
DART 1989 476/1018 478/1015 38.1 % 0.99 [ 0.91, 1.09 ]
MRC 1968 62/199 74/194 22.8 % 0.82 [ 0.62, 1.07 ]
NDHS Open 1st 1968 5/726 1/341 0.8 % 2.35 [ 0.28, 20.02 ]
Sydney Diet-Heart 1978 37/221 25/237 12.0 % 1.59 [ 0.99, 2.55 ]
Veterans Admin 1969 97/424 122/422 26.3 % 0.79 [ 0.63, 1.00 ]
Subtotal (95% CI) 2588 2209 100.0 % 0.95 [ 0.78, 1.16 ]
Total events: 677 (Higher omega 6), 700 (Lower omega 6)
Heterogeneity: Tau2 = 0.02; Chi2 = 9.56, df = 4 (P = 0.05); I2 =58%
Test for overall effect: Z = 0.49 (P = 0.63)
2 N-6 replacing MUFA
NDHS Open 1st 1968 5/726 1/341 4.1 % 2.35 [ 0.28, 20.02 ]
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(. . . Continued)
Study or subgroup Higher omega 6 Lower omega 6 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Rose 1965 15/28 11/26 26.2 % 1.27 [ 0.72, 2.23 ]
Sydney Diet-Heart 1978 37/221 25/237 29.9 % 1.59 [ 0.99, 2.55 ]
Veterans Admin 1969 97/424 122/422 39.8 % 0.79 [ 0.63, 1.00 ]
Subtotal (95% CI) 1399 1026 100.0 % 1.15 [ 0.73, 1.81 ]
Total events: 154 (Higher omega 6), 159 (Lower omega 6)
Heterogeneity: Tau2 = 0.12; Chi2 = 8.63, df = 3 (P = 0.03); I2 =65%
Test for overall effect: Z = 0.61 (P = 0.54)
3 N-6 replacing nil, low n-6
GLAMT 1993 0/54 1/57 100.0 % 0.35 [ 0.01, 8.45 ]
Subtotal (95% CI) 54 57 100.0 % 0.35 [ 0.01, 8.45 ]
Total events: 0 (Higher omega 6), 1 (Lower omega 6)
Heterogeneity: not applicable
Test for overall effect: Z = 0.64 (P = 0.52)
4 N-6 replacement unclear
MRC 1968 62/199 74/194 100.0 % 0.82 [ 0.62, 1.07 ]
Subtotal (95% CI) 199 194 100.0 % 0.82 [ 0.62, 1.07 ]
Total events: 62 (Higher omega 6), 74 (Lower omega 6)
Heterogeneity: not applicable
Test for overall effect: Z = 1.45 (P = 0.15)
5 N-6 replacing CHO
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Higher omega 6), 0 (Lower omega 6)
Heterogeneity: not applicable
Test for overall effect: not applicable
6 N-6 replacing protein
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Higher omega 6), 0 (Lower omega 6)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Chi2 = 2.14, df = 3 (P = 0.54), I2 =0.0%
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Analysis 1.29. Comparison 1 Primary outcomes - higher omega-6 vs lower omega-6, Outcome 29 CVD
events - subgroup by baseline CVD risk.
Review: Omega-6 fats for the primary and secondary prevention of cardiovascular disease
Comparison: 1 Primary outcomes - higher omega-6 vs lower omega-6
Outcome: 29 CVD events - subgroup by baseline CVD risk
Study or subgroup Higher omega 6 Lower omega 6 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Primary prevention - low CVD risk
NDHS Open 1st 1968 5/726 1/341 0.6 % 2.35 [ 0.28, 20.02 ]
Veterans Admin 1969 97/424 122/422 23.9 % 0.79 [ 0.63, 1.00 ]
Subtotal (95% CI) 1150 763 24.6 % 0.80 [ 0.64, 1.01 ]
Total events: 102 (Higher omega 6), 123 (Lower omega 6)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.98, df = 1 (P = 0.32); I2 =0.0%
Test for overall effect: Z = 1.90 (P = 0.058)
2 Primary prevention - moderate CVD risk
GLAMT 1993 0/54 1/57 0.3 % 0.35 [ 0.01, 8.45 ]
Subtotal (95% CI) 54 57 0.3 % 0.35 [ 0.01, 8.45 ]
Total events: 0 (Higher omega 6), 1 (Lower omega 6)
Heterogeneity: not applicable
Test for overall effect: Z = 0.64 (P = 0.52)
3 Secondary prevention - existing CVD
DART 1989 476/1018 478/1015 37.0 % 0.99 [ 0.91, 1.09 ]
MRC 1968 62/199 74/194 20.4 % 0.82 [ 0.62, 1.07 ]
Rose 1965 15/28 11/26 7.6 % 1.27 [ 0.72, 2.23 ]
Sydney Diet-Heart 1978 37/221 25/237 10.1 % 1.59 [ 0.99, 2.55 ]
Subtotal (95% CI) 1466 1472 75.1 % 1.04 [ 0.83, 1.29 ]
Total events: 590 (Higher omega 6), 588 (Lower omega 6)
Heterogeneity: Tau2 = 0.02; Chi2 = 6.46, df = 3 (P = 0.09); I2 =54%
Test for overall effect: Z = 0.32 (P = 0.75)
Total (95% CI) 2670 2292 100.0 % 0.97 [ 0.81, 1.15 ]
Total events: 692 (Higher omega 6), 712 (Lower omega 6)
Heterogeneity: Tau2 = 0.02; Chi2 = 10.83, df = 6 (P = 0.09); I2 =45%
Test for overall effect: Z = 0.37 (P = 0.71)
Test for subgroup differences: Chi2 = 2.91, df = 2 (P = 0.23), I2 =31%
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Analysis 1.30. Comparison 1 Primary outcomes - higher omega-6 vs lower omega-6, Outcome 30 CVD
events - subgroup by primary vs secondary prevention.
Review: Omega-6 fats for the primary and secondary prevention of cardiovascular disease
Comparison: 1 Primary outcomes - higher omega-6 vs lower omega-6
Outcome: 30 CVD events - subgroup by primary vs secondary prevention
Study or subgroup Higher omega 6 Lower omega 6 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Primary prevention - low or mod CVD risk
GLAMT 1993 0/54 1/57 0.3 % 0.35 [ 0.01, 8.45 ]
NDHS Open 1st 1968 5/726 1/341 0.6 % 2.35 [ 0.28, 20.02 ]
Veterans Admin 1969 97/424 122/422 23.9 % 0.79 [ 0.63, 1.00 ]
Subtotal (95% CI) 1204 820 24.9 % 0.80 [ 0.64, 1.00 ]
Total events: 102 (Higher omega 6), 124 (Lower omega 6)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.24, df = 2 (P = 0.54); I2 =0.0%
Test for overall effect: Z = 1.94 (P = 0.052)
2 Secondary prevention - existing CVD
DART 1989 476/1018 478/1015 37.0 % 0.99 [ 0.91, 1.09 ]
MRC 1968 62/199 74/194 20.4 % 0.82 [ 0.62, 1.07 ]
Rose 1965 15/28 11/26 7.6 % 1.27 [ 0.72, 2.23 ]
Sydney Diet-Heart 1978 37/221 25/237 10.1 % 1.59 [ 0.99, 2.55 ]
Subtotal (95% CI) 1466 1472 75.1 % 1.04 [ 0.83, 1.29 ]
Total events: 590 (Higher omega 6), 588 (Lower omega 6)
Heterogeneity: Tau2 = 0.02; Chi2 = 6.46, df = 3 (P = 0.09); I2 =54%
Test for overall effect: Z = 0.32 (P = 0.75)
Total (95% CI) 2670 2292 100.0 % 0.97 [ 0.81, 1.15 ]
Total events: 692 (Higher omega 6), 712 (Lower omega 6)
Heterogeneity: Tau2 = 0.02; Chi2 = 10.83, df = 6 (P = 0.09); I2 =45%
Test for overall effect: Z = 0.37 (P = 0.71)
Test for subgroup differences: Chi2 = 2.65, df = 1 (P = 0.10), I2 =62%
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Analysis 1.31. Comparison 1 Primary outcomes - higher omega-6 vs lower omega-6, Outcome 31 CVD
events - subgroup by omega-6 dose.
Review: Omega-6 fats for the primary and secondary prevention of cardiovascular disease
Comparison: 1 Primary outcomes - higher omega-6 vs lower omega-6
Outcome: 31 CVD events - subgroup by omega-6 dose
Study or subgroup Higher omega 6 Lower omega 6 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 N-6 < 4% E
DART 1989 476/1018 478/1015 37.0 % 0.99 [ 0.91, 1.09 ]
GLAMT 1993 0/54 1/57 0.3 % 0.35 [ 0.01, 8.45 ]
Subtotal (95% CI) 1072 1072 37.3 % 0.99 [ 0.90, 1.09 ]
Total events: 476 (Higher omega 6), 479 (Lower omega 6)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.41, df = 1 (P = 0.52); I2 =0.0%
Test for overall effect: Z = 0.17 (P = 0.86)
2 N-6 4% to 12% E
NDHS Open 1st 1968 5/726 1/341 0.6 % 2.35 [ 0.28, 20.02 ]
Sydney Diet-Heart 1978 37/221 25/237 10.1 % 1.59 [ 0.99, 2.55 ]
Veterans Admin 1969 97/424 122/422 23.9 % 0.79 [ 0.63, 1.00 ]
Subtotal (95% CI) 1371 1000 34.7 % 1.15 [ 0.61, 2.16 ]
Total events: 139 (Higher omega 6), 148 (Lower omega 6)
Heterogeneity: Tau2 = 0.19; Chi2 = 7.54, df = 2 (P = 0.02); I2 =73%
Test for overall effect: Z = 0.43 (P = 0.67)
3 N-6 > 12% E
MRC 1968 62/199 74/194 20.4 % 0.82 [ 0.62, 1.07 ]
Rose 1965 15/28 11/26 7.6 % 1.27 [ 0.72, 2.23 ]
Subtotal (95% CI) 227 220 28.0 % 0.95 [ 0.63, 1.42 ]
Total events: 77 (Higher omega 6), 85 (Lower omega 6)
Heterogeneity: Tau2 = 0.05; Chi2 = 1.88, df = 1 (P = 0.17); I2 =47%
Test for overall effect: Z = 0.27 (P = 0.79)
Total (95% CI) 2670 2292 100.0 % 0.97 [ 0.81, 1.15 ]
Total events: 692 (Higher omega 6), 712 (Lower omega 6)
Heterogeneity: Tau2 = 0.02; Chi2 = 10.83, df = 6 (P = 0.09); I2 =45%
Test for overall effect: Z = 0.37 (P = 0.71)
Test for subgroup differences: Chi2 = 0.26, df = 2 (P = 0.88), I2 =0.0%
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Analysis 1.32. Comparison 1 Primary outcomes - higher omega-6 vs lower omega-6, Outcome 32 CVD
events - subgroup by duration.
Review: Omega-6 fats for the primary and secondary prevention of cardiovascular disease
Comparison: 1 Primary outcomes - higher omega-6 vs lower omega-6
Outcome: 32 CVD events - subgroup by duration
Study or subgroup Higher omega 6 Lower omega 6 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Medium duration 1 to < 2 years in study
GLAMT 1993 0/54 1/57 0.3 % 0.35 [ 0.01, 8.45 ]
NDHS Open 1st 1968 5/726 1/341 0.6 % 2.35 [ 0.28, 20.02 ]
Subtotal (95% CI) 780 398 0.9 % 1.30 [ 0.22, 7.67 ]
Total events: 5 (Higher omega 6), 2 (Lower omega 6)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.94, df = 1 (P = 0.33); I2 =0.0%
Test for overall effect: Z = 0.29 (P = 0.77)
2 Medium-long duration 2 to < 4 years
DART 1989 476/1018 478/1015 37.0 % 0.99 [ 0.91, 1.09 ]
Rose 1965 15/28 11/26 7.6 % 1.27 [ 0.72, 2.23 ]
Subtotal (95% CI) 1046 1041 44.6 % 1.00 [ 0.91, 1.09 ]
Total events: 491 (Higher omega 6), 489 (Lower omega 6)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.69, df = 1 (P = 0.41); I2 =0.0%
Test for overall effect: Z = 0.02 (P = 0.99)
3 Long duration 4+ years in study
MRC 1968 62/199 74/194 20.4 % 0.82 [ 0.62, 1.07 ]
Sydney Diet-Heart 1978 37/221 25/237 10.1 % 1.59 [ 0.99, 2.55 ]
Veterans Admin 1969 97/424 122/422 23.9 % 0.79 [ 0.63, 1.00 ]
Subtotal (95% CI) 844 853 54.4 % 0.95 [ 0.68, 1.33 ]
Total events: 196 (Higher omega 6), 221 (Lower omega 6)
Heterogeneity: Tau2 = 0.06; Chi2 = 7.10, df = 2 (P = 0.03); I2 =72%
Test for overall effect: Z = 0.30 (P = 0.76)
Total (95% CI) 2670 2292 100.0 % 0.97 [ 0.81, 1.15 ]
Total events: 692 (Higher omega 6), 712 (Lower omega 6)
Heterogeneity: Tau2 = 0.02; Chi2 = 10.83, df = 6 (P = 0.09); I2 =45%
Test for overall effect: Z = 0.37 (P = 0.71)
Test for subgroup differences: Chi2 = 0.17, df = 2 (P = 0.92), I2 =0.0%
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Analysis 1.33. Comparison 1 Primary outcomes - higher omega-6 vs lower omega-6, Outcome 33 CVD
events - subgroup by baseline omega-6.
Review: Omega-6 fats for the primary and secondary prevention of cardiovascular disease
Comparison: 1 Primary outcomes - higher omega-6 vs lower omega-6
Outcome: 33 CVD events - subgroup by baseline omega-6
Study or subgroup Higher omega 6 Lower omega 6 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1≥ 8% E from n-6
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Higher omega 6), 0 (Lower omega 6)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 5% to < 8% E from n-6
DART 1989 476/1018 478/1015 37.0 % 0.99 [ 0.91, 1.09 ]
Sydney Diet-Heart 1978 37/221 25/237 10.1 % 1.59 [ 0.99, 2.55 ]
Subtotal (95% CI) 1239 1252 47.1 % 1.18 [ 0.76, 1.85 ]
Total events: 513 (Higher omega 6), 503 (Lower omega 6)
Heterogeneity: Tau2 = 0.08; Chi2 = 3.69, df = 1 (P = 0.05); I2 =73%
Test for overall effect: Z = 0.74 (P = 0.46)
3 < 5% E from n-6
NDHS Open 1st 1968 5/726 1/341 0.6 % 2.35 [ 0.28, 20.02 ]
Veterans Admin 1969 97/424 122/422 23.9 % 0.79 [ 0.63, 1.00 ]
Subtotal (95% CI) 1150 763 24.6 % 0.80 [ 0.64, 1.01 ]
Total events: 102 (Higher omega 6), 123 (Lower omega 6)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.98, df = 1 (P = 0.32); I2 =0.0%
Test for overall effect: Z = 1.90 (P = 0.058)
4 baseline n-6 not reported
GLAMT 1993 0/54 1/57 0.3 % 0.35 [ 0.01, 8.45 ]
MRC 1968 62/199 74/194 20.4 % 0.82 [ 0.62, 1.07 ]
Rose 1965 15/28 11/26 7.6 % 1.27 [ 0.72, 2.23 ]
Subtotal (95% CI) 281 277 28.3 % 0.90 [ 0.67, 1.21 ]
Total events: 77 (Higher omega 6), 86 (Lower omega 6)
Heterogeneity: Tau2 = 0.01; Chi2 = 2.21, df = 2 (P = 0.33); I2 =10%
Test for overall effect: Z = 0.69 (P = 0.49)
Total (95% CI) 2670 2292 100.0 % 0.97 [ 0.81, 1.15 ]
Total events: 692 (Higher omega 6), 712 (Lower omega 6)
Heterogeneity: Tau2 = 0.02; Chi2 = 10.83, df = 6 (P = 0.09); I2 =45%
Test for overall effect: Z = 0.37 (P = 0.71)
Test for subgroup differences: Chi2 = 2.35, df = 2 (P = 0.31), I2 =15%
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Analysis 1.34. Comparison 1 Primary outcomes - higher omega-6 vs lower omega-6, Outcome 34 CVD
events - subgroup by sex.
Review: Omega-6 fats for the primary and secondary prevention of cardiovascular disease
Comparison: 1 Primary outcomes - higher omega-6 vs lower omega-6
Outcome: 34 CVD events - subgroup by sex
Study or subgroup Higher omega 6 Lower omega 6 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Men only
DART 1989 476/1018 478/1015 37.0 % 0.99 [ 0.91, 1.09 ]
MRC 1968 62/199 74/194 20.4 % 0.82 [ 0.62, 1.07 ]
NDHS Open 1st 1968 5/726 1/341 0.6 % 2.35 [ 0.28, 20.02 ]
Sydney Diet-Heart 1978 37/221 25/237 10.1 % 1.59 [ 0.99, 2.55 ]
Veterans Admin 1969 97/424 122/422 23.9 % 0.79 [ 0.63, 1.00 ]
Subtotal (95% CI) 2588 2209 92.1 % 0.95 [ 0.78, 1.16 ]
Total events: 677 (Higher omega 6), 700 (Lower omega 6)
Heterogeneity: Tau2 = 0.02; Chi2 = 9.56, df = 4 (P = 0.05); I2 =58%
Test for overall effect: Z = 0.49 (P = 0.63)
2 Men and women
GLAMT 1993 0/54 1/57 0.3 % 0.35 [ 0.01, 8.45 ]
Subtotal (95% CI) 54 57 0.3 % 0.35 [ 0.01, 8.45 ]
Total events: 0 (Higher omega 6), 1 (Lower omega 6)
Heterogeneity: not applicable
Test for overall effect: Z = 0.64 (P = 0.52)
3 Sex not reported
Rose 1965 15/28 11/26 7.6 % 1.27 [ 0.72, 2.23 ]
Subtotal (95% CI) 28 26 7.6 % 1.27 [ 0.72, 2.23 ]
Total events: 15 (Higher omega 6), 11 (Lower omega 6)
Heterogeneity: not applicable
Test for overall effect: Z = 0.82 (P = 0.41)
Total (95% CI) 2670 2292 100.0 % 0.97 [ 0.81, 1.15 ]
Total events: 692 (Higher omega 6), 712 (Lower omega 6)
Heterogeneity: Tau2 = 0.02; Chi2 = 10.83, df = 6 (P = 0.09); I2 =45%
Test for overall effect: Z = 0.37 (P = 0.71)
Test for subgroup differences: Chi2 = 1.27, df = 2 (P = 0.53), I2 =0.0%
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Analysis 1.35. Comparison 1 Primary outcomes - higher omega-6 vs lower omega-6, Outcome 35 Coronary
heart disease events (overall): myocardial infarction (fatal or non-fatal) or angina.
Review: Omega-6 fats for the primary and secondary prevention of cardiovascular disease
Comparison: 1 Primary outcomes - higher omega-6 vs lower omega-6
Outcome: 35 Coronary heart disease events (overall): myocardial infarction (fatal or non-fatal) or angina
Study or subgroup Higher omega 6 Lower omega 6 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
DART 1989 339/1018 364/1015 24.6 % 0.93 [ 0.82, 1.05 ]
GLAMT 1993 0/54 1/57 0.8 % 0.35 [ 0.01, 8.45 ]
Houtsmuller 1979 8/51 30/51 10.6 % 0.27 [ 0.14, 0.52 ]
MRC 1968 50/199 50/194 19.0 % 0.97 [ 0.69, 1.37 ]
Rose 1965 12/28 9/26 10.6 % 1.24 [ 0.63, 2.44 ]
Sydney Diet-Heart 1978 35/221 23/237 14.6 % 1.63 [ 1.00, 2.67 ]
Veterans Admin 1969 60/424 78/422 19.8 % 0.77 [ 0.56, 1.04 ]
Total (95% CI) 1995 2002 100.0 % 0.88 [ 0.66, 1.17 ]
Total events: 504 (Higher omega 6), 555 (Lower omega 6)
Heterogeneity: Tau2 = 0.08; Chi2 = 20.67, df = 6 (P = 0.002); I2 =71%
Test for overall effect: Z = 0.89 (P = 0.37)
Test for subgroup differences: Not applicable
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Analysis 1.36. Comparison 1 Primary outcomes - higher omega-6 vs lower omega-6, Outcome 36 CHD
events - sensitivity analysis by fixed-effect analysis.
Review: Omega-6 fats for the primary and secondary prevention of cardiovascular disease
Comparison: 1 Primary outcomes - higher omega-6 vs lower omega-6
Outcome: 36 CHD events - sensitivity analysis by fixed-effect analysis
Study or subgroup Higher omega 6 Lower omega 6 Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
DART 1989 339/1018 364/1015 65.5 % 0.93 [ 0.82, 1.05 ]
GLAMT 1993 0/54 1/57 0.3 % 0.35 [ 0.01, 8.45 ]
Houtsmuller 1979 8/51 30/51 5.4 % 0.27 [ 0.14, 0.52 ]
MRC 1968 50/199 50/194 9.1 % 0.97 [ 0.69, 1.37 ]
Rose 1965 12/28 9/26 1.7 % 1.24 [ 0.63, 2.44 ]
Sydney Diet-Heart 1978 35/221 23/237 4.0 % 1.63 [ 1.00, 2.67 ]
Veterans Admin 1969 60/424 78/422 14.1 % 0.77 [ 0.56, 1.04 ]
Total (95% CI) 1995 2002 100.0 % 0.91 [ 0.82, 1.00 ]
Total events: 504 (Higher omega 6), 555 (Lower omega 6)
Heterogeneity: Chi2 = 20.67, df = 6 (P = 0.002); I2 =71%
Test for overall effect: Z = 1.92 (P = 0.055)
Test for subgroup differences: Not applicable
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Analysis 1.37. Comparison 1 Primary outcomes - higher omega-6 vs lower omega-6, Outcome 37 CHD
events - sensitivity analyses.
Review: Omega-6 fats for the primary and secondary prevention of cardiovascular disease
Comparison: 1 Primary outcomes - higher omega-6 vs lower omega-6
Outcome: 37 CHD events - sensitivity analyses
Study or subgroup Higher omega 6 Lower omega 6 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Studies at low risk of bias
Sydney Diet-Heart 1978 35/221 23/237 100.0 % 1.63 [ 1.00, 2.67 ]
Subtotal (95% CI) 221 237 100.0 % 1.63 [ 1.00, 2.67 ]
Total events: 35 (Higher omega 6), 23 (Lower omega 6)
Heterogeneity: not applicable
Test for overall effect: Z = 1.95 (P = 0.052)
2 Pre-2010 or prospective trials registry entry
DART 1989 339/1018 364/1015 24.6 % 0.93 [ 0.82, 1.05 ]
GLAMT 1993 0/54 1/57 0.8 % 0.35 [ 0.01, 8.45 ]
Houtsmuller 1979 8/51 30/51 10.6 % 0.27 [ 0.14, 0.52 ]
MRC 1968 50/199 50/194 19.0 % 0.97 [ 0.69, 1.37 ]
Rose 1965 12/28 9/26 10.6 % 1.24 [ 0.63, 2.44 ]
Sydney Diet-Heart 1978 35/221 23/237 14.6 % 1.63 [ 1.00, 2.67 ]
Veterans Admin 1969 60/424 78/422 19.8 % 0.77 [ 0.56, 1.04 ]
Subtotal (95% CI) 1995 2002 100.0 % 0.88 [ 0.66, 1.17 ]
Total events: 504 (Higher omega 6), 555 (Lower omega 6)
Heterogeneity: Tau2 = 0.08; Chi2 = 20.67, df = 6 (P = 0.002); I2 =71%
Test for overall effect: Z = 0.89 (P = 0.37)
3 No commercial funding
Houtsmuller 1979 8/51 30/51 30.6 % 0.27 [ 0.14, 0.52 ]
MRC 1968 50/199 50/194 35.8 % 0.97 [ 0.69, 1.37 ]
Sydney Diet-Heart 1978 35/221 23/237 33.6 % 1.63 [ 1.00, 2.67 ]
Subtotal (95% CI) 471 482 100.0 % 0.78 [ 0.33, 1.82 ]
Total events: 93 (Higher omega 6), 103 (Lower omega 6)
Heterogeneity: Tau2 = 0.50; Chi2 = 18.20, df = 2 (P = 0.00011); I2 =89%
Test for overall effect: Z = 0.57 (P = 0.57)
4 Low risk of attention bias
GLAMT 1993 0/54 1/57 0.8 % 0.35 [ 0.01, 8.45 ]
Rose 1965 12/28 9/26 16.9 % 1.24 [ 0.63, 2.44 ]
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(. . . Continued)
Study or subgroup Higher omega 6 Lower omega 6 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Veterans Admin 1969 60/424 78/422 82.3 % 0.77 [ 0.56, 1.04 ]
Subtotal (95% CI) 506 505 100.0 % 0.83 [ 0.62, 1.09 ]
Total events: 72 (Higher omega 6), 88 (Lower omega 6)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.89, df = 2 (P = 0.39); I2 =0.0%
Test for overall effect: Z = 1.34 (P = 0.18)
5 Randomised 250+ participants
DART 1989 339/1018 364/1015 41.6 % 0.93 [ 0.82, 1.05 ]
MRC 1968 50/199 50/194 21.5 % 0.97 [ 0.69, 1.37 ]
Sydney Diet-Heart 1978 35/221 23/237 13.3 % 1.63 [ 1.00, 2.67 ]
Veterans Admin 1969 60/424 78/422 23.7 % 0.77 [ 0.56, 1.04 ]
Subtotal (95% CI) 1862 1868 100.0 % 0.97 [ 0.78, 1.19 ]
Total events: 484 (Higher omega 6), 515 (Lower omega 6)
Heterogeneity: Tau2 = 0.02; Chi2 = 6.59, df = 3 (P = 0.09); I2 =54%
Test for overall effect: Z = 0.32 (P = 0.75)
6 Randomised 100+ participants
DART 1989 339/1018 364/1015 27.0 % 0.93 [ 0.82, 1.05 ]
GLAMT 1993 0/54 1/57 0.9 % 0.35 [ 0.01, 8.45 ]
Houtsmuller 1979 8/51 30/51 12.2 % 0.27 [ 0.14, 0.52 ]
MRC 1968 50/199 50/194 21.2 % 0.97 [ 0.69, 1.37 ]
Sydney Diet-Heart 1978 35/221 23/237 16.6 % 1.63 [ 1.00, 2.67 ]
Veterans Admin 1969 60/424 78/422 22.1 % 0.77 [ 0.56, 1.04 ]
Subtotal (95% CI) 1967 1976 100.0 % 0.84 [ 0.61, 1.15 ]
Total events: 492 (Higher omega 6), 546 (Lower omega 6)
Heterogeneity: Tau2 = 0.09; Chi2 = 19.88, df = 5 (P = 0.001); I2 =75%
Test for overall effect: Z = 1.09 (P = 0.28)
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Analysis 1.38. Comparison 1 Primary outcomes - higher omega-6 vs lower omega-6, Outcome 38 CHD
events - subgroup by LA or GLA.
Review: Omega-6 fats for the primary and secondary prevention of cardiovascular disease
Comparison: 1 Primary outcomes - higher omega-6 vs lower omega-6
Outcome: 38 CHD events - subgroup by LA or GLA
Study or subgroup Higher omega 6 Lower omega 6 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Mainly LA
DART 1989 339/1018 364/1015 24.6 % 0.93 [ 0.82, 1.05 ]
Houtsmuller 1979 8/51 30/51 10.6 % 0.27 [ 0.14, 0.52 ]
MRC 1968 50/199 50/194 19.0 % 0.97 [ 0.69, 1.37 ]
Rose 1965 12/28 9/26 10.6 % 1.24 [ 0.63, 2.44 ]
Sydney Diet-Heart 1978 35/221 23/237 14.6 % 1.63 [ 1.00, 2.67 ]
Veterans Admin 1969 60/424 78/422 19.8 % 0.77 [ 0.56, 1.04 ]
Subtotal (95% CI) 1941 1945 99.2 % 0.88 [ 0.66, 1.19 ]
Total events: 504 (Higher omega 6), 554 (Lower omega 6)
Heterogeneity: Tau2 = 0.09; Chi2 = 20.32, df = 5 (P = 0.001); I2 =75%
Test for overall effect: Z = 0.83 (P = 0.41)
2 GLA supplements
GLAMT 1993 0/54 1/57 0.8 % 0.35 [ 0.01, 8.45 ]
Subtotal (95% CI) 54 57 0.8 % 0.35 [ 0.01, 8.45 ]
Total events: 0 (Higher omega 6), 1 (Lower omega 6)
Heterogeneity: not applicable
Test for overall effect: Z = 0.64 (P = 0.52)
Total (95% CI) 1995 2002 100.0 % 0.88 [ 0.66, 1.17 ]
Total events: 504 (Higher omega 6), 555 (Lower omega 6)
Heterogeneity: Tau2 = 0.08; Chi2 = 20.67, df = 6 (P = 0.002); I2 =71%
Test for overall effect: Z = 0.89 (P = 0.37)
Test for subgroup differences: Chi2 = 0.32, df = 1 (P = 0.57), I2 =0.0%
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Analysis 1.39. Comparison 1 Primary outcomes - higher omega-6 vs lower omega-6, Outcome 39 CHD
events - subgroup by intervention type.
Review: Omega-6 fats for the primary and secondary prevention of cardiovascular disease
Comparison: 1 Primary outcomes - higher omega-6 vs lower omega-6
Outcome: 39 CHD events - subgroup by intervention type
Study or subgroup Higher omega 6 Lower omega 6 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Dietary advice
DART 1989 339/1018 364/1015 24.6 % 0.93 [ 0.82, 1.05 ]
Houtsmuller 1979 8/51 30/51 10.6 % 0.27 [ 0.14, 0.52 ]
Sydney Diet-Heart 1978 35/221 23/237 14.6 % 1.63 [ 1.00, 2.67 ]
Subtotal (95% CI) 1290 1303 49.9 % 0.78 [ 0.38, 1.61 ]
Total events: 382 (Higher omega 6), 417 (Lower omega 6)
Heterogeneity: Tau2 = 0.36; Chi2 = 18.09, df = 2 (P = 0.00012); I2 =89%
Test for overall effect: Z = 0.68 (P = 0.50)
2 Dietary advice plus supplement
MRC 1968 50/199 50/194 19.0 % 0.97 [ 0.69, 1.37 ]
Rose 1965 12/28 9/26 10.6 % 1.24 [ 0.63, 2.44 ]
Subtotal (95% CI) 227 220 29.5 % 1.02 [ 0.76, 1.38 ]
Total events: 62 (Higher omega 6), 59 (Lower omega 6)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.38, df = 1 (P = 0.54); I2 =0.0%
Test for overall effect: Z = 0.14 (P = 0.89)
3 Supplemental foods
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Higher omega 6), 0 (Lower omega 6)
Heterogeneity: not applicable
Test for overall effect: not applicable
4 Supplements (capsules)
GLAMT 1993 0/54 1/57 0.8 % 0.35 [ 0.01, 8.45 ]
Subtotal (95% CI) 54 57 0.8 % 0.35 [ 0.01, 8.45 ]
Total events: 0 (Higher omega 6), 1 (Lower omega 6)
Heterogeneity: not applicable
Test for overall effect: Z = 0.64 (P = 0.52)
5 Diet (all foods) provided
Veterans Admin 1969 60/424 78/422 19.8 % 0.77 [ 0.56, 1.04 ]
Subtotal (95% CI) 424 422 19.8 % 0.77 [ 0.56, 1.04 ]
Total events: 60 (Higher omega 6), 78 (Lower omega 6)
Heterogeneity: not applicable
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(. . . Continued)
Study or subgroup Higher omega 6 Lower omega 6 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Test for overall effect: Z = 1.70 (P = 0.090)
Total (95% CI) 1995 2002 100.0 % 0.88 [ 0.66, 1.17 ]
Total events: 504 (Higher omega 6), 555 (Lower omega 6)
Heterogeneity: Tau2 = 0.08; Chi2 = 20.67, df = 6 (P = 0.002); I2 =71%
Test for overall effect: Z = 0.89 (P = 0.37)
Test for subgroup differences: Chi2 = 2.15, df = 3 (P = 0.54), I2 =0.0%
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Analysis 1.40. Comparison 1 Primary outcomes - higher omega-6 vs lower omega-6, Outcome 40 CHD
events - subgroup by replacement.
Review: Omega-6 fats for the primary and secondary prevention of cardiovascular disease
Comparison: 1 Primary outcomes - higher omega-6 vs lower omega-6
Outcome: 40 CHD events - subgroup by replacement
Study or subgroup Higher omega 6 Lower omega 6 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 N-6 replacing SFA
DART 1989 339/1018 364/1015 27.0 % 0.93 [ 0.82, 1.05 ]
Houtsmuller 1979 8/51 30/51 12.5 % 0.27 [ 0.14, 0.52 ]
MRC 1968 50/199 50/194 21.4 % 0.97 [ 0.69, 1.37 ]
Sydney Diet-Heart 1978 35/221 23/237 16.9 % 1.63 [ 1.00, 2.67 ]
Veterans Admin 1969 60/424 78/422 22.3 % 0.77 [ 0.56, 1.04 ]
Subtotal (95% CI) 1913 1919 100.0 % 0.85 [ 0.61, 1.17 ]
Total events: 492 (Higher omega 6), 545 (Lower omega 6)
Heterogeneity: Tau2 = 0.10; Chi2 = 19.54, df = 4 (P = 0.00062); I2 =80%
Test for overall effect: Z = 1.02 (P = 0.31)
2 N-6 replacing MUFA
Rose 1965 12/28 9/26 13.9 % 1.24 [ 0.63, 2.44 ]
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(. . . Continued)
Study or subgroup Higher omega 6 Lower omega 6 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Sydney Diet-Heart 1978 35/221 23/237 26.3 % 1.63 [ 1.00, 2.67 ]
Veterans Admin 1969 71/424 54/422 59.8 % 1.31 [ 0.94, 1.82 ]
Subtotal (95% CI) 673 685 100.0 % 1.38 [ 1.07, 1.77 ]
Total events: 118 (Higher omega 6), 86 (Lower omega 6)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.64, df = 2 (P = 0.72); I2 =0.0%
Test for overall effect: Z = 2.47 (P = 0.013)
3 N-6 replacing nil, low n-6
GLAMT 1993 0/54 1/57 100.0 % 0.35 [ 0.01, 8.45 ]
Subtotal (95% CI) 54 57 100.0 % 0.35 [ 0.01, 8.45 ]
Total events: 0 (Higher omega 6), 1 (Lower omega 6)
Heterogeneity: not applicable
Test for overall effect: Z = 0.64 (P = 0.52)
4 N-6 replacement unclear
MRC 1968 50/199 50/194 100.0 % 0.97 [ 0.69, 1.37 ]
Subtotal (95% CI) 199 194 100.0 % 0.97 [ 0.69, 1.37 ]
Total events: 50 (Higher omega 6), 50 (Lower omega 6)
Heterogeneity: not applicable
Test for overall effect: Z = 0.15 (P = 0.88)
5 N-6 replacing CHO
Houtsmuller 1979 8/51 30/51 100.0 % 0.27 [ 0.14, 0.52 ]
Subtotal (95% CI) 51 51 100.0 % 0.27 [ 0.14, 0.52 ]
Total events: 8 (Higher omega 6), 30 (Lower omega 6)
Heterogeneity: not applicable
Test for overall effect: Z = 3.83 (P = 0.00013)
6 N-6 replacing protein
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Higher omega 6), 0 (Lower omega 6)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Chi2 = 22.26, df = 4 (P = 0.00), I2 =82%
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Analysis 1.41. Comparison 1 Primary outcomes - higher omega-6 vs lower omega-6, Outcome 41 CHD
events - subgroup by baseline CVD risk.
Review: Omega-6 fats for the primary and secondary prevention of cardiovascular disease
Comparison: 1 Primary outcomes - higher omega-6 vs lower omega-6
Outcome: 41 CHD events - subgroup by baseline CVD risk
Study or subgroup Higher omega 6 Lower omega 6 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Primary prevention - low CVD risk
Veterans Admin 1969 60/424 78/422 19.8 % 0.77 [ 0.56, 1.04 ]
Subtotal (95% CI) 424 422 19.8 % 0.77 [ 0.56, 1.04 ]
Total events: 60 (Higher omega 6), 78 (Lower omega 6)
Heterogeneity: not applicable
Test for overall effect: Z = 1.70 (P = 0.090)
2 Primary prevention - moderate CVD risk
GLAMT 1993 0/54 1/57 0.8 % 0.35 [ 0.01, 8.45 ]
Houtsmuller 1979 8/51 30/51 10.6 % 0.27 [ 0.14, 0.52 ]
Subtotal (95% CI) 105 108 11.4 % 0.27 [ 0.14, 0.52 ]
Total events: 8 (Higher omega 6), 31 (Lower omega 6)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.03, df = 1 (P = 0.87); I2 =0.0%
Test for overall effect: Z = 3.88 (P = 0.00010)
3 Secondary prevention - existing CVD
DART 1989 339/1018 364/1015 24.6 % 0.93 [ 0.82, 1.05 ]
MRC 1968 50/199 50/194 19.0 % 0.97 [ 0.69, 1.37 ]
Rose 1965 12/28 9/26 10.6 % 1.24 [ 0.63, 2.44 ]
Sydney Diet-Heart 1978 35/221 23/237 14.6 % 1.63 [ 1.00, 2.67 ]
Subtotal (95% CI) 1466 1472 68.8 % 1.05 [ 0.84, 1.32 ]
Total events: 436 (Higher omega 6), 446 (Lower omega 6)
Heterogeneity: Tau2 = 0.02; Chi2 = 5.30, df = 3 (P = 0.15); I2 =43%
Test for overall effect: Z = 0.45 (P = 0.65)
Total (95% CI) 1995 2002 100.0 % 0.88 [ 0.66, 1.17 ]
Total events: 504 (Higher omega 6), 555 (Lower omega 6)
Heterogeneity: Tau2 = 0.08; Chi2 = 20.67, df = 6 (P = 0.002); I2 =71%
Test for overall effect: Z = 0.89 (P = 0.37)
Test for subgroup differences: Chi2 = 15.42, df = 2 (P = 0.00), I2 =87%
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Analysis 1.42. Comparison 1 Primary outcomes - higher omega-6 vs lower omega-6, Outcome 42 CHD
events - subgroup by omega-6 dose.
Review: Omega-6 fats for the primary and secondary prevention of cardiovascular disease
Comparison: 1 Primary outcomes - higher omega-6 vs lower omega-6
Outcome: 42 CHD events - subgroup by omega-6 dose
Study or subgroup Higher omega 6 Lower omega 6 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 N-6 < 4% E
DART 1989 339/1018 364/1015 24.6 % 0.93 [ 0.82, 1.05 ]
GLAMT 1993 0/54 1/57 0.8 % 0.35 [ 0.01, 8.45 ]
Subtotal (95% CI) 1072 1072 25.4 % 0.93 [ 0.82, 1.05 ]
Total events: 339 (Higher omega 6), 365 (Lower omega 6)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.36, df = 1 (P = 0.55); I2 =0.0%
Test for overall effect: Z = 1.24 (P = 0.22)
2 N-6 4% to 12% E
Houtsmuller 1979 8/51 30/51 10.6 % 0.27 [ 0.14, 0.52 ]
Sydney Diet-Heart 1978 35/221 23/237 14.6 % 1.63 [ 1.00, 2.67 ]
Veterans Admin 1969 60/424 78/422 19.8 % 0.77 [ 0.56, 1.04 ]
Subtotal (95% CI) 696 710 45.1 % 0.72 [ 0.31, 1.64 ]
Total events: 103 (Higher omega 6), 131 (Lower omega 6)
Heterogeneity: Tau2 = 0.47; Chi2 = 18.24, df = 2 (P = 0.00011); I2 =89%
Test for overall effect: Z = 0.79 (P = 0.43)
3 N-6 > 12% E
MRC 1968 50/199 50/194 19.0 % 0.97 [ 0.69, 1.37 ]
Rose 1965 12/28 9/26 10.6 % 1.24 [ 0.63, 2.44 ]
Subtotal (95% CI) 227 220 29.5 % 1.02 [ 0.76, 1.38 ]
Total events: 62 (Higher omega 6), 59 (Lower omega 6)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.38, df = 1 (P = 0.54); I2 =0.0%
Test for overall effect: Z = 0.14 (P = 0.89)
Total (95% CI) 1995 2002 100.0 % 0.88 [ 0.66, 1.17 ]
Total events: 504 (Higher omega 6), 555 (Lower omega 6)
Heterogeneity: Tau2 = 0.08; Chi2 = 20.67, df = 6 (P = 0.002); I2 =71%
Test for overall effect: Z = 0.89 (P = 0.37)
Test for subgroup differences: Chi2 = 0.75, df = 2 (P = 0.69), I2 =0.0%
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Analysis 1.43. Comparison 1 Primary outcomes - higher omega-6 vs lower omega-6, Outcome 43 CHD
events - subgroup by duration.
Review: Omega-6 fats for the primary and secondary prevention of cardiovascular disease
Comparison: 1 Primary outcomes - higher omega-6 vs lower omega-6
Outcome: 43 CHD events - subgroup by duration
Study or subgroup Higher omega 6 Lower omega 6 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Medium duration 1 to < 2 years in study
GLAMT 1993 0/54 1/57 0.8 % 0.35 [ 0.01, 8.45 ]
Subtotal (95% CI) 54 57 0.8 % 0.35 [ 0.01, 8.45 ]
Total events: 0 (Higher omega 6), 1 (Lower omega 6)
Heterogeneity: not applicable
Test for overall effect: Z = 0.64 (P = 0.52)
2 Medium-long duration 2 to < 4 years
DART 1989 339/1018 364/1015 24.6 % 0.93 [ 0.82, 1.05 ]
Rose 1965 12/28 9/26 10.6 % 1.24 [ 0.63, 2.44 ]
Subtotal (95% CI) 1046 1041 35.2 % 0.94 [ 0.83, 1.05 ]
Total events: 351 (Higher omega 6), 373 (Lower omega 6)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.67, df = 1 (P = 0.41); I2 =0.0%
Test for overall effect: Z = 1.09 (P = 0.28)
3 Long duration 4+ years in study
Houtsmuller 1979 8/51 30/51 10.6 % 0.27 [ 0.14, 0.52 ]
MRC 1968 50/199 50/194 19.0 % 0.97 [ 0.69, 1.37 ]
Sydney Diet-Heart 1978 35/221 23/237 14.6 % 1.63 [ 1.00, 2.67 ]
Veterans Admin 1969 60/424 78/422 19.8 % 0.77 [ 0.56, 1.04 ]
Subtotal (95% CI) 895 904 64.1 % 0.79 [ 0.46, 1.35 ]
Total events: 153 (Higher omega 6), 181 (Lower omega 6)
Heterogeneity: Tau2 = 0.24; Chi2 = 19.08, df = 3 (P = 0.00026); I2 =84%
Test for overall effect: Z = 0.86 (P = 0.39)
Total (95% CI) 1995 2002 100.0 % 0.88 [ 0.66, 1.17 ]
Total events: 504 (Higher omega 6), 555 (Lower omega 6)
Heterogeneity: Tau2 = 0.08; Chi2 = 20.67, df = 6 (P = 0.002); I2 =71%
Test for overall effect: Z = 0.89 (P = 0.37)
Test for subgroup differences: Chi2 = 0.72, df = 2 (P = 0.70), I2 =0.0%
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Analysis 1.44. Comparison 1 Primary outcomes - higher omega-6 vs lower omega-6, Outcome 44 CHD
events - subgroup by baseline omega-6.
Review: Omega-6 fats for the primary and secondary prevention of cardiovascular disease
Comparison: 1 Primary outcomes - higher omega-6 vs lower omega-6
Outcome: 44 CHD events - subgroup by baseline omega-6
Study or subgroup Higher omega 6 Lower omega 6 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1≥ 8% E from n-6
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Higher omega 6), 0 (Lower omega 6)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 5% to < 8% E from n-6
DART 1989 339/1018 364/1015 24.6 % 0.93 [ 0.82, 1.05 ]
Sydney Diet-Heart 1978 35/221 23/237 14.6 % 1.63 [ 1.00, 2.67 ]
Subtotal (95% CI) 1239 1252 39.2 % 1.17 [ 0.68, 2.01 ]
Total events: 374 (Higher omega 6), 387 (Lower omega 6)
Heterogeneity: Tau2 = 0.13; Chi2 = 4.78, df = 1 (P = 0.03); I2 =79%
Test for overall effect: Z = 0.56 (P = 0.58)
3 < 5% E from n-6
Veterans Admin 1969 60/424 78/422 19.8 % 0.77 [ 0.56, 1.04 ]
Subtotal (95% CI) 424 422 19.8 % 0.77 [ 0.56, 1.04 ]
Total events: 60 (Higher omega 6), 78 (Lower omega 6)
Heterogeneity: not applicable
Test for overall effect: Z = 1.70 (P = 0.090)
4 Baseline omega 6 not reported
GLAMT 1993 0/54 1/57 0.8 % 0.35 [ 0.01, 8.45 ]
Houtsmuller 1979 8/51 30/51 10.6 % 0.27 [ 0.14, 0.52 ]
MRC 1968 50/199 50/194 19.0 % 0.97 [ 0.69, 1.37 ]
Rose 1965 12/28 9/26 10.6 % 1.24 [ 0.63, 2.44 ]
Subtotal (95% CI) 332 328 40.9 % 0.68 [ 0.31, 1.47 ]
Total events: 70 (Higher omega 6), 90 (Lower omega 6)
Heterogeneity: Tau2 = 0.41; Chi2 = 13.50, df = 3 (P = 0.004); I2 =78%
Test for overall effect: Z = 0.99 (P = 0.32)
Total (95% CI) 1995 2002 100.0 % 0.88 [ 0.66, 1.17 ]
Total events: 504 (Higher omega 6), 555 (Lower omega 6)
Heterogeneity: Tau2 = 0.08; Chi2 = 20.67, df = 6 (P = 0.002); I2 =71%
Test for overall effect: Z = 0.89 (P = 0.37)
Test for subgroup differences: Chi2 = 2.04, df = 2 (P = 0.36), I2 =2%
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Analysis 1.45. Comparison 1 Primary outcomes - higher omega-6 vs lower omega-6, Outcome 45 CHD
events - subgroup by sex.
Review: Omega-6 fats for the primary and secondary prevention of cardiovascular disease
Comparison: 1 Primary outcomes - higher omega-6 vs lower omega-6
Outcome: 45 CHD events - subgroup by sex
Study or subgroup Higher omega 6 Lower omega 6 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Men only
DART 1989 339/1018 364/1015 24.6 % 0.93 [ 0.82, 1.05 ]
MRC 1968 50/199 50/194 19.0 % 0.97 [ 0.69, 1.37 ]
Sydney Diet-Heart 1978 35/221 23/237 14.6 % 1.63 [ 1.00, 2.67 ]
Veterans Admin 1969 60/424 78/422 19.8 % 0.77 [ 0.56, 1.04 ]
Subtotal (95% CI) 1862 1868 78.0 % 0.97 [ 0.78, 1.19 ]
Total events: 484 (Higher omega 6), 515 (Lower omega 6)
Heterogeneity: Tau2 = 0.02; Chi2 = 6.59, df = 3 (P = 0.09); I2 =54%
Test for overall effect: Z = 0.32 (P = 0.75)
2 Women only
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Higher omega 6), 0 (Lower omega 6)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Men and women
GLAMT 1993 0/54 1/57 0.8 % 0.35 [ 0.01, 8.45 ]
Houtsmuller 1979 8/51 30/51 10.6 % 0.27 [ 0.14, 0.52 ]
Subtotal (95% CI) 105 108 11.4 % 0.27 [ 0.14, 0.52 ]
Total events: 8 (Higher omega 6), 31 (Lower omega 6)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.03, df = 1 (P = 0.87); I2 =0.0%
Test for overall effect: Z = 3.88 (P = 0.00010)
4 Sex not reported
Rose 1965 12/28 9/26 10.6 % 1.24 [ 0.63, 2.44 ]
Subtotal (95% CI) 28 26 10.6 % 1.24 [ 0.63, 2.44 ]
Total events: 12 (Higher omega 6), 9 (Lower omega 6)
Heterogeneity: not applicable
Test for overall effect: Z = 0.62 (P = 0.54)
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(. . . Continued)
Study or subgroup Higher omega 6 Lower omega 6 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Total (95% CI) 1995 2002 100.0 % 0.88 [ 0.66, 1.17 ]
Total events: 504 (Higher omega 6), 555 (Lower omega 6)
Heterogeneity: Tau2 = 0.08; Chi2 = 20.67, df = 6 (P = 0.002); I2 =71%
Test for overall effect: Z = 0.89 (P = 0.37)
Test for subgroup differences: Chi2 = 13.97, df = 2 (P = 0.00), I2 =86%
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Analysis 1.46. Comparison 1 Primary outcomes - higher omega-6 vs lower omega-6, Outcome 46 Major
adverse cardiac and cerebrovascular events (MACCEs), overall.
Review: Omega-6 fats for the primary and secondary prevention of cardiovascular disease
Comparison: 1 Primary outcomes - higher omega-6 vs lower omega-6
Outcome: 46 Major adverse cardiac and cerebrovascular events (MACCEs), overall
Study or subgroup Higher omega 6 Lower omega 6 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
DART 1989 333/1018 337/1015 57.4 % 0.99 [ 0.87, 1.12 ]
Veterans Admin 1969 60/424 87/422 42.6 % 0.69 [ 0.51, 0.93 ]
Total (95% CI) 1442 1437 100.0 % 0.84 [ 0.59, 1.20 ]
Total events: 393 (Higher omega 6), 424 (Lower omega 6)
Heterogeneity: Tau2 = 0.05; Chi2 = 4.80, df = 1 (P = 0.03); I2 =79%
Test for overall effect: Z = 0.94 (P = 0.35)
Test for subgroup differences: Not applicable
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Analysis 1.47. Comparison 1 Primary outcomes - higher omega-6 vs lower omega-6, Outcome 47 MACCEs
- sensitivity analysis by fixed-effect analysis.
Review: Omega-6 fats for the primary and secondary prevention of cardiovascular disease
Comparison: 1 Primary outcomes - higher omega-6 vs lower omega-6
Outcome: 47 MACCEs - sensitivity analysis by fixed-effect analysis
Study or subgroup Higher omega 6 Lower omega 6 Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
DART 1989 333/1018 337/1015 79.5 % 0.99 [ 0.87, 1.12 ]
Veterans Admin 1969 60/424 87/422 20.5 % 0.69 [ 0.51, 0.93 ]
Total (95% CI) 1442 1437 100.0 % 0.92 [ 0.82, 1.04 ]
Total events: 393 (Higher omega 6), 424 (Lower omega 6)
Heterogeneity: Chi2 = 4.80, df = 1 (P = 0.03); I2 =79%
Test for overall effect: Z = 1.35 (P = 0.18)
Test for subgroup differences: Not applicable
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Analysis 1.48. Comparison 1 Primary outcomes - higher omega-6 vs lower omega-6, Outcome 48 MACCEs
- sensitivity analyses.
Review: Omega-6 fats for the primary and secondary prevention of cardiovascular disease
Comparison: 1 Primary outcomes - higher omega-6 vs lower omega-6
Outcome: 48 MACCEs - sensitivity analyses
Study or subgroup Higher omega 6 Lower omega 6 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Low risk of bias
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Higher omega 6), 0 (Lower omega 6)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Pre-2010 or prospective trials registry entry
DART 1989 333/1018 337/1015 57.4 % 0.99 [ 0.87, 1.12 ]
Veterans Admin 1969 60/424 87/422 42.6 % 0.69 [ 0.51, 0.93 ]
Subtotal (95% CI) 1442 1437 100.0 % 0.84 [ 0.59, 1.20 ]
Total events: 393 (Higher omega 6), 424 (Lower omega 6)
Heterogeneity: Tau2 = 0.05; Chi2 = 4.80, df = 1 (P = 0.03); I2 =79%
Test for overall effect: Z = 0.94 (P = 0.35)
3 No commercial funding
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Higher omega 6), 0 (Lower omega 6)
Heterogeneity: not applicable
Test for overall effect: not applicable
4 Low risk of attention bias
Veterans Admin 1969 60/424 87/422 100.0 % 0.69 [ 0.51, 0.93 ]
Subtotal (95% CI) 424 422 100.0 % 0.69 [ 0.51, 0.93 ]
Total events: 60 (Higher omega 6), 87 (Lower omega 6)
Heterogeneity: not applicable
Test for overall effect: Z = 2.46 (P = 0.014)
5 Randomised 250+ participants
DART 1989 333/1018 337/1015 57.4 % 0.99 [ 0.87, 1.12 ]
Veterans Admin 1969 60/424 87/422 42.6 % 0.69 [ 0.51, 0.93 ]
Subtotal (95% CI) 1442 1437 100.0 % 0.84 [ 0.59, 1.20 ]
Total events: 393 (Higher omega 6), 424 (Lower omega 6)
Heterogeneity: Tau2 = 0.05; Chi2 = 4.80, df = 1 (P = 0.03); I2 =79%
Test for overall effect: Z = 0.94 (P = 0.35)
6 Randomised 100+ participants
DART 1989 333/1018 337/1015 57.4 % 0.99 [ 0.87, 1.12 ]
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(. . . Continued)
Study or subgroup Higher omega 6 Lower omega 6 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Veterans Admin 1969 60/424 87/422 42.6 % 0.69 [ 0.51, 0.93 ]
Subtotal (95% CI) 1442 1437 100.0 % 0.84 [ 0.59, 1.20 ]
Total events: 393 (Higher omega 6), 424 (Lower omega 6)
Heterogeneity: Tau2 = 0.05; Chi2 = 4.80, df = 1 (P = 0.03); I2 =79%
Test for overall effect: Z = 0.94 (P = 0.35)
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Analysis 1.49. Comparison 1 Primary outcomes - higher omega-6 vs lower omega-6, Outcome 49 MACCEs
- subgroup by intervention type.
Review: Omega-6 fats for the primary and secondary prevention of cardiovascular disease
Comparison: 1 Primary outcomes - higher omega-6 vs lower omega-6
Outcome: 49 MACCEs - subgroup by intervention type
Study or subgroup Higher omega 6 Lower omega 6 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Dietary advice
DART 1989 333/1018 337/1015 57.4 % 0.99 [ 0.87, 1.12 ]
Subtotal (95% CI) 1018 1015 57.4 % 0.99 [ 0.87, 1.12 ]
Total events: 333 (Higher omega 6), 337 (Lower omega 6)
Heterogeneity: not applicable
Test for overall effect: Z = 0.24 (P = 0.81)
2 Supplements (capsules)
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Higher omega 6), 0 (Lower omega 6)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Supplemental foods
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Higher omega 6), 0 (Lower omega 6)
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(. . . Continued)
Study or subgroup Higher omega 6 Lower omega 6 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Heterogeneity: not applicable
Test for overall effect: not applicable
4 Dietary advice plus supplement
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Higher omega 6), 0 (Lower omega 6)
Heterogeneity: not applicable
Test for overall effect: not applicable
5 Diet (all foods) provided
Veterans Admin 1969 60/424 87/422 42.6 % 0.69 [ 0.51, 0.93 ]
Subtotal (95% CI) 424 422 42.6 % 0.69 [ 0.51, 0.93 ]
Total events: 60 (Higher omega 6), 87 (Lower omega 6)
Heterogeneity: not applicable
Test for overall effect: Z = 2.46 (P = 0.014)
Total (95% CI) 1442 1437 100.0 % 0.84 [ 0.59, 1.20 ]
Total events: 393 (Higher omega 6), 424 (Lower omega 6)
Heterogeneity: Tau2 = 0.05; Chi2 = 4.80, df = 1 (P = 0.03); I2 =79%
Test for overall effect: Z = 0.94 (P = 0.35)
Test for subgroup differences: Chi2 = 4.76, df = 1 (P = 0.03), I2 =79%
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Analysis 1.50. Comparison 1 Primary outcomes - higher omega-6 vs lower omega-6, Outcome 50 MACCEs
- subgroup by replacement.
Review: Omega-6 fats for the primary and secondary prevention of cardiovascular disease
Comparison: 1 Primary outcomes - higher omega-6 vs lower omega-6
Outcome: 50 MACCEs - subgroup by replacement
Study or subgroup Higher omega 6 Lower omega 6 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 N-6 replacing SFA
DART 1989 333/1018 337/1015 57.4 % 0.99 [ 0.87, 1.12 ]
Veterans Admin 1969 60/424 87/422 42.6 % 0.69 [ 0.51, 0.93 ]
Subtotal (95% CI) 1442 1437 100.0 % 0.84 [ 0.59, 1.20 ]
Total events: 393 (Higher omega 6), 424 (Lower omega 6)
Heterogeneity: Tau2 = 0.05; Chi2 = 4.80, df = 1 (P = 0.03); I2 =79%
Test for overall effect: Z = 0.94 (P = 0.35)
2 N-6 replacing MUFA
Veterans Admin 1969 60/424 87/422 100.0 % 0.69 [ 0.51, 0.93 ]
Subtotal (95% CI) 424 422 100.0 % 0.69 [ 0.51, 0.93 ]
Total events: 60 (Higher omega 6), 87 (Lower omega 6)
Heterogeneity: not applicable
Test for overall effect: Z = 2.46 (P = 0.014)
3 N-6 replacing nil, low n-6
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Higher omega 6), 0 (Lower omega 6)
Heterogeneity: not applicable
Test for overall effect: not applicable
4 N-6 replacement unclear
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Higher omega 6), 0 (Lower omega 6)
Heterogeneity: not applicable
Test for overall effect: not applicable
5 N-6 replacing CHO
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Higher omega 6), 0 (Lower omega 6)
Heterogeneity: not applicable
Test for overall effect: not applicable
6 N-6 replacing protein
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Higher omega 6), 0 (Lower omega 6)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Chi2 = 0.77, df = 1 (P = 0.38), I2 =0.0%
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Analysis 1.51. Comparison 1 Primary outcomes - higher omega-6 vs lower omega-6, Outcome 51 MACCEs
- subgroup by baseline CVD risk.
Review: Omega-6 fats for the primary and secondary prevention of cardiovascular disease
Comparison: 1 Primary outcomes - higher omega-6 vs lower omega-6
Outcome: 51 MACCEs - subgroup by baseline CVD risk
Study or subgroup Higher omega 6 Lower omega 6 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Primary prevention - low CVD risk
Veterans Admin 1969 60/424 87/422 42.6 % 0.69 [ 0.51, 0.93 ]
Subtotal (95% CI) 424 422 42.6 % 0.69 [ 0.51, 0.93 ]
Total events: 60 (Higher omega 6), 87 (Lower omega 6)
Heterogeneity: not applicable
Test for overall effect: Z = 2.46 (P = 0.014)
2 Primary prevention - moderate CVD risk
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Higher omega 6), 0 (Lower omega 6)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Secondary prevention - existing CVD
DART 1989 333/1018 337/1015 57.4 % 0.99 [ 0.87, 1.12 ]
Subtotal (95% CI) 1018 1015 57.4 % 0.99 [ 0.87, 1.12 ]
Total events: 333 (Higher omega 6), 337 (Lower omega 6)
Heterogeneity: not applicable
Test for overall effect: Z = 0.24 (P = 0.81)
Total (95% CI) 1442 1437 100.0 % 0.84 [ 0.59, 1.20 ]
Total events: 393 (Higher omega 6), 424 (Lower omega 6)
Heterogeneity: Tau2 = 0.05; Chi2 = 4.80, df = 1 (P = 0.03); I2 =79%
Test for overall effect: Z = 0.94 (P = 0.35)
Test for subgroup differences: Chi2 = 4.76, df = 1 (P = 0.03), I2 =79%
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Analysis 1.52. Comparison 1 Primary outcomes - higher omega-6 vs lower omega-6, Outcome 52 MACCEs
- subgroup by omega-6 dose.
Review: Omega-6 fats for the primary and secondary prevention of cardiovascular disease
Comparison: 1 Primary outcomes - higher omega-6 vs lower omega-6
Outcome: 52 MACCEs - subgroup by omega-6 dose
Study or subgroup Higher omega 6 Lower omega 6 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 N-6 < 4% E
DART 1989 333/1018 337/1015 57.4 % 0.99 [ 0.87, 1.12 ]
Subtotal (95% CI) 1018 1015 57.4 % 0.99 [ 0.87, 1.12 ]
Total events: 333 (Higher omega 6), 337 (Lower omega 6)
Heterogeneity: not applicable
Test for overall effect: Z = 0.24 (P = 0.81)
2 N-6 4% to 12% E
Veterans Admin 1969 60/424 87/422 42.6 % 0.69 [ 0.51, 0.93 ]
Subtotal (95% CI) 424 422 42.6 % 0.69 [ 0.51, 0.93 ]
Total events: 60 (Higher omega 6), 87 (Lower omega 6)
Heterogeneity: not applicable
Test for overall effect: Z = 2.46 (P = 0.014)
3 N-6 > 12% E
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Higher omega 6), 0 (Lower omega 6)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 1442 1437 100.0 % 0.84 [ 0.59, 1.20 ]
Total events: 393 (Higher omega 6), 424 (Lower omega 6)
Heterogeneity: Tau2 = 0.05; Chi2 = 4.80, df = 1 (P = 0.03); I2 =79%
Test for overall effect: Z = 0.94 (P = 0.35)
Test for subgroup differences: Chi2 = 4.76, df = 1 (P = 0.03), I2 =79%
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Analysis 1.53. Comparison 1 Primary outcomes - higher omega-6 vs lower omega-6, Outcome 53 MACCEs
- subgroup by duration.
Review: Omega-6 fats for the primary and secondary prevention of cardiovascular disease
Comparison: 1 Primary outcomes - higher omega-6 vs lower omega-6
Outcome: 53 MACCEs - subgroup by duration
Study or subgroup Higher omega 6 Lower omega 6 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Medium duration 1 to < 2 years in study
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Higher omega 6), 0 (Lower omega 6)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Medium-long duration 2 to < 4 years
DART 1989 333/1018 337/1015 57.4 % 0.99 [ 0.87, 1.12 ]
Subtotal (95% CI) 1018 1015 57.4 % 0.99 [ 0.87, 1.12 ]
Total events: 333 (Higher omega 6), 337 (Lower omega 6)
Heterogeneity: not applicable
Test for overall effect: Z = 0.24 (P = 0.81)
3 Long duration 4+ years in study
Veterans Admin 1969 60/424 87/422 42.6 % 0.69 [ 0.51, 0.93 ]
Subtotal (95% CI) 424 422 42.6 % 0.69 [ 0.51, 0.93 ]
Total events: 60 (Higher omega 6), 87 (Lower omega 6)
Heterogeneity: not applicable
Test for overall effect: Z = 2.46 (P = 0.014)
Total (95% CI) 1442 1437 100.0 % 0.84 [ 0.59, 1.20 ]
Total events: 393 (Higher omega 6), 424 (Lower omega 6)
Heterogeneity: Tau2 = 0.05; Chi2 = 4.80, df = 1 (P = 0.03); I2 =79%
Test for overall effect: Z = 0.94 (P = 0.35)
Test for subgroup differences: Chi2 = 4.76, df = 1 (P = 0.03), I2 =79%
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Analysis 1.54. Comparison 1 Primary outcomes - higher omega-6 vs lower omega-6, Outcome 54 MACCEs
- subgroup by baseline omega-6.
Review: Omega-6 fats for the primary and secondary prevention of cardiovascular disease
Comparison: 1 Primary outcomes - higher omega-6 vs lower omega-6
Outcome: 54 MACCEs - subgroup by baseline omega-6
Study or subgroup Higher omega 6 Lower omega 6 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1≥ 8% E from n-6
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Higher omega 6), 0 (Lower omega 6)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 5% to < 8% E from n-6
DART 1989 333/1018 337/1015 57.4 % 0.99 [ 0.87, 1.12 ]
Subtotal (95% CI) 1018 1015 57.4 % 0.99 [ 0.87, 1.12 ]
Total events: 333 (Higher omega 6), 337 (Lower omega 6)
Heterogeneity: not applicable
Test for overall effect: Z = 0.24 (P = 0.81)
3 < 5% E from n-6
Veterans Admin 1969 60/424 87/422 42.6 % 0.69 [ 0.51, 0.93 ]
Subtotal (95% CI) 424 422 42.6 % 0.69 [ 0.51, 0.93 ]
Total events: 60 (Higher omega 6), 87 (Lower omega 6)
Heterogeneity: not applicable
Test for overall effect: Z = 2.46 (P = 0.014)
4 Baseline n-6 not reported
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Higher omega 6), 0 (Lower omega 6)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 1442 1437 100.0 % 0.84 [ 0.59, 1.20 ]
Total events: 393 (Higher omega 6), 424 (Lower omega 6)
Heterogeneity: Tau2 = 0.05; Chi2 = 4.80, df = 1 (P = 0.03); I2 =79%
Test for overall effect: Z = 0.94 (P = 0.35)
Test for subgroup differences: Chi2 = 4.76, df = 1 (P = 0.03), I2 =79%
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Analysis 1.55. Comparison 1 Primary outcomes - higher omega-6 vs lower omega-6, Outcome 55 Stroke:
fatal or non-fatal (overall).
Review: Omega-6 fats for the primary and secondary prevention of cardiovascular disease
Comparison: 1 Primary outcomes - higher omega-6 vs lower omega-6
Outcome: 55 Stroke: fatal or non-fatal (overall)
Study or subgroup Higher omega 6 Lower omega 6 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
DART 1989 10/1018 3/1015 29.2 % 3.32 [ 0.92, 12.04 ]
MRC 1968 2/199 0/194 10.4 % 4.88 [ 0.24, 100.89 ]
Sydney Diet-Heart 1978 2/221 2/237 19.3 % 1.07 [ 0.15, 7.55 ]
Veterans Admin 1969 13/424 22/422 41.1 % 0.59 [ 0.30, 1.15 ]
Total (95% CI) 1862 1868 100.0 % 1.36 [ 0.45, 4.11 ]
Total events: 27 (Higher omega 6), 27 (Lower omega 6)
Heterogeneity: Tau2 = 0.65; Chi2 = 6.79, df = 3 (P = 0.08); I2 =56%
Test for overall effect: Z = 0.55 (P = 0.58)
Test for subgroup differences: Not applicable
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Analysis 1.56. Comparison 1 Primary outcomes - higher omega-6 vs lower omega-6, Outcome 56 Stroke -
sensitivity analysis by fixed-effect analysis.
Review: Omega-6 fats for the primary and secondary prevention of cardiovascular disease
Comparison: 1 Primary outcomes - higher omega-6 vs lower omega-6
Outcome: 56 Stroke - sensitivity analysis by fixed-effect analysis
Study or subgroup Higher omega 6 Lower omega 6 Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
DART 1989 10/1018 3/1015 10.9 % 3.32 [ 0.92, 12.04 ]
MRC 1968 2/199 0/194 1.8 % 4.88 [ 0.24, 100.89 ]
Sydney Diet-Heart 1978 2/221 2/237 7.0 % 1.07 [ 0.15, 7.55 ]
Veterans Admin 1969 13/424 22/422 80.2 % 0.59 [ 0.30, 1.15 ]
Total (95% CI) 1862 1868 100.0 % 1.00 [ 0.59, 1.68 ]
Total events: 27 (Higher omega 6), 27 (Lower omega 6)
Heterogeneity: Chi2 = 6.79, df = 3 (P = 0.08); I2 =56%
Test for overall effect: Z = 0.00 (P = 1.0)
Test for subgroup differences: Not applicable
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Analysis 1.57. Comparison 1 Primary outcomes - higher omega-6 vs lower omega-6, Outcome 57 Stroke -
sensitivity analyses.
Review: Omega-6 fats for the primary and secondary prevention of cardiovascular disease
Comparison: 1 Primary outcomes - higher omega-6 vs lower omega-6
Outcome: 57 Stroke - sensitivity analyses
Study or subgroup Higher omega 6 Lower omega 6 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Low risk of bias
Sydney Diet-Heart 1978 2/221 2/237 100.0 % 1.07 [ 0.15, 7.55 ]
Subtotal (95% CI) 221 237 100.0 % 1.07 [ 0.15, 7.55 ]
Total events: 2 (Higher omega 6), 2 (Lower omega 6)
Heterogeneity: not applicable
Test for overall effect: Z = 0.07 (P = 0.94)
2 Pre-2010 or prospective trials registry entry
DART 1989 10/1018 3/1015 29.2 % 3.32 [ 0.92, 12.04 ]
MRC 1968 2/199 0/194 10.4 % 4.88 [ 0.24, 100.89 ]
Sydney Diet-Heart 1978 2/221 2/237 19.3 % 1.07 [ 0.15, 7.55 ]
Veterans Admin 1969 13/424 22/422 41.1 % 0.59 [ 0.30, 1.15 ]
Subtotal (95% CI) 1862 1868 100.0 % 1.36 [ 0.45, 4.11 ]
Total events: 27 (Higher omega 6), 27 (Lower omega 6)
Heterogeneity: Tau2 = 0.65; Chi2 = 6.79, df = 3 (P = 0.08); I2 =56%
Test for overall effect: Z = 0.55 (P = 0.58)
3 No commercial funding
MRC 1968 2/199 0/194 29.3 % 4.88 [ 0.24, 100.89 ]
Sydney Diet-Heart 1978 2/221 2/237 70.7 % 1.07 [ 0.15, 7.55 ]
Subtotal (95% CI) 420 431 100.0 % 1.67 [ 0.32, 8.62 ]
Total events: 4 (Higher omega 6), 2 (Lower omega 6)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.69, df = 1 (P = 0.40); I2 =0.0%
Test for overall effect: Z = 0.61 (P = 0.54)
4 Low risk of attention bias
Veterans Admin 1969 13/424 22/422 100.0 % 0.59 [ 0.30, 1.15 ]
Subtotal (95% CI) 424 422 100.0 % 0.59 [ 0.30, 1.15 ]
Total events: 13 (Higher omega 6), 22 (Lower omega 6)
Heterogeneity: not applicable
Test for overall effect: Z = 1.55 (P = 0.12)
5 Randomised 250+ participants
DART 1989 10/1018 3/1015 29.2 % 3.32 [ 0.92, 12.04 ]
MRC 1968 2/199 0/194 10.4 % 4.88 [ 0.24, 100.89 ]
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(. . . Continued)
Study or subgroup Higher omega 6 Lower omega 6 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Sydney Diet-Heart 1978 2/221 2/237 19.3 % 1.07 [ 0.15, 7.55 ]
Veterans Admin 1969 13/424 22/422 41.1 % 0.59 [ 0.30, 1.15 ]
Subtotal (95% CI) 1862 1868 100.0 % 1.36 [ 0.45, 4.11 ]
Total events: 27 (Higher omega 6), 27 (Lower omega 6)
Heterogeneity: Tau2 = 0.65; Chi2 = 6.79, df = 3 (P = 0.08); I2 =56%
Test for overall effect: Z = 0.55 (P = 0.58)
6 Randomised 100+ participants
DART 1989 10/1018 3/1015 29.2 % 3.32 [ 0.92, 12.04 ]
MRC 1968 2/199 0/194 10.4 % 4.88 [ 0.24, 100.89 ]
Sydney Diet-Heart 1978 2/221 2/237 19.3 % 1.07 [ 0.15, 7.55 ]
Veterans Admin 1969 13/424 22/422 41.1 % 0.59 [ 0.30, 1.15 ]
Subtotal (95% CI) 1862 1868 100.0 % 1.36 [ 0.45, 4.11 ]
Total events: 27 (Higher omega 6), 27 (Lower omega 6)
Heterogeneity: Tau2 = 0.65; Chi2 = 6.79, df = 3 (P = 0.08); I2 =56%
Test for overall effect: Z = 0.55 (P = 0.58)
0.01 0.1 1 10 100
Favours higher omega 6 Favours lower omega 6
171Omega-6 fats for the primary and secondary prevention of cardiovascular disease (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.58. Comparison 1 Primary outcomes - higher omega-6 vs lower omega-6, Outcome 58 Stroke -
subgroup by intervention type.
Review: Omega-6 fats for the primary and secondary prevention of cardiovascular disease
Comparison: 1 Primary outcomes - higher omega-6 vs lower omega-6
Outcome: 58 Stroke - subgroup by intervention type
Study or subgroup Higher omega 6 Lower omega 6 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Dietary advice
DART 1989 10/1018 3/1015 29.2 % 3.32 [ 0.92, 12.04 ]
Sydney Diet-Heart 1978 2/221 2/237 19.3 % 1.07 [ 0.15, 7.55 ]
Subtotal (95% CI) 1239 1252 48.5 % 2.36 [ 0.81, 6.91 ]
Total events: 12 (Higher omega 6), 5 (Lower omega 6)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.90, df = 1 (P = 0.34); I2 =0.0%
Test for overall effect: Z = 1.57 (P = 0.12)
2 Supplements (capsules)
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Higher omega 6), 0 (Lower omega 6)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Supplemental foods
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Higher omega 6), 0 (Lower omega 6)
Heterogeneity: not applicable
Test for overall effect: not applicable
4 Dietary advice plus supplement
MRC 1968 2/199 0/194 10.4 % 4.88 [ 0.24, 100.89 ]
Subtotal (95% CI) 199 194 10.4 % 4.88 [ 0.24, 100.89 ]
Total events: 2 (Higher omega 6), 0 (Lower omega 6)
Heterogeneity: not applicable
Test for overall effect: Z = 1.02 (P = 0.31)
5 Diet (all foods) provided
Veterans Admin 1969 13/424 22/422 41.1 % 0.59 [ 0.30, 1.15 ]
Subtotal (95% CI) 424 422 41.1 % 0.59 [ 0.30, 1.15 ]
Total events: 13 (Higher omega 6), 22 (Lower omega 6)
Heterogeneity: not applicable
Test for overall effect: Z = 1.55 (P = 0.12)
Total (95% CI) 1862 1868 100.0 % 1.36 [ 0.45, 4.11 ]
Total events: 27 (Higher omega 6), 27 (Lower omega 6)
Heterogeneity: Tau2 = 0.65; Chi2 = 6.79, df = 3 (P = 0.08); I2 =56%
Test for overall effect: Z = 0.55 (P = 0.58)
Test for subgroup differences: Chi2 = 5.81, df = 2 (P = 0.05), I2 =66%
0.01 0.1 1 10 100
Favours higher omega 6 Favours lower omega 6
172Omega-6 fats for the primary and secondary prevention of cardiovascular disease (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.59. Comparison 1 Primary outcomes - higher omega-6 vs lower omega-6, Outcome 59 Stroke -
subgroup by replacement.
Review: Omega-6 fats for the primary and secondary prevention of cardiovascular disease
Comparison: 1 Primary outcomes - higher omega-6 vs lower omega-6
Outcome: 59 Stroke - subgroup by replacement
Study or subgroup Higher omega 6 Lower omega 6 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 N-6 replacing SFA
DART 1989 10/1018 3/1015 29.2 % 3.32 [ 0.92, 12.04 ]
MRC 1968 2/199 0/194 10.4 % 4.88 [ 0.24, 100.89 ]
Sydney Diet-Heart 1978 2/221 2/237 19.3 % 1.07 [ 0.15, 7.55 ]
Veterans Admin 1969 13/424 22/422 41.1 % 0.59 [ 0.30, 1.15 ]
Subtotal (95% CI) 1862 1868 100.0 % 1.36 [ 0.45, 4.11 ]
Total events: 27 (Higher omega 6), 27 (Lower omega 6)
Heterogeneity: Tau2 = 0.65; Chi2 = 6.79, df = 3 (P = 0.08); I2 =56%
Test for overall effect: Z = 0.55 (P = 0.58)
2 N-6 replacing MUFA
Sydney Diet-Heart 1978 2/221 2/237 10.6 % 1.07 [ 0.15, 7.55 ]
Veterans Admin 1969 13/424 22/422 89.4 % 0.59 [ 0.30, 1.15 ]
Subtotal (95% CI) 645 659 100.0 % 0.63 [ 0.33, 1.18 ]
Total events: 15 (Higher omega 6), 24 (Lower omega 6)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.33, df = 1 (P = 0.57); I2 =0.0%
Test for overall effect: Z = 1.44 (P = 0.15)
3 N-6 replacing nil, low n-6
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Higher omega 6), 0 (Lower omega 6)
Heterogeneity: not applicable
Test for overall effect: not applicable
4 N-6 replacement unclear
MRC 1968 2/199 0/194 100.0 % 4.88 [ 0.24, 100.89 ]
Subtotal (95% CI) 199 194 100.0 % 4.88 [ 0.24, 100.89 ]
Total events: 2 (Higher omega 6), 0 (Lower omega 6)
Heterogeneity: not applicable
Test for overall effect: Z = 1.02 (P = 0.31)
5 N-6 replacing CHO
Subtotal (95% CI) 0 0 Not estimable
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(. . . Continued)
Study or subgroup Higher omega 6 Lower omega 6 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Total events: 0 (Higher omega 6), 0 (Lower omega 6)
Heterogeneity: not applicable
Test for overall effect: not applicable
6 N-6 replacing protein
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Higher omega 6), 0 (Lower omega 6)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Chi2 = 2.83, df = 2 (P = 0.24), I2 =29%
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Analysis 1.60. Comparison 1 Primary outcomes - higher omega-6 vs lower omega-6, Outcome 60 Stroke -
subgroup by baseline CVD risk.
Review: Omega-6 fats for the primary and secondary prevention of cardiovascular disease
Comparison: 1 Primary outcomes - higher omega-6 vs lower omega-6
Outcome: 60 Stroke - subgroup by baseline CVD risk
Study or subgroup Higher omega 6 Lower omega 6 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Primary prevention - low CVD risk
Veterans Admin 1969 13/424 22/422 41.1 % 0.59 [ 0.30, 1.15 ]
Subtotal (95% CI) 424 422 41.1 % 0.59 [ 0.30, 1.15 ]
Total events: 13 (Higher omega 6), 22 (Lower omega 6)
Heterogeneity: not applicable
Test for overall effect: Z = 1.55 (P = 0.12)
2 Primary prevention - moderate CVD risk
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Higher omega 6), 0 (Lower omega 6)
Heterogeneity: not applicable
Test for overall effect: not applicable
0.01 0.1 1 10 100
Favours higher omega 6 Favours lower omega 6
(Continued . . . )
174Omega-6 fats for the primary and secondary prevention of cardiovascular disease (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(. . . Continued)
Study or subgroup Higher omega 6 Lower omega 6 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
3 Secondary prevention - existing CVD
DART 1989 10/1018 3/1015 29.2 % 3.32 [ 0.92, 12.04 ]
MRC 1968 2/199 0/194 10.4 % 4.88 [ 0.24, 100.89 ]
Sydney Diet-Heart 1978 2/221 2/237 19.3 % 1.07 [ 0.15, 7.55 ]
Subtotal (95% CI) 1438 1446 58.9 % 2.56 [ 0.93, 7.04 ]
Total events: 14 (Higher omega 6), 5 (Lower omega 6)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.10, df = 2 (P = 0.58); I2 =0.0%
Test for overall effect: Z = 1.82 (P = 0.069)
Total (95% CI) 1862 1868 100.0 % 1.36 [ 0.45, 4.11 ]
Total events: 27 (Higher omega 6), 27 (Lower omega 6)
Heterogeneity: Tau2 = 0.65; Chi2 = 6.79, df = 3 (P = 0.08); I2 =56%
Test for overall effect: Z = 0.55 (P = 0.58)
Test for subgroup differences: Chi2 = 5.62, df = 1 (P = 0.02), I2 =82%
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Analysis 1.61. Comparison 1 Primary outcomes - higher omega-6 vs lower omega-6, Outcome 61 Stroke -
subgroup by omega-6 dose.
Review: Omega-6 fats for the primary and secondary prevention of cardiovascular disease
Comparison: 1 Primary outcomes - higher omega-6 vs lower omega-6
Outcome: 61 Stroke - subgroup by omega-6 dose
Study or subgroup Higher omega 6 Lower omega 6 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 N-6 < 4% E
DART 1989 10/1018 3/1015 29.2 % 3.32 [ 0.92, 12.04 ]
Subtotal (95% CI) 1018 1015 29.2 % 3.32 [ 0.92, 12.04 ]
Total events: 10 (Higher omega 6), 3 (Lower omega 6)
Heterogeneity: not applicable
Test for overall effect: Z = 1.83 (P = 0.067)
2 N-6≥ 4% to < 12% E
Sydney Diet-Heart 1978 2/221 2/237 19.3 % 1.07 [ 0.15, 7.55 ]
Veterans Admin 1969 13/424 22/422 41.1 % 0.59 [ 0.30, 1.15 ]
Subtotal (95% CI) 645 659 60.4 % 0.63 [ 0.33, 1.18 ]
Total events: 15 (Higher omega 6), 24 (Lower omega 6)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.33, df = 1 (P = 0.57); I2 =0.0%
Test for overall effect: Z = 1.44 (P = 0.15)
3 N-6≥ 12% E
MRC 1968 2/199 0/194 10.4 % 4.88 [ 0.24, 100.89 ]
Subtotal (95% CI) 199 194 10.4 % 4.88 [ 0.24, 100.89 ]
Total events: 2 (Higher omega 6), 0 (Lower omega 6)
Heterogeneity: not applicable
Test for overall effect: Z = 1.02 (P = 0.31)
Total (95% CI) 1862 1868 100.0 % 1.36 [ 0.45, 4.11 ]
Total events: 27 (Higher omega 6), 27 (Lower omega 6)
Heterogeneity: Tau2 = 0.65; Chi2 = 6.79, df = 3 (P = 0.08); I2 =56%
Test for overall effect: Z = 0.55 (P = 0.58)
Test for subgroup differences: Chi2 = 6.39, df = 2 (P = 0.04), I2 =69%
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Analysis 1.62. Comparison 1 Primary outcomes - higher omega-6 vs lower omega-6, Outcome 62 Stroke -
subgroup by duration.
Review: Omega-6 fats for the primary and secondary prevention of cardiovascular disease
Comparison: 1 Primary outcomes - higher omega-6 vs lower omega-6
Outcome: 62 Stroke - subgroup by duration
Study or subgroup Higher omega 6 Lower omega 6 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Medium duration 1 to < 2 years in study
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Higher omega 6), 0 (Lower omega 6)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Medium-long duration 2 to < 4 years
DART 1989 10/1018 3/1015 29.2 % 3.32 [ 0.92, 12.04 ]
Subtotal (95% CI) 1018 1015 29.2 % 3.32 [ 0.92, 12.04 ]
Total events: 10 (Higher omega 6), 3 (Lower omega 6)
Heterogeneity: not applicable
Test for overall effect: Z = 1.83 (P = 0.067)
3 Long duration 4+ years in study
MRC 1968 2/199 0/194 10.4 % 4.88 [ 0.24, 100.89 ]
Sydney Diet-Heart 1978 2/221 2/237 19.3 % 1.07 [ 0.15, 7.55 ]
Veterans Admin 1969 13/424 22/422 41.1 % 0.59 [ 0.30, 1.15 ]
Subtotal (95% CI) 844 853 70.8 % 0.69 [ 0.36, 1.33 ]
Total events: 17 (Higher omega 6), 24 (Lower omega 6)
Heterogeneity: Tau2 = 0.01; Chi2 = 2.03, df = 2 (P = 0.36); I2 =2%
Test for overall effect: Z = 1.11 (P = 0.27)
Total (95% CI) 1862 1868 100.0 % 1.36 [ 0.45, 4.11 ]
Total events: 27 (Higher omega 6), 27 (Lower omega 6)
Heterogeneity: Tau2 = 0.65; Chi2 = 6.79, df = 3 (P = 0.08); I2 =56%
Test for overall effect: Z = 0.55 (P = 0.58)
Test for subgroup differences: Chi2 = 4.55, df = 1 (P = 0.03), I2 =78%
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Analysis 1.63. Comparison 1 Primary outcomes - higher omega-6 vs lower omega-6, Outcome 63 Stroke -
subgroup by baseline omega-6.
Review: Omega-6 fats for the primary and secondary prevention of cardiovascular disease
Comparison: 1 Primary outcomes - higher omega-6 vs lower omega-6
Outcome: 63 Stroke - subgroup by baseline omega-6
Study or subgroup Higher omega 6 Lower omega 6 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1≥ 8% E from n-6
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Higher omega 6), 0 (Lower omega 6)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 5% to < 8% E from n-6
DART 1989 10/1018 3/1015 29.2 % 3.32 [ 0.92, 12.04 ]
Sydney Diet-Heart 1978 2/221 2/237 19.3 % 1.07 [ 0.15, 7.55 ]
Subtotal (95% CI) 1239 1252 48.5 % 2.36 [ 0.81, 6.91 ]
Total events: 12 (Higher omega 6), 5 (Lower omega 6)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.90, df = 1 (P = 0.34); I2 =0.0%
Test for overall effect: Z = 1.57 (P = 0.12)
3 < 5% E from n-6
Veterans Admin 1969 13/424 22/422 41.1 % 0.59 [ 0.30, 1.15 ]
Subtotal (95% CI) 424 422 41.1 % 0.59 [ 0.30, 1.15 ]
Total events: 13 (Higher omega 6), 22 (Lower omega 6)
Heterogeneity: not applicable
Test for overall effect: Z = 1.55 (P = 0.12)
4 Baseline n-6 not reported
MRC 1968 2/199 0/194 10.4 % 4.88 [ 0.24, 100.89 ]
Subtotal (95% CI) 199 194 10.4 % 4.88 [ 0.24, 100.89 ]
Total events: 2 (Higher omega 6), 0 (Lower omega 6)
Heterogeneity: not applicable
Test for overall effect: Z = 1.02 (P = 0.31)
Total (95% CI) 1862 1868 100.0 % 1.36 [ 0.45, 4.11 ]
Total events: 27 (Higher omega 6), 27 (Lower omega 6)
Heterogeneity: Tau2 = 0.65; Chi2 = 6.79, df = 3 (P = 0.08); I2 =56%
Test for overall effect: Z = 0.55 (P = 0.58)
Test for subgroup differences: Chi2 = 5.81, df = 2 (P = 0.05), I2 =66%
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Analysis 1.64. Comparison 1 Primary outcomes - higher omega-6 vs lower omega-6, Outcome 64 Stroke -
subgroup by stroke type.
Review: Omega-6 fats for the primary and secondary prevention of cardiovascular disease
Comparison: 1 Primary outcomes - higher omega-6 vs lower omega-6
Outcome: 64 Stroke - subgroup by stroke type
Study or subgroup Higher omega 6 Lower omega 6 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Ischaemic stroke
DART 1989 7/1018 1/1015 43.7 % 6.98 [ 0.86, 56.62 ]
Subtotal (95% CI) 1018 1015 43.7 % 6.98 [ 0.86, 56.62 ]
Total events: 7 (Higher omega 6), 1 (Lower omega 6)
Heterogeneity: not applicable
Test for overall effect: Z = 1.82 (P = 0.069)
2 Haemorrhagic stroke
DART 1989 3/1018 2/1015 56.3 % 1.50 [ 0.25, 8.93 ]
Subtotal (95% CI) 1018 1015 56.3 % 1.50 [ 0.25, 8.93 ]
Total events: 3 (Higher omega 6), 2 (Lower omega 6)
Heterogeneity: not applicable
Test for overall effect: Z = 0.44 (P = 0.66)
Total (95% CI) 2036 2030 100.0 % 2.93 [ 0.64, 13.49 ]
Total events: 10 (Higher omega 6), 3 (Lower omega 6)
Heterogeneity: Tau2 = 0.25; Chi2 = 1.25, df = 1 (P = 0.26); I2 =20%
Test for overall effect: Z = 1.38 (P = 0.17)
Test for subgroup differences: Chi2 = 1.20, df = 1 (P = 0.27), I2 =17%
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Analysis 1.65. Comparison 1 Primary outcomes - higher omega-6 vs lower omega-6, Outcome 65 Stroke -
subgroup by fatality.
Review: Omega-6 fats for the primary and secondary prevention of cardiovascular disease
Comparison: 1 Primary outcomes - higher omega-6 vs lower omega-6
Outcome: 65 Stroke - subgroup by fatality
Study or subgroup Higher omega 6 Lower omega 6 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Fatal stroke
Sydney Diet-Heart 1978 2/221 2/237 30.7 % 1.07 [ 0.15, 7.55 ]
Veterans Admin 1969 3/424 9/422 69.3 % 0.33 [ 0.09, 1.22 ]
Subtotal (95% CI) 645 659 100.0 % 0.48 [ 0.16, 1.40 ]
Total events: 5 (Higher omega 6), 11 (Lower omega 6)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.96, df = 1 (P = 0.33); I2 =0.0%
Test for overall effect: Z = 1.35 (P = 0.18)
2 Non-fatal stroke
Veterans Admin 1969 10/424 13/422 100.0 % 0.77 [ 0.34, 1.73 ]
Subtotal (95% CI) 424 422 100.0 % 0.77 [ 0.34, 1.73 ]
Total events: 10 (Higher omega 6), 13 (Lower omega 6)
Heterogeneity: not applicable
Test for overall effect: Z = 0.64 (P = 0.52)
Test for subgroup differences: Chi2 = 0.47, df = 1 (P = 0.49), I2 =0.0%
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Analysis 2.1. Comparison 2 Secondary outcomes - higher omega-6 vs lower omega-6, Outcome 1
Myocardial infarction (MI), overall.
Review: Omega-6 fats for the primary and secondary prevention of cardiovascular disease
Comparison: 2 Secondary outcomes - higher omega-6 vs lower omega-6
Outcome: 1 Myocardial infarction (MI), overall
Study or subgroup Higher omega 6 Lower omega 6 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
DART 1989 197/1018 225/1015 71.1 % 0.87 [ 0.74, 1.04 ]
GLAMT 1993 0/54 1/57 0.2 % 0.35 [ 0.01, 8.45 ]
Houtsmuller 1979 0/51 6/51 0.3 % 0.08 [ 0.00, 1.33 ]
MRC 1968 39/199 40/194 13.3 % 0.95 [ 0.64, 1.41 ]
NDHS Open 1st 1968 4/726 1/341 0.4 % 1.88 [ 0.21, 16.75 ]
Rose 1965 9/28 7/26 3.0 % 1.19 [ 0.52, 2.74 ]
Veterans Admin 1969 36/424 44/422 11.7 % 0.81 [ 0.54, 1.24 ]
Total (95% CI) 2500 2106 100.0 % 0.88 [ 0.76, 1.02 ]
Total events: 285 (Higher omega 6), 324 (Lower omega 6)
Heterogeneity: Tau2 = 0.0; Chi2 = 4.43, df = 6 (P = 0.62); I2 =0.0%
Test for overall effect: Z = 1.75 (P = 0.081)
Test for subgroup differences: Not applicable
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Analysis 2.2. Comparison 2 Secondary outcomes - higher omega-6 vs lower omega-6, Outcome 2 MI -
sensitivity analysis by fixed-effect analysis.
Review: Omega-6 fats for the primary and secondary prevention of cardiovascular disease
Comparison: 2 Secondary outcomes - higher omega-6 vs lower omega-6
Outcome: 2 MI - sensitivity analysis by fixed-effect analysis
Study or subgroup Higher omega 6 Lower omega 6 Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
DART 1989 197/1018 225/1015 69.0 % 0.87 [ 0.74, 1.04 ]
GLAMT 1993 0/54 1/57 0.4 % 0.35 [ 0.01, 8.45 ]
Houtsmuller 1979 0/51 6/51 2.0 % 0.08 [ 0.00, 1.33 ]
MRC 1968 39/199 40/194 12.4 % 0.95 [ 0.64, 1.41 ]
NDHS Open 1st 1968 4/726 1/341 0.4 % 1.88 [ 0.21, 16.75 ]
Rose 1965 9/28 7/26 2.2 % 1.19 [ 0.52, 2.74 ]
Veterans Admin 1969 36/424 44/422 13.5 % 0.81 [ 0.54, 1.24 ]
Total (95% CI) 2500 2106 100.0 % 0.87 [ 0.75, 1.00 ]
Total events: 285 (Higher omega 6), 324 (Lower omega 6)
Heterogeneity: Chi2 = 4.43, df = 6 (P = 0.62); I2 =0.0%
Test for overall effect: Z = 1.94 (P = 0.053)
Test for subgroup differences: Not applicable
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Analysis 2.3. Comparison 2 Secondary outcomes - higher omega-6 vs lower omega-6, Outcome 3 MI -
sensitivity analyses.
Review: Omega-6 fats for the primary and secondary prevention of cardiovascular disease
Comparison: 2 Secondary outcomes - higher omega-6 vs lower omega-6
Outcome: 3 MI - sensitivity analyses
Study or subgroup Higher omega 6 Lower omega 6 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Low summary risk of bias
NDHS Open 1st 1968 4/726 1/341 100.0 % 1.88 [ 0.21, 16.75 ]
Subtotal (95% CI) 726 341 100.0 % 1.88 [ 0.21, 16.75 ]
Total events: 4 (Higher omega 6), 1 (Lower omega 6)
Heterogeneity: not applicable
Test for overall effect: Z = 0.57 (P = 0.57)
2 Pre-2010 or prospective trials registry entry
DART 1989 197/1018 225/1015 71.1 % 0.87 [ 0.74, 1.04 ]
GLAMT 1993 0/54 1/57 0.2 % 0.35 [ 0.01, 8.45 ]
Houtsmuller 1979 0/51 6/51 0.3 % 0.08 [ 0.00, 1.33 ]
MRC 1968 39/199 40/194 13.3 % 0.95 [ 0.64, 1.41 ]
NDHS Open 1st 1968 4/726 1/341 0.4 % 1.88 [ 0.21, 16.75 ]
Rose 1965 9/28 7/26 3.0 % 1.19 [ 0.52, 2.74 ]
Veterans Admin 1969 36/424 44/422 11.7 % 0.81 [ 0.54, 1.24 ]
Subtotal (95% CI) 2500 2106 100.0 % 0.88 [ 0.76, 1.02 ]
Total events: 285 (Higher omega 6), 324 (Lower omega 6)
Heterogeneity: Tau2 = 0.0; Chi2 = 4.43, df = 6 (P = 0.62); I2 =0.0%
Test for overall effect: Z = 1.75 (P = 0.081)
3 No commercial funding
Houtsmuller 1979 0/51 6/51 15.0 % 0.08 [ 0.00, 1.33 ]
MRC 1968 39/199 40/194 62.9 % 0.95 [ 0.64, 1.41 ]
NDHS Open 1st 1968 4/726 1/341 22.0 % 1.88 [ 0.21, 16.75 ]
Subtotal (95% CI) 976 586 100.0 % 0.76 [ 0.22, 2.65 ]
Total events: 43 (Higher omega 6), 47 (Lower omega 6)
Heterogeneity: Tau2 = 0.61; Chi2 = 3.50, df = 2 (P = 0.17); I2 =43%
Test for overall effect: Z = 0.43 (P = 0.66)
4 Low risk of attention bias
GLAMT 1993 0/54 1/57 1.3 % 0.35 [ 0.01, 8.45 ]
NDHS Open 1st 1968 4/726 1/341 2.8 % 1.88 [ 0.21, 16.75 ]
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(. . . Continued)
Study or subgroup Higher omega 6 Lower omega 6 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Rose 1965 9/28 7/26 19.5 % 1.19 [ 0.52, 2.74 ]
Veterans Admin 1969 36/424 44/422 76.4 % 0.81 [ 0.54, 1.24 ]
Subtotal (95% CI) 1232 846 100.0 % 0.89 [ 0.62, 1.28 ]
Total events: 49 (Higher omega 6), 53 (Lower omega 6)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.43, df = 3 (P = 0.70); I2 =0.0%
Test for overall effect: Z = 0.63 (P = 0.53)
5 Randomised 250+ participants
DART 1989 197/1018 225/1015 73.7 % 0.87 [ 0.74, 1.04 ]
MRC 1968 39/199 40/194 13.7 % 0.95 [ 0.64, 1.41 ]
NDHS Open 1st 1968 4/726 1/341 0.4 % 1.88 [ 0.21, 16.75 ]
Veterans Admin 1969 36/424 44/422 12.2 % 0.81 [ 0.54, 1.24 ]
Subtotal (95% CI) 2367 1972 100.0 % 0.88 [ 0.76, 1.02 ]
Total events: 276 (Higher omega 6), 310 (Lower omega 6)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.75, df = 3 (P = 0.86); I2 =0.0%
Test for overall effect: Z = 1.73 (P = 0.083)
6 Randomised 100+ participants
DART 1989 197/1018 225/1015 73.3 % 0.87 [ 0.74, 1.04 ]
GLAMT 1993 0/54 1/57 0.2 % 0.35 [ 0.01, 8.45 ]
Houtsmuller 1979 0/51 6/51 0.3 % 0.08 [ 0.00, 1.33 ]
MRC 1968 39/199 40/194 13.7 % 0.95 [ 0.64, 1.41 ]
NDHS Open 1st 1968 4/726 1/341 0.4 % 1.88 [ 0.21, 16.75 ]
Veterans Admin 1969 36/424 44/422 12.1 % 0.81 [ 0.54, 1.24 ]
Subtotal (95% CI) 2472 2080 100.0 % 0.87 [ 0.75, 1.01 ]
Total events: 276 (Higher omega 6), 317 (Lower omega 6)
Heterogeneity: Tau2 = 0.0; Chi2 = 3.89, df = 5 (P = 0.57); I2 =0.0%
Test for overall effect: Z = 1.85 (P = 0.065)
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Analysis 2.4. Comparison 2 Secondary outcomes - higher omega-6 vs lower omega-6, Outcome 4 MI -
subgroup by intervention type.
Review: Omega-6 fats for the primary and secondary prevention of cardiovascular disease
Comparison: 2 Secondary outcomes - higher omega-6 vs lower omega-6
Outcome: 4 MI - subgroup by intervention type
Study or subgroup Higher omega 6 Lower omega 6 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Dietary advice
DART 1989 197/1018 225/1015 71.1 % 0.87 [ 0.74, 1.04 ]
Houtsmuller 1979 0/51 6/51 0.3 % 0.08 [ 0.00, 1.33 ]
Subtotal (95% CI) 1069 1066 71.4 % 0.40 [ 0.04, 3.75 ]
Total events: 197 (Higher omega 6), 231 (Lower omega 6)
Heterogeneity: Tau2 = 1.93; Chi2 = 2.82, df = 1 (P = 0.09); I2 =65%
Test for overall effect: Z = 0.81 (P = 0.42)
2 Supplements (capsules)
GLAMT 1993 0/54 1/57 0.2 % 0.35 [ 0.01, 8.45 ]
Subtotal (95% CI) 54 57 0.2 % 0.35 [ 0.01, 8.45 ]
Total events: 0 (Higher omega 6), 1 (Lower omega 6)
Heterogeneity: not applicable
Test for overall effect: Z = 0.64 (P = 0.52)
3 Supplemental foods
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Higher omega 6), 0 (Lower omega 6)
Heterogeneity: not applicable
Test for overall effect: not applicable
4 Dietary advice plus supplement
MRC 1968 39/199 40/194 13.3 % 0.95 [ 0.64, 1.41 ]
Rose 1965 9/28 7/26 3.0 % 1.19 [ 0.52, 2.74 ]
Subtotal (95% CI) 227 220 16.3 % 0.99 [ 0.69, 1.42 ]
Total events: 48 (Higher omega 6), 47 (Lower omega 6)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.24, df = 1 (P = 0.63); I2 =0.0%
Test for overall effect: Z = 0.05 (P = 0.96)
5 Diet (all foods) provided
NDHS Open 1st 1968 4/726 1/341 0.4 % 1.88 [ 0.21, 16.75 ]
Veterans Admin 1969 36/424 44/422 11.7 % 0.81 [ 0.54, 1.24 ]
Subtotal (95% CI) 1150 763 12.2 % 0.84 [ 0.56, 1.27 ]
Total events: 40 (Higher omega 6), 45 (Lower omega 6)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.54, df = 1 (P = 0.46); I2 =0.0%
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(. . . Continued)
Study or subgroup Higher omega 6 Lower omega 6 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Test for overall effect: Z = 0.84 (P = 0.40)
Total (95% CI) 2500 2106 100.0 % 0.88 [ 0.76, 1.02 ]
Total events: 285 (Higher omega 6), 324 (Lower omega 6)
Heterogeneity: Tau2 = 0.0; Chi2 = 4.43, df = 6 (P = 0.62); I2 =0.0%
Test for overall effect: Z = 1.75 (P = 0.081)
Test for subgroup differences: Chi2 = 1.24, df = 3 (P = 0.74), I2 =0.0%
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Analysis 2.5. Comparison 2 Secondary outcomes - higher omega-6 vs lower omega-6, Outcome 5 MI -
subgroup by replacement.
Review: Omega-6 fats for the primary and secondary prevention of cardiovascular disease
Comparison: 2 Secondary outcomes - higher omega-6 vs lower omega-6
Outcome: 5 MI - subgroup by replacement
Study or subgroup Higher omega 6 Lower omega 6 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 N-6 replacing SFA
DART 1989 197/1018 225/1015 73.5 % 0.87 [ 0.74, 1.04 ]
Houtsmuller 1979 0/51 6/51 0.3 % 0.08 [ 0.00, 1.33 ]
MRC 1968 39/199 40/194 13.7 % 0.95 [ 0.64, 1.41 ]
NDHS Open 1st 1968 4/726 1/341 0.4 % 1.88 [ 0.21, 16.75 ]
Veterans Admin 1969 36/424 44/422 12.1 % 0.81 [ 0.54, 1.24 ]
Subtotal (95% CI) 2418 2023 100.0 % 0.87 [ 0.75, 1.01 ]
Total events: 276 (Higher omega 6), 316 (Lower omega 6)
Heterogeneity: Tau2 = 0.0; Chi2 = 3.57, df = 4 (P = 0.47); I2 =0.0%
Test for overall effect: Z = 1.82 (P = 0.069)
2 N-6 replacing MUFA
NDHS Open 1st 1968 4/726 1/341 2.8 % 1.88 [ 0.21, 16.75 ]
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(. . . Continued)
Study or subgroup Higher omega 6 Lower omega 6 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Rose 1965 9/28 7/26 19.7 % 1.19 [ 0.52, 2.74 ]
Veterans Admin 1969 36/424 44/422 77.4 % 0.81 [ 0.54, 1.24 ]
Subtotal (95% CI) 1178 789 100.0 % 0.90 [ 0.62, 1.30 ]
Total events: 49 (Higher omega 6), 52 (Lower omega 6)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.10, df = 2 (P = 0.58); I2 =0.0%
Test for overall effect: Z = 0.56 (P = 0.57)
3 N-6 replacing nil, low n-6
GLAMT 1993 0/54 1/57 100.0 % 0.35 [ 0.01, 8.45 ]
Subtotal (95% CI) 54 57 100.0 % 0.35 [ 0.01, 8.45 ]
Total events: 0 (Higher omega 6), 1 (Lower omega 6)
Heterogeneity: not applicable
Test for overall effect: Z = 0.64 (P = 0.52)
4 N-6 replacement unclear
MRC 1968 39/199 40/194 100.0 % 0.95 [ 0.64, 1.41 ]
Subtotal (95% CI) 199 194 100.0 % 0.95 [ 0.64, 1.41 ]
Total events: 39 (Higher omega 6), 40 (Lower omega 6)
Heterogeneity: not applicable
Test for overall effect: Z = 0.25 (P = 0.80)
5 N-6 replacing CHO
Houtsmuller 1979 0/51 6/51 100.0 % 0.08 [ 0.00, 1.33 ]
Subtotal (95% CI) 51 51 100.0 % 0.08 [ 0.00, 1.33 ]
Total events: 0 (Higher omega 6), 6 (Lower omega 6)
Heterogeneity: not applicable
Test for overall effect: Z = 1.76 (P = 0.078)
6 N-6 replacing protein
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Higher omega 6), 0 (Lower omega 6)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Chi2 = 3.30, df = 4 (P = 0.51), I2 =0.0%
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Analysis 2.6. Comparison 2 Secondary outcomes - higher omega-6 vs lower omega-6, Outcome 6 MI -
subgroup by baseline CVD risk.
Review: Omega-6 fats for the primary and secondary prevention of cardiovascular disease
Comparison: 2 Secondary outcomes - higher omega-6 vs lower omega-6
Outcome: 6 MI - subgroup by baseline CVD risk
Study or subgroup Higher omega 6 Lower omega 6 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Primary prevention - low CVD risk
NDHS Open 1st 1968 4/726 1/341 0.4 % 1.88 [ 0.21, 16.75 ]
Veterans Admin 1969 36/424 44/422 11.7 % 0.81 [ 0.54, 1.24 ]
Subtotal (95% CI) 1150 763 12.2 % 0.84 [ 0.56, 1.27 ]
Total events: 40 (Higher omega 6), 45 (Lower omega 6)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.54, df = 1 (P = 0.46); I2 =0.0%
Test for overall effect: Z = 0.84 (P = 0.40)
2 Primary prevention - moderate CVD risk
GLAMT 1993 0/54 1/57 0.2 % 0.35 [ 0.01, 8.45 ]
Houtsmuller 1979 0/51 6/51 0.3 % 0.08 [ 0.00, 1.33 ]
Subtotal (95% CI) 105 108 0.5 % 0.15 [ 0.02, 1.26 ]
Total events: 0 (Higher omega 6), 7 (Lower omega 6)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.51, df = 1 (P = 0.47); I2 =0.0%
Test for overall effect: Z = 1.74 (P = 0.081)
3 Secondary prevention - existing CVD
DART 1989 197/1018 225/1015 71.1 % 0.87 [ 0.74, 1.04 ]
MRC 1968 39/199 40/194 13.3 % 0.95 [ 0.64, 1.41 ]
Rose 1965 9/28 7/26 3.0 % 1.19 [ 0.52, 2.74 ]
Subtotal (95% CI) 1245 1235 87.4 % 0.89 [ 0.77, 1.04 ]
Total events: 245 (Higher omega 6), 272 (Lower omega 6)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.63, df = 2 (P = 0.73); I2 =0.0%
Test for overall effect: Z = 1.43 (P = 0.15)
Total (95% CI) 2500 2106 100.0 % 0.88 [ 0.76, 1.02 ]
Total events: 285 (Higher omega 6), 324 (Lower omega 6)
Heterogeneity: Tau2 = 0.0; Chi2 = 4.43, df = 6 (P = 0.62); I2 =0.0%
Test for overall effect: Z = 1.75 (P = 0.081)
Test for subgroup differences: Chi2 = 2.73, df = 2 (P = 0.25), I2 =27%
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Analysis 2.7. Comparison 2 Secondary outcomes - higher omega-6 vs lower omega-6, Outcome 7 MI -
subgroup by omega-6 dose.
Review: Omega-6 fats for the primary and secondary prevention of cardiovascular disease
Comparison: 2 Secondary outcomes - higher omega-6 vs lower omega-6
Outcome: 7 MI - subgroup by omega-6 dose
Study or subgroup Higher omega 6 Lower omega 6 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 N-6 < 4% E
DART 1989 197/1018 225/1015 71.1 % 0.87 [ 0.74, 1.04 ]
GLAMT 1993 0/54 1/57 0.2 % 0.35 [ 0.01, 8.45 ]
Subtotal (95% CI) 1072 1072 71.3 % 0.87 [ 0.73, 1.03 ]
Total events: 197 (Higher omega 6), 226 (Lower omega 6)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.31, df = 1 (P = 0.58); I2 =0.0%
Test for overall effect: Z = 1.60 (P = 0.11)
2 N-6 4% to 12% E
Houtsmuller 1979 0/51 6/51 0.3 % 0.08 [ 0.00, 1.33 ]
NDHS Open 1st 1968 4/726 1/341 0.4 % 1.88 [ 0.21, 16.75 ]
Veterans Admin 1969 36/424 44/422 11.7 % 0.81 [ 0.54, 1.24 ]
Subtotal (95% CI) 1201 814 12.4 % 0.70 [ 0.21, 2.29 ]
Total events: 40 (Higher omega 6), 51 (Lower omega 6)
Heterogeneity: Tau2 = 0.52; Chi2 = 3.28, df = 2 (P = 0.19); I2 =39%
Test for overall effect: Z = 0.59 (P = 0.55)
3 N-6 > 12% E
MRC 1968 39/199 40/194 13.3 % 0.95 [ 0.64, 1.41 ]
Rose 1965 9/28 7/26 3.0 % 1.19 [ 0.52, 2.74 ]
Subtotal (95% CI) 227 220 16.3 % 0.99 [ 0.69, 1.42 ]
Total events: 48 (Higher omega 6), 47 (Lower omega 6)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.24, df = 1 (P = 0.63); I2 =0.0%
Test for overall effect: Z = 0.05 (P = 0.96)
Total (95% CI) 2500 2106 100.0 % 0.88 [ 0.76, 1.02 ]
Total events: 285 (Higher omega 6), 324 (Lower omega 6)
Heterogeneity: Tau2 = 0.0; Chi2 = 4.43, df = 6 (P = 0.62); I2 =0.0%
Test for overall effect: Z = 1.75 (P = 0.081)
Test for subgroup differences: Chi2 = 0.58, df = 2 (P = 0.75), I2 =0.0%
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Analysis 2.8. Comparison 2 Secondary outcomes - higher omega-6 vs lower omega-6, Outcome 8 MI -
subgroup by duration.
Review: Omega-6 fats for the primary and secondary prevention of cardiovascular disease
Comparison: 2 Secondary outcomes - higher omega-6 vs lower omega-6
Outcome: 8 MI - subgroup by duration
Study or subgroup Higher omega 6 Lower omega 6 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Medium duration 1 to < 2 years in study
GLAMT 1993 0/54 1/57 0.2 % 0.35 [ 0.01, 8.45 ]
NDHS Open 1st 1968 4/726 1/341 0.4 % 1.88 [ 0.21, 16.75 ]
Subtotal (95% CI) 780 398 0.6 % 1.10 [ 0.18, 6.65 ]
Total events: 4 (Higher omega 6), 2 (Lower omega 6)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.72, df = 1 (P = 0.39); I2 =0.0%
Test for overall effect: Z = 0.10 (P = 0.92)
2 Medium-long duration 2 to < 4 years in study
DART 1989 197/1018 225/1015 71.1 % 0.87 [ 0.74, 1.04 ]
Rose 1965 9/28 7/26 3.0 % 1.19 [ 0.52, 2.74 ]
Subtotal (95% CI) 1046 1041 74.1 % 0.88 [ 0.75, 1.04 ]
Total events: 206 (Higher omega 6), 232 (Lower omega 6)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.52, df = 1 (P = 0.47); I2 =0.0%
Test for overall effect: Z = 1.45 (P = 0.15)
3 Long duration 4+ years in study
Houtsmuller 1979 0/51 6/51 0.3 % 0.08 [ 0.00, 1.33 ]
MRC 1968 39/199 40/194 13.3 % 0.95 [ 0.64, 1.41 ]
Veterans Admin 1969 36/424 44/422 11.7 % 0.81 [ 0.54, 1.24 ]
Subtotal (95% CI) 674 667 25.3 % 0.84 [ 0.55, 1.27 ]
Total events: 75 (Higher omega 6), 90 (Lower omega 6)
Heterogeneity: Tau2 = 0.05; Chi2 = 3.17, df = 2 (P = 0.20); I2 =37%
Test for overall effect: Z = 0.83 (P = 0.41)
Total (95% CI) 2500 2106 100.0 % 0.88 [ 0.76, 1.02 ]
Total events: 285 (Higher omega 6), 324 (Lower omega 6)
Heterogeneity: Tau2 = 0.0; Chi2 = 4.43, df = 6 (P = 0.62); I2 =0.0%
Test for overall effect: Z = 1.75 (P = 0.081)
Test for subgroup differences: Chi2 = 0.11, df = 2 (P = 0.95), I2 =0.0%
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Analysis 2.9. Comparison 2 Secondary outcomes - higher omega-6 vs lower omega-6, Outcome 9 MI -
subgroup by statin use.
Review: Omega-6 fats for the primary and secondary prevention of cardiovascular disease
Comparison: 2 Secondary outcomes - higher omega-6 vs lower omega-6
Outcome: 9 MI - subgroup by statin use
Study or subgroup Higher omega 6 Lower omega 6 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1≥ 50% of control group on statins
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Higher omega 6), 0 (Lower omega 6)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 < 50% of control group on statins
DART 1989 197/1018 225/1015 71.1 % 0.87 [ 0.74, 1.04 ]
Houtsmuller 1979 0/51 6/51 0.3 % 0.08 [ 0.00, 1.33 ]
MRC 1968 39/199 40/194 13.3 % 0.95 [ 0.64, 1.41 ]
NDHS Open 1st 1968 4/726 1/341 0.4 % 1.88 [ 0.21, 16.75 ]
Rose 1965 9/28 7/26 3.0 % 1.19 [ 0.52, 2.74 ]
Veterans Admin 1969 36/424 44/422 11.7 % 0.81 [ 0.54, 1.24 ]
Subtotal (95% CI) 2446 2049 99.8 % 0.88 [ 0.76, 1.02 ]
Total events: 285 (Higher omega 6), 323 (Lower omega 6)
Heterogeneity: Tau2 = 0.0; Chi2 = 4.10, df = 5 (P = 0.53); I2 =0.0%
Test for overall effect: Z = 1.72 (P = 0.085)
3 Statin use unclear
GLAMT 1993 0/54 1/57 0.2 % 0.35 [ 0.01, 8.45 ]
Subtotal (95% CI) 54 57 0.2 % 0.35 [ 0.01, 8.45 ]
Total events: 0 (Higher omega 6), 1 (Lower omega 6)
Heterogeneity: not applicable
Test for overall effect: Z = 0.64 (P = 0.52)
Total (95% CI) 2500 2106 100.0 % 0.88 [ 0.76, 1.02 ]
Total events: 285 (Higher omega 6), 324 (Lower omega 6)
Heterogeneity: Tau2 = 0.0; Chi2 = 4.43, df = 6 (P = 0.62); I2 =0.0%
Test for overall effect: Z = 1.75 (P = 0.081)
Test for subgroup differences: Chi2 = 0.32, df = 1 (P = 0.57), I2 =0.0%
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Analysis 2.10. Comparison 2 Secondary outcomes - higher omega-6 vs lower omega-6, Outcome 10 MI -
subgroup by baseline omega-6.
Review: Omega-6 fats for the primary and secondary prevention of cardiovascular disease
Comparison: 2 Secondary outcomes - higher omega-6 vs lower omega-6
Outcome: 10 MI - subgroup by baseline omega-6
Study or subgroup Higher omega 6 Lower omega 6 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1≥ 8% E from n-6
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Higher omega 6), 0 (Lower omega 6)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 5% to < 8% E from n-6
DART 1989 197/1018 225/1015 71.1 % 0.87 [ 0.74, 1.04 ]
Subtotal (95% CI) 1018 1015 71.1 % 0.87 [ 0.74, 1.04 ]
Total events: 197 (Higher omega 6), 225 (Lower omega 6)
Heterogeneity: not applicable
Test for overall effect: Z = 1.56 (P = 0.12)
3 < 5% E from omega 6
NDHS Open 1st 1968 4/726 1/341 0.4 % 1.88 [ 0.21, 16.75 ]
Veterans Admin 1969 36/424 44/422 11.7 % 0.81 [ 0.54, 1.24 ]
Subtotal (95% CI) 1150 763 12.2 % 0.84 [ 0.56, 1.27 ]
Total events: 40 (Higher omega 6), 45 (Lower omega 6)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.54, df = 1 (P = 0.46); I2 =0.0%
Test for overall effect: Z = 0.84 (P = 0.40)
4 Baseline n-6 not reported
GLAMT 1993 0/54 1/57 0.2 % 0.35 [ 0.01, 8.45 ]
Houtsmuller 1979 0/51 6/51 0.3 % 0.08 [ 0.00, 1.33 ]
MRC 1968 39/199 40/194 13.3 % 0.95 [ 0.64, 1.41 ]
Rose 1965 9/28 7/26 3.0 % 1.19 [ 0.52, 2.74 ]
Subtotal (95% CI) 332 328 16.7 % 0.90 [ 0.52, 1.57 ]
Total events: 48 (Higher omega 6), 54 (Lower omega 6)
Heterogeneity: Tau2 = 0.08; Chi2 = 3.88, df = 3 (P = 0.28); I2 =23%
Test for overall effect: Z = 0.36 (P = 0.72)
Total (95% CI) 2500 2106 100.0 % 0.88 [ 0.76, 1.02 ]
Total events: 285 (Higher omega 6), 324 (Lower omega 6)
Heterogeneity: Tau2 = 0.0; Chi2 = 4.43, df = 6 (P = 0.62); I2 =0.0%
Test for overall effect: Z = 1.75 (P = 0.081)
Test for subgroup differences: Chi2 = 0.05, df = 2 (P = 0.98), I2 =0.0%
0.5 0.7 1 1.5 2
Favours higher omega 6 Favours lower omega 6
192Omega-6 fats for the primary and secondary prevention of cardiovascular disease (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 2.11. Comparison 2 Secondary outcomes - higher omega-6 vs lower omega-6, Outcome 11 MI -
subgroup by sex.
Review: Omega-6 fats for the primary and secondary prevention of cardiovascular disease
Comparison: 2 Secondary outcomes - higher omega-6 vs lower omega-6
Outcome: 11 MI - subgroup by sex
Study or subgroup Higher omega 6 Lower omega 6 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Men and women
GLAMT 1993 0/54 1/57 0.2 % 0.35 [ 0.01, 8.45 ]
Houtsmuller 1979 0/51 6/51 0.3 % 0.08 [ 0.00, 1.33 ]
Subtotal (95% CI) 105 108 0.5 % 0.15 [ 0.02, 1.26 ]
Total events: 0 (Higher omega 6), 7 (Lower omega 6)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.51, df = 1 (P = 0.47); I2 =0.0%
Test for overall effect: Z = 1.74 (P = 0.081)
2 Sex not reported
Rose 1965 9/28 7/26 3.0 % 1.19 [ 0.52, 2.74 ]
Subtotal (95% CI) 28 26 3.0 % 1.19 [ 0.52, 2.74 ]
Total events: 9 (Higher omega 6), 7 (Lower omega 6)
Heterogeneity: not applicable
Test for overall effect: Z = 0.42 (P = 0.68)
3 Men only
DART 1989 197/1018 225/1015 71.1 % 0.87 [ 0.74, 1.04 ]
MRC 1968 39/199 40/194 13.3 % 0.95 [ 0.64, 1.41 ]
NDHS Open 1st 1968 4/726 1/341 0.4 % 1.88 [ 0.21, 16.75 ]
Veterans Admin 1969 36/424 44/422 11.7 % 0.81 [ 0.54, 1.24 ]
Subtotal (95% CI) 2367 1972 96.6 % 0.88 [ 0.76, 1.02 ]
Total events: 276 (Higher omega 6), 310 (Lower omega 6)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.75, df = 3 (P = 0.86); I2 =0.0%
Test for overall effect: Z = 1.73 (P = 0.083)
Total (95% CI) 2500 2106 100.0 % 0.88 [ 0.76, 1.02 ]
Total events: 285 (Higher omega 6), 324 (Lower omega 6)
Heterogeneity: Tau2 = 0.0; Chi2 = 4.43, df = 6 (P = 0.62); I2 =0.0%
Test for overall effect: Z = 1.75 (P = 0.081)
Test for subgroup differences: Chi2 = 3.16, df = 2 (P = 0.21), I2 =37%
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Analysis 2.12. Comparison 2 Secondary outcomes - higher omega-6 vs lower omega-6, Outcome 12 Angina.
Review: Omega-6 fats for the primary and secondary prevention of cardiovascular disease
Comparison: 2 Secondary outcomes - higher omega-6 vs lower omega-6
Outcome: 12 Angina
Study or subgroup Higher omega 6 Lower omega 6 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Houtsmuller 1979 8/51 24/51 38.3 % 0.33 [ 0.17, 0.67 ]
MRC 1968 1/199 4/194 11.4 % 0.24 [ 0.03, 2.16 ]
Rose 1965 3/28 2/26 16.3 % 1.39 [ 0.25, 7.68 ]
Veterans Admin 1969 11/424 10/422 34.0 % 1.09 [ 0.47, 2.55 ]
Total (95% CI) 702 693 100.0 % 0.61 [ 0.27, 1.40 ]
Total events: 23 (Higher omega 6), 40 (Lower omega 6)
Heterogeneity: Tau2 = 0.34; Chi2 = 6.18, df = 3 (P = 0.10); I2 =51%
Test for overall effect: Z = 1.17 (P = 0.24)
Test for subgroup differences: Not applicable
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Analysis 2.13. Comparison 2 Secondary outcomes - higher omega-6 vs lower omega-6, Outcome 13 Sudden
cardiac death.
Review: Omega-6 fats for the primary and secondary prevention of cardiovascular disease
Comparison: 2 Secondary outcomes - higher omega-6 vs lower omega-6
Outcome: 13 Sudden cardiac death
Study or subgroup Higher omega 6 Lower omega 6 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
MRC 1968 8/199 7/194 23.4 % 1.11 [ 0.41, 3.01 ]
Rose 1965 3/28 2/26 7.9 % 1.39 [ 0.25, 7.68 ]
Veterans Admin 1969 18/424 27/422 68.6 % 0.66 [ 0.37, 1.19 ]
Total (95% CI) 651 642 100.0 % 0.79 [ 0.49, 1.29 ]
Total events: 29 (Higher omega 6), 36 (Lower omega 6)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.23, df = 2 (P = 0.54); I2 =0.0%
Test for overall effect: Z = 0.94 (P = 0.35)
Test for subgroup differences: Not applicable
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Analysis 2.14. Comparison 2 Secondary outcomes - higher omega-6 vs lower omega-6, Outcome 14 Heart
failure.
Review: Omega-6 fats for the primary and secondary prevention of cardiovascular disease
Comparison: 2 Secondary outcomes - higher omega-6 vs lower omega-6
Outcome: 14 Heart failure
Study or subgroup Higher omega 6 Lower omega 6 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
DART 1989 3/1018 6/1015 84.2 % 0.50 [ 0.13, 1.99 ]
MRC 1968 1/199 0/194 15.8 % 2.93 [ 0.12, 71.37 ]
Total (95% CI) 1217 1209 100.0 % 0.66 [ 0.19, 2.35 ]
Total events: 4 (Higher omega 6), 6 (Lower omega 6)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.00, df = 1 (P = 0.32); I2 =0.0%
Test for overall effect: Z = 0.64 (P = 0.52)
Test for subgroup differences: Not applicable
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Analysis 2.15. Comparison 2 Secondary outcomes - higher omega-6 vs lower omega-6, Outcome 15
Revascularisation - angioplasty or coronary artery bypass grafting.
Review: Omega-6 fats for the primary and secondary prevention of cardiovascular disease
Comparison: 2 Secondary outcomes - higher omega-6 vs lower omega-6
Outcome: 15 Revascularisation - angioplasty or coronary artery bypass grafting
Study or subgroup Higher omega 6 Lower omega 6 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Vijayakumar 2014 2/100 2/100 100.0 % 1.00 [ 0.14, 6.96 ]
Total (95% CI) 100 100 100.0 % 1.00 [ 0.14, 6.96 ]
Total events: 2 (Higher omega 6), 2 (Lower omega 6)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Test for subgroup differences: Not applicable
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Analysis 2.16. Comparison 2 Secondary outcomes - higher omega-6 vs lower omega-6, Outcome 16
Peripheral arterial disease events.
Review: Omega-6 fats for the primary and secondary prevention of cardiovascular disease
Comparison: 2 Secondary outcomes - higher omega-6 vs lower omega-6
Outcome: 16 Peripheral arterial disease events
Study or subgroup Higher omega 6 Lower omega 6 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
DART 1989 0/1018 1/1015 2.6 % 0.33 [ 0.01, 8.15 ]
NDHS Open 1st 1968 1/726 0/341 2.6 % 1.41 [ 0.06, 34.55 ]
Veterans Admin 1969 26/424 25/422 94.8 % 1.04 [ 0.61, 1.76 ]
Total (95% CI) 2168 1778 100.0 % 1.01 [ 0.60, 1.70 ]
Total events: 27 (Higher omega 6), 26 (Lower omega 6)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.51, df = 2 (P = 0.77); I2 =0.0%
Test for overall effect: Z = 0.05 (P = 0.96)
Test for subgroup differences: Not applicable
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Analysis 2.17. Comparison 2 Secondary outcomes - higher omega-6 vs lower omega-6, Outcome 17 Serum
total cholesterol (TC), mmol/L.
Review: Omega-6 fats for the primary and secondary prevention of cardiovascular disease
Comparison: 2 Secondary outcomes - higher omega-6 vs lower omega-6
Outcome: 17 Serum total cholesterol (TC), mmol/L
Study or subgroup Higher omega 6 Lower omega 6
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
DART 1989 855 6.29 (1.13) 860 6.55 (1.1) 15.4 % -0.26 [ -0.37, -0.15 ]
Houtsmuller 1979 48 6.43 (0.65) 48 6.9 (0.81) 11.0 % -0.47 [ -0.76, -0.18 ]
Mendis 2001 (1) 26 -0.42 (0.5447) 28 -0.58 (0.7221) 9.9 % 0.16 [ -0.18, 0.50 ]
MRC 1968 (2) 88 -1.11 (0) 89 -0.47 (0) Not estimable
NDHS Faribault 1968 (3) 50 -1.09 (0.73) 51 -0.18 (0.59) 11.9 % -0.91 [ -1.17, -0.65 ]
NDHS Open 1st 1968 (4) 311 -0.7 (0.69) 309 -0.25 (0.6) 15.4 % -0.45 [ -0.55, -0.35 ]
Rose 1965 (5) 13 -0.51 (1.25) 13 -0.02 (0.94) 3.2 % -0.49 [ -1.34, 0.36 ]
Sydney Diet-Heart 1978 221 6.5 (1.2) 237 6.8 (1.1) 13.1 % -0.30 [ -0.51, -0.09 ]
Veterans Admin 1969 423 4.93 (3.72) 420 5.3 (1.87) 8.7 % -0.37 [ -0.77, 0.03 ]
Vijayakumar 2014 94 3.92 (1.15) 96 3.86 (0.74) 11.4 % 0.06 [ -0.22, 0.34 ]
Total (95% CI) 2129 2151 100.0 % -0.33 [ -0.50, -0.16 ]
Heterogeneity: Tau2 = 0.05; Chi2 = 42.56, df = 8 (P<0.00001); I2 =81%
Test for overall effect: Z = 3.84 (P = 0.00012)
Test for subgroup differences: Not applicable
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Analysis 2.18. Comparison 2 Secondary outcomes - higher omega-6 vs lower omega-6, Outcome 18 TC,
mmol/L - sensitivity analysis by fixed-effect analysis.
Review: Omega-6 fats for the primary and secondary prevention of cardiovascular disease
Comparison: 2 Secondary outcomes - higher omega-6 vs lower omega-6
Outcome: 18 TC, mmol/L - sensitivity analysis by fixed-effect analysis
Study or subgroup Higher omega 6 Lower omega 6
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
DART 1989 855 6.29 (1.13) 860 6.55 (1.1) 33.9 % -0.26 [ -0.37, -0.15 ]
Houtsmuller 1979 48 6.43 (0.65) 48 6.9 (0.81) 4.4 % -0.47 [ -0.76, -0.18 ]
Mendis 2001 (1) 26 -0.42 (0.5447) 28 -0.58 (0.7221) 3.3 % 0.16 [ -0.18, 0.50 ]
MRC 1968 (2) 88 -1.11 (0) 89 -0.47 (0) Not estimable
NDHS Faribault 1968 (3) 50 -1.09 (0.73) 51 -0.18 (0.59) 5.6 % -0.91 [ -1.17, -0.65 ]
NDHS Open 1st 1968 (4) 311 -0.7 (0.69) 309 -0.25 (0.6) 36.5 % -0.45 [ -0.55, -0.35 ]
Rose 1965 (5) 13 -0.51 (1.25) 13 -0.02 (0.94) 0.5 % -0.49 [ -1.34, 0.36 ]
Sydney Diet-Heart 1978 221 6.5 (1.2) 237 6.8 (1.1) 8.5 % -0.30 [ -0.51, -0.09 ]
Veterans Admin 1969 423 4.93 (3.72) 420 5.3 (1.87) 2.4 % -0.37 [ -0.77, 0.03 ]
Vijayakumar 2014 94 3.92 (1.15) 96 3.86 (0.74) 5.0 % 0.06 [ -0.22, 0.34 ]
Total (95% CI) 2129 2151 100.0 % -0.35 [ -0.41, -0.29 ]
Heterogeneity: Chi2 = 42.56, df = 8 (P<0.00001); I2 =81%
Test for overall effect: Z = 11.24 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 2.19. Comparison 2 Secondary outcomes - higher omega-6 vs lower omega-6, Outcome 19 TC,
mmol/L - sensitivity analyses.
Review: Omega-6 fats for the primary and secondary prevention of cardiovascular disease
Comparison: 2 Secondary outcomes - higher omega-6 vs lower omega-6
Outcome: 19 TC, mmol/L - sensitivity analyses
Study or subgroup Higher omega 6 Lower omega 6
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Studies at low risk of bias
NDHS Faribault 1968 50 -1.09 (0.73) 51 -0.18 (0.59) 29.7 % -0.91 [ -1.17, -0.65 ]
NDHS Open 1st 1968 311 -0.7 (0.69) 309 -0.25 (0.6) 37.8 % -0.45 [ -0.55, -0.35 ]
Sydney Diet-Heart 1978 221 6.5 (1.2) 237 6.8 (1.1) 32.5 % -0.30 [ -0.51, -0.09 ]
Subtotal (95% CI) 582 597 100.0 % -0.54 [ -0.82, -0.26 ]
Heterogeneity: Tau2 = 0.05; Chi2 = 13.69, df = 2 (P = 0.001); I2 =85%
Test for overall effect: Z = 3.75 (P = 0.00018)
2 Pre-2010 or prospective trials registry entry
DART 1989 855 6.29 (1.13) 860 6.55 (1.1) 18.0 % -0.26 [ -0.37, -0.15 ]
Houtsmuller 1979 48 6.43 (0.65) 48 6.9 (0.81) 12.2 % -0.47 [ -0.76, -0.18 ]
Mendis 2001 26 -0.42 (0.5447) 28 -0.58 (0.7221) 10.9 % 0.16 [ -0.18, 0.50 ]
MRC 1968 88 -1.11 (0) 89 -0.47 (0) Not estimable
NDHS Faribault 1968 50 -1.09 (0.73) 51 -0.18 (0.59) 13.3 % -0.91 [ -1.17, -0.65 ]
NDHS Open 1st 1968 311 -0.7 (0.69) 309 -0.25 (0.6) 18.1 % -0.45 [ -0.55, -0.35 ]
Rose 1965 13 -0.51 (1.25) 13 -0.02 (0.94) 3.3 % -0.49 [ -1.34, 0.36 ]
Sydney Diet-Heart 1978 221 6.5 (1.2) 237 6.8 (1.1) 14.9 % -0.30 [ -0.51, -0.09 ]
Veterans Admin 1969 423 4.93 (3.72) 420 5.3 (1.87) 9.4 % -0.37 [ -0.77, 0.03 ]
Subtotal (95% CI) 2035 2055 100.0 % -0.38 [ -0.55, -0.22 ]
Heterogeneity: Tau2 = 0.04; Chi2 = 33.50, df = 7 (P = 0.00002); I2 =79%
Test for overall effect: Z = 4.45 (P < 0.00001)
3 No commercial funding
Houtsmuller 1979 48 6.43 (0.65) 48 6.9 (0.81) 18.5 % -0.47 [ -0.76, -0.18 ]
Mendis 2001 26 -0.42 (0.5447) 28 -0.58 (0.7221) 17.1 % 0.16 [ -0.18, 0.50 ]
MRC 1968 88 -1.11 (0) 89 -0.47 (0) Not estimable
NDHS Faribault 1968 50 -1.09 (0.73) 51 -0.18 (0.59) 19.6 % -0.91 [ -1.17, -0.65 ]
NDHS Open 1st 1968 311 -0.7 (0.69) 309 -0.25 (0.6) 23.8 % -0.45 [ -0.55, -0.35 ]
Sydney Diet-Heart 1978 221 6.5 (1.2) 237 6.8 (1.1) 21.1 % -0.30 [ -0.51, -0.09 ]
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(. . . Continued)
Study or subgroup Higher omega 6 Lower omega 6
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Subtotal (95% CI) 744 762 100.0 % -0.41 [ -0.66, -0.16 ]
Heterogeneity: Tau2 = 0.07; Chi2 = 26.38, df = 4 (P = 0.00003); I2 =85%
Test for overall effect: Z = 3.18 (P = 0.0015)
4 Low risk of attention bias
Mendis 2001 26 -0.42 (0.5447) 28 -0.58 (0.7221) 17.2 % 0.16 [ -0.18, 0.50 ]
NDHS Faribault 1968 50 -1.09 (0.73) 51 -0.18 (0.59) 18.8 % -0.91 [ -1.17, -0.65 ]
NDHS Open 1st 1968 311 -0.7 (0.69) 309 -0.25 (0.6) 21.2 % -0.45 [ -0.55, -0.35 ]
Rose 1965 13 -0.51 (1.25) 13 -0.02 (0.94) 8.3 % -0.49 [ -1.34, 0.36 ]
Veterans Admin 1969 423 4.93 (3.72) 420 5.3 (1.87) 16.0 % -0.37 [ -0.77, 0.03 ]
Vijayakumar 2014 94 3.92 (1.15) 96 3.86 (0.74) 18.5 % 0.06 [ -0.22, 0.34 ]
Subtotal (95% CI) 917 917 100.0 % -0.33 [ -0.64, -0.02 ]
Heterogeneity: Tau2 = 0.12; Chi2 = 36.96, df = 5 (P<0.00001); I2 =86%
Test for overall effect: Z = 2.06 (P = 0.039)
5 Randomised 250+ participants
DART 1989 855 6.29 (1.13) 860 6.55 (1.1) 36.1 % -0.26 [ -0.37, -0.15 ]
MRC 1968 88 -1.11 (0) 89 -0.47 (0) Not estimable
NDHS Open 1st 1968 311 -0.7 (0.69) 309 -0.25 (0.6) 36.8 % -0.45 [ -0.55, -0.35 ]
Sydney Diet-Heart 1978 221 6.5 (1.2) 237 6.8 (1.1) 19.5 % -0.30 [ -0.51, -0.09 ]
Veterans Admin 1969 423 4.93 (3.72) 420 5.3 (1.87) 7.6 % -0.37 [ -0.77, 0.03 ]
Subtotal (95% CI) 1898 1915 100.0 % -0.35 [ -0.47, -0.23 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 6.72, df = 3 (P = 0.08); I2 =55%
Test for overall effect: Z = 5.69 (P < 0.00001)
6 Randomised 100+ participants
DART 1989 855 6.29 (1.13) 860 6.55 (1.1) 20.5 % -0.26 [ -0.37, -0.15 ]
MRC 1968 88 -1.11 (0) 89 -0.47 (0) Not estimable
NDHS Faribault 1968 50 -1.09 (0.73) 51 -0.18 (0.59) 15.6 % -0.91 [ -1.17, -0.65 ]
NDHS Open 1st 1968 311 -0.7 (0.69) 309 -0.25 (0.6) 20.6 % -0.45 [ -0.55, -0.35 ]
Sydney Diet-Heart 1978 221 6.5 (1.2) 237 6.8 (1.1) 17.2 % -0.30 [ -0.51, -0.09 ]
Veterans Admin 1969 423 4.93 (3.72) 420 5.3 (1.87) 11.2 % -0.37 [ -0.77, 0.03 ]
Vijayakumar 2014 94 3.92 (1.15) 96 3.86 (0.74) 15.0 % 0.06 [ -0.22, 0.34 ]
Subtotal (95% CI) 2042 2062 100.0 % -0.37 [ -0.56, -0.18 ]
Heterogeneity: Tau2 = 0.04; Chi2 = 32.97, df = 5 (P<0.00001); I2 =85%
Test for overall effect: Z = 3.82 (P = 0.00014)
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Analysis 2.20. Comparison 2 Secondary outcomes - higher omega-6 vs lower omega-6, Outcome 20 TC,
mmol/L - subgroup by intervention type.
Review: Omega-6 fats for the primary and secondary prevention of cardiovascular disease
Comparison: 2 Secondary outcomes - higher omega-6 vs lower omega-6
Outcome: 20 TC, mmol/L - subgroup by intervention type
Study or subgroup Higher omega 6 Lower omega 6
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Dietary advice
DART 1989 855 6.29 (1.13) 860 6.55 (1.1) 72.5 % -0.26 [ -0.37, -0.15 ]
Houtsmuller 1979 48 6.43 (0.65) 48 6.9 (0.81) 9.4 % -0.47 [ -0.76, -0.18 ]
Sydney Diet-Heart 1978 221 6.5 (1.2) 237 6.8 (1.1) 18.1 % -0.30 [ -0.51, -0.09 ]
Subtotal (95% CI) 1124 1145 100.0 % -0.29 [ -0.38, -0.20 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.76, df = 2 (P = 0.42); I2 =0.0%
Test for overall effect: Z = 6.26 (P < 0.00001)
2 Supplements (capsules)
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Supplemental foods
Vijayakumar 2014 94 3.92 (1.15) 96 3.86 (0.74) 100.0 % 0.06 [ -0.22, 0.34 ]
Subtotal (95% CI) 94 96 100.0 % 0.06 [ -0.22, 0.34 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.43 (P = 0.67)
4 Dietary advice plus supplement
Mendis 2001 26 -0.42 (0.5447) 28 -0.58 (0.7221) 68.7 % 0.16 [ -0.18, 0.50 ]
MRC 1968 88 -1.11 (0) 89 -0.47 (0) Not estimable
Rose 1965 13 -0.51 (1.25) 13 -0.02 (0.94) 31.3 % -0.49 [ -1.34, 0.36 ]
Subtotal (95% CI) 127 130 100.0 % -0.04 [ -0.63, 0.55 ]
Heterogeneity: Tau2 = 0.10; Chi2 = 1.94, df = 1 (P = 0.16); I2 =48%
Test for overall effect: Z = 0.14 (P = 0.89)
5 Diet (all foods) provided
NDHS Faribault 1968 50 -1.09 (0.73) 51 -0.18 (0.59) 33.4 % -0.91 [ -1.17, -0.65 ]
NDHS Open 1st 1968 311 -0.7 (0.69) 309 -0.25 (0.6) 40.8 % -0.45 [ -0.55, -0.35 ]
Veterans Admin 1969 423 4.93 (3.72) 420 5.3 (1.87) 25.9 % -0.37 [ -0.77, 0.03 ]
Subtotal (95% CI) 784 780 100.0 % -0.58 [ -0.91, -0.26 ]
Heterogeneity: Tau2 = 0.06; Chi2 = 10.95, df = 2 (P = 0.004); I2 =82%
Test for overall effect: Z = 3.54 (P = 0.00041)
Test for subgroup differences: Chi2 = 9.81, df = 3 (P = 0.02), I2 =69%
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Analysis 2.21. Comparison 2 Secondary outcomes - higher omega-6 vs lower omega-6, Outcome 21 TC,
mmol/L - subgroup by replacement.
Review: Omega-6 fats for the primary and secondary prevention of cardiovascular disease
Comparison: 2 Secondary outcomes - higher omega-6 vs lower omega-6
Outcome: 21 TC, mmol/L - subgroup by replacement
Study or subgroup Higher omega 6 Lower omega 6
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 N-6 replacing SFA
DART 1989 855 6.29 (1.13) 860 6.55 (1.1) 18.2 % -0.26 [ -0.37, -0.15 ]
Houtsmuller 1979 48 6.43 (0.65) 48 6.9 (0.81) 12.4 % -0.47 [ -0.76, -0.18 ]
MRC 1968 88 -1.11 (0) 89 -0.47 (0) Not estimable
NDHS Faribault 1968 50 -1.09 (0.73) 51 -0.18 (0.59) 13.5 % -0.91 [ -1.17, -0.65 ]
NDHS Open 1st 1968 311 -0.7 (0.69) 309 -0.25 (0.6) 18.3 % -0.45 [ -0.55, -0.35 ]
Sydney Diet-Heart 1978 221 6.5 (1.2) 237 6.8 (1.1) 15.1 % -0.30 [ -0.51, -0.09 ]
Veterans Admin 1969 423 4.93 (3.72) 420 5.3 (1.87) 9.5 % -0.37 [ -0.77, 0.03 ]
Vijayakumar 2014 94 3.92 (1.15) 96 3.86 (0.74) 13.0 % 0.06 [ -0.22, 0.34 ]
Subtotal (95% CI) 2090 2110 100.0 % -0.38 [ -0.56, -0.21 ]
Heterogeneity: Tau2 = 0.04; Chi2 = 33.44, df = 6 (P<0.00001); I2 =82%
Test for overall effect: Z = 4.38 (P = 0.000012)
2 N-6 replacing MUFA
NDHS Faribault 1968 50 -1.09 (0.73) 51 -0.18 (0.59) 22.6 % -0.91 [ -1.17, -0.65 ]
NDHS Open 1st 1968 311 -0.7 (0.69) 309 -0.25 (0.6) 31.0 % -0.45 [ -0.55, -0.35 ]
Rose 1965 13 -0.51 (1.25) 13 -0.02 (0.94) 5.4 % -0.49 [ -1.34, 0.36 ]
Sydney Diet-Heart 1978 221 6.5 (1.2) 237 6.8 (1.1) 25.3 % -0.30 [ -0.51, -0.09 ]
Veterans Admin 1969 423 4.93 (3.72) 420 5.3 (1.87) 15.7 % -0.37 [ -0.77, 0.03 ]
Subtotal (95% CI) 1018 1030 100.0 % -0.51 [ -0.72, -0.29 ]
Heterogeneity: Tau2 = 0.04; Chi2 = 13.95, df = 4 (P = 0.01); I2 =71%
Test for overall effect: Z = 4.57 (P < 0.00001)
3 N-6 replacing nil, low n-6
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
4 N-6 replacement unclear
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(. . . Continued)
Study or subgroup Higher omega 6 Lower omega 6
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Mendis 2001 26 -0.42 (0.5447) 28 -0.58 (0.7221) 100.0 % 0.16 [ -0.18, 0.50 ]
MRC 1968 88 -1.11 (0) 89 -0.47 (0) Not estimable
Subtotal (95% CI) 114 117 100.0 % 0.16 [ -0.18, 0.50 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.92 (P = 0.36)
5 N-6 replacing CHO
Houtsmuller 1979 48 6.43 (0.65) 48 6.9 (0.81) 100.0 % -0.47 [ -0.76, -0.18 ]
Subtotal (95% CI) 48 48 100.0 % -0.47 [ -0.76, -0.18 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.14 (P = 0.0017)
6 N-6 replacing protein
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Chi2 = 11.32, df = 3 (P = 0.01), I2 =73%
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Analysis 2.22. Comparison 2 Secondary outcomes - higher omega-6 vs lower omega-6, Outcome 22 TC,
mmol/L - subgroup by baseline CVD risk.
Review: Omega-6 fats for the primary and secondary prevention of cardiovascular disease
Comparison: 2 Secondary outcomes - higher omega-6 vs lower omega-6
Outcome: 22 TC, mmol/L - subgroup by baseline CVD risk
Study or subgroup Higher omega 6 Lower omega 6
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Primary prevention - low CVD risk
Mendis 2001 26 -0.42 (0.5447) 28 -0.58 (0.7221) 23.5 % 0.16 [ -0.18, 0.50 ]
NDHS Faribault 1968 50 -1.09 (0.73) 51 -0.18 (0.59) 25.7 % -0.91 [ -1.17, -0.65 ]
NDHS Open 1st 1968 311 -0.7 (0.69) 309 -0.25 (0.6) 29.0 % -0.45 [ -0.55, -0.35 ]
Veterans Admin 1969 423 4.93 (3.72) 420 5.3 (1.87) 21.8 % -0.37 [ -0.77, 0.03 ]
Subtotal (95% CI) 810 808 100.0 % -0.41 [ -0.77, -0.05 ]
Heterogeneity: Tau2 = 0.11; Chi2 = 24.61, df = 3 (P = 0.00002); I2 =88%
Test for overall effect: Z = 2.23 (P = 0.026)
2 Primary prevention - moderate CVD risk
Houtsmuller 1979 48 6.43 (0.65) 48 6.9 (0.81) 100.0 % -0.47 [ -0.76, -0.18 ]
Subtotal (95% CI) 48 48 100.0 % -0.47 [ -0.76, -0.18 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.14 (P = 0.0017)
3 Secondary prevention - existing CVD
DART 1989 855 6.29 (1.13) 860 6.55 (1.1) 47.3 % -0.26 [ -0.37, -0.15 ]
MRC 1968 88 -1.11 (0) 89 -0.47 (0) Not estimable
Rose 1965 13 -0.51 (1.25) 13 -0.02 (0.94) 3.2 % -0.49 [ -1.34, 0.36 ]
Sydney Diet-Heart 1978 221 6.5 (1.2) 237 6.8 (1.1) 28.6 % -0.30 [ -0.51, -0.09 ]
Vijayakumar 2014 94 3.92 (1.15) 96 3.86 (0.74) 20.9 % 0.06 [ -0.22, 0.34 ]
Subtotal (95% CI) 1271 1295 100.0 % -0.21 [ -0.37, -0.06 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 5.32, df = 3 (P = 0.15); I2 =44%
Test for overall effect: Z = 2.66 (P = 0.0077)
Test for subgroup differences: Chi2 = 2.82, df = 2 (P = 0.24), I2 =29%
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Analysis 2.23. Comparison 2 Secondary outcomes - higher omega-6 vs lower omega-6, Outcome 23 TC,
mmol/L - subgroup by omega-6 dose.
Review: Omega-6 fats for the primary and secondary prevention of cardiovascular disease
Comparison: 2 Secondary outcomes - higher omega-6 vs lower omega-6
Outcome: 23 TC, mmol/L - subgroup by omega-6 dose
Study or subgroup Higher omega 6 Lower omega 6
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 N-6 < 4% E
DART 1989 855 6.29 (1.13) 860 6.55 (1.1) 57.7 % -0.26 [ -0.37, -0.15 ]
Mendis 2001 26 -0.42 (0.5447) 28 -0.58 (0.7221) 42.3 % 0.16 [ -0.18, 0.50 ]
Subtotal (95% CI) 881 888 100.0 % -0.08 [ -0.49, 0.32 ]
Heterogeneity: Tau2 = 0.07; Chi2 = 5.36, df = 1 (P = 0.02); I2 =81%
Test for overall effect: Z = 0.40 (P = 0.69)
2 N-6 4% to 12% E
Houtsmuller 1979 48 6.43 (0.65) 48 6.9 (0.81) 8.5 % -0.47 [ -0.76, -0.18 ]
NDHS Open 1st 1968 311 -0.7 (0.69) 309 -0.25 (0.6) 70.5 % -0.45 [ -0.55, -0.35 ]
Sydney Diet-Heart 1978 221 6.5 (1.2) 237 6.8 (1.1) 16.4 % -0.30 [ -0.51, -0.09 ]
Veterans Admin 1969 423 4.93 (3.72) 420 5.3 (1.87) 4.6 % -0.37 [ -0.77, 0.03 ]
Subtotal (95% CI) 1003 1014 100.0 % -0.42 [ -0.51, -0.34 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.74, df = 3 (P = 0.63); I2 =0.0%
Test for overall effect: Z = 9.71 (P < 0.00001)
3 N-6 > 12% E
MRC 1968 88 -1.11 (0) 89 -0.47 (0) Not estimable
NDHS Faribault 1968 50 -1.09 (0.73) 51 -0.18 (0.59) 37.1 % -0.91 [ -1.17, -0.65 ]
Rose 1965 13 -0.51 (1.25) 13 -0.02 (0.94) 26.0 % -0.49 [ -1.34, 0.36 ]
Vijayakumar 2014 94 3.92 (1.15) 96 3.86 (0.74) 36.9 % 0.06 [ -0.22, 0.34 ]
Subtotal (95% CI) 245 249 100.0 % -0.44 [ -1.20, 0.31 ]
Heterogeneity: Tau2 = 0.38; Chi2 = 25.26, df = 2 (P<0.00001); I2 =92%
Test for overall effect: Z = 1.15 (P = 0.25)
Test for subgroup differences: Chi2 = 2.60, df = 2 (P = 0.27), I2 =23%
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Analysis 2.24. Comparison 2 Secondary outcomes - higher omega-6 vs lower omega-6, Outcome 24 TC,
mmol/L - subgroup by duration.
Review: Omega-6 fats for the primary and secondary prevention of cardiovascular disease
Comparison: 2 Secondary outcomes - higher omega-6 vs lower omega-6
Outcome: 24 TC, mmol/L - subgroup by duration
Study or subgroup Higher omega 6 Lower omega 6
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Medium duration 1 to < 2 years in study
Mendis 2001 26 -0.42 (0.5447) 28 -0.58 (0.7221) 30.7 % 0.16 [ -0.18, 0.50 ]
NDHS Faribault 1968 50 -1.09 (0.73) 51 -0.18 (0.59) 33.0 % -0.91 [ -1.17, -0.65 ]
NDHS Open 1st 1968 311 -0.7 (0.69) 309 -0.25 (0.6) 36.3 % -0.45 [ -0.55, -0.35 ]
Subtotal (95% CI) 387 388 100.0 % -0.41 [ -0.87, 0.04 ]
Heterogeneity: Tau2 = 0.15; Chi2 = 24.41, df = 2 (P<0.00001); I2 =92%
Test for overall effect: Z = 1.79 (P = 0.074)
2 Medium-long duration 2 to < 4 years
DART 1989 855 6.29 (1.13) 860 6.55 (1.1) 55.3 % -0.26 [ -0.37, -0.15 ]
Rose 1965 13 -0.51 (1.25) 13 -0.02 (0.94) 8.3 % -0.49 [ -1.34, 0.36 ]
Vijayakumar 2014 94 3.92 (1.15) 96 3.86 (0.74) 36.4 % 0.06 [ -0.22, 0.34 ]
Subtotal (95% CI) 962 969 100.0 % -0.16 [ -0.43, 0.10 ]
Heterogeneity: Tau2 = 0.03; Chi2 = 4.90, df = 2 (P = 0.09); I2 =59%
Test for overall effect: Z = 1.21 (P = 0.23)
3 Long duration 4+ years in study
Houtsmuller 1979 48 6.43 (0.65) 48 6.9 (0.81) 28.7 % -0.47 [ -0.76, -0.18 ]
MRC 1968 88 -1.11 (0) 89 -0.47 (0) Not estimable
Sydney Diet-Heart 1978 221 6.5 (1.2) 237 6.8 (1.1) 55.5 % -0.30 [ -0.51, -0.09 ]
Veterans Admin 1969 423 4.93 (3.72) 420 5.3 (1.87) 15.7 % -0.37 [ -0.77, 0.03 ]
Subtotal (95% CI) 780 794 100.0 % -0.36 [ -0.52, -0.20 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.85, df = 2 (P = 0.65); I2 =0.0%
Test for overall effect: Z = 4.48 (P < 0.00001)
Test for subgroup differences: Chi2 = 1.79, df = 2 (P = 0.41), I2 =0.0%
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Analysis 2.25. Comparison 2 Secondary outcomes - higher omega-6 vs lower omega-6, Outcome 25 TC,
mmol/L - subgroup by statin use.
Review: Omega-6 fats for the primary and secondary prevention of cardiovascular disease
Comparison: 2 Secondary outcomes - higher omega-6 vs lower omega-6
Outcome: 25 TC, mmol/L - subgroup by statin use
Study or subgroup Higher omega 6 Lower omega 6
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1≥ 50% of control group on statins
Vijayakumar 2014 94 3.92 (1.15) 96 3.86 (0.74) 100.0 % 0.06 [ -0.22, 0.34 ]
Subtotal (95% CI) 94 96 100.0 % 0.06 [ -0.22, 0.34 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.43 (P = 0.67)
2 < 50% of control group on statins
DART 1989 855 6.29 (1.13) 860 6.55 (1.1) 18.0 % -0.26 [ -0.37, -0.15 ]
Houtsmuller 1979 48 6.43 (0.65) 48 6.9 (0.81) 12.2 % -0.47 [ -0.76, -0.18 ]
Mendis 2001 26 -0.42 (0.5447) 28 -0.58 (0.7221) 10.9 % 0.16 [ -0.18, 0.50 ]
MRC 1968 88 -1.11 (0) 89 -0.47 (0) Not estimable
NDHS Faribault 1968 50 -1.09 (0.73) 51 -0.18 (0.59) 13.3 % -0.91 [ -1.17, -0.65 ]
NDHS Open 1st 1968 311 -0.7 (0.69) 309 -0.25 (0.6) 18.1 % -0.45 [ -0.55, -0.35 ]
Rose 1965 13 -0.51 (1.25) 13 -0.02 (0.94) 3.3 % -0.49 [ -1.34, 0.36 ]
Sydney Diet-Heart 1978 221 6.5 (1.2) 237 6.8 (1.1) 14.9 % -0.30 [ -0.51, -0.09 ]
Veterans Admin 1969 423 4.93 (3.72) 420 5.3 (1.87) 9.4 % -0.37 [ -0.77, 0.03 ]
Subtotal (95% CI) 2035 2055 100.0 % -0.38 [ -0.55, -0.22 ]
Heterogeneity: Tau2 = 0.04; Chi2 = 33.50, df = 7 (P = 0.00002); I2 =79%
Test for overall effect: Z = 4.45 (P < 0.00001)
3 Statin use unclear
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Chi2 = 7.26, df = 1 (P = 0.01), I2 =86%
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Analysis 2.26. Comparison 2 Secondary outcomes - higher omega-6 vs lower omega-6, Outcome 26 TC,
mmol/L - subgroup by baseline omega-6.
Review: Omega-6 fats for the primary and secondary prevention of cardiovascular disease
Comparison: 2 Secondary outcomes - higher omega-6 vs lower omega-6
Outcome: 26 TC, mmol/L - subgroup by baseline omega-6
Study or subgroup Higher omega 6 Lower omega 6
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1≥ 8% E from n-6
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
2 5% to < 8% E from n-6
DART 1989 855 6.29 (1.13) 860 6.55 (1.1) 80.0 % -0.26 [ -0.37, -0.15 ]
Sydney Diet-Heart 1978 221 6.5 (1.2) 237 6.8 (1.1) 20.0 % -0.30 [ -0.51, -0.09 ]
Subtotal (95% CI) 1076 1097 100.0 % -0.27 [ -0.36, -0.17 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.11, df = 1 (P = 0.74); I2 =0.0%
Test for overall effect: Z = 5.56 (P < 0.00001)
3 < 5% E from n-6
NDHS Faribault 1968 50 -1.09 (0.73) 51 -0.18 (0.59) 33.4 % -0.91 [ -1.17, -0.65 ]
NDHS Open 1st 1968 311 -0.7 (0.69) 309 -0.25 (0.6) 40.8 % -0.45 [ -0.55, -0.35 ]
Veterans Admin 1969 423 4.93 (3.72) 420 5.3 (1.87) 25.9 % -0.37 [ -0.77, 0.03 ]
Subtotal (95% CI) 784 780 100.0 % -0.58 [ -0.91, -0.26 ]
Heterogeneity: Tau2 = 0.06; Chi2 = 10.95, df = 2 (P = 0.004); I2 =82%
Test for overall effect: Z = 3.54 (P = 0.00041)
4 Baseline n-6 not reported
Houtsmuller 1979 48 6.43 (0.65) 48 6.9 (0.81) 29.9 % -0.47 [ -0.76, -0.18 ]
Mendis 2001 26 -0.42 (0.5447) 28 -0.58 (0.7221) 27.9 % 0.16 [ -0.18, 0.50 ]
MRC 1968 88 -1.11 (0) 89 -0.47 (0) Not estimable
Rose 1965 13 -0.51 (1.25) 13 -0.02 (0.94) 11.5 % -0.49 [ -1.34, 0.36 ]
Vijayakumar 2014 94 3.92 (1.15) 96 3.86 (0.74) 30.7 % 0.06 [ -0.22, 0.34 ]
Subtotal (95% CI) 269 274 100.0 % -0.13 [ -0.48, 0.21 ]
Heterogeneity: Tau2 = 0.08; Chi2 = 10.42, df = 3 (P = 0.02); I2 =71%
Test for overall effect: Z = 0.76 (P = 0.45)
Test for subgroup differences: Chi2 = 4.12, df = 2 (P = 0.13), I2 =51%
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Analysis 2.27. Comparison 2 Secondary outcomes - higher omega-6 vs lower omega-6, Outcome 27 TC,
mmol/L - subgroup by sex.
Review: Omega-6 fats for the primary and secondary prevention of cardiovascular disease
Comparison: 2 Secondary outcomes - higher omega-6 vs lower omega-6
Outcome: 27 TC, mmol/L - subgroup by sex
Study or subgroup Higher omega 6 Lower omega 6
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Men and women
Houtsmuller 1979 48 6.43 (0.65) 48 6.9 (0.81) 33.8 % -0.47 [ -0.76, -0.18 ]
Mendis 2001 26 -0.42 (0.5447) 28 -0.58 (0.7221) 31.6 % 0.16 [ -0.18, 0.50 ]
Vijayakumar 2014 94 3.92 (1.15) 96 3.86 (0.74) 34.6 % 0.06 [ -0.22, 0.34 ]
Subtotal (95% CI) 168 172 100.0 % -0.09 [ -0.47, 0.30 ]
Heterogeneity: Tau2 = 0.09; Chi2 = 9.64, df = 2 (P = 0.01); I2 =79%
Test for overall effect: Z = 0.45 (P = 0.65)
2 Sex not reported
Rose 1965 13 -0.51 (1.25) 13 -0.02 (0.94) 100.0 % -0.49 [ -1.34, 0.36 ]
Subtotal (95% CI) 13 13 100.0 % -0.49 [ -1.34, 0.36 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.13 (P = 0.26)
3 Men only
DART 1989 855 6.29 (1.13) 860 6.55 (1.1) 24.9 % -0.26 [ -0.37, -0.15 ]
MRC 1968 88 -1.11 (0) 89 -0.47 (0) Not estimable
NDHS Faribault 1968 50 -1.09 (0.73) 51 -0.18 (0.59) 17.8 % -0.91 [ -1.17, -0.65 ]
NDHS Open 1st 1968 311 -0.7 (0.69) 309 -0.25 (0.6) 25.1 % -0.45 [ -0.55, -0.35 ]
Sydney Diet-Heart 1978 221 6.5 (1.2) 237 6.8 (1.1) 20.1 % -0.30 [ -0.51, -0.09 ]
Veterans Admin 1969 423 4.93 (3.72) 420 5.3 (1.87) 12.1 % -0.37 [ -0.77, 0.03 ]
Subtotal (95% CI) 1948 1966 100.0 % -0.44 [ -0.63, -0.26 ]
Heterogeneity: Tau2 = 0.03; Chi2 = 23.33, df = 4 (P = 0.00011); I2 =83%
Test for overall effect: Z = 4.68 (P < 0.00001)
Test for subgroup differences: Chi2 = 2.77, df = 2 (P = 0.25), I2 =28%
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Analysis 2.28. Comparison 2 Secondary outcomes - higher omega-6 vs lower omega-6, Outcome 28 Serum
triglycerides (TG), mmol/L.
Review: Omega-6 fats for the primary and secondary prevention of cardiovascular disease
Comparison: 2 Secondary outcomes - higher omega-6 vs lower omega-6
Outcome: 28 Serum triglycerides (TG), mmol/L
Study or subgroup Higher omega 6 Lower omega 6
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Dullart 1992 16 1.3 (1.2) 20 1.8 (2.24) 3.3 % -0.50 [ -1.64, 0.64 ]
Houtsmuller 1979 48 0.79 (0.6) 48 1.05 (0.6) 24.0 % -0.26 [ -0.50, -0.02 ]
Mendis 2001 (1) 26 0.35 (0.5199) 28 -0.23 (0.98) 15.2 % 0.58 [ 0.17, 0.99 ]
Sydney Diet-Heart 1978 221 1.6 (0.9) 237 1.7 (0.9) 28.3 % -0.10 [ -0.26, 0.06 ]
Vijayakumar 2014 94 1.27 (0.51) 96 1.23 (0.53) 29.2 % 0.04 [ -0.11, 0.19 ]
Total (95% CI) 405 429 100.0 % -0.01 [ -0.23, 0.21 ]
Heterogeneity: Tau2 = 0.04; Chi2 = 14.05, df = 4 (P = 0.01); I2 =72%
Test for overall effect: Z = 0.06 (P = 0.95)
Test for subgroup differences: Not applicable
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Analysis 2.29. Comparison 2 Secondary outcomes - higher omega-6 vs lower omega-6, Outcome 29 Low-
density lipoprotein (LDL), mmol/L.
Review: Omega-6 fats for the primary and secondary prevention of cardiovascular disease
Comparison: 2 Secondary outcomes - higher omega-6 vs lower omega-6
Outcome: 29 Low-density lipoprotein (LDL), mmol/L
Study or subgroup Higher omega 6 Lower omega 6
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Mendis 2001 (1) 26 -0.65 (0.718) 28 -0.58 (0.9284) 15.5 % -0.07 [ -0.51, 0.37 ]
Vijayakumar 2014 94 2.32 (0.75) 96 2.35 (0.56) 84.5 % -0.03 [ -0.22, 0.16 ]
Total (95% CI) 120 124 100.0 % -0.04 [ -0.21, 0.14 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.03, df = 1 (P = 0.87); I2 =0.0%
Test for overall effect: Z = 0.41 (P = 0.68)
Test for subgroup differences: Not applicable
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Analysis 2.30. Comparison 2 Secondary outcomes - higher omega-6 vs lower omega-6, Outcome 30 High-
density lipoprotein (HDL), mmol/L.
Review: Omega-6 fats for the primary and secondary prevention of cardiovascular disease
Comparison: 2 Secondary outcomes - higher omega-6 vs lower omega-6
Outcome: 30 High-density lipoprotein (HDL), mmol/L
Study or subgroup Higher omega 6 Lower omega 6
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
DART 1989 855 1.04 (0.29) 860 1.05 (0.28) 87.3 % -0.01 [ -0.04, 0.02 ]
Dullart 1992 16 1.28 (0.37) 20 1.29 (0.37) 1.1 % -0.01 [ -0.25, 0.23 ]
Mendis 2001 (1) 26 0.26 (0.1981) 28 0.27 (0.2063) 5.5 % -0.01 [ -0.12, 0.10 ]
Vijayakumar 2014 94 1.15 (0.42) 96 1.12 (0.28) 6.1 % 0.03 [ -0.07, 0.13 ]
Total (95% CI) 991 1004 100.0 % -0.01 [ -0.03, 0.02 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.56, df = 3 (P = 0.91); I2 =0.0%
Test for overall effect: Z = 0.59 (P = 0.56)
Test for subgroup differences: Not applicable
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Analysis 2.31. Comparison 2 Secondary outcomes - higher omega-6 vs lower omega-6, Outcome 31 Body
weight, kg.
Review: Omega-6 fats for the primary and secondary prevention of cardiovascular disease
Comparison: 2 Secondary outcomes - higher omega-6 vs lower omega-6
Outcome: 31 Body weight, kg
Study or subgroup Higher omega 6 Lower omega 6
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Black 1994 58 80 (0) 57 76.5 (0) Not estimable
Dullart 1992 16 77 (10) 20 76 (11.2) 57.9 % 1.00 [ -5.94, 7.94 ]
MRC 1968 88 0 (0) 89 -1.4 (0) Not estimable
Schirmer 2007 13 72.5 (12.94) 17 81.3 (15.92) 42.1 % -8.80 [ -19.13, 1.53 ]
Total (95% CI) 175 183 100.0 % -3.12 [ -12.60, 6.36 ]
Heterogeneity: Tau2 = 27.86; Chi2 = 2.38, df = 1 (P = 0.12); I2 =58%
Test for overall effect: Z = 0.65 (P = 0.52)
Test for subgroup differences: Not applicable
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Analysis 2.32. Comparison 2 Secondary outcomes - higher omega-6 vs lower omega-6, Outcome 32 Body
mass index, kg/m&supStart;2&supEnd;.
Review: Omega-6 fats for the primary and secondary prevention of cardiovascular disease
Comparison: 2 Secondary outcomes - higher omega-6 vs lower omega-6
Outcome: 32 Body mass index, kg/m
2
Study or subgroup Higher omega 6 Lower omega 6
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Sydney Diet-Heart 1978 179 24.3 (1.5) 192 24.5 (2) 100.0 % -0.20 [ -0.56, 0.16 ]
Total (95% CI) 179 192 100.0 % -0.20 [ -0.56, 0.16 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.09 (P = 0.27)
Test for subgroup differences: Not applicable
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Analysis 2.33. Comparison 2 Secondary outcomes - higher omega-6 vs lower omega-6, Outcome 33 Fat
weight, kg.
Review: Omega-6 fats for the primary and secondary prevention of cardiovascular disease
Comparison: 2 Secondary outcomes - higher omega-6 vs lower omega-6
Outcome: 33 Fat weight, kg
Study or subgroup Higher omega 6 Lower omega 6
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Schirmer 2007 13 22.6 (9.05) 17 30.3 (10.18) 100.0 % -7.70 [ -14.60, -0.80 ]
Total (95% CI) 13 17 100.0 % -7.70 [ -14.60, -0.80 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.19 (P = 0.029)
Test for subgroup differences: Not applicable
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Analysis 3.1. Comparison 3 Tertiary outcomes - higher omega-6 vs lower omega-6, Outcome 1 BP - systolic
and diastolic blood pressure, mmHg.
Review: Omega-6 fats for the primary and secondary prevention of cardiovascular disease
Comparison: 3 Tertiary outcomes - higher omega-6 vs lower omega-6
Outcome: 1 BP - systolic and diastolic blood pressure, mmHg
Study or subgroup Higher omega 6 Lower omega 6
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 sBP - systolic blood pressure, mmHg
MRC 1968 88 2 (0) 89 0 (0) Not estimable
Sydney Diet-Heart 1978 221 136.8 (16.1) 237 137.9 (16.1) 100.0 % -1.10 [ -4.05, 1.85 ]
Subtotal (95% CI) 309 326 100.0 % -1.10 [ -4.05, 1.85 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.73 (P = 0.46)
2 dBP - diastolic blood pressure
MRC 1968 88 -1 (0) 89 3 (0) Not estimable
Sydney Diet-Heart 1978 221 88.4 (9.4) 237 88.7 (9.6) 100.0 % -0.30 [ -2.04, 1.44 ]
Subtotal (95% CI) 309 326 100.0 % -0.30 [ -2.04, 1.44 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.34 (P = 0.74)
Test for subgroup differences: Chi2 = 0.21, df = 1 (P = 0.65), I2 =0.0%
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Analysis 3.2. Comparison 3 Tertiary outcomes - higher omega-6 vs lower omega-6, Outcome 2 Dropouts.
Review: Omega-6 fats for the primary and secondary prevention of cardiovascular disease
Comparison: 3 Tertiary outcomes - higher omega-6 vs lower omega-6
Outcome: 2 Dropouts
Study or subgroup Higher omega 6 Lower omega 6 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Bates 1978 (1) 3/29 6/29 11.7 % 0.50 [ 0.14, 1.81 ]
Bates 1978 (2) 0/29 1/29 3.2 % 0.33 [ 0.01, 7.86 ]
Dullart 1992 2/20 4/20 9.2 % 0.50 [ 0.10, 2.43 ]
GLAMT 1993 10/54 17/57 19.2 % 0.62 [ 0.31, 1.23 ]
Mendis 2001 4/30 2/30 8.9 % 2.00 [ 0.40, 10.11 ]
Rose 1965 3/28 5/26 11.3 % 0.56 [ 0.15, 2.10 ]
Veterans Admin 1969 117/424 58/422 24.2 % 2.01 [ 1.51, 2.67 ]
Vijayakumar 2014 6/99 4/99 12.3 % 1.50 [ 0.44, 5.15 ]
Total (95% CI) 713 712 100.0 % 0.94 [ 0.52, 1.72 ]
Total events: 145 (Higher omega 6), 97 (Lower omega 6)
Heterogeneity: Tau2 = 0.37; Chi2 = 18.16, df = 7 (P = 0.01); I2 =61%
Test for overall effect: Z = 0.19 (P = 0.85)
Test for subgroup differences: Not applicable
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Analysis 3.3. Comparison 3 Tertiary outcomes - higher omega-6 vs lower omega-6, Outcome 3 Other
serious adverse events.
Review: Omega-6 fats for the primary and secondary prevention of cardiovascular disease
Comparison: 3 Tertiary outcomes - higher omega-6 vs lower omega-6
Outcome: 3 Other serious adverse events
Study or subgroup Higher PUFA Lower PUFA Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Pulmonary embolism
DART 1989 4/1018 2/1015 77.6 % 1.99 [ 0.37, 10.86 ]
Rose 1965 1/28 0/26 22.4 % 2.79 [ 0.12, 65.66 ]
Subtotal (95% CI) 1046 1041 100.0 % 2.15 [ 0.48, 9.57 ]
Total events: 5 (Higher PUFA), 2 (Lower PUFA)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.03, df = 1 (P = 0.85); I2 =0.0%
Test for overall effect: Z = 1.00 (P = 0.32)
2 Multiple Sclerosis worsened or had acute attack - GLA supplement
Bates 1977 24/76 21/76 9.8 % 1.14 [ 0.70, 1.87 ]
Bates 1978 51/58 46/58 90.2 % 1.11 [ 0.94, 1.30 ]
Subtotal (95% CI) 134 134 100.0 % 1.11 [ 0.95, 1.30 ]
Total events: 75 (Higher PUFA), 67 (Lower PUFA)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.02, df = 1 (P = 0.89); I2 =0.0%
Test for overall effect: Z = 1.35 (P = 0.18)
Test for subgroup differences: Chi2 = 0.74, df = 1 (P = 0.39), I2 =0.0%
0.2 0.5 1 2 5
Favours higher PUFA Favours lower PUFA
A D D I T I O N A L T A B L E S
Table 1. Risk of bias assessment - detailed assessment methods
Risk of bias element Criteria for low risk of bias Criteria for unclear Criteria for high risk of bias
Selection bias: random se-
quence generation
The study authors needed to
have described themethod used
to generate the allocation se-
quence in sufficient detail to al-
low an assessment of whether
it should produce comparable
groups. For example ”the ran-
domisation sequence was com-
puter generated“. We allowed
The study authors have not de-
scribed their method in suffi-
cient detail for the assessment
of whether it would produce
comparable groups. For exam-
ple, the authors state ”the trial
was randomised“ and provide
no further information
The randomisationmethodwas
assessed as not truly random
and may not produce compara-
ble groups
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Table 1. Risk of bias assessment - detailed assessment methods (Continued)
that a goodmethodof randomi-
sation was strongly implied if
the authors discussed stratifi-
cation and/or blocking. There-
fore, if the authors were not
explicit about their randomisa-
tion method but did describe
stratification or blocking we as-
sessed this as low risk
Selection bias: allocation con-
cealment
The study authors needed to
have described themethod used
to conceal allocation sequence
in sufficient detail to determine
whether the allocations could
have been foreseen in advance
of, or during, enrolment. Good
methods included putting allo-
cation codes in opaque sealed
envelopes (ideally prepared by
someone outside the treatment
or assessment teams and se-
quentially numbered), using a
telephone allocation system af-
ter the participants had con-
sented to participate or provid-
ing a random number that links
to a specific set of capsules pre-
pared and distributed centrally
or by an arms-length pharma-
cist
The authors gave insufficient
detail as to method.
The allocation was known in
advance of participants con-
senting to take part in the study
Performance bias: blinding of
participants and personnel
The study authors needed to
have described all measures
used, if any, to blind study par-
ticipants and personnel from
knowledge of which interven-
tion a participant received. Ide-
ally, they should also have pro-
vided information relating to
whether the intended blinding
was effective. For example, the
authors could say ”both the in-
tervention and placebo capsules
looked and tasted the same.“
However, if the study authors
did not provide information on
whether the blinding was ef-
fective, but sufficient detail was
Insufficient methodological de-
tails were provided e.g. ”the
study was blinded.“
The study was unblinded or
where blinding was broken, e.
g. ”the capsules were visually
identical but the participants re-
ported a strong fishy flavour in
the intervention group only.“
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Table 1. Risk of bias assessment - detailed assessment methods (Continued)
given on a good method of
blinding, then it was assumed
that the blinding was effective
and the risk of bias was low
Detection bias: blinding of
outcome assessment
Study authors needed to have
described measures used, if
any, to blind outcome asses-
sors from knowledge of which
intervention a participant re-
ceived. Ideally, they should also
have provided information re-
lating to whether the intended
blinding was effective. For ex-
ample, the authors could say
”the outcome assessors had no
knowledge of the group alloca-
tion, and both the intervention
and placebo capsules looked
and tasted the same so the
self-assessment scales were also
blinded.“ However, if the study
authors did not provide infor-
mation onwhether the blinding
was effective, but sufficient de-
tail was given on a goodmethod
of blinding of the assessors, then
we assumed that the blinding
was effective and the risk of bias
is low. All biochemical assess-
ment (lipids, glucose, CRP, in-
sulin, PSA etc.) were consid-
ered at low risk of detection bias
if outcome assessor blinding or
double-blinding was stated
Insufficient methodological de-
tails were provided e.g. ”the
study was blinded.“
The study was unblinded or
blinding was broken, e.g. for
a self-assessment measure ”the
capsules were visually identical
but the participants reported a
strong fishy flavour in the inter-
vention group only.“
Because the level of blinding
could vary by outcome, assess-
ment of risk of bias was based
on blinding of the review’s pri-
mary outcome(s). Where pri-
mary outcomes had different
assessments, we opted for the
higher risk of bias but noted
that that risk of bias was lower
for other outcomes
Attrition bias: incomplete
outcome data
The study authors needed tode-
scribe the completeness of out-
come data for each main out-
come, including attrition and
exclusions from the analysis.
They needed to report the num-
ber of attrition/exclusions, the
numbers in each group at each
time point, reasons for attri-
tion/exclusion and any re-inclu-
sions in analyses. Ideally, they
would report how they imputed
any missing data e.g. last obser-
The authors didn’t state reasons
for attrition/exclusion or were
unclear about the numbers lost
to attrition/exclusion in each
study arm
The authors demonstrated a
substantial difference in the
rates of attrition/exclusions be-
tween the study arms and/or >
20% of the baseline sample was
lost over a year (> 10% over 6
months)
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Table 1. Risk of bias assessment - detailed assessment methods (Continued)
vation carried forward. There
needed to be a reasonable bal-
ance of attrition/exclusions be-
tween study arms and≤ 20%of
the sample should be lost over a
year
Reporting bias: selective out-
come reporting
The study authors needed to
have published their trial proto-
col or trials registry entry before
the end of the study’s recruit-
ment period i.e. prospectively.
They needed to have reported
on all of the primary and sec-
ondary outcomes listed in the
protocol/registry entry. Report-
ing additional secondary out-
comes in the results paper(s), al-
though not ideal, was deemed
to still be low risk
No trial protocol or trials reg-
istry entry was found, it was
registered retrospectively, or the
dates of registration and partic-
ipant recruitment were unclear
The study authors did not re-
port at least one primary or sec-
ondary outcome listed in the
protocol/registry entry OR the
results paper(s) reported a pri-
mary outcome that was not
listed at all in the protocol or
not listed as a primary outcome
in the protocol
Other sources of bias: atten-
tion bias
The study authors needed to
have reported that participants
in all study arms received the
same amount of attention and
time from researchers and clin-
ical teams. For example, ”All
participants attended the clinic
for a baseline assessment which
took 2 hours. They were then
followed with monthly tele-
phone calls, and finally at-
tended for a 6 month assess-
ment at the clinic which took
1 hour.“ If the study only dif-
fered by the content of the cap-
sules, and the assessment sched-
ule was not stated to differ be-
tween the two arms, it was as-
sumed to be at low risk
The authors did not state the
attention each arm received.
Participants in different arms
received different amounts of
attention. For example ”The in-
tervention group only attended
for additional assessments at
months 2, 4, and6“ or ”the rates
of relapse differed substantially
between the groupswhich led to
differing amounts of treatment
time and attention,“ or ”the in-
tervention group received a 40
minute dietary education ses-
sion.“
Other sources of bias: limited
compliance
The study authors needed to
have reported on the level
of compliance in all arms in
sufficient detail to determine
whether the study results were
robust. We followed a flow
chart to make this determi-
nation. A statistically signifi-
cant difference between the in-
Compliance not reported or not
in a way that could be inter-
preted
Measures of compliance were
reported but fell below the ap-
propriate thresholds
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Table 1. Risk of bias assessment - detailed assessment methods (Continued)
tervention and control groups
in a body measure of at least
50% of the text fatty acids.
Where no body measures were
reported, then estimated com-
pliance needed to be greater
than 64% (proportion comply-
ing multiplied by compliance
threshold)
Other sources of bias: other In the absence of any additional
issues this item was coded ”low
risk of bias“
- If fraud concerns had been
raised and the paper had been
withdrawn, or the author had
been found guilty of fraud by a
legal or medical entity the paper
was excluded from the review.
However if fraud concerns were
raised, but the journal had not
withdrawn the paper, and the
author had not been formally
sanctioned; then the study was
included in the review, but con-
cerns were raised here, and the
risk of bias for this item was
high
A P P E N D I C E S
Appendix 1. Search strategies for the original version of this review
The Cochrane Library
#1MeSH descriptor: (Fatty Acids, Omega-6) this term only
#2”omega 6“
#3(n-6 near/4 acid*)
#4(”n 6“ near/4 acid*)
#5omega-6
#6”linoleic acid*“
#7(poly* near/4 unsat* near/4 fatty acid*)
#8PUFA
#9MeSH descriptor: (Dietary Fats, Unsaturated) this term only
#10MeSH descriptor: (Corn Oil) this term only
#11((corn or maize or mazola) near/4 oil*)
#12maydol
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#13lipomul*
#14MeSH descriptor: (Cottonseed Oil) this term only
#15cottonseed*
#16”cotton seed*“
#17MeSH descriptor: (Soybean Oil) this term only
#18intralipid or nutrilipid
#19((soy bean or soybean) near/4 (oil* or fat* or sauce*))
#20(so?a near/4 oil*)
#21so?aoil*
#22(soy near/4 oil*)
#23soyacal or travamulsion
#24(sunflower near/4 oil*)
#25helianth*
#26MeSH descriptor: (Safflower Oil) this term only
#27(safflower near/4 oil*) .tw.
#28liposyn
#29(grapeseed near/4 oil*)
#30#1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20
or #21 or #22 or #23 or #24 or #25 or #26 or #27 or #28 or #29
#31MeSH descriptor: (Cardiovascular Diseases) explode all trees
#32cardio*
#33cardia*
#34heart*
#35coronary*
#36angina*
#37ventric*
#38myocard*
#39pericard*
#40isch?em*
#41emboli*
#42arrhythmi*
#43thrombo*
#44atrial next fibrillat*
#45tachycardi*
#46endocardi*
#47(sick next sinus)
#48MeSH descriptor: (Stroke) explode all trees
#49(stroke or stokes)
#50cerebrovasc*
#51cerebral next vascular
#52apoplexy
#53(brain near/2 accident*)
#54((brain* or cerebral or lacunar) near/2 infarct*)
#55MeSH descriptor: (Hypertension) explode all trees
#56hypertensi*
#57(peripheral next arter* next disease*)
#58((high or increased or elevated) near/2 blood pressure)
#59MeSH descriptor: (Hyperlipidemias) explode all trees
#60hyperlipid*
#61hyperlip?emia*
#62hypercholesterol*
#63hypercholester?emia*
#64hyperlipoprotein?emia*
223Omega-6 fats for the primary and secondary prevention of cardiovascular disease (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
#65hypertriglycerid?emia*
#66MeSH descriptor: (Arteriosclerosis) explode all trees
#67MeSH descriptor: (Cholesterol) explode all trees
#68cholesterol
#69”coronary risk factor*“
#70MeSH descriptor: (Blood Pressure) this term only
#71”blood pressure“
#72#31 or #32 or #33 or #34 or #35 or #36 or #37 or #38 or #39 or #40 or #41 or #42 or #43 or #44 or #45 or #46 or #47 or #48 or
#49 or #50 or #51 or #52 or #53 or #54 or #55 or #56 or #57 or #58 or #59 or #60 or #61 or #62 or #63 or #64 or #65 or #66 or #
67 or #68 or #69 or #70 or #71
#73#30 and #72
MEDLINE
1. Fatty Acids, Omega-6/
2. omega 6.tw.
3. (n-6 adj4 acid*).tw.
4. (n 6 adj4 acid*).tw.
5. omega-6.tw.
6. linoleic acid*.tw.
7. (poly* adj4 unsat* adj4 fatty acid*).tw.
8. PUFA.tw.
9. Dietary Fats, Unsaturated/
10. corn oil/
11. ((corn or maize or mazola) adj4 oil*).tw.
12. maydol.tw.
13. lipomul*.tw.
14. cottonseed oil/
15. cottonseed*.tw.
16. cotton seed*.tw.
17. soybean oil/
18. intralipid.tw.
19. nutrilipid.tw.
20. ((soy bean or soybean) adj4 (oil* or fat* or sauce*)).tw.
21. (so?a adj4 oil*).tw.
22. so?aoil*.tw.
23. (soy adj4 oil*).tw.
24. soyacal.tw.
25. travamulsion.tw.
26. (sunflower adj4 oil*).tw.
27. helianth*.tw.
28. Safflower Oil/
29. (safflower adj4 oil*).tw.
30. liposyn.tw.
31. (grapeseed adj4 oil*).tw.
32. or/1-31
33. exp Cardiovascular Diseases/
34. cardio*.tw.
35. cardia*.tw.
36. heart*.tw.
37. coronary*.tw.
38. angina*.tw.
39. ventric*.tw.
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40. myocard*.tw.
41. pericard*.tw.
42. isch?em*.tw.
43. emboli*.tw.
44. arrhythmi*.tw.
45. thrombo*.tw.
46. atrial fibrillat*.tw.
47. tachycardi*.tw.
48. endocardi*.tw.
49. (sick adj sinus).tw.
50. exp Stroke/
51. (stroke or stokes).tw.
52. cerebrovasc*.tw.
53. cerebral vascular.tw.
54. apoplexy.tw.
55. (brain adj2 accident*).tw.
56. ((brain* or cerebral or lacunar) adj2 infarct*).tw.
57. exp Hypertension/
58. hypertensi*.tw.
59. peripheral arter* disease*.tw.
60. ((high or increased or elevated) adj2 blood pressure).tw.
61. exp Hyperlipidemias/
62. hyperlipid*.tw.
63. hyperlip?emia*.tw.
64. hypercholesterol*.tw.
65. hypercholester?emia*.tw.
66. hyperlipoprotein?emia*.tw.
67. hypertriglycerid?emia*.tw.
68. exp Arteriosclerosis/
69. exp Cholesterol/
70. cholesterol.tw.
71. ”coronary risk factor* “.tw.
72. Blood Pressure/
73. blood pressure.tw.
74. or/33-73
75. 32 and 74
76. randomized controlled trial.pt.
77. controlled clinical trial.pt.
78. randomized.ab.
79. placebo.ab.
80. drug therapy.fs.
81. randomly.ab.
82. trial.ab.
83. groups.ab.
84. 76 or 77 or 78 or 79 or 80 or 81 or 82 or 83
85. exp animals/ not humans.sh.
86. 84 not 85
87. 75 and 86
EMBASE
1. omega 6 fatty acid/
2. omega 6.tw.
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3. (n-6 adj4 acid*).tw.
4. (n 6 adj4 acid*).tw.
5. omega-6.tw.
6. linoleic acid*.tw.
7. (poly* adj4 unsat* adj4 fatty acid*).tw.
8. PUFA.tw.
9. edible oil/
10. corn oil/
11. ((corn or maize or mazola) adj4 oil*).tw.
12. maydol.tw.
13. lipomul*.tw.
14. cotton seed oil/
15. cottonseed*.tw.
16. cotton seed*.tw.
17. soybean oil/
18. intralipid.tw.
19. nutrilipid.tw.
20. ((soy bean or soybean) adj4 (oil* or fat* or sauce*)).tw.
21. (so?a adj4 oil*).tw.
22. so?aoil*.tw.
23. (soy adj4 oil*).tw.
24. soyacal.tw.
25. travamulsion.tw.
26. sunflower oil/
27. (sunflower adj4 oil*).tw.
28. helianth*.tw.
29. safflower oil/
30. (safflower adj4 oil*).tw.
31. liposyn.tw.
32. (grapeseed adj4 oil*).tw.
33. or/1-32
34. exp cardiovascular disease/
35. cardio*.tw.
36. cardia*.tw.
37. heart*.tw.
38. coronary*.tw.
39. angina*.tw.
40. ventric*.tw.
41. myocard*.tw.
42. pericard*.tw.
43. isch?em*.tw.
44. emboli*.tw.
45. arrhythmi*.tw.
46. thrombo*.tw.
47. atrial fibrillat*.tw.
48. tachycardi*.tw.
49. endocardi*.tw.
50. (sick adj sinus).tw.
51. exp cerebrovascular disease/
52. (stroke or stokes).tw.
53. cerebrovasc*.tw.
54. cerebral vascular.tw.
55. apoplexy.tw.
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56. (brain adj2 accident*).tw.
57. ((brain* or cerebral or lacunar) adj2 infarct*).tw.
58. exp hypertension/
59. hypertensi*.tw.
60. peripheral arter* disease*.tw.
61. ((high or increased or elevated) adj2 blood pressure).tw.
62. exp hyperlipidemia/
63. hyperlipid*.tw.
64. hyperlip?emia*.tw.
65. hypercholesterol*.tw.
66. hypercholester?emia*.tw.
67. hyperlipoprotein?emia*.tw.
68. hypertriglycerid?emia*.tw.
69. exp Arteriosclerosis/
70. exp Cholesterol/
71. cholesterol.tw.
72. ”coronary risk factor*“.tw.
73. Blood Pressure/
74. blood pressure.tw.
75. or/34-74
76. 33 and 75
77. random$.tw.
78. factorial$.tw.
79. crossover$.tw.
80. cross over$.tw.
81. cross-over$.tw.
82. placebo$.tw.
83. (doubl$ adj blind$).tw.
84. (singl$ adj blind$).tw.
85. assign$.tw.
86. allocat$.tw.
87. volunteer$.tw.
88. crossover procedure/
89. double blind procedure/
90. randomized controlled trial/
91. single blind procedure/
92. 77 or 78 or 79 or 80 or 81 or 82 or 83 or 84 or 85 or 86 or 87 or 88 or 89 or 90 or 91
93. (animal/ or nonhuman/) not human/
94. 92 not 93
95. 76 and 94
96. limit 95 to embase
Web of Science
# 19 #18 AND #17
# 18 TS=(random* or blind* or allocat* or assign* or trial* or placebo* or crossover* or cross-over*)
# 17 #16 AND #8
# 16 #15 OR #14 OR #13 OR #12 OR #11 OR #10 OR #9
# 15 TS=(hyperlipid* OR hyperlip?emia* OR hypercholesterol* OR hypercholester?emia* OR hyperlipoprotein?emia* OR hyper-
triglycerid?emia*)
# 14 TS=(”high blood pressure“)
# 13 TS=(hypertensi* OR ”peripheral arter* disease*“)
# 12 TS=(stroke OR stokes OR cerebrovasc* OR cerebral OR apoplexy OR (brain SAME accident*) OR (brain SAME infarct*))
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# 11 TS=(”atrial fibrillat*“ OR tachycardi* OR endocardi*)
# 10 TS=(pericard* OR isch?em* OR emboli* OR arrhythmi* OR thrombo*)
# 9 TS=(cardio* OR cardia* OR heart* OR coronary* OR angina* OR ventric* OR myocard*)
# 8 #7 OR #6 OR #5 OR #4 OR #3 OR #2 OR #1
# 7 TS=((grapeseed near/4 oil*))
# 6 TS=((safflower N4 oil*) or liposyn)
# 5 TS=((sunflower N4 oil*) or helianth*)
# 4 TS=(((soy bean or soybean) N4 (oil* or fat* or sauce*)) or (so?a N4 oil*) or intralipid or nutrilipid or so?aoil* or (soy near/4 oil*)
or soyacal or travamulsion)
# 3 TS=(cottonseed* or ”cotton seed*“)
# 2 TS=(((corn or maize or mazola) N4 oil*) or maydol or lipomul*)
# 1 TS=(”omega 6“ or ”omega-6“ or (n-6 N4 acid*) or (”n 6“ N4 acid*) or ”linoleic acid*“ or (poly* N4 unsat* N4 fatty acid*) or
PUFA)
Clinical trial registers
Omega 6 and Cardio*
Omega 6 and primary prevention OR risk AND Cardio*
Omega 6
Appendix 2. Search strategies for this update of the review
CENTRAL
#1 MeSH descriptor: (Fatty Acids, Essential) explode all trees
#2 MeSH descriptor: (Fatty Acids, Unsaturated) this term only
#3 ((polyunsaturat* or poly-unsaturat*) near/3 fat*)
#4 (poly* adj4 unsat* near/4 fatty acid*)
#5 PUFA
#6 MeSH descriptor: (Fatty Acids, Omega-6) explode all trees
#7 omega-6
#8 (n-6 near/4 acid*) or (”n 6“ near/4 acid*)
#9 linoleic acid*
#10 MeSH descriptor: (Corn Oil) this term only
#11 MeSH descriptor: (Cottonseed Oil) this term only
#12 MeSH descriptor: (Olive Oil) this term only
#13 MeSH descriptor: (Safflower Oil) this term only
#14 MeSH descriptor: (Sesame Oil) this term only
#15 MeSH descriptor: (Soybean Oil) this term only
#16 ((corn or maize or mazola) near/4 oil*)
#17 (cottonseed* or (cotton next seed*))
#18 (olive near/4 oil*)
#19 (safflower near/4 oil*)
#20 (sesame near/4 oil*)
#21 ((soy bean or soybean) near/4 (oil* or fat*))
#22 (so?a near/4 oil*)
#23 so?aoil*
#24 (soy near/4 oil*)
#25 (sunflower near/4 oil*)
#26 helianth*
#27 (grapeseed near/4 oil*)
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#28 (canola near/4 oil*)
#29 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 or #
20 or #21 or #22 or #23 or #24 or #25 or #26 or #27 or #28
MEDLINE Ovid
1. exp fatty acids, essential/
2. fatty acids, unsaturated/
3. ((polyunsaturat* or poly-unsaturat*) adj3 fat*).ti,ab.
4. (poly* adj4 unsat* adj4 fatty acid*).ti,ab.
5. PUFA.ti,ab.
6. exp fatty acids, omega-6/
7. omega-6.ti,ab.
8. (n-6 adj4 acid*).ti,ab.
9. linoleic acid*.ti,ab.
10. corn oil/ or cottonseed oil/ or olive oil/ or safflower oil/ or sesame oil/ or soybean oil/
11. ((corn or maize or mazola) adj4 oil*).ti,ab.
12. (cottonseed* or (cotton adj seed*)).ti,ab.
13. (olive adj4 oil*).ti,ab.
14. (safflower adj4 oil*).ti,ab.
15. (sesame adj4 oil*).ti,ab.
16. ((soy bean or soybean) adj4 (oil* or fat*)).ti,ab.
17. (so?a adj4 oil*).ti,ab.
18. so?aoil*.ti,ab.
19. (soy adj4 oil*).ti,ab.
20. (sunflower adj4 oil*).ti,ab.
21. helianth*.ti,ab.
22. (grapeseed adj4 oil*).ti,ab.
23. (canola adj4 oil*).ti,ab.
24. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23
25. randomized controlled trial.pt.
26. controlled clinical trial.pt.
27. randomized.ab.
28. placebo.ab.
29. clinical trials as topic.sh.
30. randomly.ab.
31. trial.ti.
32. 25 or 26 or 27 or 28 or 29 or 30 or 31
33. exp animals/ not humans.sh.
34. 32 not 33
35. 24 and 34
Embase Ovid
1. exp essential fatty acid/
2. unsaturated fatty acid/ or docosapentaenoic acid/ or omega 6 fatty acid/ or polyunsaturated fatty acid/
3. ((polyunsaturat* or poly-unsaturat*) adj3 fat*).ti,ab.
4. (poly* adj4 unsat* adj4 fatty acid*).ti,ab.
5. PUFA.ti,ab.
6. omega-6.ti,ab.
7. (n-6 adj4 acid*).ti,ab.
8. linoleic acid*.ti,ab.
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9. edible oil/ or canola oil/ or corn oil/ or cotton seed oil/ or olive oil/ or safflower oil/ or safflower oil plus soybean oil/ or sesame seed
oil/ or soybean oil/ or sunflower oil/
10. ((corn or maize or mazola) adj4 oil*).ti,ab.
11. (cottonseed* or (cotton adj seed*)).ti,ab.
12. (olive adj4 oil*).ti,ab.
13. (safflower adj4 oil*).ti,ab.
14. (sesame adj4 oil*).ti,ab.
15. ((soy bean or soybean) adj4 (oil* or fat*)).ti,ab.
16. (so?a adj4 oil*).ti,ab.
17. so?aoil*.ti,ab.
18. (soy adj4 oil*).ti,ab.
19. (sunflower adj4 oil*).ti,ab.
20. helianth*.ti,ab.
21. (grapeseed adj4 oil*).ti,ab.
22. (canola adj4 oil*).ti,ab.
23. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22
24. double blind procedure/
25. single blind procedure/
26. randomized controlled trial/
27. ((double* or single*) adj blind*).ti,ab.
28. (random* or placebo*).ti,ab.
29. 24 or 25 or 26 or 27 or 28
30. (animal/ or nonhuman/) not human/
31. 29 not 30
32. 23 and 31
ClinicalTrials.gov and WHO International Clinical Trials Registry Platform
We searched ClinicalTrials.gov ( www.ClinicalTrials.gov) and the WHO International Clinical Trials Registry Platform (ICTRP,
www.who.int/ictrp/en) during September 2016:
(PUFA OR polyunsaturate* OR poly-unsaturate* OR omega-3 OR omega3 OR omega6 OR omega-6 OR fish* OR marine* OR n-3
OR n-6 OR EPA OR DHA OR ALA OR linoleic* OR linolenic*) AND (fat* OR oil* OR supplement* OR capsule*)
Appendix 3. Studies excluded due to duration < 12 months
Excluded studies - excluded due to duration of less than 12 months
Ahrén 2009
(CRSSTD: 2912017)
Ahrén B, Mari A, Fyfe CL, Tsofliou F, Sneddon AA, Wahle KW, et al. Effects of conjugated linoleic acid plus n-3 polyunsaturated
fatty acids on insulin secretion and estimated insulin sensitivity in men. European Journal of Clinical Nutrition 2009;63(6):778-86.
(CRSREF: 2912018)
Allman-Farinelli 1999
(CRSSTD: 2912019)
Allman-Farinelli MA, Hall D, Kingham K, Pang D, Petocz P, Favaloro EJ. Comparison of the effects of two low fat diets with different
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WH A T ’ S N E W
Last assessed as up-to-date: 2 May 2017.
Date Event Description
5 December 2017 New search has been performed For the update from Al-Khudairy 2015, we have intro-
duced some changes, broadening the review to fit with
the request of the World Health Organization (WHO)
NutritionGuidance Expert AdvisoryGroup (NUGAG)
Subgroup on Diet and Health, who requested the up-
date
1. We included studies in a wider variety of adults,
such as those with diabetes or cardiovascular disease at
baseline, as the original review was of primary
prevention only and excluded diabetes.
2. Effects of dietary changes needed to be assessed
over at least one year.
3. We included studies that compared higher
omega-6 fat intake with lower omega-6 fat intake (not
only usual diet).
4. We added new pre-planned subgroups requested
by WHO.
5 December 2017 New citation required and conclusions have changed The earlier review found no studies examining the ef-
fects of either increased or decreased omega-6 fats on
our primary clinical outcomes for cardiovascular dis-
ease. For this update we included 19 randomised con-
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trolled trials in 6461 participants over 1 to 8 years. We
have now included studies reporting all-cause mortal-
ity, cardiovascular deaths and events, coronary heart dis-
ease events, major adverse cardiac and cerebrovascular
events, and stroke. We have also updated data on long-
term effects of omega-6 fats on lipids and adiposity, and
we have added data on individual cardiovascular events
(all secondary outcomes)
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
For the update, we introduced some changes from Al-Khudairy 2015 to broaden the review to fit with the requirements of WHO
NUGAG Subgroup on Diet and Health.
1. We included studies in a wider variety of adults, such as those with diabetes or CVD at baseline, as the original review was of
primary prevention only and excluded diabetes.
2. Effects of dietary changes needed to be assessed over at least one year.
3. We included studies that compared higher omega-6 fat intake with lower omega-6 fat intake (not only usual diet).
4. We carried out sensitivity and subgroup analyses for primary review outcomes as planned, and also for key outcomes.
5. Addition of new pre-planned subgroups requested by WHO NUGAG Subgroup on Diet and Health .
6. We performed meta-regression to look for dose-response and duration effects of omega-6 fats within this review and across
studies from three reviews (this review, omega-3 (Abdelhamid 2018a) and total PUFA (Abdelhamid 2018b)).
For this review update we intended to assess causality (another aspect of performance bias, where a study intervention included changes
other than the change in omega-6 fat intake, when there would be high risk of bias) when assessing risk of bias, but as we limited
inclusion to studies where the dietary changes were limited to dietary fats, this was not needed and so omitted. We also intended to
assess whether a study was pre-registered on a trials register (registration date was before outcome data collection began; Roberts 2015),
but we incorporated the issue of pre-registration into selective outcome reporting and did not use it as a separate form of assessment.
242Omega-6 fats for the primary and secondary prevention of cardiovascular disease (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
I N D E X T E R M S
Medical Subject Headings (MeSH)
∗Blood Pressure; Cardiovascular Diseases [∗prevention & control]; Cholesterol [∗blood]; Cholesterol, HDL [blood]; Cholesterol, LDL
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